
<html lang="en"     class="pb-page"  data-request-id="4d49260d-55ce-4deb-9f99-3bc7f96ec2a3"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;article:article:10.1021/acs.jmedchem.9b01283;ctype:string:Journal Content;wgroup:string:ACHS website Group;website:website:acspubs;issue:issue:10.1021/jmcmar.2019.62.issue-21;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Identification and Optimization of Mechanism-Based Fluoroallylamine Inhibitors of Lysyl Oxidase-like 2/3" /></meta><meta name="dc.Creator" content="Alison D.  Findlay" /></meta><meta name="dc.Creator" content="Jonathan S.  Foot" /></meta><meta name="dc.Creator" content="Alberto  Buson" /></meta><meta name="dc.Creator" content="Mandar  Deodhar" /></meta><meta name="dc.Creator" content="Andrew G.  Jarnicki" /></meta><meta name="dc.Creator" content="Philip M.  Hansbro" /></meta><meta name="dc.Creator" content="Gang  Liu" /></meta><meta name="dc.Creator" content="Heidi  Schilter" /></meta><meta name="dc.Creator" content="Craig I.  Turner" /></meta><meta name="dc.Creator" content="Wenbin  Zhou" /></meta><meta name="dc.Creator" content="Wolfgang  Jarolimek" /></meta><meta name="dc.Description" content="Lysyl oxidase-like 2 (LOXL2) is a secreted enzyme that catalyzes the formation of cross-links in extracellular matrix proteins, namely, collagen and elastin, and is indicated in fibrotic diseases. ..." /></meta><meta name="Description" content="Lysyl oxidase-like 2 (LOXL2) is a secreted enzyme that catalyzes the formation of cross-links in extracellular matrix proteins, namely, collagen and elastin, and is indicated in fibrotic diseases. ..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="October 3, 2019" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.9b01283" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="Copyright © 2019 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.9b01283" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.9b01283" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.9b01283" /></link>
        
    
    

<title>Identification and Optimization of Mechanism-Based Fluoroallylamine Inhibitors of Lysyl Oxidase-like 2/3 | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.9b01283" /></meta><meta property="og:title" content="Identification and Optimization of Mechanism-Based Fluoroallylamine Inhibitors of Lysyl Oxidase-like 2/3" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-21/acs.jmedchem.9b01283/20191108/images/large/jm9b01283_0012.jpeg" /></meta><meta property="og:description" content="Lysyl oxidase-like 2 (LOXL2) is a secreted enzyme that catalyzes the formation of cross-links in extracellular matrix proteins, namely, collagen and elastin, and is indicated in fibrotic diseases. Herein, we report the identification and subsequent optimization of a series of indole-based fluoroallylamine inhibitors of LOXL2. The result of this medicinal chemistry campaign is PXS-5120A (12k), a potent, irreversible inhibitor that is &gt;300-fold selective for LOXL2 over LOX. PXS-5120A also shows potent inhibition of LOXL3, an emerging therapeutic target for lung fibrosis. Key to the development of this compound was the utilization of a compound oxidation assay. PXS-5120A was optimized to show negligible substrate activity in vitro for related amine oxidase family members, leading to metabolic stability. PXS-5120A, in a pro-drug form (PXS-5129A, 12o), displayed anti-fibrotic activity in models of liver and lung fibrosis, thus confirming LOXL2 as an important target in diseases where collagen cross-linking is implicated." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.9b01283"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.9b01283">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.9b01283&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.9b01283&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.9b01283&amp;href=/doi/10.1021/acs.jmedchem.9b01283" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2019</span><span class="cit-fg-volume">, 62</span><span class="cit-fg-issue">, 21</span><span class="cit-fg-pageRange">, 9874-9889</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/62/21" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.9b01238" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.9b01301" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Identification and Optimization of Mechanism-Based Fluoroallylamine Inhibitors of Lysyl Oxidase-like 2/3</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Alison D. Findlay</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Alison D. Findlay</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Pharmaxis Ltd, 20 Rodborough Road, Frenchs Forest, Sydney, New South Wales 2086, Australia</div></div><span class="conrtib-corresp"><strong>*</strong>E-mail: <a href="/cdn-cgi/l/email-protection#22434e4b514d4c0c444b4c464e435b62524a43504f435a4b510c414d4f0c4357"><span class="__cf_email__" data-cfemail="eb8a8782988485c58d82858f878a92ab9b838a99868a938298c5888486c58a9e">[email protected]</span></a>. Phone: +61 2 9454 7200. Fax: +61 2 9451 3622 (A.D.F.).</span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Alison+D.++Findlay">Alison D. Findlay</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jonathan S. Foot</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jonathan S. Foot</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Pharmaxis Ltd, 20 Rodborough Road, Frenchs Forest, Sydney, New South Wales 2086, Australia</div></div><span class="conrtib-corresp"><strong>*</strong>E-mail: <a href="/cdn-cgi/l/email-protection#4a2025242b3e222b24642c25253e0a3a222b38272b32233964292527642b3f"><span class="__cf_email__" data-cfemail="7f1510111e0b171e11511910100b3f0f171e0d121e07160c511c1012511e0a">[email protected]</span></a>. Phone: +61 2 9454 7200. Fax: +61 2 9451 3622 (J.S.F.).</span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jonathan+S.++Foot">Jonathan S. Foot</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-1642-1742" title="Orcid link">http://orcid.org/0000-0003-1642-1742</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Alberto Buson</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Alberto Buson</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Pharmaxis Ltd, 20 Rodborough Road, Frenchs Forest, Sydney, New South Wales 2086, Australia</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Alberto++Buson">Alberto Buson</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Mandar Deodhar</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Mandar Deodhar</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Pharmaxis Ltd, 20 Rodborough Road, Frenchs Forest, Sydney, New South Wales 2086, Australia</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Mandar++Deodhar">Mandar Deodhar</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Andrew G. Jarnicki</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Andrew G. Jarnicki</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Centre for Healthy Lungs, The University of Newcastle and Hunter Medical Research Institute, Newcastle, New South Wales 2300, Australia</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Andrew+G.++Jarnicki">Andrew G. Jarnicki</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Philip M. Hansbro</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Philip M. Hansbro</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Centre for Healthy Lungs, The University of Newcastle and Hunter Medical Research Institute, Newcastle, New South Wales 2300, Australia</div><div class="loa-info-affiliations-info">Centre for Inflammation, Centenary Institute, Sydney, New South Wales 2050, Australia</div><div class="loa-info-affiliations-info">Faculty of Science, University of Technology Sydney, Ultimo, New South Wales 2007, Australia</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Philip+M.++Hansbro">Philip M. Hansbro</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Gang Liu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Gang Liu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Centre for Inflammation, Centenary Institute, Sydney, New South Wales 2050, Australia</div><div class="loa-info-affiliations-info">Faculty of Science, University of Technology Sydney, Ultimo, New South Wales 2007, Australia</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Gang++Liu">Gang Liu</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Heidi Schilter</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Heidi Schilter</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Pharmaxis Ltd, 20 Rodborough Road, Frenchs Forest, Sydney, New South Wales 2086, Australia</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Heidi++Schilter">Heidi Schilter</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Craig I. Turner</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Craig I. Turner</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Pharmaxis Ltd, 20 Rodborough Road, Frenchs Forest, Sydney, New South Wales 2086, Australia</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Craig+I.++Turner">Craig I. Turner</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Wenbin Zhou</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Wenbin Zhou</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Pharmaxis Ltd, 20 Rodborough Road, Frenchs Forest, Sydney, New South Wales 2086, Australia</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Wenbin++Zhou">Wenbin Zhou</a></span></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Wolfgang Jarolimek</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Wolfgang Jarolimek</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Pharmaxis Ltd, 20 Rodborough Road, Frenchs Forest, Sydney, New South Wales 2086, Australia</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Wolfgang++Jarolimek">Wolfgang Jarolimek</a></span></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.9b01283&amp;href=/doi/10.1021%2Facs.jmedchem.9b01283" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2019</span></span><span class="cit-volume">, 62</span><span class="cit-issue">, 21</span><span class="cit-pageRange">, 9874–9889</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">October 3, 2019</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>7 August 2019</li><li><span class="item_label"><b>Published</b> online</span>3 October 2019</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 14 November 2019</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.9b01283" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b01283</a></div><div class="article_header-article-copyright"><strong>Copyright © 2019 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D9874%26pageCount%3D16%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DAlison%2BD.%2BFindlay%252C%2BJonathan%2BS.%2BFoot%252C%2BAlberto%2BBuson%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D62%26issueNum%3D21%26contentID%3Dacs.jmedchem.9b01283%26title%3DIdentification%2Band%2BOptimization%2Bof%2BMechanism-Based%2BFluoroallylamine%2BInhibitors%2Bof%2BLysyl%2BOxidase-like%2B2%252F3%26numPages%3D16%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D9889%26publicationDate%3DNovember%2B2019">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.9b01283"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">1221</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">8</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.9b01283" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Identification and Optimization of Mechanism-Based Fluoroallylamine Inhibitors of Lysyl Oxidase-like 2/3&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Alison&quot;,&quot;last_name&quot;:&quot;D. Findlay&quot;},{&quot;first_name&quot;:&quot;Jonathan&quot;,&quot;last_name&quot;:&quot;S. Foot&quot;},{&quot;first_name&quot;:&quot;Alberto&quot;,&quot;last_name&quot;:&quot;Buson&quot;},{&quot;first_name&quot;:&quot;Mandar&quot;,&quot;last_name&quot;:&quot;Deodhar&quot;},{&quot;first_name&quot;:&quot;Andrew&quot;,&quot;last_name&quot;:&quot;G. Jarnicki&quot;},{&quot;first_name&quot;:&quot;Philip&quot;,&quot;last_name&quot;:&quot;M. Hansbro&quot;},{&quot;first_name&quot;:&quot;Gang&quot;,&quot;last_name&quot;:&quot;Liu&quot;},{&quot;first_name&quot;:&quot;Heidi&quot;,&quot;last_name&quot;:&quot;Schilter&quot;},{&quot;first_name&quot;:&quot;Craig&quot;,&quot;last_name&quot;:&quot;I. Turner&quot;},{&quot;first_name&quot;:&quot;Wenbin&quot;,&quot;last_name&quot;:&quot;Zhou&quot;},{&quot;first_name&quot;:&quot;Wolfgang&quot;,&quot;last_name&quot;:&quot;Jarolimek&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2019&quot;,&quot;month&quot;:&quot;10&quot;,&quot;day&quot;:&quot;03&quot;,&quot;issue&quot;:&quot;21&quot;,&quot;volume&quot;:&quot;62&quot;,&quot;pages&quot;:&quot;9874-9889&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.9b01283&quot;},&quot;abstract&quot;:&quot;Lysyl oxidase-like 2 (LOXL2) is a secreted enzyme that catalyzes the formation of cross-links in extracellular matrix proteins, namely, collagen and elastin, and is indicated in fibrotic diseases. Herein, we report the identification and subsequent optimization of a series of indole-based fluoroallylamine inhibitors of LOXL2. The result of this medicinal chemistry campaign is PXS-5120A (12k), a potent, irreversible inhibitor that is &gt;300-fold selective for LOXL2 over LOX. PXS-5120A also shows potent inhibition of LOXL3, an emerging therapeutic target for lung fibrosis. Key to the development of this compound was the utilization of a compound oxidation assay. PXS-5120A was optimized to show negligible substrate activity in vitro for related amine oxidase family members, leading to metabolic stability. PXS-5120A, in a pro-drug form (PXS-5129A, 12o), displayed anti-fibrotic activity in models of liver and lung fibrosis, thus confirming LOXL2 as an important target in diseases where collagen cross-linking is impl&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.9b01283&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b01283" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.9b01283&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b01283" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.9b01283&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b01283" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.9b01283&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b01283&amp;href=/doi/10.1021/acs.jmedchem.9b01283" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.9b01283" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.9b01283" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (1 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b01283&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.9b01283%26sid%3Dliteratum%253Aachs%26pmid%3D31580073%26genre%3Darticle%26aulast%3DFindlay%26date%3D2019%26atitle%3DIdentification%2Band%2BOptimization%2Bof%2BMechanism-Based%2BFluoroallylamine%2BInhibitors%2Bof%2BLysyl%2BOxidase-like%2B2%252F3%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D62%26issue%3D21%26spage%3D9874%26epage%3D9889%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (2)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=291181" title="Amines">Amines</a>,</li><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=291793" title="Inhibition">Inhibition</a>,</li><li><a href="/action/doSearch?ConceptID=291089" title="Plasma">Plasma</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/62/21" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-21/jmcmar.2019.62.issue-21/20191114/jmcmar.2019.62.issue-21.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-21/acs.jmedchem.9b01283/20191108/images/medium/jm9b01283_0012.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-21/acs.jmedchem.9b01283/20191108/images/large/jm9b01283_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01283&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Lysyl oxidase-like 2 (LOXL2) is a secreted enzyme that catalyzes the formation of cross-links in extracellular matrix proteins, namely, collagen and elastin, and is indicated in fibrotic diseases. Herein, we report the identification and subsequent optimization of a series of indole-based fluoroallylamine inhibitors of LOXL2. The result of this medicinal chemistry campaign is <b>PXS-5120A</b> (<b>12k</b>), a potent, irreversible inhibitor that is >300-fold selective for LOXL2 over LOX. <b>PXS-5120A</b> also shows potent inhibition of LOXL3, an emerging therapeutic target for lung fibrosis. Key to the development of this compound was the utilization of a compound oxidation assay. <b>PXS-5120A</b> was optimized to show negligible substrate activity in vitro for related amine oxidase family members, leading to metabolic stability. <b>PXS-5120A</b>, in a pro-drug form (<b>PXS-5129A</b>, <b>12o</b>), displayed anti-fibrotic activity in models of liver and lung fibrosis, thus confirming LOXL2 as an important target in diseases where collagen cross-linking is implicated.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_78771" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_78771" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">In most organisms, including humans, two families of amine oxidases are responsible for the metabolism of various mono-, di- and polyamines produced endogenously or absorbed from exogenous sources. The first of these families use covalently bound flavin adenine dinucleotide (FAD) as the cofactor and includes the monoamine oxidases (MAOs; MAO-A and MAO-B), involved in the metabolism of neuroactive amines such as dopamine, serotonin, and norepinephrine;<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> polyamine oxidase (PAO), which oxidatively deaminates spermine and spermidine;<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> and lysine-specific histone demethylases, such as LSD1 (or KDM1A), that are involved in epigenetic function.<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a></div><div class="NLM_p">The second family of amines oxidases are dependent on copper and utilize an oxidized tyrosine residue as the cofactor.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> Within this family, there are two subclasses. The first one consists of the amine oxidase, copper-containing [<i>AOC</i>, utilizing the topaquinone (TPQ) cofactor] subclass encompassing diamine oxidase (DAO; <i>AOC1</i>), involved in the metabolism of histamine;<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> retinal specific amine oxidase (RAO; <i>AOC2</i>) found predominantly in the eye;<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> semicarbazide-sensitive amine oxidase [SSAO, also known as vascular adhesion protein-1 (VAP-1); <i>AOC3</i>], an ectoenzyme involved in leukocyte recruitment;<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> and plasma amine oxidase (<i>AOC4</i>) which is found in all mammals except rats, mice, and humans (who lack a functional <i>AOC4</i> gene).<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> The second subclass consists of the lysyl oxidase (LOX) family [utilizing the lysine tyrosylquinone (LTQ) cofactor].</div><div class="NLM_p">There are five members of the human LOX protein family, designated LOX and LOX-like 1–4 (LOXL1–4).<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> The expression pattern of LOX family members can alter depending on cell type, differentiation state, development state, and disease state.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> The LOX family acts as key regulators in the cross-linking of elastin and collagen fibrils, through the oxidation and condensation of the ε-amino group of specific lysine and hydroxylysine residues.<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> A fine balance of elasticity and mechanical stiffness is required to maintain the appropriate function in various tissues such as the lung and heart, and this balance is dependent on LOX/LOXL activity.<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> Upregulation of one or more of the LOX family enzymes can lead to aberrant cross-linking, causing excessive local collagen deposition and propagation of pro-fibrotic signaling within the extracellular matrix (ECM). If left unchecked, this can induce tissue scarring, fibrosis, and destruction of function, eventually leading to organ failure.<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a></div><div class="NLM_p">Under normal physiological conditions, LOX is ubiquitously expressed in most human tissues at higher levels than other family members<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> and is essential in the development of the healthy bone, respiratory system, and cardiovascular function.<a onclick="showRef(event, 'ref14 ref15 ref16'); return false;" href="javascript:void(0);" class="ref ref14 ref15 ref16">(14−16)</a> In contrast, LOXL2 mRNA and protein levels are upregulated in fibrotic tissues and diverse solid tumors when compared with normal human tissues.<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> LOXL2 is also considered a biomarker for progression in various diseases, such as liver and lung fibrosis, scleroderma, and cancer.<a onclick="showRef(event, 'ref18 ref19 ref20 ref21'); return false;" href="javascript:void(0);" class="ref ref18 ref19 ref20 ref21">(18−21)</a> Given the important role that LOXL2 appears to play in certain fibrotic diseases, selective inhibition of LOXL2 over LOX offers clear advantages for their long-term treatment.</div><div class="NLM_p">LOXL2 is significantly increased in human cholangiopathies and is proposed to contribute to bile duct injury through suppression of E-cadherin in biliary epithelial cells.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> Ikenaga et al. have shown that LOXL2 mediates collagen cross-linking and fibrotic matrix stabilization during liver fibrosis and independently promotes fibrogenic hepatic progenitor cell (HPC) differentiation.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> Moreover, using the murine LOXL2 antibody AB0023,<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> the authors have shown that inhibition of LOXL2 can promote a reversal of advanced parenchymal liver fibrosis in mice. How critical the role of LOXL2 and its enzymatic activity is in hepatic fibrosis compared to the other members of the LOX family is yet to be fully proven,<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> with evidence that in some instances LOX can also act as a biomarker for liver fibrosis.<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a></div><div class="NLM_p">LOXL2 is also of interest as a therapeutic target in lung fibrosis, including idiopathic pulmonary fibrosis (IPF).<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> LOXL2 is over-expressed in patients with IPF<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> and is reported to activate lung fibroblasts via regulation of the TGF-β/Smad signaling pathway.<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a></div><div class="NLM_p">A humanized monoclonal LOXL2 antibody AB0024 (simtuzumab) had been advanced into clinical trials, including two fibrosis indications (IPF and NASH).<a onclick="showRef(event, 'ref30 ref31'); return false;" href="javascript:void(0);" class="ref ref30 ref31">(30,31)</a> While simtuzumab was found to be safe and well tolerated, there was no sign of clinical benefit. Although this result has thrown doubt on the viability of LOXL2 as a target, it is important to note that the antibody only partially (∼40%) inhibits the catalytic activity of the enzyme<a onclick="showRef(event, 'cit17a ref24'); return false;" href="javascript:void(0);" class="ref cit17a ref24">(17a,24)</a> and is therefore unlikely to have a significant effect on collagen cross-linking. Additionally, the absence of a pharmacodynamic assay for LOXL2 inhibition meant that target inhibition with these dosing regimens was not confirmed, nor was penetration into the organ of interest.<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> To this end, a small molecule with appropriate drug-like qualities offers an opportunity to fully evaluate the therapeutic potential of LOXL2 inhibition.</div><div class="NLM_p">Scarce examples of small-molecule LOX inhibitors exist, with β-aminopropionitrile (BAPN) (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>) long serving as the archetypal pan-LOX inhibitor.<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> More recently, Springer et al.<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> disclosed an aminomethylthiophene-based inhibitor CCT365626 (<b>1</b>) with sub-micromolar potency for both the LOX and LOXL2 isoforms; however, no selectivity data were provided for the other family members. PharmAkea have reported the development of a series of aminomethyl pyridine-based, selective LOXL2 inhibitors,<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> of which PAT-1251 (<b>2</b>) completed phase I trials at the end of 2016.<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> Although enzyme inhibition in humans seems to have been achieved with <b>2</b>, it appears short lived (complete recovery 24 h after a single dose of 1000 mg per healthy volunteer was reported),<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> and the therapeutic implications of such a profile are at present unclear.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-21/acs.jmedchem.9b01283/20191108/images/medium/jm9b01283_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-21/acs.jmedchem.9b01283/20191108/images/large/jm9b01283_0001.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Chemical structures of BAPN, CCT365623 (<b>1</b>), PAT-1251 (<b>2</b>), and <b>PXS-5153A</b> (<b>3</b>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-21/acs.jmedchem.9b01283/20191108/images/large/jm9b01283_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01283&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">We have recently reported the structure of <b>PXS-5153A</b> (<b>3</b>) and outlined its efficacy in two models of liver fibrosis and a model of myocardial infarction.<a onclick="showRef(event, 'cit17b'); return false;" href="javascript:void(0);" class="ref cit17b">(17b)</a><b>PXS-5153A</b> was developed in tandem to the chemical series reported herein with the purpose of producing a tool compound to establish a proof of concept for in vivo inhibition of LOXL2 in models of fibrosis. <b>PXS-5153A</b> was found to have good potency for LOXL2 (pIC<sub>50</sub> = 7.7, see also <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>) and reasonable selectivity over LOX (∼70-fold, see also <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>). Importantly, <b>PXS-5153A</b> was found to possess a pharmacokinetic profile that allowed for low dosing of the molecule in in vivo models. Unfortunately, <b>PXS-5153A</b> is recognized as a substrate by both SSAO and plasma amine oxidase (data shown in <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>), and that precluded the molecule from being developed further. The present work outlines the identification and optimization of an indole-based structural class (closely related to <b>PXS-5153A</b>) and strategies to improve on the potency, selectivity and, most importantly, potential for oxidation by SSAO and plasma amine oxidase, the latter to enable pre-clinical toxicological evaluation of this class of LOXL2 inhibitors in higher order mammals (dog, pig, monkey, etc.).</div><div class="NLM_p">These studies led to the identification of <b>12k</b> (<b>PXS-5120A</b>), a potent LOXL2/3 inhibitor which demonstrated efficacy in models of both liver and lung fibrosis, in addition to the previously reported benefits in a diabetic nephropathy model.<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a></div><div id="sec1_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i3" class="anchor-spacer"></div><h3 class="article-section__title" id="_i3"> Inhibitor Design</h3><div class="NLM_p">Common to the quinone-containing AOC family of enzymes is the ability to recognize and oxidize short length arylalkyl-based primary amines (histamine, dopamine, tyramine, and benzylamine). With SSAO/VAP-1, this has been exploited using a variety of 3-, 4-, and 5-atom length aryl substituted fluoroallylamine groups (e.g., mofegiline, <b>PXS-4159A</b>, LJP 1586, and <b>PXS-4681A</b>)<a onclick="showRef(event, 'ref38 ref39 ref40 ref41'); return false;" href="javascript:void(0);" class="ref ref38 ref39 ref40 ref41">(38−41)</a> These fluoroallylamines are recognized as substrates and are therefore capable of binding to the quinone cofactor directly. In the case of SSAO, it is thought that this leads to the activation of the previously unreactive vinyl fluoride moiety toward nucleophilic attack, thereby enabling formation of a further covalent bond within the active site and irreversibly inhibiting enzyme function (<a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>).<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a></div><figure id="sch1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-21/acs.jmedchem.9b01283/20191108/images/medium/jm9b01283_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-21/acs.jmedchem.9b01283/20191108/images/large/jm9b01283_0008.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Proposed Mechanism of Inhibition of SSAO/VAP-1 by Fluoroallylamine-Based compounds<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-21/acs.jmedchem.9b01283/20191108/images/large/jm9b01283_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01283&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Scheme shows the proposed mechanism of inhibition of SSAO by fluoroallylamine-based inhibitors. Black arrows portray the normal catalytic turnover of amine substrates, and the red arrows show how the installation of a vinyl fluoride into the molecule can redirect the pathway, resulting in the covalent alkylation of the protein active site. “Nu”: nucleophilic amino acid residue in the active site.</p></p></figure><div class="NLM_p">Given the success of this approach in selectively targeting the SSAO TPQ cofactor, we sought to design a novel series of inhibitors of LOXL2 based on a similar tactic, targeting the LTQ cofactor. As no detailed structural information regarding the target was available at the outset of our synthetic campaign,<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a> we screened several fluoroallylamine templates to identify a tractable starting point and extend the utility of these scaffolds. We found that a previously reported fluoroallylamine <b>4</b><a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(44)</a> displayed modest LOXL2 inhibition, albeit with no selectivity over LOX (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>) nor SSAO. Further exploration of the fluoroallylamine motif afforded the (<i>Z</i>)-isomer, <b>5</b>, a compound with improved LOXL2 potency and reduced SSAO activity. This fluoroallylamine configuration was deemed to be a suitable starting point for further investigation.</div><figure id="fig2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-21/acs.jmedchem.9b01283/20191108/images/medium/jm9b01283_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-21/acs.jmedchem.9b01283/20191108/images/large/jm9b01283_0002.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Identification of a suitable fluoroallylamine configuration.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-21/acs.jmedchem.9b01283/20191108/images/large/jm9b01283_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01283&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i5">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_00061" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_00061" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">With a view to identifying the features necessary for boosting LOXL2 potency and opening a selectivity window over LOX, we opted to replace the central linking phenol moiety appended to the fluoroallylamine in <b>5</b> with a 1,2,3-triazole and expand on the substitution of the terminal phenyl ring. This enabled rapid exploration via Cu(I)-catalyzed Huisgen cycloaddition reaction<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a> between appropriately functionalized alkynes <b>6a–h</b> and azide <b>9</b>, derived from the previously reported alcohol <b>7</b>,<a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(44)</a> affording a suite of 1,2,3-triazole-based inhibitors <b>10a–h</b> (<a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a> and <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>). While recombinant human LOXL2 was used for functional assays, bovine aorta LOX was utilized for selectivity screening the analogues, as it was found that this was pharmacologically similar to human fibroblast LOX and was more readily available.</div><figure id="sch2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-21/acs.jmedchem.9b01283/20191108/images/medium/jm9b01283_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-21/acs.jmedchem.9b01283/20191108/images/large/jm9b01283_0009.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of 1,2,3-Triazole-Based Inhibitors <b>10a–h</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-21/acs.jmedchem.9b01283/20191108/images/large/jm9b01283_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01283&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) propargyl bromide, K<sub>2</sub>CO<sub>3</sub>, MeCN, rt; (b) MsCl, Et<sub>3</sub>N, acetone, then LiBr, 0 °C to rt; (c) NaN<sub>3</sub>, DMF, rt; (d) CuSO<sub>4</sub>(H<sub>2</sub>O)<sub>5</sub>, sodium ascorbate, <i>t</i>-BuOH, rt; (e) (i) TFA, DCM, rt; (ii) HCl, Et<sub>2</sub>O/EtOAc, rt.</p></p></figure><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. LOXL2 and LOX Inhibition by 1,2,3-Triazole Analogues <b>10a–h</b></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compound</th><th class="colsep0 rowsep0" align="center">R group</th><th class="colsep0 rowsep0" align="center" char="±">LOXL2<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a><sup>,</sup><a class="ref internalNav" href="#t1fn2" aria-label="b">b</a><sup>,</sup><a class="ref internalNav" href="#t1fn3" aria-label="c">c</a> (pIC<sub>50</sub> ± SD)</th><th class="colsep0 rowsep0" align="center" char="±">LOX<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a><sup>,</sup><a class="ref internalNav" href="#t1fn2" aria-label="b">b</a><sup>,</sup><a class="ref internalNav" href="#t1fn3" aria-label="c">c</a> (pIC<sub>50</sub> ± SD)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">BAPN</td><td class="colsep0 rowsep0" align="left">n/a</td><td class="colsep0 rowsep0" align="char" char="±">6.4 ± 0.12</td><td class="colsep0 rowsep0" align="char" char="±">5.7 ± 0.13</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>10a</b></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="char" char="±">6.5 ± 0.08</td><td class="colsep0 rowsep0" align="char" char="±">6.3 ± 0.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>10b</b></td><td class="colsep0 rowsep0" align="left">4-<i>t</i>Bu</td><td class="colsep0 rowsep0" align="char" char="±">6.1 ± 0.05</td><td class="colsep0 rowsep0" align="char" char="±">6.3 ± 0.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>10c</b></td><td class="colsep0 rowsep0" align="left">4-SO<sub>2</sub>Me</td><td class="colsep0 rowsep0" align="char" char="±">6.7 ± 0.3</td><td class="colsep0 rowsep0" align="char" char="±">6.2 ± 0.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>10d</b></td><td class="colsep0 rowsep0" align="left">2-SO<sub>2</sub>Me</td><td class="colsep0 rowsep0" align="char" char="±">5.7 ± 0.07</td><td class="colsep0 rowsep0" align="char" char="±">5.5 ± 0.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>10e</b></td><td class="colsep0 rowsep0" align="left">3-SO<sub>2</sub>Me</td><td class="colsep0 rowsep0" align="char" char="±">6.1 ± 0.05</td><td class="colsep0 rowsep0" align="char" char="±">6.0 ± 0.05</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>10f</b></td><td class="colsep0 rowsep0" align="left">4-CONMe<sub>2</sub></td><td class="colsep0 rowsep0" align="char" char="±">6.1 ± 0.1</td><td class="colsep0 rowsep0" align="char" char="±">5.5 ± 0.4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>10g</b></td><td class="colsep0 rowsep0" align="left">4-SO<sub>2</sub>NMe<sub>2</sub></td><td class="colsep0 rowsep0" align="char" char="±">7.3 ± 0.1</td><td class="colsep0 rowsep0" align="char" char="±">6.1 ± 0.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>10h</b></td><td class="colsep0 rowsep0" align="left">2-Cl, 4-SO<sub>2</sub>NMe<sub>2</sub></td><td class="colsep0 rowsep0" align="char" char="±">7.7 ± 0.09</td><td class="colsep0 rowsep0" align="char" char="±">6.1 ± 0.2</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup><sup>a</sup></sup><p class="last">The measurement of enzymatic activities was based on the detection of hydrogen peroxide with an AR oxidation assay.<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a></p></div><div class="footnote" id="t1fn2"><sup><sup>b</sup></sup><p class="last">Minimum of <i>n</i> = 2 for each experiment.</p></div><div class="footnote" id="t1fn3"><sup><sup>c</sup></sup><p class="last">“LOXL2” = recombinant human LOXL2 and “LOX” = bovine aorta LOX; SD = standard deviation.</p></div></div></div><div class="NLM_p">Introduction of simple alkyl groups such as a <i>t</i>-butyl group (<b>10b</b>) was found to have a slightly detrimental effect on LOXL2 potency relative to the unsubstituted example, <b>10a</b>, while introduction of the electron-withdrawing methyl sulfone marginally improved potency (<b>10c</b>), importantly favoring LOXL2 over LOX (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>). In terms of the optimal position for substitution, 4-SO<sub>2</sub>Me was preferred over 2-SO<sub>2</sub>Me (<b>10d</b>) and 3-SO<sub>2</sub>Me (<b>10e</b>). While replacement of the <i>para</i>-methyl sulfone with 4-CONMe<sub>2</sub> (<b>10f</b>) showed no benefit, a significant improvement in LOXL2 potency was achieved upon introduction of the dimethylsulfonamide moiety, as in <b>10g</b>. The introduction of a chloro substituent in the <i>ortho</i>-position in <b>10h</b> resulted in a further increase in LOXL2 potency. Evaluation of <b>10g</b> and <b>10h</b> for off-target amine oxidase activity showed that although neither inhibited SSAO (pIC<sub>50</sub> < 4.5), both were inhibitors of DAO (pIC<sub>50</sub> of 6.5 for each), and <b>10g</b> (but not <b>10h</b>) also inhibited MAO-B (pIC<sub>50</sub> 6.9).</div><div class="NLM_p">Given the presence of the primary amine, we next evaluated the most potent analogues to establish if these compounds were recognized as substrates.</div><div class="NLM_p">Amine oxidase substrate activity may effectively act as a clearance pathway, reducing available inhibitor levels. Furthermore, it has the potential to produce oxidative stress and undesirable species in vivo, owing to the fact that hydrogen peroxide and the corresponding aldehyde species are byproducts of the enzyme reaction. In addition, plasma amine oxidase substrate activity can complicate pre-clinical development because of its differential presence between species (aside from rodents and humans, the <i>AOC4</i> gene product is present in all mammalian species, especially the dog).<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> Thus, rapid “turnover” by the related amine oxidases was potentially a major limitation and recognized as an important development consideration. To monitor, and thereby enable optimization of this, compound oxidation assays to measure the relative substrate activity by SSAO and plasma amine oxidase were introduced into the screening cascade.</div><div class="NLM_p">Both compounds were rapidly turned over in the SSAO and plasma amine oxidase oxidation assays, and when incubated in dog plasma, <b>10h</b> was found to be completely consumed, with 0% parent compound remaining after 1 h. Pre-incubation of the dog plasma with semicarbazide (to inhibit SSAO and plasma amine oxidase) confirmed that this degradation was dependent on the activity of these related amine oxidases (data not shown).</div><div class="NLM_p">In efforts to improve these aspects, we opted to explore the effect of both linker and core modifications (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>). Because of the observed high turnover by SSAO of the triazole-linked compounds, we chose to first evaluate this parameter and identify an alternative chemo-type that would not be recognized as a substrate by SSAO.</div><figure id="fig3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-21/acs.jmedchem.9b01283/20191108/images/medium/jm9b01283_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-21/acs.jmedchem.9b01283/20191108/images/large/jm9b01283_0003.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Variation of the linker and core regions.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-21/acs.jmedchem.9b01283/20191108/images/large/jm9b01283_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01283&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Alternative linkers (CH<sub>2</sub>NH, <b>10i</b>, and CH<sub>2</sub>, <b>10j</b>, in place of CH<sub>2</sub>O) revealed little difference in terms of potency relative to <b>10g</b> (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>), nor in turnover by SSAO. Removing rotatable bonds to the biaryl structure <b>10k</b> was tolerated, providing a more compact and less flexible structure with reasonable potency for LOXL2 and good selectivity over LOX; however, significant SSAO turnover was still observed. Replacing the 1,2,3-triazole with a pyrrole (<b>11a</b> and <b>11b</b>) maintained potency without improving turnover. Moving to the 2-methylindole scaffold with a direct link to the aryl sulfonamide (<b>12a</b> and <b>12b</b>) resulted in a reduction in turnover by SSAO. Presumably, this improvement was due to the increase in steric bulk attached directly to the fluoroallylamine warhead rather than an electronic effect, given the turnover of the related pyrroles <b>11a</b> and <b>11b</b>. Interestingly for both the pyrroles and indoles, a switch from <i>para</i>- to <i>meta</i>-SO<sub>2</sub>NMe<sub>2</sub> provided an increase in LOXL2 potency as well as improved selectivity over LOX.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Structure–Activity Relationships of Linker and Core-Based Modifications</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-21/acs.jmedchem.9b01283/20191108/images/medium/jm9b01283_0011.gif" alt="" id="gr11" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup><sup>a</sup></sup><p class="last">The measurement of enzymatic activities was based on the detection of hydrogen peroxide with an AR oxidation assay.<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a></p></div><div class="footnote" id="t2fn2"><sup><sup>b</sup></sup><p class="last">Minimum of <i>n</i> = 2 for each experiment.</p></div><div class="footnote" id="t2fn3"><sup><sup>c</sup></sup><p class="last">Compound oxidation assay measuring the amount of hydrogen peroxide generated at a single concentration (30 μM) of compound, relative to DMSO; SD = standard deviation.</p></div></div><div></div></div><div class="NLM_p">Further profiling against the family of amine oxidases showed <b>12b</b> to be a highly selective inhibitor of LOXL2, with no inhibition of MAO-A or B (pIC<sub>50</sub>s < 4.5), and minimal activity towards SSAO or DAO (pIC<sub>50</sub> of 5.1 and 5.4 respectively). However, despite these improvements, <b>12b</b> was rapidly turned over by plasma amine oxidase, meaning that further modification was required to enable identification of a compound suitable for preclinical evaluation in higher mammals (e.g., dog, monkey, pig). Equally, additional improvements in selectivity were desired to enable accurate evaluation of the effects of LOXL2 inhibition over LOX in preclinical models of disease.</div><div class="NLM_p">As the 3-substituted dimethylsulfonamide aryl ring appeared necessary for LOXL2 potency and selectivity over LOX, we chose to “fix” this moiety and investigate substitution of the indole aromatic ring (<a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a> and <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>). Introduction of an electron-withdrawing dimethyl amide group (<b>12c</b>, <b>12d</b>, and <b>12e</b>) at the 5-, 6-, or 7-position significantly improved SSAO and plasma amine oxidase substrate activity such that these compounds were not turned over at all by either enzyme. Potency for the 5- and 6-substituted examples also significantly improved; however, the 7-substituted example showed a dramatic drop-off in LOXL2 inhibition. Given the slightly better potency displayed by <b>12c</b>, further examples were pursued with substitution in the 5-position. A chloro group was equally well tolerated (<b>12f</b>), as was a free phenol group (<b>12g</b>); however, switching to the methoxy group (<b>12h</b>) drastically increased turnover by SSAO. A reverse sulfonamide (<b>12i</b>) also showed an increase in plasma amine oxidase turnover. Introduction of a methyl sulfone (<b>12j</b>) improved LOXL2 potency further, but this was accompanied by an increase in turnover by SSAO and plasma amine oxidase. Switching to a carboxylic acid afforded a similarly potent compound <b>12k</b> (<b>PXS-5120A</b>) with improved selectivity over LOX (>300-fold) and minimal turnover, an effect that was not mirrored in the 6-position (<b>12l</b>). Tetrazole (<b>12m</b>) was not a viable bioisosteric replacement of the carboxylic acid in this case, leading to a drop in potency, while the ethyl ester <b>12o</b> (<b>PXS-5129A</b>), which can be regarded as a pro-drug form of <b>12k</b> (<b>PXS-5120A</b>), had good potency but moderate SSAO turnover. Removal of the fluorine group from the allylamine warhead (<b>12n</b>, also <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>D) led to a 100-fold drop in potency, consistent with its proposed role in the mechanism of inhibition.</div><figure id="fig4" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-21/acs.jmedchem.9b01283/20191108/images/medium/jm9b01283_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-21/acs.jmedchem.9b01283/20191108/images/large/jm9b01283_0004.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Mechanistic studies on <b>4</b> (<b>PXS-5120A</b>). (A) LOXL2 inhibition by <b>PXS-5120A</b>, which is time-dependent. (B) Substrate competition; rising concentrations of the substrate putrescine compete with LOXL2 inhibition by <b>PXS-5120A</b>, suggesting that <b>PXS-5120A</b> acts directly through interacting with the catalytic cofactor. (C) Jump dilution; 1 h soak with an inhibitor (at a concentration equivalent to 30 × IC<sub>50</sub>) followed by a 100-fold dilution, before addition of putrescine. Assay readout at 30 min after substrate addition. No significant return of activity was observed for either BAPN or <b>PXS-5120A</b>. (D) Washout experiment using bound LOXL2; time course of substrate turnover post washout showing the return of enzyme activity over time after exposure to the inhibitor. Neither <b>PXS-5120A</b> nor BAPN (plots overlapping) showed any return of activity over background after 30 min. <i>des</i>-Fluoro <b>PXS-5120A</b>, <b>12n</b>, shows a return of enzyme activity to a level of ∼75% of that observed where no inhibitor was present pre-washout.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-21/acs.jmedchem.9b01283/20191108/images/large/jm9b01283_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01283&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="sch3" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-21/acs.jmedchem.9b01283/20191108/images/medium/jm9b01283_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-21/acs.jmedchem.9b01283/20191108/images/large/jm9b01283_0010.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of 2-Methyl, 3-Aryl Indole-Based Inhibitors <b>12b–12o</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-21/acs.jmedchem.9b01283/20191108/images/large/jm9b01283_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01283&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) NBS, then DMAP, Boc<sub>2</sub>O, CH<sub>2</sub>Cl<sub>2</sub>, rt; (b) aryl boronic acid/ester, Pd(PPh<sub>3</sub>)<sub>4</sub>, K<sub>2</sub>CO<sub>3</sub> (aq), dioxane, 80 °C, then TFA, CH<sub>2</sub>Cl<sub>2</sub>, rt; (c) Cs<sub>2</sub>CO<sub>3</sub>, DMF, rt; (d) LiOH, MeOH, THF, H<sub>2</sub>O, rt; (e) if R = CONMe<sub>2</sub> group, then Me<sub>2</sub>NH, HATU, DIPEA, DMF, rt; (f) either 2 M HCl (in Et<sub>2</sub>O), MeOH, or TFA, CH<sub>2</sub>Cl<sub>2</sub>, then HCl (in Et<sub>2</sub>O).</p></p></figure><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Optimization of the Indole Core</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compound</th><th class="colsep0 rowsep0" align="center">R group</th><th class="colsep0 rowsep0" align="center" char="±">LOXL2<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a><sup>,</sup><a class="ref internalNav" href="#t3fn2" aria-label="b">b</a> (pIC<sub>50</sub> ± SD)</th><th class="colsep0 rowsep0" align="center" char="±">LOX<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a><sup>,</sup><a class="ref internalNav" href="#t3fn2" aria-label="b">b</a> (pIC<sub>50</sub> ± SD)</th><th class="colsep0 rowsep0" align="center" char=".">oxidation by SSAO<a class="ref internalNav" href="#t3fn3" aria-label="c">c</a></th><th class="colsep0 rowsep0" align="center" char=".">oxidation by <i>AOC4</i><a class="ref internalNav" href="#t3fn3" aria-label="c">c</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>12b</b></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="char" char="±">7.0 ± 0.07</td><td class="colsep0 rowsep0" align="char" char="±">5.7 ± 0.1</td><td class="colsep0 rowsep0" align="char" char=".">1.4</td><td class="colsep0 rowsep0" align="char" char=".">>4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>12c</b></td><td class="colsep0 rowsep0" align="left">5-CO<sub>2</sub>NMe<sub>2</sub></td><td class="colsep0 rowsep0" align="char" char="±">7.6 ± 0.14</td><td class="colsep0 rowsep0" align="char" char="±">5.8 ± 0.20</td><td class="colsep0 rowsep0" align="char" char=".">1.2</td><td class="colsep0 rowsep0" align="char" char=".">1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>12d</b></td><td class="colsep0 rowsep0" align="left">6-CO<sub>2</sub>NMe<sub>2</sub></td><td class="colsep0 rowsep0" align="char" char="±">7.2 ± 0.02</td><td class="colsep0 rowsep0" align="char" char="±">6.1 ± 0.01</td><td class="colsep0 rowsep0" align="char" char=".">1</td><td class="colsep0 rowsep0" align="char" char=".">1.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>12e</b></td><td class="colsep0 rowsep0" align="left">7-CO<sub>2</sub>NMe<sub>2</sub></td><td class="colsep0 rowsep0" align="char" char="±">5.5 ± 0.05</td><td class="colsep0 rowsep0" align="char" char="±">4.7 ± 0.11</td><td class="colsep0 rowsep0" align="char" char=".">1.1</td><td class="colsep0 rowsep0" align="char" char=".">1.4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>12f</b></td><td class="colsep0 rowsep0" align="left">5-Cl</td><td class="colsep0 rowsep0" align="char" char="±">6.9 ± 0.11</td><td class="colsep0 rowsep0" align="char" char="±">5.5 ± 0.03</td><td class="colsep0 rowsep0" align="char" char=".">1.2</td><td class="colsep0 rowsep0" align="char" char=".">1.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>12g</b></td><td class="colsep0 rowsep0" align="left">5-OH</td><td class="colsep0 rowsep0" align="char" char="±">7.3 ± 0.03</td><td class="colsep0 rowsep0" align="char" char="±">5.9 ± 0.18</td><td class="colsep0 rowsep0" align="char" char=".">1</td><td class="colsep0 rowsep0" align="char" char=".">1.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>12h</b></td><td class="colsep0 rowsep0" align="left">5-OMe</td><td class="colsep0 rowsep0" align="char" char="±">7.1 ± 0.10</td><td class="colsep0 rowsep0" align="char" char="±">5.8 ± 0.04</td><td class="colsep0 rowsep0" align="char" char=".">4.6</td><td class="colsep0 rowsep0" align="char" char=".">1.6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>12i</b></td><td class="colsep0 rowsep0" align="left">5-NHSO<sub>2</sub>Me</td><td class="colsep0 rowsep0" align="char" char="±">7.7 ± 0.07</td><td class="colsep0 rowsep0" align="char" char="±">6.0 ± 0.07</td><td class="colsep0 rowsep0" align="char" char=".">1</td><td class="colsep0 rowsep0" align="char" char=".">1.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>12j</b></td><td class="colsep0 rowsep0" align="left">5-SO<sub>2</sub>Me</td><td class="colsep0 rowsep0" align="char" char="±">8.3 ± 0.17</td><td class="colsep0 rowsep0" align="char" char="±">6.4 ± 0.06</td><td class="colsep0 rowsep0" align="char" char=".">1.3</td><td class="colsep0 rowsep0" align="char" char=".">1.3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>12k</b><b>PXS-5120A</b></td><td class="colsep0 rowsep0" align="left">5-CO<sub>2</sub>H</td><td class="colsep0 rowsep0" align="char" char="±">8.4 ± 0.04</td><td class="colsep0 rowsep0" align="char" char="±">5.8 ± 0.10</td><td class="colsep0 rowsep0" align="char" char=".">1</td><td class="colsep0 rowsep0" align="char" char=".">1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>12l</b></td><td class="colsep0 rowsep0" align="left">6-CO<sub>2</sub>H</td><td class="colsep0 rowsep0" align="char" char="±">6.3 ± 0.02</td><td class="colsep0 rowsep0" align="char" char="±">4.8 ± 0.03</td><td class="colsep0 rowsep0" align="char" char=".">1.1</td><td class="colsep0 rowsep0" align="char" char=".">1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>12m</b></td><td class="colsep0 rowsep0" align="left">5-tetrazole</td><td class="colsep0 rowsep0" align="char" char="±">6.9 ± 0.03</td><td class="colsep0 rowsep0" align="char" char="±">4.8 ± 0.21</td><td class="colsep0 rowsep0" align="char" char="."><a class="ref internalNav" href="#t3fn4" aria-label="d">d</a></td><td class="colsep0 rowsep0" align="char" char=".">1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>12n</b></td><td class="colsep0 rowsep0" align="left">5-CO<sub>2</sub>H <i>des</i>-fluoro</td><td class="colsep0 rowsep0" align="char" char="±">6.1 ± 0.07</td><td class="colsep0 rowsep0" align="char" char="±">5.5 ± 0.18</td><td class="colsep0 rowsep0" align="char" char=".">1</td><td class="colsep0 rowsep0" align="char" char=".">1.3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>12o</b><b>PXS-5129A</b></td><td class="colsep0 rowsep0" align="left">5-CO<sub>2</sub>Et</td><td class="colsep0 rowsep0" align="char" char="±">7.1 ± 0.09</td><td class="colsep0 rowsep0" align="char" char="±">5.2 ± 0.12</td><td class="colsep0 rowsep0" align="char" char=".">2.4</td><td class="colsep0 rowsep0" align="char" char=".">1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>PXS-5153A</b></td><td class="colsep0 rowsep0" align="left">n/a</td><td class="colsep0 rowsep0" align="char" char="±">7.7 ± 0.23</td><td class="colsep0 rowsep0" align="char" char="±">5.9 ± 0.09</td><td class="colsep0 rowsep0" align="char" char=".">1.6</td><td class="colsep0 rowsep0" align="char" char=".">6.4</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup><sup>a</sup></sup><p class="last">The measurement of enzymatic activities was based on the detection of hydrogen peroxide with an AR oxidation assay.<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a></p></div><div class="footnote" id="t3fn2"><sup><sup>b</sup></sup><p class="last">Minimum of <i>n</i> = 2 for each experiment.</p></div><div class="footnote" id="t3fn3"><sup><sup>c</sup></sup><p class="last">Compound oxidation assay measuring the amount of hydrogen peroxide generated at a single concentration (30 μM) of compound, relative to DMSO.</p></div><div class="footnote" id="t3fn4"><sup><sup>d</sup></sup><p class="last">Not tested; SD = standard deviation.</p></div></div></div><div class="NLM_p"><b>PXS-5120A</b> (<b>12k</b>) exhibited good selectivity over the related amine oxidase enzymes and showed limited auxiliary pharmacology in standard profiling assays (the compound was tested at 10 μM against 119 different off-targets; see <a href="/doi/suppl/10.1021/acs.jmedchem.9b01283/suppl_file/jm9b01283_si_001.pdf" class="ext-link">Supporting Information</a>. Only the peripheral benzodiazepine receptor was inhibited by >50%). Importantly, <b>PXS-5120A</b> exhibited similar potency for LOXL2 across all species tested (<a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>), allowing for easier translation of our in vivo findings when transitioning into the clinic. In a functional assay measuring the ability of the compound to inhibit the cross-linking of rat collagen in vitro,<a onclick="showRef(event, 'cit17b'); return false;" href="javascript:void(0);" class="ref cit17b">(17b)</a><b>PXS-5120A</b> displayed dose-dependent inhibition of cross-linking, with a calculated IC<sub>50</sub> of 13 nM. Comparison with <b>PXS-5153A</b> in the same assay showed this to be a ∼3-fold improvement, in line with the improved potency in the primary LOXL2 assay (see <a href="/doi/suppl/10.1021/acs.jmedchem.9b01283/suppl_file/jm9b01283_si_001.pdf" class="ext-link">Figure S1</a> and <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>). <b>PXS-5120A</b> is metabolically stable in vitro and has moderate protein plasma binding.</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. In Vitro Profile of <b>12k</b> (<b>PXS-5120A</b>)</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">assay—potency and selectivity</th><th class="colsep0 rowsep0" align="center" char=".">IC<sub>50</sub> (nM)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">recombinant human LOXL2</td><td class="colsep0 rowsep0" align="char" char=".">5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">human fibroblast LOXL2</td><td class="colsep0 rowsep0" align="char" char=".">9</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">recombinant mouse LOXL2</td><td class="colsep0 rowsep0" align="char" char=".">6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">recombinant rat LOXL2</td><td class="colsep0 rowsep0" align="char" char=".">6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">collagen oxidation assay</td><td class="colsep0 rowsep0" align="char" char=".">13</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">recombinant human DAO</td><td class="colsep0 rowsep0" align="char" char=".">>10 000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">recombinant human SSAO, MAO-A/B</td><td class="colsep0 rowsep0" align="char" char=".">>30 000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">human fibroblast LOX</td><td class="colsep0 rowsep0" align="char" char=".">1260</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">bovine LOX (aorta)</td><td class="colsep0 rowsep0" align="char" char=".">1780</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">murine LOX (lung fibroblasts)</td><td class="colsep0 rowsep0" align="char" char=".">1754</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">recombinant human LOXL1</td><td class="colsep0 rowsep0" align="char" char=".">2260</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">recombinant human LOXL3</td><td class="colsep0 rowsep0" align="char" char=".">16</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">recombinant human LOXL4</td><td class="colsep0 rowsep0" align="char" char=".">280</td></tr></tbody></table><table class="table "><colgroup><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">assay—ADME parameters</th><th class="colsep0 rowsep0" align="center">result</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">PPB (rat/dog/human), % bound</td><td class="colsep0 rowsep0" align="left">88/86/92</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">plasma stability (rat, dog, and human) <i>t</i><sub>1/2</sub></td><td class="colsep0 rowsep0" align="left">>120 min</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">microsomal stability (rat, dog, and human) <i>t</i><sub>1/2</sub></td><td class="colsep0 rowsep0" align="left">>90 min</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">hepatocyte stability (rat, dog, and human) <i>t</i><sub>1/2</sub></td><td class="colsep0 rowsep0" align="left">>120 min</td></tr></tbody></table></div></div><div class="NLM_p">Profiling of the other LOXL family members (<a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>) shows that <b>PXS-5120A</b> is a potent inhibitor of the LOXL3 enzyme and a moderate blocker of LOXL4. The reason for selectivity for the LOXL2/3 enzymes over LOXL4 is not immediately obvious. All three of these LOXL enzymes are closely related in terms of protein domains, expressing a signal peptide domain and four scavenger receptor cysteine-rich (SRCR) domains, in addition to their catalytically active LOX domain (in contrast to the LOX and LOXL1 isoforms that are secreted in a propeptide form devoid of SRCR domains). All three possess a high degree of homology at the C-terminal enzymatically active region of the peptide.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> Given the lack of structural information concerning the active forms of the LOX enzymes,<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a> comparisons of the active sites are limited to analysis of residues in the immediate vicinity of the LTQ cofactors and the copper binding domains. One potentially significant difference between the LOXL2/3 isoforms and LOXL4 is observed between the four conserved histidine residues in the copper binding domain, wherein the presence of negatively charged aspartate (LOXL2) and glutamate (LOXL3) residues is in contrast to a neutral glutamine residue in LOXL4. It is possible that these negatively charged residues impart a subtle structural change, leading to the observed preference of <b>PXS-5120A</b> for LOXL2/3 over LOXL4.</div><div class="NLM_p">Interestingly, LOXL3 has recently been implicated in the pathology of pulmonary fibrosis,<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> where it is thought to be involved in both the activation of fibroblasts, and the transition of fibroblasts to myofibroblasts. Upregulation of both LOXL2 and LOXL3 has also been observed in a carbon tetrachloride (CCl<sub>4</sub>)-driven rat model of liver fibrosis, suggesting that both enzymes may play a role in the development of acute hepatic injury as well.<a onclick="showRef(event, 'cit17b'); return false;" href="javascript:void(0);" class="ref cit17b">(17b)</a> These reports indicate that inhibition of LOXL2, with additional inhibition of LOXL3, would represent a more effective approach for disease modulation than targeting a single protein, and therefore have a higher chance in the successful treatment of fibrotic lung and liver disease.</div><div class="NLM_p"><b>PXS-5120A</b> displayed (a) time-dependent LOXL2 inhibition (apparent <i>K</i><sub><i>i</i></sub> = 83 nM and <i>k</i><sub>inact</sub> = 0.89 min<sup>–1</sup>) (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figures <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>A and <a href="/doi/suppl/10.1021/acs.jmedchem.9b01283/suppl_file/jm9b01283_si_001.pdf" class="ext-link">S2</a>); (b) substrate competition, in which increasing concentrations of the reference substrate, putrescine, reduced inhibition by <b>PXS-5120A</b> in a competitive manner (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>B) and (c) irreversible inhibition in jump dilution experiments, in which, after 100-fold dilution from a 30 × IC<sub>50</sub> concentration of the inhibitor, maximal inhibition (>80%) of the enzyme activity was maintained when substrate was re-introduced (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>C). To confirm that the mechanism of inactivation was indeed driven by the presence of the fluoroallylamine group on the warhead, the <i>des</i>-fluoro analogue <b>12n</b> was profiled head to head with <b>PXS-5120A</b> (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>D) in a bound LOXL2 washout assay. Monitoring the enzyme activity for 30 min after washout showed that <b>12n</b> had been mostly displaced, whereas <b>PXS-5120A</b> (and BAPN) prevented recovery of enzyme activity, reaffirming that the vinyl fluoride plays a critical role in the mechanism of inhibition of the enzyme. Furthermore, analysis of compound oxidation (in the absence of substrate) of <b>12n</b> versus <b>PXS-5120A</b> by LOXL2, in a similar manner to what has been described above for SSAO and plasma amine oxidase, shows that whereas <b>PXS-5120A</b> has no detectable substrate activity (oxidative turnover after 30 min relative to DMSO = 1), <b>12n</b> is turned over substantially (relative oxidation = 6 at 30 min). Taken together, these observations support the hypothesis that <b>PXS-5120A</b> acts as an irreversible inhibitor of LOXL2 through a mechanism based on the displacement of the fluorine atom from the fluoroallylamine warhead moiety. Further experiments [e.g., protein digest—liquid chromatography–mass spectrometry (LCMS) or X-ray crystallography] would be required to unequivocally prove the proposed mode of action of <b>PXS-5120A</b> and verify if it is covalently bound to the cofactor.</div><div class="NLM_p"><b>PXS-5120A</b> was found to be poorly absorbed and rapidly excreted in both rats and mice, leading to very low oral bioavailability (<1%, data not shown). <b>PXS-5129A</b>, however, was found to be readily absorbed following oral gavage, and once in the circulation, rapidly hydrolyzed to release <b>PXS-5120</b> (free base) in vivo, affording plasma concentrations well above the LOXL2 IC<sub>50</sub> (6 nM, equivalent to ∼3 ng/mL) for a prolonged period (>6 h) in mice, while remaining well below the IC<sub>50</sub> for LOX throughout (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>).</div><figure id="fig5" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-21/acs.jmedchem.9b01283/20191108/images/medium/jm9b01283_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-21/acs.jmedchem.9b01283/20191108/images/large/jm9b01283_0005.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Mouse plasma profile of <b>PXS-5120</b> (free base of <b>PXS-5120A</b>) after oral (20 mg/kg) administration of the corresponding ethyl ester, <b>PXS-5129A</b>. Pharmacokinetic analysis of <b>PXS-5129A</b> and <b>PXS-5120</b> in BALB/c mice, showing the hydrolysis of <b>PXS-5129A</b> in vivo to afford therapeutically relevant plasma concentrations of <b>PXS-5120</b>. The plasma concentrations of both <b>PXS-5129A</b> and <b>PXS-5120</b> were quantified by LCMS/MS. Each data point represents an average of 3 animals.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-21/acs.jmedchem.9b01283/20191108/images/large/jm9b01283_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01283&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">With the drug/pro-drug pairing of <b>PXS-5120A</b>/<b>5129A</b> in hand we next sought to test the theory that selective inhibition of LOXL2 (and LOXL3) over LOX could affect a therapeutic outcome in relevant models of disease where LOXL2 was either significantly upregulated or has been shown to play a clear role in the disease pathology through aberrant collagen cross-linking.</div><div class="NLM_p">To evaluate <b>PXS-5120A</b>/<b>PXS-5129A</b> as a potential therapy for hepatic injury, a 6-week carbon tetrachloride (CCl<sub>4</sub>)-induced mouse model of liver fibrosis was used, with both prophylactic (15 mg/kg, weeks 1–6, <i>n</i> = 12) and therapeutic (5 and 15 mg/kg, weeks 4–6, <i>n</i> = 15/group) once daily, oral administration of <b>PXS-5129A</b> employed. BAPN (2 mg/mL in drinking water, provided ad libitum and changed every second day for 6 weeks, <i>n</i> = 15) and imatinib<a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(47)</a> (orally dosed at 50 mg/kg, daily for weeks 1–6, <i>n</i> = 12) were included as controls. At the end of the study, 4% of the total liver area was fibrotic in the CCl<sub>4</sub>-no treatment group [as quantified by both Picro Sirius Red and α-smooth muscle actin (α-SMA) staining]. No beneficial effect was observed in the Picro Sirius Red readout with the positive controls (BAPN and imatinib) (see <a href="/doi/suppl/10.1021/acs.jmedchem.9b01283/suppl_file/jm9b01283_si_001.pdf" class="ext-link">Figure S3</a>), and only the lower dose of <b>PXS-5129A</b> showed a significant reduction in the fibrotic area. Given that Picro Sirius Red measures total collagen content (cross-linked and soluble), it is possible that the effects of the compound are underestimated by the overwhelming quantity of soluble collagen (i.e., although the total collagen content is unchanged, the proportion of cross-linked to soluble collagen is different). To account for this possible issue, the area of fibrosis was also quantified by staining for α-SMA, a marker of myofibroblast formation (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figures <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a> and <a href="/doi/suppl/10.1021/acs.jmedchem.9b01283/suppl_file/jm9b01283_si_001.pdf" class="ext-link">S4</a>). In this readout, both positive controls showed a strong anti-fibrotic effect when dosed prophylactically, suggesting that the mechanical stress on the myofibroblasts had been reduced. When dosed prophylactically, <b>PXS-5129A</b> also reduced the fibrotic area, similar to the positive controls. Additionally, therapeutic dosing effected a significant decrease in fibrosis at both 5 and 15 mg/kg doses. In this study, no significant effect on alanine aminotransferase (ALT) or aspartate aminotransferase (AST) liver function markers was observed for <b>PXS-5120A</b>/<b>PXS-5129A</b>, nor imatinib, whereas BAPN increased ALT and AST levels (<a href="/doi/suppl/10.1021/acs.jmedchem.9b01283/suppl_file/jm9b01283_si_001.pdf" class="ext-link">Figure S5</a>).</div><figure id="fig6" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-21/acs.jmedchem.9b01283/20191108/images/medium/jm9b01283_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-21/acs.jmedchem.9b01283/20191108/images/large/jm9b01283_0006.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Inhibition of CCl<sub>4</sub>-induced liver fibrosis by <b>PXS-5120A</b>/<b>PXS-5129A</b>. Quantitative measurement of fibrosis in a 6 week model of CCl<sub>4</sub>-induced liver fibrosis in BALB/c mice, and the anti-fibrotic effects of <b>PXS-5129A</b>, BAPN, and imatinib. The area of fibrosis was quantified by staining for α-SMA and is measured as a percentage of the total liver area. <b>PXS-5129A</b> reduces fibrosis when dosed both prophylactically at 15 mg/kg (6 weeks, blue bar) and therapeutically at 5 and 15 mg/kg (weeks 4–6, green bars). Results are expressed as mean ± SEM. #<i>p</i> < 0.05, ##<i>p</i> < 0.01 and ###<i>p</i> < 0.001, vs group 2 (CCl<sub>4</sub> + vehicle); data analysis was performed by one-way ANOVA followed by Dunnett’s multiple comparison test.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-21/acs.jmedchem.9b01283/20191108/images/large/jm9b01283_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01283&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p"><b>PXS-5120A</b>/<b>PXS-5129A</b> was also evaluated in a 28 day bleomycin-induced mouse model of lung fibrosis, using therapeutic (5 and 15 mg/kg, days 7–27, <i>n</i> = 12/group) once daily, ip administration of <b>PXS-5129A</b>. Imatinib (50 mg/kg, days 7–27, <i>n</i> = 12) was again included as a positive control.<a onclick="showRef(event, 'ref48'); return false;" href="javascript:void(0);" class="ref ref48">(48)</a> An increase in fibrosis, as measured by the Ashcroft score,<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a> was observed at day 28 and therapeutic treatment with imatinib (50 mg/kg ip) afforded a small but significant reduction (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figures <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a> and <a href="/doi/suppl/10.1021/acs.jmedchem.9b01283/suppl_file/jm9b01283_si_001.pdf" class="ext-link">S6</a>). <b>PXS-5129A</b> resulted in a dose-dependent reduction of the Ashcroft score, with the 15 mg/kg dose reaching similar effect size to the positive control imatinib. The anti-fibrotic reduction seen with imatinib in this instance is consistent with the reported effects of this drug; however, the extent of the anti-fibrotic effect of imatinib is muted compared to historical data (a reduction of 50–70% is reported).<a onclick="showRef(event, 'ref48'); return false;" href="javascript:void(0);" class="ref ref48">(48)</a> Given the variability of this model (potency of bleomycin used, route and frequency of administration, strain and age of mice used, etc.), this disparity is not unexpected, and the model serves to re-inforce the therapeutic potential of <b>PXS-5129A</b> in models of fibrotic disease.</div><figure id="fig7" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-21/acs.jmedchem.9b01283/20191108/images/medium/jm9b01283_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-21/acs.jmedchem.9b01283/20191108/images/large/jm9b01283_0007.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Inhibition of bleomycin-induced lung fibrosis by <b>PXS-5120A</b>/<b>PXS-5129A</b>. Determination of the anti-fibrotic effects of <b>PXS-5129A</b> and imatinib in a 28 day bleomycin-induced lung fibrosis in C57BL/6 mice. Analysis of the amount of fibrosis as measured by the Ashcroft score.<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a><b>PXS-5129A</b> reduces fibrosis when dosed therapeutically at 15 mg/kg (from day 7 onwards, blue bars). Results are expressed as mean ± SEM. #<i>p</i> < 0.05, ##<i>p</i> < 0.01 and ###<i>p</i> < 0.001, vs group 2 (bleo + vehicle); data analysis was performed by one-way ANOVA followed by Dunnett’s multiple comparison test.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-21/acs.jmedchem.9b01283/20191108/images/large/jm9b01283_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01283&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i12">Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_13373" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_13373" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">In summary, we have identified a fluoroallylamine-based lead (<b>4</b>), with inhibitory activity against SSAO, LOX, and LOXL2, which has been further developed into a potent and selective inhibitor of LOXL2 (and LOXL3). Rapid exploration for additional pharmacophoric interaction points was carried out by a “Click-Chemistry” approach, resulting in the identification of a dimethyl sulfonamide as a key recognition feature required for LOXL2 potency. The potential for turnover by the related amine oxidases, SSAO and plasma amine oxidase, led us to develop a compound oxidation assay for these enzymes, which subsequently aided in the identification of the 2-methylindole core with decreased SSAO substrate activity.</div><div class="NLM_p">Modification of the 5-position of the indole proved most effective for further optimizing LOXL2 potency and eliminating plasma amine oxidase-mediated turnover of these compounds. This afforded <b>PXS-5120A</b>, an irreversible inhibitor of LOXL2 with single-digit nanomolar potency for LOXL2, the most potent LOXL2 inhibitor reported to date. Importantly for both liver and lung diseases, the additional inhibition of LOXL3 activity affords a dual inhibitor with an increased chance of reducing fibrosis in disease states.</div><div class="NLM_p"><b>PXS-5120A</b> is selective (∼300-fold) over the related LOX enzyme, which is believed to be vital for maintaining the structural integrity of the skin, heart, and bone function. Equally <b>PXS-5120A</b> shows no off-target inhibition of the related amine oxidases and, importantly, is not recognized as a substrate by either SSAO or plasma amine oxidase (the <i>AOC4</i> gene product), affording a metabolically stable compound in vitro, well suited for assessing the in vivo potential of LOXL2/LOXL3 inhibition.</div><div class="NLM_p">As the zwitterionic nature of the compound rendered it unsuitable for direct oral administration, a pro-drug approach was employed, and the administration of <b>PXS-5129A</b> (the corresponding ethyl ester derivative of <b>PXS-5120A</b>) in two different animal models of disease successfully demonstrated the promise of selective LOXL2/3 inhibition for the treatment of liver and lung fibrosis at doses as low as 5 mg/kg.</div><div class="NLM_p last">Further progress regarding mechanism-based, orally bioavailable (without the need for a pro-drug) inhibitors of LOXL2/3 with a fast onset of inhibition and sustained target occupancy will be reported in due course.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i13">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_71715" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_71715" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i14" class="anchor-spacer"></div><h3 class="article-section__title" id="_i14"> Chemistry General Methods</h3><div class="NLM_p">Purity was determined by HPLC and <sup>1</sup>H NMR. Unless otherwise stated, the purity of final compounds was ≥95%. HPLC spectra were recorded on an Agilent LCMS 1100 instrument using reverse-phase conditions (acetonitrile/water, containing 0.1% formic acid). <sup>1</sup>H NMR and <sup>19</sup>F NMR spectra were recorded using a Bruker 300 MHz NMR spectrometer. Chemical shifts (δ) are reported as parts per million (ppm) relative to tetramethylsilane (internal standard). All commercially available solvents and reagents were used as received. Where appropriate, reactions were carried out under an argon atmosphere. Reactions were monitored by either analytical thin-layer chromatography or by LCMS. Flash column chromatography was conducted under medium pressure either on silica (Merck silica gel 40–63 μm) or on prepacked silica gel cartridges using a flash chromatography system (CombiFlash Rf200, Teledyne Isco systems, USA), and eluents were monitored by UV light (λ = 254/280 nm). Low-resolution mass spectra (MS) were obtained as electrospray–atmospheric pressure ionization mass spectra, which were recorded on an Agilent LCMS 1100 instrument using reverse-phase conditions (acetonitrile/water, containing 0.1% formic acid). Melting points were obtained using a MEL-TEMP Electrothermal melting point apparatus. All animal experiments performed were conducted in compliance with institutional guidelines and approval from local ethics committees. The general chemical methods outlined in the experimental are exemplified for the more important molecules and may therefore be referred to before they are described in detail.</div><div id="sec4_1_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i15" class="anchor-spacer"></div><h4 class="article-section__title" id="_i15"> (<i>S</i>,<i>Z</i>)-4-(4-Amino-2-fluorobut-2-enyloxy)-<i>N</i>-(1-phenyl ethyl)benzenesulfonamide (<b>5</b>)</h4><div class="NLM_p last">It was synthesized using chemistry outlined in ref <a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(44)</a>.</div></div><div id="sec4_1_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i16" class="anchor-spacer"></div><h4 class="article-section__title" id="_i16"> (<i>Z</i>)-<i>tert</i>-Butyl 3-Fluoro-4-hydroxybut-2-enylcarbamate (<b>7</b>)</h4><div class="NLM_p">To a stirring solution of 3-amino-1,2-propanediol (20.0 g, 0.22 mol) in water (200 mL) at 0–5 °C was added di-<i>tert</i>-butyl dicarbonate (55.5 mL, 0.24 mol). After adjusting the alkalinity of the solution to pH ≈ 9 by addition of aq NaOH (6 N), the mixture was left to stir at rt for 18 h. The reaction mixture was cooled to 0–5 °C and then acidified to pH ≈ 6 before the addition of sodium metaperiodate (56.3 g, 0.26 mol). The resulting suspension was stirred at rt for 2 h. The mixture was filtered to remove all solids, and the filtrate was transferred to a separatory funnel and extracted with ethyl acetate (200 mL). Sodium chloride was added to the aqueous layer until a saturated solution was obtained. The aqueous layer was then extracted further with ethyl acetate (100 mL). The combined organics were dried over Na<sub>2</sub>SO<sub>4</sub> and then concentrated in vacuo to give crude <i>tert</i>-butyl 2-oxoethylcarbamate (45.7 g) as a yellow gum. The crude material was used in the subsequent step without purification.</div><div class="NLM_p">To a stirring suspension of crude <i>tert</i>-butyl 2-oxoethylcarbamate (43.7 g, 0.22 mol) and magnesium sulfate (32.0 g) in acetonitrile (200 mL) at 0 °C under N<sub>2</sub> were added sequentially ethyl 2-fluorophosphonoacetate (55.7 mL, 0.27 mol) and 1,8-diazabicyclo[5.4.0]undec-7-ene (32.8 mL, 0.22 mol). The reaction mixture was allowed to warm to rt, and stirring was continued for 3 h. After removing the solvent under reduced pressure, the residue was taken up in ethyl acetate (200 mL) and then transferred to a separatory funnel. The organics were washed successively with aq HCl (2 M; 100 mL × 2), aq NaOH (2 M; 100 mL × 2), and brine (100 mL). After drying over MgSO<sub>4</sub>, the organics were concentrated in vacuo to give the crude, desired product as a mixture of <i>E</i>/<i>Z</i> isomers (2:3; 57.0 g). This crude material was progressed to the next step without purification.</div><div class="NLM_p last">To a stirring solution of crude <i>E</i>/<i>Z</i>-ethyl 4-(<i>tert</i>-butoxycarbonylamino)-2-fluorobut-2-enoate (18.0 g, 72.8 mmol) in THF (150 mL) at 0 °C under N<sub>2</sub> was added diisobutylaluminum hydride (1 M in toluene, 182 mL, 182 mmol) dropwise over 45 min. After complete addition, the mixture was left to stir at 0 °C for 3 h. The reaction mixture was transferred to a separatory funnel and added dropwise to a stirring mixture of ice (100 g) and aq NaOH (2 M; 200 mL). The mixture was stirred for 2 h. The quenched reaction mixture was extracted with diethyl ether (100 mL × 2), and the combined organics were washed with brine (100 mL). After drying over MgSO<sub>4</sub>, the organics were concentrated in vacuo to give the crude alcohol as a mixture of <i>E</i>/<i>Z</i> isomers. This mixture was purified over silica gel (135 g), eluting with 25% ethyl acetate in <i>n</i>-hexane to give (<i>Z</i>)-<i>tert</i>-butyl 3-fluoro-4-hydroxybut-2-enylcarbamate (<b>7</b>; 6.20 g, 30% over three steps) and (<i>E</i>)-<i>tert</i>-butyl 3-fluoro-4-hydroxybut-2-enylcarbamate (1.85 g, 8.9% over three steps). (<i>Z</i>)-<i>tert</i>-Butyl 3-fluoro-4-hydroxybut-2-enylcarbamate (<b>7</b>): <sup>1</sup>H NMR (300 MHz; CDCl<sub>3</sub>): δ ppm 1.46 (9H, s), 3.84 (2H, dd, <i>J</i> = 6.2, 6.2 Hz), 4.13 (2H, d, <i>J</i> = 13.9 Hz), 4.68 (1H, br s), 5.03 (1H, dt, <i>J</i> = 36.0, 7.1 Hz). (<i>E</i>)-<i>tert</i>-Butyl 3-fluoro-4-hydroxybut-2-enylcarbamate: <sup>1</sup>H NMR (200 MHz; CDCl<sub>3</sub>): δ ppm 1.43 (9H, s), 3.72 (2H, dd, <i>J</i> = 7.5, 5.4 Hz), 4.25 (2H, d, <i>J</i> = 21.5 Hz), 4.85 (1H, br s), 5.18 (1H, dt, <i>J</i> = 19.2, 8.5 Hz).</div></div><div id="sec4_1_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i17" class="anchor-spacer"></div><h4 class="article-section__title" id="_i17"> (<i>Z</i>)-<i>tert</i>-Butyl 4-Bromo-3-fluorobut-2-enylcarbamate (<b>8</b>)</h4><div class="NLM_p last">To a stirring solution of (<i>Z</i>)-<i>tert</i>-butyl 3-fluoro-4-hydroxybut-2-enylcarbamate (<b>7</b>, 6.20 g, 30.2 mmol) and triethylamine (6.32 mL, 45.3 mmol) in acetone (100 mL) at 0 °C was added methanesulfonyl chloride (2.81 mL, 36.3 mmol) dropwise. After complete addition, the mixture was left to stir at 0 °C for 30 min. After this time, lithium bromide (13.1 g, 0.15 mol) was added portion-wise, and the resulting suspension was stirred for a further 2 h. The reaction mixture was filtered to remove all solids, and the filtrate was concentrated under reduced pressure. The residue was partitioned between water (50 mL) and CH<sub>2</sub>Cl<sub>2</sub> (50 mL), and the aqueous layer was extracted with further CH<sub>2</sub>Cl<sub>2</sub> (50 mL × 2). The combined organics were dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated in vacuo. The crude residue was purified over silica gel (100 g) eluting with <i>n</i>-hexane followed by 25% ethyl acetate in <i>n</i>-hexane to afford (<i>Z</i>)-<i>tert</i>-butyl 4-bromo-3-fluorobut-2-enylcarbamate (<b>8</b>; 7.00 g, 86%) as a colorless solid. <sup>1</sup>H NMR (300 MHz; CDCl<sub>3</sub>): δ ppm 1.46 (9H, s), 3.85 (2H, dd, <i>J</i> = 6.2, 6.2 Hz), 3.96 (2H, d, <i>J</i> = 19.5 Hz), 4.66 (1H, br s), 5.16 (1H, dt, <i>J</i> = 34.0, 6.5 Hz). <sup>19</sup>F NMR (282 MHz; CDCl<sub>3</sub>): δ ppm −112.03.</div></div><div id="sec4_1_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i18" class="anchor-spacer"></div><h4 class="article-section__title" id="_i18"> (<i>Z</i>)-<i>tert</i>-Butyl 4-Azido-3-fluorobut-2-enylcarbamate (<b>9</b>)</h4><div class="NLM_p last">To a stirring solution of (<i>Z</i>)-<i>tert</i>-butyl 4-bromo-3-fluorobut-2-enylcarbamate (<b>8</b>) (500 mg, 1.86 mmol) in acetone (10 mL) was added sodium azide (606 mg, 9.32 mmol). The resulting suspension was stirred at rt overnight. The reaction mixture was filtered, and the filter cake was washed with acetone. The filtrate was concentrated under vacuum, and the residue was taken up in ethyl acetate (40 mL) and transferred to a separatory funnel. The organic layer was washed successively with water (20 mL) and brine (20 mL) and then dried over Na<sub>2</sub>SO<sub>4</sub>. After removal of the solvent in vacuo, (<i>Z</i>)-<i>tert</i>-butyl 4-azido-3-fluorobut-2-enylcarbamate (460 mg, 100%) was obtained as a colorless oil. This material was used without purification. <sup>1</sup>H NMR (300 MHz; CDCl<sub>3</sub>): δ ppm 1.46 (9H, s), 3.82 (2H, d, <i>J</i> = 16.4 Hz), 3.83–3.91 (2H, m), 4.66 (1H, br s), 5.06 (1H, dt, <i>J</i> = 35.1, 6.8 Hz).</div></div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i19" class="anchor-spacer"></div><h3 class="article-section__title" id="_i19"> Triazole-Linked Examples</h3><div class="NLM_p">Compounds <b>10a–10k</b> were synthesized from commercially available phenols according to general methods A and E or F. These compounds were generated as part of a combinatorial library wherein only final compounds with a purity of ≥80% were tested in the primary screening assays. Where primary potency for LOXL2 was <100 nM (i.e., pIC<sub>50</sub> > 7.0), compounds were either remade or re-purified to ensure that final potency was ≥95%.</div><div id="sec4_2_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i20" class="anchor-spacer"></div><h4 class="article-section__title" id="_i20"> General Method A: Preparation of <i>N</i>,<i>N</i>-Dimethyl-4-prop-2-ynoxy-benzenesulfonamide</h4><div class="NLM_p">To 4-Hydroxy-<i>N</i>,<i>N</i>-dimethyl-benzenesulfonamide (150 mg, 0.75 mmol) and potassium carbonate (515 mg, 3.73 mmol) in MeCN (8 mL) was added propargyl bromide (80% in toluene) (0.25 mL, 2.24 mmol), and the resulting suspension was heated at 60 °C overnight. The reaction mixture was filtered, and the filtrate was concentrated in vacuo. The residue was taken up in ethyl acetate (50 mL) and transferred to a separatory funnel. The organic layer was washed with water followed by brine then dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated in vacuo to give <i>N</i>,<i>N</i>-dimethyl-4-prop-2-ynoxy-benzenesulfonamide (160 mg, 90%) as a yellow oil. <sup>1</sup>H NMR (300 MHz; CDCl<sub>3</sub>): δ ppm 2.60 (1H, t, <i>J</i> = 2.4 Hz), 2.71 (6H, s), 4.79 (2H, d, <i>J</i> = 2.4 Hz), 7.12 (2H, d, <i>J</i> = 6.0 Hz), 7.75 (2H, d, <i>J</i> = 6.0 Hz).</div><div class="NLM_p last">To a stirred solution of <i>N</i>,<i>N</i>-dimethyl-4-prop-2-ynoxy-benzenesulfonamide (66 mg, 0.28 mmol) in <i>t</i>-BuOH (1 mL) and water (1 mL) were added sodium ascorbate (1 M in water) (0.1 mL, 0.1 mmol) and copper sulfate pentahydrate (1 M in water) (25 μL, 0.025 mmol), followed by a solution of <i>tert</i>-butyl <i>N</i>-[(<i>Z</i>)-4-azido-3-fluoro-but-2-enyl]carbamate (<b>9</b>) (58 mg, 0.25 mmol) in <i>t</i>-BuOH (0.5 mL). The resulting solution was then stirred at rt overnight. The reaction mixture was partitioned between ethyl acetate and water, and the organic layer was washed with brine and then dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated in vacuo. The crude residue was purified over silica gel eluting with 50–100% EtOAc/hexane. Product <i>tert</i>-butyl <i>N</i>-[(<i>Z</i>)-4-[4-[[4-(dimethyl-sulfamoyl)phenoxy]methyl]triazol-1-yl]-3-fluoro-but-2-enyl]carbamate (84 mg, 72%) was obtained as a colorless gum. <sup>1</sup>H NMR (300 MHz; CDCl<sub>3</sub>): δ ppm 2.69 (6H, d, <i>J</i> = 0.9 Hz), 3.86 (2H, t, <i>J</i> = 6.6 Hz), 4.76 (1H, s), 5.07 (2H, d, <i>J</i> = 16.6 Hz), 5.28 (3H, m), 7.09 (2H, d, <i>J</i> = 6.0 Hz), 7.74 (2H, d, <i>J</i> = 6.0 Hz), 7.78 (1H, s).</div></div><div id="sec4_2_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i21" class="anchor-spacer"></div><h4 class="article-section__title" id="_i21"> (<i>Z</i>)-3-Fluoro-4-(4-(phenoxymethyl)-1<i>H</i>-1,2,3-triazol-1-yl)but-2-en-1-amine Hydrochloride (<b>10a</b>)</h4><div class="NLM_p last">It was obtained as an off-white solid; <sup>1</sup>H NMR (300 MHz; DMSO-<i>d</i><sub>6</sub>): δ ppm 3.45–3.57 (2H, m), 5.15 (2H, s), 5.38 (2H, d, <i>J</i> = 17.6 Hz), 5.43 (1H, dt, <i>J</i> = 35.3, 7.3 Hz), 6.96 (1H, dd, <i>J</i> = 7.3, 7.3 Hz), 7.04 (2H, d, <i>J</i> = 7.8 Hz), 7.31 (2H, dd, <i>J</i> = 7.4, 8.6 Hz), 8.31 (1H, s). LCMS <i>m</i>/<i>z</i>: 263.0 (MH<sup>+</sup>). Purity 89%.</div></div><div id="sec4_2_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i22" class="anchor-spacer"></div><h4 class="article-section__title" id="_i22"> (<i>Z</i>)-4-(4-((4-<i>tert</i>-Butylphenoxy)methyl)-1<i>H</i>-1,2,3-triazol-1-yl)-3-fluorobut-2-en-1-amine Hydrochloride (<b>10b</b>)</h4><div class="NLM_p last">It was obtained as a brown solid; <sup>1</sup>H NMR (300 MHz; DMSO-<i>d</i><sub>6</sub>): δ ppm 1.25 (9H, s), 3.45–3.57 (2H, m), 5.12 (2H, s), 5.38 (2H, d, <i>J</i> = 17.5 Hz), 5.42 (1H, dt, <i>J</i> = 35.3, 7.3 Hz), 6.95 (2H, d, <i>J</i> = 8.9 Hz), 7.30 (2H, d, <i>J</i> = 8.9 Hz), 8.27 (2H, br s), 8.30 (1H, s). Purity 87%.</div></div><div id="sec4_2_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i23" class="anchor-spacer"></div><h4 class="article-section__title" id="_i23"> (<i>Z</i>)-3-Fluoro-4-(4-((4-(methylsulfonyl)phenoxy)methyl)-1<i>H</i>-1,2,3-triazol-1-yl)but-2-en-1-amine Hydrochloride (<b>10c</b>)</h4><div class="NLM_p last">It was obtained as an off-white solid; <sup>1</sup>H NMR (300 MHz; DMSO-<i>d</i><sub>6</sub>): δ ppm 3.17 (3H, s), 3.46–3.57 (2H, m), 5.30 (2H, s), 5.40 (2H, d, <i>J</i> = 17.6 Hz), 5.41 (1H, dt, <i>J</i> = 35.2, 7.4 Hz), 7.28 (2H, d, <i>J</i> = 8.9 Hz), 7.86 (2H, d, <i>J</i> = 8.9 Hz), 8.19 (2H, br s), 8.36 (1H, s).</div></div><div id="sec4_2_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i24" class="anchor-spacer"></div><h4 class="article-section__title" id="_i24"> (<i>Z</i>)-3-Fluoro-4-(4-((2-(methylsulfonyl)phenoxy)methyl)-1<i>H</i>-1,2,3-triazol-1-yl)but-2-en-1-amine Hydrochloride (<b>10d</b>)</h4><div class="NLM_p last">It was obtained as an off-white solid; <sup>1</sup>H NMR (300 MHz; DMSO-<i>d</i><sub>6</sub>): δ ppm 3.24 (3H, s), 3.46–3.58 (2H, m), 5.32–5.51 (5H, m), 7.20 (1H, ddd, <i>J</i> = 7.7, 7.7, 1.0 Hz), 7.52 (1H, d, <i>J</i> = 7.8 Hz), 7.72 (1H, ddd, <i>J</i> = 7.4, 8.4, 1.8 Hz), 7.82 (1H, dd, <i>J</i> = 7.8, 1.8 Hz), 8.34 (1H, s). Purity 86%.</div></div><div id="sec4_2_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i25" class="anchor-spacer"></div><h4 class="article-section__title" id="_i25"> (<i>Z</i>)-3-Fluoro-4-(4-((3-(methylsulfonyl)phenoxy)methyl)-1<i>H</i>-1,2,3-triazol-1-yl)but-2-en-1-amine Hydrochloride (<b>10e</b>)</h4><div class="NLM_p last">It was obtained as an off-white solid; <sup>1</sup>H NMR (300 MHz; DMSO-<i>d</i><sub>6</sub>): δ ppm 3.24 (3H, s), 3.47–3.58 (2H, m), 5.30 (2H, s), 5.40 (1H, dt, <i>J</i> = 35.2, 7.3 Hz), 5.40 (2H, d, <i>J</i> = 17.6 Hz), 7.41 (1H, ddd, <i>J</i> = 8.1, 2.5, 1.1 Hz), 7.48–7.63 (3H, m), 8.12 (2H, br s), 8.33 (1H, s). Purity 86%.</div></div><div id="sec4_2_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i26" class="anchor-spacer"></div><h4 class="article-section__title" id="_i26"> (<i>Z</i>)-4-((1-(4-Amino-2-fluorobut-2-enyl)-1<i>H</i>-1,2,3-triazol-4-yl)methoxy)-<i>N</i>,<i>N</i>-dimethylbenzamide Hydrochloride (<b>10f</b>)</h4><div class="NLM_p last">It was obtained as an off-white solid; <sup>1</sup>H NMR (300 MHz; DMSO-<i>d</i><sub>6</sub>): δ ppm 2.95 (6H, s), 3.48–3.59 (2H, m), 5.22 (2H, s), 5.37 (1H, dt, <i>J</i> = 35.0, 7.4 Hz), 5.39 (2H, d, <i>J</i> = 17.3 Hz), 7.08 (2H, d, <i>J</i> = 8.8 Hz), 7.39 (2H, d, <i>J</i> = 8.8 Hz), 8.04 (2H, br s), 8.30 (1H, s). LCMS <i>m</i>/<i>z</i>: 334.2 (MH<sup>+</sup>). Purity 84%.</div></div><div id="sec4_2_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i27" class="anchor-spacer"></div><h4 class="article-section__title" id="_i27"> (<i>Z</i>)-4-((1-(4-Amino-2-fluorobut-2-enyl)-1<i>H</i>-1,2,3-triazol-4-yl)methoxy)-<i>N</i>,<i>N</i>-dimethylbenzenesulfonamide Hydrochloride (<b>10g</b>)</h4><div class="NLM_p last">It was obtained as a white solid; mp 200–202 °C; <sup>1</sup>H NMR (300 MHz; DMSO-<i>d</i><sub>6</sub>): δ ppm 2.57 (6H, s), 3.46–3.57 (2H, m), 5.29 (2H, s), 5.40 (2H, d, <i>J</i> = 17.7 Hz), 5.43 (1H, dt, <i>J</i> = 35.3, 7.3 Hz), 7.29 (2H, d, <i>J</i> = 8.9 Hz), 7.70 (2H, d, <i>J</i> = 8.9 Hz), 8.23 (2H, br s), 8.37 (1H, s). <sup>19</sup>F NMR (282 MHz; DMSO-<i>d</i><sub>6</sub>): δ ppm −109.6. LCMS <i>m</i>/<i>z</i>: 370.0 (MH<sup>+</sup>).</div></div><div id="sec4_2_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i28" class="anchor-spacer"></div><h4 class="article-section__title" id="_i28"> (<i>Z</i>)-4-((1-(4-Amino-2-fluorobut-2-enyl)-1<i>H</i>-1,2,3-triazol-4-yl)methoxy)-3-chloro-<i>N</i>,<i>N</i>-dimethylbenzenesulfonamide Hydrochloride (<b>10h</b>)</h4><div class="NLM_p last">It was obtained as a white solid; mp 110–112 °C; <sup>1</sup>H NMR (300 MHz; DMSO-<i>d</i><sub>6</sub>): δ ppm 2.62 (6H, s), 3.53 (2H, m), 5.32–5.49 (5H, m), 7.64 (1H, d, <i>J</i> = 8.7 Hz), 7.72–7.77 (2H, m), 8.08 (3H, br s), 8.37 (1H, s). <sup>19</sup>F NMR (282 MHz; DMSO-<i>d</i><sub>6</sub>): δ ppm −109.6. LCMS <i>m</i>/<i>z</i>: 404.0/406.0 (MH<sup>+</sup>).</div></div><div id="sec4_2_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i29" class="anchor-spacer"></div><h4 class="article-section__title" id="_i29"> (<i>Z</i>)-4-((1-(4-Amino-2-fluorobut-2-enyl)-1<i>H</i>-1,2,3-triazol-4-yl)methylamino)-<i>N</i>,<i>N</i>-dimethylbenzene Sulfonamide Hydrochloride (<b>10i</b>)</h4><div class="NLM_p last">It was obtained as a white solid; <sup>1</sup>H NMR (300 MHz; DMSO-<i>d</i><sub>6</sub>): δ ppm 2.52 (6H, s), 3.45–3.56 (2H, m), 4.40 (2H, s), 5.33 (2H, d, <i>J</i> = 17.2 Hz), 5.37 (1H, dt, <i>J</i> = 35.2, 7.2 Hz), 6.79 (2H, d, <i>J</i> = 8.9 Hz), 7.43 (2H, d, <i>J</i> = 8.8 Hz), 8.08 (1H, s), 8.16 (2H, br s). LCMS <i>m</i>/<i>z</i>: 369.0 (MH<sup>+</sup>).</div></div><div id="sec4_2_11" class="NLM_sec NLM_sec_level_3"><div id="ac_i30" class="anchor-spacer"></div><h4 class="article-section__title" id="_i30"> (<i>Z</i>)-4-((1-(4-Amino-2-fluorobut-2-en-1-yl)-1<i>H</i>-1,2,3-triazol-4-yl)methyl)-<i>N</i>,<i>N</i>-dimethylbenzenesulfonamide Hydrochloride (<b>10j</b>)</h4><div class="NLM_p last">It was obtained as a white solid. <sup>1</sup>H NMR (300 MHz; CD<sub>3</sub>OD): δ ppm 2.68 (6H, s), 3.67 (2H, d, <i>J</i> = 7.5 Hz), 4.20 (2H, s), 5.27–5.43 (3H, m), 7.53 (2H, d, <i>J</i> = 8.1 Hz), 7.74 (2H, d, <i>J</i> = 8.1 Hz), 7.91 (1H, br s). LCMS <i>m</i>/<i>z</i>: 354.0 (MH<sup>+</sup>).</div></div><div id="sec4_2_12" class="NLM_sec NLM_sec_level_3"><div id="ac_i31" class="anchor-spacer"></div><h4 class="article-section__title" id="_i31"> (<i>Z</i>)-4-(1-(4-Amino-2-fluorobut-2-en-1-yl)-1<i>H</i>-1,2,3-triazol-4-yl)-<i>N</i>,<i>N</i>-dimethylbenzenesulfonamide Hydrochloride (<b>10k</b>)</h4><div class="NLM_p">It was obtained as a sticky white solid. <sup>1</sup>H NMR (300 MHz; CD<sub>3</sub>OD): δ ppm 2.73 (6H, s), 3.71 (2H, d, <i>J</i> = 7.2 Hz), 5.33–5.49 (3H, m), 7.88 (2H, d, <i>J</i> = 6.6 Hz), 8.10 (2H, d, <i>J</i> = 6.6 Hz), 8.59 (1H, s). LCMS <i>m</i>/<i>z</i>: 340.0 (MH<sup>+</sup>).</div><div class="NLM_p last">Compounds <b>11a</b> and <b>11b</b> were synthesized starting from the commercially available <i>tert</i>-butyl 3-bromo-1<i>H</i>-pyrrole-1-carboxylate according to general methods B and E.</div></div><div id="sec4_2_13" class="NLM_sec NLM_sec_level_3"><div id="ac_i32" class="anchor-spacer"></div><h4 class="article-section__title" id="_i32"> (<i>Z</i>)-4-(1-(4-Amino-2-fluorobut-2-en-1-yl)-1<i>H</i>-pyrrol-3-yl)-<i>N</i>,<i>N</i>-dimethylbenzenesulfonamide Hydrochloride (<b>11a</b>)</h4><div class="NLM_p last">It was obtained as a sticky white solid. <sup>1</sup>H NMR (300 MHz; CD<sub>3</sub>OD): δ ppm 2.72 (6H, s), 3.66 (2H, d, <i>J</i> = 7.5 Hz), 4.81 (2H, partially obscured by H<sub>2</sub>O), 5.08 (1H, dt, <i>J</i> = 33.3, 7.2 Hz), 6.60 (1H, m), 6.87 (1H, m), 7.33 (1H, m), 7.69–7.76 (4H, m). LCMS <i>m</i>/<i>z</i>: 338.0 (MH<sup>+</sup>). Purity 91%.</div></div><div id="sec4_2_14" class="NLM_sec NLM_sec_level_3"><div id="ac_i33" class="anchor-spacer"></div><h4 class="article-section__title" id="_i33"> (<i>Z</i>)-3-(1-(4-Amino-2-fluorobut-2-en-1-yl)-1<i>H</i>-pyrrol-3-yl)-<i>N</i>,<i>N</i>-dimethylbenzenesulfonamide Hydrochloride (<b>11b</b>)</h4><div class="NLM_p last">It was obtained as a sticky yellow solid. <sup>1</sup>H NMR (300 MHz; CD<sub>3</sub>OD): δ ppm 2.70 (6H, s), 3.66 (2H, d, <i>J</i> = 7.5 Hz), 4.83 (2H, partially obscured by H<sub>2</sub>O), 5.09 (1H, dt, <i>J</i> = 33.0, 7.5 Hz), 6.55 (1H, m), 6.86 (1H, m), 7.29 (1H, m), 7.32–7.58 (2H, m), 7.79–7.84 (2H, m). LCMS <i>m</i>/<i>z</i>: 338.0 (MH<sup>+</sup>). Purity 93%.</div></div></div><div id="sec4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i34" class="anchor-spacer"></div><h3 class="article-section__title" id="_i34"> Indole-Linked Examples</h3><div class="NLM_p">Compounds <b>12a</b>, <b>b</b>, <b>f</b>, <b>g</b>, <b>h</b>, <b>i</b>, and <b>j</b> were synthesized from commercially available indoles according to general methods B and E. Compounds <b>12c</b>, <b>d</b>, and <b>e</b> were synthesized from commercially available indoles according to general methods B, C, D, and E. Compounds <b>12k</b> (<b>PXS-5120A</b>) and <b>12l</b> were synthesized from commercially available indoles according to general methods B, C, and F. Compound <b>12m</b> was synthesized from commercially available 2-methyl-1<i>H</i>-indole-5-carbonitrile according to general method B followed by cycloaddition with sodium azide,<a onclick="showRef(event, 'ref50'); return false;" href="javascript:void(0);" class="ref ref50">(50)</a> prior to removal of the Boc group according to general method E. Compound <b>12n</b> (<i>des</i>-fluoro analogue of <b>PXS-5120A</b>) was synthesized from the commercially available indole and 1-(<i>tert</i>-butoxycarbonylamino)-4-bromo-2-butene<a onclick="showRef(event, 'ref51'); return false;" href="javascript:void(0);" class="ref ref51">(51)</a> according to general methods B, C, and F. Compound <b>12o</b> (<b>PXS-5129A</b>) was synthesized from the commercially available indole ethyl 2-methyl-1<i>H</i>-indole-5-carboxylate according to general methods B and G.</div><div id="sec4_3_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i35" class="anchor-spacer"></div><h4 class="article-section__title" id="_i35"> General Method B: Preparation of (<i>Z</i>)-Ethyl 1-(4-((<i>tert</i>-Butoxycarbonyl)amino)-2-fluorobut-2-en-1-yl)-3-(3-(<i>N</i>,<i>N</i>-dimethylsulfamoyl)phenyl)-2-methyl-1<i>H</i>-indole-5-carboxylate</h4><div class="NLM_p">To a stirred solution of ethyl 2-methyl-1<i>H</i>-indole-5-carboxylate (500 mg, 2.46 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (15 mL) at rt under nitrogen was added <i>N</i>-bromosuccinimide (460 mg, 2.58 mmol) in one lot. The resulting mixture was stirred at rt for 1 h and then cooled to 0 °C before the addition of 4-(dimethylamino) pyridine (300 mg, 2.46 mmol) followed by a solution of di-<i>tert</i>-butyl dicarbonate (1.07 g, 4.90 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (5 mL). The mixture was allowed to slowly warm to rt over 1 h, concentrated in vacuo, and purified over silica gel (40 g), eluting with 10% ethyl acetate in <i>n</i>-hexane, to afford 1-<i>tert</i>-butyl 5-ethyl 3-bromo-2-methyl-1<i>H</i>-indole-1,5-dicarboxylate (760 mg, 81%) as a white solid. <sup>1</sup>H NMR (300 MHz; CDCl<sub>3</sub>): δ ppm 1.45 (3H, t, <i>J</i> = 7.2 Hz), 1.71 (9H, s), 2.68 (3H, s), 4.44 (2H, q, <i>J</i> = 7.2 Hz), 8.02 (1H, dd, <i>J</i> = 9.0, 1.8 Hz), 8.16 (1H, d, <i>J</i> = 9.0 Hz), 8.19 (1H, d, <i>J</i> = 1.8 Hz).</div><div class="NLM_p">A stirred solution of 1-<i>tert</i>-butyl 5-ethyl 3-bromo-2-methyl-1<i>H</i>-indole-1,5-dicarboxylate (900 mg, 2.35 mmol), <i>N</i>,<i>N</i>-dimethyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzenesulfonamide (186 mg, 0.60 mmol), aqueous potassium carbonate (2 M, 21.2 mL, 42.4 mmol) and 1,4-dioxane (9 mL) was degassed by passing a stream of nitrogen through it for 5 min. Tetrakis(triphenylphosphine)palladium(0) (272 mg, 0.24 mmol) was then added under nitrogen and the reaction mixture heated at 90 °C for 16 h. The reaction was allowed to cool to rt, filtered through Celite and washed with ethyl acetate (20 mL). The organic layer was separated and the aqueous layer extracted with ethyl acetate (20 mL × 2). The combined organic layers were dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated in vacuo. The residue thus obtained was dissolved in CH<sub>2</sub>Cl<sub>2</sub> (4 mL) and trifluoroacetic acid (4 mL) added. The mixture was stirred at rt for 1 h, then concentrated in vacuo. Methanol (5 mL) was added to the residue and the resultant precipitate filtered, washed with methanol (1 mL × 2) and dried under vacuum to afford ethyl 3-(3-(<i>N</i>,<i>N</i>-dimethylsulfamoyl)phenyl)-2-methyl-1<i>H</i>-indole-5-carboxylate (585 mg, 51%) as a yellow solid. <sup>1</sup>H NMR (300 MHz; CDCl<sub>3</sub>): δ ppm 1.41 (3H, t, <i>J</i> = 7.1 Hz), 2.56 (3H, s), 2.84 (6H, s), 4.39 (2H, q, <i>J</i> = 7.0 Hz), 7.39 (1H, d, <i>J</i> = 8.5 Hz), 7.69 (1H, d, <i>J</i> = 7.7 Hz), 7.75–7.80 (2H, m), 7.92–7.96 (2H, m), 8.27 (1H, br s), 8.36 (1H, br s).</div><div class="NLM_p last">A mixture of ethyl 3-(3-(<i>N</i>,<i>N</i>-dimethylsulfamoyl)phenyl)-2-methyl-1<i>H</i>-indole-5-carboxylate (130 mg, 0.34 mmol), cesium carbonate (132 mg, 0.4 mmol), and (<i>Z</i>)-<i>tert</i>-butyl(4-bromo-3-fluorobut-2-en-1-yl)carbamate (<b>8</b>) (99 mg, 0.37 mmol) in dimethylformamide (DMF, 1.3 mL) was stirred at rt overnight. Water (13 mL) was then added, followed by brine (2.6 mL). The resultant suspension was stirred at rt for 5 min, and the precipitate was then filtered and dried under vacuum. The crude solid thus obtained was purified over silica gel (25 g) eluting with a mixture of <i>n</i>-hexane, CH<sub>2</sub>Cl<sub>2</sub>, and ethyl acetate in a ratio of 4:4:1 and then 2:2:1 to afford (<i>Z</i>)-ethyl 1-(4-((<i>tert</i>-butoxycarbonyl)amino)-2-fluorobut-2-en-1-yl)-3-(3-(<i>N</i>,<i>N</i>-dimethylsulfamoyl)phenyl)-2-methyl-1<i>H</i>-indole-5-carboxylate (150 mg, 78%) as a light gray oil. <sup>1</sup>H NMR (300 MHz; CDCl<sub>3</sub>): δ ppm 1.40 (3H, t, <i>J</i> = 7.1 Hz), 1.42 (9H, s), 2.51 (3H, s), 2.83 (6H, s), 3.82 (2H, apparent t, <i>J</i> = 5.2 Hz), 4.38 (2H, q, <i>J</i> = 7.1 Hz), 4.73–4.87 (1H, m), 4.86 (2H, d, <i>J</i> = 9.8 Hz), 7.35 (1H, d, <i>J</i> = 8.7 Hz), 7.65–7.79 (3H, m), 7.90 (1H, dd, <i>J</i> = 1.6, 1.6 Hz), 7.97 (1H, dd, <i>J</i> = 8.7, 1.6 Hz), 8.33 (1H, d, <i>J</i> = 1.2 Hz).</div></div><div id="sec4_3_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i36" class="anchor-spacer"></div><h4 class="article-section__title" id="_i36"> General Procedure C; Preparation of (<i>Z</i>)-1-(4-((<i>tert</i>-Butoxycarbonyl)amino)-2-fluorobut-2-en-1-yl)-3-(3-(<i>N</i>,<i>N</i>-dimethylsulfamoyl)phenyl)-2-methyl-1<i>H</i>-indole-5-carboxylic Acid</h4><div class="NLM_p last">To a stirred solution of (<i>Z</i>)-ethyl 1-(4-((<i>tert</i>-butoxycarbonyl)amino)-2-fluorobut-2-en-1-yl)-3-(3-(<i>N</i>,<i>N</i>-dimethylsulfamoyl)phenyl)-2-methyl-1<i>H</i>-indole-5-carboxylate (469 mg, 0.82 mmol) in methanol (18 mL) was added aqueous KOH (10% w/v, 9 mL). The mixture was heated at 60 °C for 1 h and then cooled to rt and concentrated in vacuo. The residue thus obtained was taken up in water (20 mL), and the resulting solution acidified to pH 4.5 by the addition of HCl (2 M). The product was extracted with ethyl acetate (20 mL × 3), and the combined organic layers dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated in vacuo to afford (<i>Z</i>)-1-(4-((<i>tert</i>-butoxycarbonyl)amino)-2-fluorobut-2-en-1-yl)-3-(3-(<i>N</i>,<i>N</i>-dimethylsulfamoyl)phenyl)-2-methyl-1<i>H</i>-indole-5-carboxylic acid (390 mg, 87%) as an off-white solid. <sup>1</sup>H NMR (300 MHz; DMSO-<i>d</i><sub>6</sub>): δ ppm 1.36 (9H, s), 2.52 (3H, s), 2.70 (6H, s), 3.58 (2H, br s), 4.98–5.17 (1H, m), 5.15 (2H, d, <i>J</i> = 14.2 Hz), 7.00 (1H, br s), 7.68 (1H, d, <i>J</i> = 8.7 Hz), 7.71–7.83 (5H, m), 8.18 (1H, d, <i>J</i> = 1.1 Hz), 12.49 (1H, br s).</div></div><div id="sec4_3_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i37" class="anchor-spacer"></div><h4 class="article-section__title" id="_i37"> General Method D: Preparation of (<i>Z</i>)-<i>tert</i>-Butyl(4-(5-(dimethylcarbamoyl)-3-(3-(<i>N</i>,<i>N</i>-dimethylsulfamoyl)phenyl)-2-methyl-1<i>H</i>-indol-1-yl)-3-fluorobut-2-en-1-yl)carbamate</h4><div class="NLM_p last">To a stirred mixture of dimethylamine hydrochloride (10 mg, 0.12 mmol) in DMF (0.5 mL) at rt was added triethylamine (57 μL, 0.41 mmol). After 10 min, (<i>Z</i>)-1-(4-((<i>tert</i>-butoxycarbonyl)amino)-2-fluorobut-2-en-1-yl)-3-(3-(<i>N</i>,<i>N</i>-dimethylsulfamoyl)phenyl)-2-methyl-1<i>H</i>-indole-5-carboxylic acid (45 mg, 0.08 mmol) was added, followed by hexafluorophosphate azabenzotriazole tetramethyl uronium (HATU, 38 mg, 0.10 mmol). The resulting mixture was stirred at rt for 2 h and then diluted with water (10 mL). The pale yellow solid thus obtained was filtered and washed with 1 M HCl (5 mL) and water (5 mL), and then dried in oven at 60 °C to afford (<i>Z</i>)-<i>tert</i>-butyl(4-(5-(dimethylcarbamoyl)-3-(3-(<i>N</i>,<i>N</i>-dimethylsulfamoyl)phenyl)-2-methyl-1<i>H</i>-indol-1-yl)-3-fluorobut-2-en-1-yl)carbamate (45 mg, 95%) as a pale yellow solid. <sup>1</sup>H NMR (300 MHz; CDCl<sub>3</sub>): δ ppm 1.43 (9H, s), 2.52 (3H, s), 2.79 (6H, s), 3.10 (6H, br s), 3.82–3.86 (2H, m), 4.71–4.86 (1H, m), 4.84 (2H, d, <i>J</i> = 9.5 Hz), 7.34 (2H, apparent d, <i>J</i> = 1.1 Hz), 7.65 (1H, dd, <i>J</i> = 7.6, 7.6 Hz), 7.71–7.77 (3H, m), 7.87 (1H, dd, <i>J</i> = 1.5, 1.5 Hz).</div></div><div id="sec4_3_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i38" class="anchor-spacer"></div><h4 class="article-section__title" id="_i38"> (<i>Z</i>)-4-(1-(4-Amino-2-fluorobut-2-en-1-yl)-2-methyl-1<i>H</i>-indol-3-yl)-<i>N</i>,<i>N</i>-dimethylbenzenesulfonamide Hydrochloride (<b>12a</b>)</h4><div class="NLM_p last">It was obtained as a glassy solid; mp 145–150 °C; <sup>1</sup>H NMR (300 MHz; DMSO-<i>d</i><sub>6</sub>): δ ppm 2.55 (3H, s), 2.68 (6H, s), 3.41–3.53 (2H, m), 5.06 (1H, dt, <i>J</i> = 36.0, 7.3 Hz), 5.20 (2H, d, <i>J</i> = 12.2 Hz), 7.13 (1H, dd, <i>J</i> = 7.4, 7.4 Hz), 7.21 (1H, dd, <i>J</i> = 7.4, 7.4 Hz), 7.61 (2H, apparent d, <i>J</i> = 7.9 Hz), 7.74 (2H, d, <i>J</i> = 8.4 Hz), 7.85 (2H, d, <i>J</i> = 8.4 Hz), 8.04 (3H, br s). LCMS <i>m</i>/<i>z</i>: 402.2 (MH<sup>+</sup>).</div></div><div id="sec4_3_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i39" class="anchor-spacer"></div><h4 class="article-section__title" id="_i39"> (<i>Z</i>)-3-(1-(4-Amino-2-fluorobut-2-en-1-yl)-2-methyl-1<i>H</i>-indol-3-yl)-<i>N</i>,<i>N</i>-dimethylbenzenesulfonamide Hydrochloride (<b>12b</b>)</h4><div class="NLM_p last">It was obtained as a white solid; mp 242–245 °C; <sup>1</sup>H NMR (300 MHz; DMSO-<i>d</i><sub>6</sub>): δ ppm 2.52 (3H, s), 2.70 (6H, s), 3.47 (2H, br. d, <i>J</i> = 7.1 Hz), 5.04 (1H, dt, <i>J</i> = 36.0, 7.2 Hz), 51.9 (2H, d, <i>J</i> = 12.3 Hz), 7.13 (1H, ddd, <i>J</i> = 7.0, 7.0, 1.0 Hz), 7.21 (1H, ddd, <i>J</i> = 6.9, 6.9, 1.1 Hz), 7.53 (1H, d, <i>J</i> = 7.6 Hz), 7.61 (1H, d, <i>J</i> = 8.0 Hz), 7.70 (1H, dd, <i>J</i> = 7.2, 1.8 Hz), 7.73–7.76 (1H, m), 7.79 (1H, d, <i>J</i> = 7.9 Hz), 7.83 (1H, dd, <i>J</i> = 7.6, 1.7 Hz), 7.97 (3H, br s). LCMS <i>m</i>/<i>z</i>: 402.2 (MH<sup>+</sup>).</div></div><div id="sec4_3_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i40" class="anchor-spacer"></div><h4 class="article-section__title" id="_i40"> General Method E: Preparation of (<i>Z</i>)-1-(4-Amino-2-fluorobut-2-en-1-yl)-3-(3-(<i>N</i>,<i>N</i>-dimethylsulfamoyl)phenyl)-<i>N</i>,<i>N</i>,2-trimethyl-1<i>H</i>-indole-5-carboxamide Hydrochloride (<b>12c</b>)</h4><div class="NLM_p last">To a stirred solution of (<i>Z</i>)-<i>tert</i>-butyl(4-(5-(dimethylcarbamoyl)-3-(3-(<i>N</i>,<i>N</i>-dimethylsulfamoyl)phenyl)-2-methyl-1<i>H</i>-indol-1-yl)-3-fluorobut-2-en-1-yl)carbamate (45 mg, 0.08 mmol) in methanol (1 mL) was added HCl (2 M in diethyl ether, 4 mL, 8 mmol). The reaction was then stirred for 90 min at rt and then concentrated in vacuo. Ethyl acetate (2 mL) was added, and the resulting suspension was stirred for 5 min, during which time a forming a fine white solid precipitated. The white solid was collected and dried to afford (<i>Z</i>)-1-(4-amino-2-fluorobut-2-en-1-yl)-3-(3-(<i>N</i>,<i>N</i>-dimethylsulfamoyl)phenyl)-<i>N</i>,<i>N</i>,2-trimethyl-1<i>H</i>-indole-5-carboxamide hydrochloride (37 mg, 98%) as a white solid; <sup>1</sup>H NMR (300 MHz; DMSO-<i>d</i><sub>6</sub>): δ ppm 2.54 (3H, s), 2.69 (6H, s), 2.97 (6H, s), 3.43–3.54 (2H, m), 5.09 (1H, dt, <i>J</i> = 36.0, 7.5 Hz), 5.23 (2H, d, <i>J</i> = 12.5 Hz), 7.28 (1H, dd, <i>J</i> = 8.4, 1.4 Hz), 7.56 (1H, d, <i>J</i> = 1.3 Hz), 7.66 (1H, d, <i>J</i> = 8.5 Hz), 7.69–7.86 (4H, m), 7.98 (2H, br s). LCMS <i>m</i>/<i>z</i>: 473.2 (MH<sup>+</sup>).</div></div><div id="sec4_3_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i41" class="anchor-spacer"></div><h4 class="article-section__title" id="_i41"> (<i>Z</i>)-1-(4-Amino-2-fluorobut-2-en-1-yl)-3-(3-(<i>N</i>,<i>N</i>-dimethylsulfamoyl)phenyl)-<i>N</i>,<i>N</i>,2-trimethyl-1<i>H</i>-indole-6-carboxamide Hydrochloride (<b>12d</b>)</h4><div class="NLM_p last">It was obtained as a white solid; mp 140–145 °C; <sup>1</sup>H NMR (300 MHz; CD<sub>3</sub>OD): δ ppm 2.58 (3H, s), 2.78 (6H, s), 3.12 (3H, br s), 3.16 (3H, br s), 3.63 (2H, br. d, <i>J</i> = 7.3 Hz), 4.89 (1H, dt, <i>J</i> = 34.2, 7.5 Hz), 5.18 (2H, d, <i>J</i> = 9.1 Hz), 7.24 (1H, dd, <i>J</i> = 8.3, 1.3 Hz), 7.59–7.65 (2H, m), 7.75–7.87 (4H m). LCMS <i>m</i>/<i>z</i>: 473.2 (MH<sup>+</sup>).</div></div><div id="sec4_3_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i42" class="anchor-spacer"></div><h4 class="article-section__title" id="_i42"> (<i>Z</i>)-1-(4-Amino-2-fluorobut-2-en-1-yl)-3-(3-(<i>N</i>,<i>N</i>-dimethylsulfamoyl)phenyl)-<i>N</i>,<i>N</i>,2-trimethyl-1<i>H</i>-indole-7-carboxamide Hydrochloride (<b>12e</b>)</h4><div class="NLM_p last">It was obtained as a white solid; mp 244–246 °C; <sup>1</sup>H NMR (300 MHz; CD<sub>3</sub>OD): δ ppm 2.53 (3H, s), 2.78 (6H, s), 2.94 (3H, s), 3.24 (3H, s), 3.47–3.73 (2H, m), 4.36 (1H, dt, <i>J</i> = 34.2, 7.5 Hz), 4.84 (1H, m), 5.20 (1H, d, <i>J</i> = 18.9 Hz), 7.14 (1H, d, <i>J</i> = 7.2 Hz), 7.23 (1H, t, <i>J</i> = 7.5 Hz) 7.65 (1H, d, <i>J</i> = 7.8 Hz), 7.79–7.85 (4H, m). LCMS <i>m</i>/<i>z</i>: 473.2 (MH<sup>+</sup>).</div></div><div id="sec4_3_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i43" class="anchor-spacer"></div><h4 class="article-section__title" id="_i43"> (<i>Z</i>)-3-(1-(4-Amino-2-fluorobut-2-en-1-yl)-5-chloro-2-methyl-1<i>H</i>-indol-3-yl)-<i>N</i>,<i>N</i>-dimethylbenzenesulfonamide Hydrochloride (<b>12f</b>)</h4><div class="NLM_p last">It was obtained as a white solid; mp 214–216 °C; <sup>1</sup>H NMR (300 MHz; DMSO-<i>d</i><sub>6</sub>): δ ppm 2.50 (3H, partially obscured by DMSO peak), 2.70 (6H, s), 3.47 (2H, s), 5.09 (1H, dt, <i>J</i> = 36.0, 7.2 Hz), 5.22 (2H, d, <i>J</i> = 13.5 Hz), 7.23 (1H, d, <i>J</i> = 8.7 Hz), 7.47 (1H, s), 7.65–7.85 (5H, m). LCMS <i>m</i>/<i>z</i>: 436.0/438.0 (MH<sup>+</sup>).</div></div><div id="sec4_3_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i44" class="anchor-spacer"></div><h4 class="article-section__title" id="_i44"> (<i>Z</i>)-3-(1-(4-Amino-2-fluorobut-2-en-1-yl)-5-hydroxy-2-methyl-1<i>H</i>-indol-3-yl)-<i>N</i>,<i>N</i>-dimethylbenzenesulfonamide Hydrochloride (<b>12g</b>)</h4><div class="NLM_p last">It was obtained as a white solid; decomposes at 130 °C; <sup>1</sup>H NMR (300 MHz; DMSO-<i>d</i><sub>6</sub>): δ ppm 2.50 (3H, partially obscured by DMSO peak), 2.70 (6H, s), 3.47 (2H, s), 4.92–5.22 (3H, m), 6.69 (1H, d, <i>J</i> = 8.7 Hz), 6.88 (1H, s), 7.38 (1H, d, <i>J</i> = 8.7 Hz), 7.65–7.77 (4H, m), 8.00 (3H, br s), 8.90 (1H, s). LCMS <i>m</i>/<i>z</i>: 473.2 (MH<sup>+</sup>). LCMS <i>m</i>/<i>z</i>: 418.2 (MH<sup>+</sup>).</div></div><div id="sec4_3_11" class="NLM_sec NLM_sec_level_3"><div id="ac_i45" class="anchor-spacer"></div><h4 class="article-section__title" id="_i45"> (<i>Z</i>)-3-(1-(4-Amino-2-fluorobut-2-en-1-yl)-5-methoxy-2-methyl-1<i>H</i>-indol-3-yl)-<i>N</i>,<i>N</i>-dimethylbenzenesulfonamide Hydrochloride (<b>12h</b>)</h4><div class="NLM_p last">It was obtained as a white sticky solid; <sup>1</sup>H NMR (300 MHz; DMSO-<i>d</i><sub>6</sub>): δ ppm 2.50 (3H, partially obscured by DMSO peak), 2.71 (6H, s), 3.46 (2H, d, <i>J</i> = 6.6 Hz), 3.73 (3H, s), 5.01 (1H, dt, <i>J</i> = 36.0, 7.2 Hz), 5.10 (2H, d, <i>J</i> = 12.0 Hz), 7.84 (1H, d, <i>J</i> = 9.0 Hz), 7.00 (1H, s), 7.51 (1H, d, <i>J</i> = 8.7 Hz), 7.68–7.81 (4H, m), 7.96 (3H, br s). LCMS <i>m</i>/<i>z</i>: 432.2 (MH<sup>+</sup>).</div></div><div id="sec4_3_12" class="NLM_sec NLM_sec_level_3"><div id="ac_i46" class="anchor-spacer"></div><h4 class="article-section__title" id="_i46"> (<i>Z</i>)-3-(1-(4-Amino-2-fluorobut-2-en-1-yl)-2-methyl-5-(methylsulfonamido)-1<i>H</i>-indol-3-yl)-<i>N</i>,<i>N</i>-dimethylbenzenesulfonamide Hydrochloride (<b>12i</b>)</h4><div class="NLM_p last">It was obtained as a white solid; mp 162–170 °C; <sup>1</sup>H NMR (300 MHz; CD<sub>3</sub>OD): δ ppm 2.55 (3H, s), 2.79 (6H, s), 2.89 (3H, s), 3.63 (2H, d, <i>J</i> = 7.2 Hz), 4.87 (1H, partially obscured by H<sub>2</sub>O peak), 5.12 (1H, d, <i>J</i> = 8.4 Hz), 7.14 (1H, d, <i>J</i> = 8.7 Hz), 7.50 (2H, m) 7.75 (1H, m), 7.85 (1H, s). LCMS <i>m</i>/<i>z</i>: 495.3 (MH<sup>+</sup>).</div></div><div id="sec4_3_13" class="NLM_sec NLM_sec_level_3"><div id="ac_i47" class="anchor-spacer"></div><h4 class="article-section__title" id="_i47"> (<i>Z</i>)-3-(1-(4-Amino-2-fluorobut-2-en-1-yl)-2-methyl-5-(methylsulfonyl)-1<i>H</i>-indol-3-yl)-<i>N</i>,<i>N</i>-dimethylbenzenesulfonamide Hydrochloride (<b>12j</b>)</h4><div class="NLM_p last">It was obtained as a white solid; mp 285–289 °C; <sup>1</sup>H NMR (300 MHz; DMSO-<i>d</i><sub>6</sub>): δ ppm 2.57 (3H, s), 2.72 (6H, s), 3.18 (3H, s), 3.47 (2H, s), 5.09 (1H, dt, <i>J</i> = 36.0, 7.2 Hz), 5.32 (2H, d, <i>J</i> = 12.9 Hz), 7.73–7.91 (6H, m), 8.05 (3H, br s). LCMS <i>m</i>/<i>z</i>: 480.2 (MH<sup>+</sup>).</div></div><div id="sec4_3_14" class="NLM_sec NLM_sec_level_3"><div id="ac_i48" class="anchor-spacer"></div><h4 class="article-section__title" id="_i48"> General Method F: Preparation of (<i>Z</i>)-1-(4-Amino-2-fluorobut-2-en-1-yl)-3-(3-(<i>N</i>,<i>N</i>-dimethylsulfamoyl)phenyl)-2-methyl-1<i>H</i>-indole-5-carboxylic Acid Hydrochloride (<b>12k</b>—<b>PXS-5120A</b>)</h4><div class="NLM_p last">To a stirred solution of (<i>Z</i>)-1-(4-((<i>tert</i>-butoxycarbonyl)amino)-2-fluorobut-2-en-1-yl)-3-(3-(<i>N</i>,<i>N</i>-dimethylsulfamoyl)phenyl)-2-methyl-1<i>H</i>-indole-5-carboxylic acid (200 mg, 0.37 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (4 mL) was added trifluoroacetic acid (1 mL). The resulting mixture was stirred at rt for 1 h and then concentrated in vacuo. The solid thus obtained was purified over C-18-reversed phase silica gel (40 g), eluting over a gradient of 20–50% acetonitrile in water (+0.1% HCl) to afford (<i>Z</i>)-1-(4-amino-2-fluorobut-2-en-1-yl)-3-(3-(<i>N</i>,<i>N</i>-dimethylsulfamoyl)phenyl)-2-methyl-1<i>H</i>-indole-5-carboxylic acid hydrochloride (102 mg, 58%) as an off-white solid; mp 253–254 °C; <sup>1</sup>H NMR (300 MHz; DMSO-<i>d</i><sub>6</sub>): δ ppm 2.55 (3H, s), 2.71 (6H, s), 3.48 (2H, br d, <i>J</i> = 7.0 Hz), 5.09 (1H, dt, <i>J</i> = 35.9, 7.3 Hz), 5.26 (2H, d, <i>J</i> = 12.8 Hz), 7.69–7.86 (6H, m), 7.94 (1H, br s), 8.20 (1H, d, <i>J</i> = 1.2 Hz), 12.58 (1H, br s). <sup>19</sup>F NMR (282 MHz; DMSO-<i>d</i><sub>6</sub>): δ ppm −109.2. LCMS <i>m</i>/<i>z</i>: 446.3 (MH<sup>+</sup>).</div></div><div id="sec4_3_15" class="NLM_sec NLM_sec_level_3"><div id="ac_i49" class="anchor-spacer"></div><h4 class="article-section__title" id="_i49"> (<i>Z</i>)-1-(4-Amino-2-fluorobut-2-en-1-yl)-3-(3-(<i>N</i>,<i>N</i>-dimethylsulfamoyl)phenyl)-2-methyl-1<i>H</i>-indole-6-carboxylic Acid Hydrochloride (<b>12l</b>)</h4><div class="NLM_p last">It was obtained as a white solid; mp 255–257 °C; <sup>1</sup>H NMR (300 MHz; DMSO-<i>d</i><sub>6</sub>): δ ppm 2.56 (3H, s), 2.70 (6H, s), 3.49 (2H, br s), 5.02 (1H, dt, <i>J</i> = 35.9, 7.3 Hz), 5.32 (2H, d, <i>J</i> = 12.0 Hz), 7.58 (1H, d, <i>J</i> = 8.3 Hz), 7.70–7.88 (5H, m), 7.94 (2H, br s), 8.25 (1H, s), 12.67 (1H, s). LCMS <i>m</i>/<i>z</i>: 446.2 (MH<sup>+</sup>).</div></div><div id="sec4_3_16" class="NLM_sec NLM_sec_level_3"><div id="ac_i50" class="anchor-spacer"></div><h4 class="article-section__title" id="_i50"> (<i>Z</i>)-3-(1-(4-Amino-2-fluorobut-2-en-1-yl)-2-methyl-5-(1<i>H</i>-tetrazol-5-yl)-1<i>H</i>-indol-3-yl)-<i>N</i>,<i>N</i>-dimethylbenzenesulfonamide Hydrochloride (<b>12m</b>)</h4><div class="NLM_p last">It was obtained as an off-white solid; mp 242–247 °C; <sup>1</sup>H NMR (300 MHz; CD<sub>3</sub>OD): δ ppm 2.60 (3H, s), 2.80 (6H, s), 3.65 (2H, d, <i>J</i> = 7.5 Hz), 4.95 (1H, partially obscured by H<sub>2</sub>O peak), 5.22 (2H, d, <i>J</i> = 9.6 Hz), 7.72 (1H, d, <i>J</i> = 8.7 Hz), 7.81–7.93 (5H, m), 8.27 (1H, s). LCMS <i>m</i>/<i>z</i>: 469.6 (M<sup>+</sup>).</div></div><div id="sec4_3_17" class="NLM_sec NLM_sec_level_3"><div id="ac_i51" class="anchor-spacer"></div><h4 class="article-section__title" id="_i51"> (<i>E</i>)-1-(4-Aminobut-2-en-1-yl)-3-(3-(<i>N</i>,<i>N</i>-dimethylsulfamoyl)phenyl)-2-methyl-1<i>H</i>-indole-5-carboxylic Acid Hydrochloride (<b>12n</b>)</h4><div class="NLM_p last">It was obtained as a brown solid; mp 224–227 °C; <sup>1</sup>H NMR (300 MHz; CD<sub>3</sub>OD): δ ppm 2.54 (s, 3H), 2.79 (s, 6H), 3.52 (d, <i>J</i> = 6.8 Hz, 2H), 5.00 (dd, <i>J</i> = 4.4, 1.9 Hz, 2H), 5.26 (dt, <i>J</i> = 15.5, 6.6 Hz, 1H), 6.33–6.02 (m, 1H), 7.46 (d, <i>J</i> = 8.6 Hz, 1H), 7.95–7.72 (m, 5H), 8.31 (d, <i>J</i> = 1.6 Hz, 1H). LCMS <i>m</i>/<i>z</i>: 428.2 (M<sup>+</sup>).</div></div><div id="sec4_3_18" class="NLM_sec NLM_sec_level_3"><div id="ac_i52" class="anchor-spacer"></div><h4 class="article-section__title" id="_i52"> General Method G: Preparation of (<i>Z</i>)-Ethyl 1-(4-Amino-2-fluorobut-2-en-1-yl)-3-(3-(<i>N</i>,<i>N</i>-dimethylsulfamoyl)phenyl)-2-methyl-1<i>H</i>-indole-5-carboxylate Hydrochloride (<b>12o</b>—<b>PXS-5129A</b>)</h4><div class="NLM_p last">To a stirred solution of (<i>Z</i>)-ethyl 1-(4-((<i>tert</i>-butoxycarbonyl)amino)-2-fluorobut-2-en-1-yl)-3-(3-(<i>N</i>,<i>N</i>-dimethylsulfamoyl)phenyl)-2-methyl-1<i>H</i>-indole-5-carboxylate (510 mg, 0.89 mmol) in ethanol (5 mL) was added HCl (2 M in diethyl ether, 20 mL, 40 mmol). The reaction was stirred for 5 h at rt and then concentrated in vacuo. Diethyl ether (25 mL) was added, and the resulting suspension stirred for 5 min, during which time a fine off-white solid precipitated. The solid was collected and dried to afford ethyl (<i>Z</i>)-1-(4-amino-2-fluorobut-2-en-1-yl)-3-(3-(<i>N</i>,<i>N</i>-dimethylsulfamoyl)phenyl)-2-methyl-1<i>H</i>-indole-5-carboxylate hydrochloride (403 mg, 89%) as an off-white solid; mp 145–147 °C; <sup>1</sup>H NMR (300 MHz; DMSO-<i>d</i><sub>6</sub>): δ ppm 1.30 (3H, t, <i>J</i> = 7.1 Hz), 2.55 (3H, s), 2.73 (6H, s), 3.48 (2H, br. d, <i>J</i> = 7.3 Hz), 4.28 (2H, q, <i>J</i> = 7.1 Hz), 5.11 (1H, dt, <i>J</i> = 33.8, 7.5 Hz), 5.27 (2H, d, <i>J</i> = 8.8 Hz), 7.72–7.86 (6H, m), 8.02 (3H, br s), 8.19 (1H, d, <i>J</i> = 1.2 Hz). <sup>19</sup>F NMR (282 MHz; DMSO-<i>d</i><sub>6</sub>): δ ppm −109.3 LCMS <i>m</i>/<i>z</i>: 474.2 (MH<sup>+</sup>).</div></div></div><div id="sec4_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i53" class="anchor-spacer"></div><h3 class="article-section__title" id="_i53"> Enzymatic Assays</h3><div class="NLM_p">The measurement of all of the enzymatic activities was based on the detection of hydrogen peroxide with an Amplex-Red (AR) oxidation assay,<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a> miniaturized in a 384 well format, with the appropriate combination of substrate and assay buffer for each individual enzyme. After 30 min pre-incubation of the enzyme at 37 °C with the test compound (or with different incubation times for the time-dependency assay), one volume of reaction mixture containing 120 μM AR (Life Technologies), 1.5 U/mL horseradish peroxidase (HRP, Sigma-Aldrich), and the specific substrate was mixed to each sample. The relative fluorescence units (RFU) were then measured every 2.5 min for 30 min at 37 °C, excitation 565 nm and emission 590, on a BMG Clariostar Microplate Reader. All the substrates were used at concentrations related to their <i>K</i><sub>m</sub> toward the corresponding enzyme, or with a range of different concentrations for the substrate competition experiments. LOX assay buffer contained 1.2 M urea, 50 mM sodium borate buffer, pH 8.2, and 100 μM β-aminoproprionitrile (BAPN, Sigma-Aldrich) was used for positive control.</div><div class="NLM_p">Recombinant human and mouse LOXL2 (R&D Systems) were challenged with 5 mM putrescine (Sigma-Aldrich) as the substrate. Recombinant rat LOXL2 was purified in-house from a proprietary clone supplied by Dr. Fernando Rodríguez Pascual, University of Madrid, Spain.</div><div class="NLM_p">Bovine LOX was extracted by adapting the methodology from Shieh et al.<a onclick="showRef(event, 'ref52'); return false;" href="javascript:void(0);" class="ref ref52">(52)</a> from calf aorta (mixed sex): the homogenized tissue was washed extensively with phosphate-buffered saline (PBS) to remove LOX inhibitors and readily soluble proteins and then extracted in 4 M urea, 50 mM sodium borate buffer, pH 8.2. The supernatant was washed and concentrated by means of Amicon 10 kDa centrifuge filters (Millipore) in 1.2 M urea, 50 mM sodium borate buffer, pH 8.2, and in the presence of protease inhibitors, and challenged with 10 mM Putrescine (Sigma-Aldrich) as the substrate.</div><div class="NLM_p">Human fibroblast LOX and LOXL2 were obtained from the conditioned medium IMR90 cells (ATCC CCL-186) as follows: cells were cultured in MEM and 10% fetal bovine serum (FBS), supplemented with 1% penicillin/streptomycin and nonessential amino acids until 80% confluent, rinsed once with phenol red free and 0.1% FBS medium, and then fed with this medium for 48–72 h. The medium was then collected and concentrated 40-fold by centrifugation in Millipore/Amicon filtration tubes with a 10 kDa cutoff membrane. The separation between LOX (∼30 kDa) and LOXL2 (>90 kDa) was obtained by applying a second filtration with a 50 kDa cutoff membrane, after having adjusted the buffer to 50 mM sodium borate and 6 M urea, pH 8.2, to facilitate the separation of the isozymes. After the separation, the urea concentration of the samples was diluted back to 1.2 M with 50 mM sodium borate, pH 8.2. Mouse lung fibroblast LOX was obtained in a similar fashion to humans, extracting the fibroblasts from homogenized mouse lung tissue and culturing as above.</div><div class="NLM_p">Recombinant human LOXL1 was expressed and purified from cDNA (GeneArt) and 10 mM putrescine was used as a substrate, and 2 mM putrescine was used as the substrate for recombinant human LOXL3 (R&D Systems) and LOXL4 (Dr. Fernando Rodríguez Pascual, university of Madrid, Spain) assays.</div><div class="NLM_p last">Recombinant human semicarbazide-sensitive amine oxidase (SSAO/VAP1), DAO, MAO-A, and MAO-B assays were performed as previously described.<a onclick="showRef(event, 'ref53'); return false;" href="javascript:void(0);" class="ref ref53">(53)</a></div></div><div id="sec4_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i54" class="anchor-spacer"></div><h3 class="article-section__title" id="_i54"> Collagen Oxidation</h3><div class="NLM_p last">The collagen oxidation assay was based on the release of hydrogen peroxide as previously described.<a onclick="showRef(event, 'cit17b'); return false;" href="javascript:void(0);" class="ref cit17b">(17b)</a> In a 384 black well plate, 25 μL of collagen (rat tail, type I, Thermo Fisher, 1.5 mg/mL in 50 mM sodium borate buffer, pH 8.2) was combined with 25 μL rhLOXL2 (R&D Systems) with or without the pan-LOX inhibitor BAPN (100 μM, Sigma-Aldrich) or <b>PXS-5120A</b>. A reaction mixture using AR (120 μM; Life Technologies) and HRP (1.5 U/mL; Sigma-Aldrich) was prepared in 50 mM sodium borate buffer, and 50 μL of the reaction mixture was added into each well. The RFU were read every 1 min for 3 h at 37 °C, excitation 565 nm and emission 590 nm (Clariostar, BMG labtech). The slope per minute of the kinetic curves for each sample was calculated using MARS data analysis software (BMG labtech) in the linear phase (between the 20–40 min time points).</div></div><div id="sec4_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i55" class="anchor-spacer"></div><h3 class="article-section__title" id="_i55"> Off-Target Profiling</h3><div class="NLM_p last"><b>PXS-5120A</b> was tested at Eurofins Scientific (formerly Cerep), France, at a concentration of 10 μM against a panel of 119 enzyme and receptor proteins according to standard conditions. Inhibition/reduction of radioligand binding of >50% was considered a hit. See the <a href="/doi/suppl/10.1021/acs.jmedchem.9b01283/suppl_file/jm9b01283_si_001.pdf" class="ext-link">Supporting Information</a> for a full readout of the targets profiled.</div></div><div id="sec4_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i56" class="anchor-spacer"></div><h3 class="article-section__title" id="_i56"> Determination of Kinetic Parameters</h3><div class="NLM_p last">The kinetic parameters for <b>PXS-5120A</b> and LOXL2 were determined according to the Kitz–Wilson method as previously described for SSAO.<a onclick="showRef(event, 'ref54 ref55'); return false;" href="javascript:void(0);" class="ref ref54 ref55">(54,55)</a></div></div><div id="sec4_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i57" class="anchor-spacer"></div><h3 class="article-section__title" id="_i57"> Compound Oxidation Assay</h3><div class="NLM_p last">This assay measures the substrate turnover of a compound relative to the background (dimethyl sulfoxide only). Compound oxidation by either SSAO or AOC4 (from diluted dog serum) was measured by fluorometric assay<a onclick="showRef(event, 'ref56'); return false;" href="javascript:void(0);" class="ref ref56">(56)</a> over a period of 40 min at 37 °C in HEPES buffer in the presence of AR (20 μM), HRP (4 U/mL), and the test compound (at a final concentration of 30 μM). The total formation of resorufin over time was measured using an Optima reader (BMG Labtech GmbH, Ortenburg, Germany) at 37 °C. Benzylamine (at 600 μM) was used as the positive control. The relative values for benzylamine controls were 101.9 [±5.7 standard error of the mean (SEM), <i>n</i> = 17] for human recombinant SSAO, and 25.5 (±2.9 SEM, <i>n</i> = 17) for dog AOC4, relative to DMSO levels. Values around 1 identify compounds that are indistinguishable from DMSO = no turnover.</div></div><div id="sec4_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i58" class="anchor-spacer"></div><h3 class="article-section__title" id="_i58"> Substrate Competition Experiment</h3><div class="NLM_p last">The measurement of substrate competition was based on the release of hydrogen peroxide as described above for the standard assay protocol. Recombinant LOXL2 was incubated with the inhibitor and differing concentrations of the substrate (putrescine) prior to addition of the reaction mixture.</div></div><div id="sec4_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i59" class="anchor-spacer"></div><h3 class="article-section__title" id="_i59"> Jump Dilution Experiment</h3><div class="NLM_p last">The measurement of the residence time was based on the detection of hydrogen peroxide with an AR oxidation assay, and as described in the report by Copeland et al.<a onclick="showRef(event, 'ref57'); return false;" href="javascript:void(0);" class="ref ref57">(57)</a> in a 96-well format. The target was incubated with the test compound at 30 × IC<sub>50</sub> for 60 min at 37 °C in SnapStrip PCR vials. After the incubation, a 50-fold dilution was carried out by adding the standard assay buffer, immediately followed by a 1:2 dilution with an equal volume of reaction mixture and subjected to measurement as described in the enzymatic assay methodology. The target percentage activity was measured as a function of time after the dilution event.</div></div><div id="sec4_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i60" class="anchor-spacer"></div><h3 class="article-section__title" id="_i60"> Washout Experiment with Plate Bound LOXL2</h3><div class="NLM_p last">Flat, clear bottom, high binding 96 well plates were spotted with 30 μL of 30 nM LOXL2 in coating buffer (3.03 g/L Na<sub>2</sub>CO<sub>3</sub>, 6 g/L NaHCO<sub>3</sub>, pH 9.6), then sealed and left 24 h at 4 °C. After the wells were washed three times in TBS-T (0.05% Tween 20), 100 μL of PBS plus ions (1 mM MgCl<sub>2</sub> and 2 mM CaCl<sub>2</sub>) were added to the wells and incubated for 30 min at 37 °C in the presence of the inhibitors at a concentration of 10 × IC<sub>50</sub>. Wells were then emptied and washed three times with PBS plus ions, before receiving 200 μL of AR/HRP reaction mix (60 μM AR, 2 U/mL HRP, 5 mM putrescine) just before being measured as described in the enzymatic assay methodology.</div></div><div id="sec4_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i61" class="anchor-spacer"></div><h3 class="article-section__title" id="_i61"> ADME Assays</h3><div class="NLM_p last">Protein plasma binding, microsomal, and plasma stability studies were carried out at Sundia Meditech Company (Shanghai, China). Hepatocyte stability studies were carried out at GVK Bio (Hyderabad, India).</div></div><div id="sec4_13" class="NLM_sec NLM_sec_level_2"><div id="ac_i62" class="anchor-spacer"></div><h3 class="article-section__title" id="_i62"> In Vivo Studies in Mice</h3><div class="NLM_p last">All animal experiments mentioned in the article were conducted in compliance with institutional guidelines.</div></div><div id="sec4_14" class="NLM_sec NLM_sec_level_2"><div id="ac_i63" class="anchor-spacer"></div><h3 class="article-section__title" id="_i63"> Pharmacokinetic Studies in Mice</h3><div class="NLM_p last">Studies were performed by GVK Bio (Hyderabad, India) with local ethics approval. Male BALB/c mice were administered <b>PXS-5129A</b> by oral gavage at 20 mg/kg (<i>n</i> = 3). Plasma was analyzed for <b>PXS-5129A</b> and <b>PXS-5120A</b> by high-performance LCMS/MS.</div></div><div id="sec4_15" class="NLM_sec NLM_sec_level_2"><div id="ac_i64" class="anchor-spacer"></div><h3 class="article-section__title" id="_i64"> CCl<sub>4</sub>-Induced Liver Fibrosis/Cirrhosis Model</h3><div class="NLM_p last">The study was performed by PharmaLegacy (Shanghai, China) with approval from the local ethics committee. Female BALB/c mice were injected intraperitoneally with CCl<sub>4</sub> (ip). 1 mL/kg 25% CCl<sub>4</sub> in olive oil (100 μL for a regular mouse with body weight of 25 g), twice per week for a total period of 6 weeks. Animals were sacrificed 48 h after the last CCl<sub>4</sub> administration. Test articles were dosed as outlined in the main text, sham group <i>n</i> = 6, vehicle group <i>n</i> = 12. ALT and AST levels were assessed in the plasma. One lobe of the liver tissue was fixed in 10% formalin and stained for Picro Sirius Red and α-SMA. Slides were scanned using a uSCOPE-GX device with a 20× lens (Microscopes International). Images were then further expanded 20× electronically and a histomorphometric evaluation was performed to determine the area of fibrosis as a percentage of the total liver area.</div></div><div id="sec4_16" class="NLM_sec NLM_sec_level_2"><div id="ac_i65" class="anchor-spacer"></div><h3 class="article-section__title" id="_i65"> Bleomycin-Induced Lung Fibrosis Model</h3><div class="NLM_p last">The study was performed at the University of Newcastle with approval from the local ethics committee. Female 6- to 8-week old C57BL/6 mice were anesthetized with isoflurane and then administered bleomycin sulphate (BP Biomedicals, NSW, Aust.) intranasally at a dose of 0.05 U/mouse in a total volume of 50 μL PBS. Control mice received the same volume of PBS, and mice were sacrificed after 28 days.<a onclick="showRef(event, 'ref58'); return false;" href="javascript:void(0);" class="ref ref58">(58)</a> Test articles were dosed as outlined in the main text, sham group <i>n</i> = 6, vehicle group <i>n</i> = 12. Formalin-fixed lung sections stained with haematoxylin and eosin were assessed for fibrosis in all mice as per the scale outlined by Ashcroft et al.<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a> The whole lung sections were imaged by an Aperio CS2 scanner (Lecia Biosystems), and all pictures were visualized and analyzed using the Aperio ImageScope system (Leica Biosystems). Scoring was performed on randomized and masked slides. Thirty frames per slide were taken at 20× magnification by computerized software and then assessed one by one manually. Results of the 30 pictures were then averaged, and they represent the value for one individual mouse lung.</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i66"><a href="/doi/suppl/10.1021/acs.jmedchem.9b01283" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_11733" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_11733" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a href="/" class="ext-link">ACS Publications website</a> at DOI: <a href="/doi/abs/10.1021/acs.jmedchem.9b01283" class="ext-link">10.1021/acs.jmedchem.9b01283</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Collagen oxidation assay; Kitz–Wilson plot for <b>PXS-5120A</b>; Picro Sirius Red and ALT/AST readouts from the CCl<sub>4</sub> liver fibrosis model; IHC staining for both models; analytical data for key compounds; and CEREP off-target screening results for <b>PXS-5120A</b> (<b>12k</b>) (<a href="/doi/suppl/10.1021/acs.jmedchem.9b01283/suppl_file/jm9b01283_si_001.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">Molecular formula (SMILES string) of each compound along with relevant in vitro data (<a href="/doi/suppl/10.1021/acs.jmedchem.9b01283/suppl_file/jm9b01283_si_002.csv" class="ext-link">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b01283/suppl_file/jm9b01283_si_001.pdf">jm9b01283_si_001.pdf (1.65 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b01283/suppl_file/jm9b01283_si_002.csv">jm9b01283_si_002.csv (3.15 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.9b01283" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_06825" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_06825" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Alison D. Findlay</span> - <span class="hlFld-Affiliation affiliation">Pharmaxis
Ltd, 20 Rodborough Road, Frenchs Forest, Sydney, New South Wales 2086, Australia</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#6a0b0603190504440c03040e060b132a1a020b18070b12031944090507440b1f"><span class="__cf_email__" data-cfemail="dabbb6b3a9b5b4f4bcb3b4beb6bba39aaab2bba8b7bba2b3a9f4b9b5b7f4bbaf">[email protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jonathan S. Foot</span> - <span class="hlFld-Affiliation affiliation">Pharmaxis
Ltd, 20 Rodborough Road, Frenchs Forest, Sydney, New South Wales 2086, Australia</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-1642-1742" title="Orcid link">http://orcid.org/0000-0003-1642-1742</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#274d484946534f4649094148485367574f46554a465f4e540944484a094652"><span class="__cf_email__" data-cfemail="cba1a4a5aabfa3aaa5e5ada4a4bf8bbba3aab9a6aab3a2b8e5a8a4a6e5aabe">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Alberto Buson</span> - <span class="hlFld-Affiliation affiliation">Pharmaxis
Ltd, 20 Rodborough Road, Frenchs Forest, Sydney, New South Wales 2086, Australia</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Mandar Deodhar</span> - <span class="hlFld-Affiliation affiliation">Pharmaxis
Ltd, 20 Rodborough Road, Frenchs Forest, Sydney, New South Wales 2086, Australia</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Andrew G. Jarnicki</span> - <span class="hlFld-Affiliation affiliation">Centre
for Healthy Lungs, The University of Newcastle
and Hunter Medical Research Institute, Newcastle, New South Wales 2300, Australia</span>; 
    <span>Present Address:
                        Dept. Pharmacology and Therapeutics, University of Melbourne, Parkville, Victoria 3010, Australia</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Philip M. Hansbro</span> - <span class="hlFld-Affiliation affiliation">Centre
for Healthy Lungs, The University of Newcastle
and Hunter Medical Research Institute, Newcastle, New South Wales 2300, Australia</span>; 
    <span class="hlFld-Affiliation affiliation">Centre
for Inflammation, Centenary Institute, Sydney, New South Wales 2050, Australia</span>; 
    <span class="hlFld-Affiliation affiliation">Faculty
of Science, University of Technology Sydney, Ultimo, New South Wales 2007, Australia</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Gang Liu</span> - <span class="hlFld-Affiliation affiliation">Centre
for Inflammation, Centenary Institute, Sydney, New South Wales 2050, Australia</span>; 
    <span class="hlFld-Affiliation affiliation">Faculty
of Science, University of Technology Sydney, Ultimo, New South Wales 2007, Australia</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Heidi Schilter</span> - <span class="hlFld-Affiliation affiliation">Pharmaxis
Ltd, 20 Rodborough Road, Frenchs Forest, Sydney, New South Wales 2086, Australia</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Craig I. Turner</span> - <span class="hlFld-Affiliation affiliation">Pharmaxis
Ltd, 20 Rodborough Road, Frenchs Forest, Sydney, New South Wales 2086, Australia</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Wenbin Zhou</span> - <span class="hlFld-Affiliation affiliation">Pharmaxis
Ltd, 20 Rodborough Road, Frenchs Forest, Sydney, New South Wales 2086, Australia</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Wolfgang Jarolimek</span> - <span class="hlFld-Affiliation affiliation">Pharmaxis
Ltd, 20 Rodborough Road, Frenchs Forest, Sydney, New South Wales 2086, Australia</span></div></li></ul></li><li></li><li><span class="author-information-subsection-header">Funding</span><p>All studies were fully funded by Pharmaxis Ltd., 20 Rodborough Road, Frenchs Forest, NSW 2086, Australia. P.M.H. was additionally supported by a fellowship from the National Health and Medical Research Council (NHMRC) of Australia (1079187).</p></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare the following competing financial interest(s): Throughout the duration of the studies present in this manuscript, ADF, JSF, AB, MD, HS, CIT, WZ and WJ were employed by Pharmaxis Ltd., and held shares in the company. The studies carried out by PMH, AGJ and GL were wholly funded by Pharmaxis Ltd. PMH has previously held grants partly funded by Pharmaxis Ltd.<br /></br></div></li></ul></div><div class="ack" id="ack1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i68">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_84131" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_84131" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The authors would like to thank Dr. Fernando Rodríguez Pascual, University of Madrid, Spain, for kindly providing recombinant rat LOXL2 clones and recombinant human LOXL4 protein.</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations</td></tr><tr><td class="NLM_term">ALT</td><td class="NLM_def"><p class="first last">alanine aminotransferase</p></td></tr><tr><td class="NLM_term">AOC</td><td class="NLM_def"><p class="first last">amine oxidase, copper containing</p></td></tr><tr><td class="NLM_term">AST</td><td class="NLM_def"><p class="first last">aspartate aminotransferase</p></td></tr><tr><td class="NLM_term">BAPN</td><td class="NLM_def"><p class="first last">β-aminopropionitrile</p></td></tr><tr><td class="NLM_term">DAO</td><td class="NLM_def"><p class="first last">diamine oxidase</p></td></tr><tr><td class="NLM_term">DIPEA</td><td class="NLM_def"><p class="first last">diisopropyl ethylamine</p></td></tr><tr><td class="NLM_term">ECM</td><td class="NLM_def"><p class="first last">extracellular matrix</p></td></tr><tr><td class="NLM_term">EMT</td><td class="NLM_def"><p class="first last">epithelial–mesenchymal transition</p></td></tr><tr><td class="NLM_term">FAD</td><td class="NLM_def"><p class="first last">flavin adenine dinucleotide</p></td></tr><tr><td class="NLM_term">HATU</td><td class="NLM_def"><p class="first last">hexafluorophosphate azabenzotriazole tetramethyl uronium</p></td></tr><tr><td class="NLM_term">HIF-1α</td><td class="NLM_def"><p class="first last">hypoxia-inducible factor-1α</p></td></tr><tr><td class="NLM_term">HLM</td><td class="NLM_def"><p class="first last">human liver microsomes</p></td></tr><tr><td class="NLM_term">HPC</td><td class="NLM_def"><p class="first last">hepatic progenitor cell</p></td></tr><tr><td class="NLM_term">HRP</td><td class="NLM_def"><p class="first last">horseradish peroxidase</p></td></tr><tr><td class="NLM_term">IPF</td><td class="NLM_def"><p class="first last">idiopathic pulmonary fibrosis</p></td></tr><tr><td class="NLM_term">KDM1A</td><td class="NLM_def"><p class="first last">lysine (K)-specific demethylase 1A</p></td></tr><tr><td class="NLM_term">LOX</td><td class="NLM_def"><p class="first last">lysyl oxidase</p></td></tr><tr><td class="NLM_term">LOXL</td><td class="NLM_def"><p class="first last">lysyl oxidase-like</p></td></tr><tr><td class="NLM_term">LOXL2</td><td class="NLM_def"><p class="first last">lysyl oxidase-like 2</p></td></tr><tr><td class="NLM_term">LOXL3</td><td class="NLM_def"><p class="first last">lysyl oxidase-like 3</p></td></tr><tr><td class="NLM_term">LSD1</td><td class="NLM_def"><p class="first last">lysine-specific histone demethylase 1A</p></td></tr><tr><td class="NLM_term">LTQ</td><td class="NLM_def"><p class="first last">lysine tyrosylquinone</p></td></tr><tr><td class="NLM_term">MAO</td><td class="NLM_def"><p class="first last">monoamine oxidase</p></td></tr><tr><td class="NLM_term">NASH</td><td class="NLM_def"><p class="first last">non-alcoholic steatohepatitis</p></td></tr><tr><td class="NLM_term">PAO</td><td class="NLM_def"><p class="first last">polyamine oxidase</p></td></tr><tr><td class="NLM_term">SRCR</td><td class="NLM_def"><p class="first last">scavenger receptor cysteine-rich</p></td></tr><tr><td class="NLM_term">α-SMA</td><td class="NLM_def"><p class="first last">α-smooth muscle actin</p></td></tr><tr><td class="NLM_term">SSAO</td><td class="NLM_def"><p class="first last">semicarbazide-sensitive amine oxidase</p></td></tr><tr><td class="NLM_term">TGFβ</td><td class="NLM_def"><p class="first last">transforming growth factor beta</p></td></tr><tr><td class="NLM_term">TPQ</td><td class="NLM_def"><p class="first last">topaquinone</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i70">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_41302" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_41302" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 58 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dostert, P. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benedetti, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tipton, K. F.</span></span> <span> </span><span class="NLM_article-title">Interactions of monoamine oxidase with substrates and inhibitors</span>. <i>Med. Res. Rev.</i> <span class="NLM_year" style="font-weight: bold;">1989</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">45</span>– <span class="NLM_lpage">89</span>, <span class="refDoi"> DOI: 10.1002/med.2610090104</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=10.1002%2Fmed.2610090104" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=2644497" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=1%3ACAS%3A528%3ADyaL1MXhtlSrtbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=1989&pages=45-89&author=P.+L.+Dostertauthor=M.+S.+Benedettiauthor=K.+F.+Tipton&title=Interactions+of+monoamine+oxidase+with+substrates+and+inhibitors&doi=10.1002%2Fmed.2610090104"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Interactions of monoamine oxidase with substrates and inhibitors</span></div><div class="casAuthors">Dostert, Philippe L.; Strolin Benedetti, Margherita; Tipton, Keith F.</div><div class="citationInfo"><span class="NLM_cas:title">Medicinal Research Reviews</span>
        (<span class="NLM_cas:date">1989</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">45-89</span>CODEN:
                <span class="NLM_cas:coden">MRREDD</span>;
        ISSN:<span class="NLM_cas:issn">0198-6325</span>.
    </div><div class="casAbstract">A review with 312 refs. on the substrate and inhibitor interactions of the A and B forms of monoamine oxidase (MAO).  The topics discussed include mechanistic and stereochem. aspects of MAO-substrate interactions, MAO-B and MAO-A substrate specificities, and kinetic and mechanistic aspects of MAO interaction with noncovalent and mechanism-based inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqrnQPMDeH2erVg90H21EOLACvtfcHk0lgcNAeakSFjgw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL1MXhtlSrtbs%253D&md5=784879e53b063fc1550f9b8dd9c0298d</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1002%2Fmed.2610090104&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fmed.2610090104%26sid%3Dliteratum%253Aachs%26aulast%3DDostert%26aufirst%3DP.%2BL.%26aulast%3DBenedetti%26aufirst%3DM.%2BS.%26aulast%3DTipton%26aufirst%3DK.%2BF.%26atitle%3DInteractions%2520of%2520monoamine%2520oxidase%2520with%2520substrates%2520and%2520inhibitors%26jtitle%3DMed.%2520Res.%2520Rev.%26date%3D1989%26volume%3D9%26spage%3D45%26epage%3D89%26doi%3D10.1002%2Fmed.2610090104" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Holtta, E.</span></span> <span> </span><span class="NLM_article-title">Oxidation of spermidine and spermine in rat liver: purification and properties of polyamine oxidase</span>. <i>Biochemistry</i> <span class="NLM_year" style="font-weight: bold;">1977</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">91</span>– <span class="NLM_lpage">100</span>, <span class="refDoi"> DOI: 10.1021/bi00620a015</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bi00620a015" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=1%3ACAS%3A528%3ADyaE2sXmslarsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=1977&pages=91-100&author=E.+Holtta&title=Oxidation+of+spermidine+and+spermine+in+rat+liver%3A+purification+and+properties+of+polyamine+oxidase&doi=10.1021%2Fbi00620a015"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Oxidation of spermidine and spermine in rat liver:  purification and properties of polyamine oxidase</span></div><div class="casAuthors">Holtta, Erkki</div><div class="citationInfo"><span class="NLM_cas:title">Biochemistry</span>
        (<span class="NLM_cas:date">1977</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">91-100</span>CODEN:
                <span class="NLM_cas:coden">BICHAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-2960</span>.
    </div><div class="casAbstract">A novel enzyme responsible for the oxidn. of spermidine and spermine was found in rat liver.  Spermidine is degraded to putrescine and 3-aminopropionaldehyde, and spermine is cleaved to spermidine and 3-aminopropionaldehyde.  A single enzyme catalyzing both reactions and designated as polyamine oxidase (I) was purified 4000-fold to electrophoretic homogeneity.  I appears to be a flavoprotein, contg. FAD as a prosthetic group.  H2O2 is evolved in the reaction and no other electron acceptors except mol. O were found.  The mol. wt. of I is approx. 60,000 and the sedimentation coeff. 4.5 S.  I appears to be a single polypeptide chain since no evidence for structural subunits was obtained.  I is sensitive to SH and carbonyl group reagents.  The optimum pH value for the oxidn. of polyamines was ∼10.  The reaction velocities were enhanced by various aldehydes, esp. certain arom. aldehydes.  I appears to be localized in peroxisomes of liver cells, although the existence of an isoenzyme in the cytosolic fraction was not definitively ruled out.  No marked changes were obsd. in the activity of I oxidase in rat liver after partial hepatectomy, CCl4 poisoning, and after treatment with growth hormone or thioacetamide, conditions which are known to alter profoundly the metab. and accumulation of polyamines.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq7b2EGIYg_drVg90H21EOLACvtfcHk0ljXEPomAZFmFg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaE2sXmslarsA%253D%253D&md5=506a5112dd6ef581cab177eb07a4fd54</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1021%2Fbi00620a015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi00620a015%26sid%3Dliteratum%253Aachs%26aulast%3DHoltta%26aufirst%3DE.%26atitle%3DOxidation%2520of%2520spermidine%2520and%2520spermine%2520in%2520rat%2520liver%253A%2520purification%2520and%2520properties%2520of%2520polyamine%2520oxidase%26jtitle%3DBiochemistry%26date%3D1977%26volume%3D16%26spage%3D91%26epage%3D100%26doi%3D10.1021%2Fbi00620a015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lan, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matson, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mulligan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whetstine, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cole, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casero, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, Y.</span></span> <span> </span><span class="NLM_article-title">Histone demethylation mediated by the nuclear amine oxidase homolog LSD1</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>119</i></span>,  <span class="NLM_fpage">941</span>– <span class="NLM_lpage">953</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2004.12.012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=10.1016%2Fj.cell.2004.12.012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=15620353" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=1%3ACAS%3A528%3ADC%252BD2MXltlSitg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=119&publication_year=2004&pages=941-953&author=Y.+Shiauthor=F.+Lanauthor=C.+Matsonauthor=P.+Mulliganauthor=J.+R.+Whetstineauthor=P.+A.+Coleauthor=R.+A.+Caseroauthor=Y.+Shi&title=Histone+demethylation+mediated+by+the+nuclear+amine+oxidase+homolog+LSD1&doi=10.1016%2Fj.cell.2004.12.012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Histone demethylation mediated by the nuclear amine oxidase homolog LSD1</span></div><div class="casAuthors">Shi, Yujiang; Lan, Fei; Matson, Caitlin; Mulligan, Peter; Whetstine, Johnathan R.; Cole, Philip A.; Casero, Robert A.; Shi, Yang</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">119</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">941-953</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Posttranslational modifications of histone N-terminal tails impact chromatin structure and gene transcription.  While the extent of histone acetylation is detd. by both acetyltransferases and deacetylases, it has been unclear whether histone methylation is also regulated by enzymes with opposing activities.  Here, we provide evidence that LSD1 (KIAA0601), a nuclear homolog of amine oxidases, functions as a histone demethylase and transcriptional corepressor.  LSD1 specifically demethylates histone H3 lysine 4, which is linked to active transcription.  Lysine demethylation occurs via an oxidn. reaction that generates formaldehyde.  Importantly, RNAi inhibition of LSD1 causes an increase in H3 lysine 4 methylation and concomitant derepression of target genes, suggesting that LSD1 represses transcription via histone demethylation.  The results thus identify a histone demethylase conserved from S. pombe to human and reveal dynamic regulation of histone methylation by both histone methylases and demethylases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrXHr-8kwGdXrVg90H21EOLACvtfcHk0ljXEPomAZFmFg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXltlSitg%253D%253D&md5=3474569204255e90a832667ba654748b</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2004.12.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2004.12.012%26sid%3Dliteratum%253Aachs%26aulast%3DShi%26aufirst%3DY.%26aulast%3DLan%26aufirst%3DF.%26aulast%3DMatson%26aufirst%3DC.%26aulast%3DMulligan%26aufirst%3DP.%26aulast%3DWhetstine%26aufirst%3DJ.%2BR.%26aulast%3DCole%26aufirst%3DP.%2BA.%26aulast%3DCasero%26aufirst%3DR.%2BA.%26aulast%3DShi%26aufirst%3DY.%26atitle%3DHistone%2520demethylation%2520mediated%2520by%2520the%2520nuclear%2520amine%2520oxidase%2520homolog%2520LSD1%26jtitle%3DCell%26date%3D2004%26volume%3D119%26spage%3D941%26epage%3D953%26doi%3D10.1016%2Fj.cell.2004.12.012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Finney, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moon, H.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ronnebaum, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lantz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mure, M.</span></span> <span> </span><span class="NLM_article-title">Human copper-dependent amine oxidases</span>. <i>Arch. Biochem. Biophys.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>546</i></span>,  <span class="NLM_fpage">19</span>– <span class="NLM_lpage">32</span>, <span class="refDoi"> DOI: 10.1016/j.abb.2013.12.022</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=10.1016%2Fj.abb.2013.12.022" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=24407025" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=1%3ACAS%3A528%3ADC%252BC2cXksFaisbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=546&publication_year=2014&pages=19-32&author=J.+Finneyauthor=H.-J.+Moonauthor=T.+Ronnebaumauthor=M.+Lantzauthor=M.+Mure&title=Human+copper-dependent+amine+oxidases&doi=10.1016%2Fj.abb.2013.12.022"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Human copper-dependent amine oxidases</span></div><div class="casAuthors">Finney, Joel; Moon, Hee-Jung; Ronnebaum, Trey; Lantz, Mason; Mure, Minae</div><div class="citationInfo"><span class="NLM_cas:title">Archives of Biochemistry and Biophysics</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">546</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">19-32</span>CODEN:
                <span class="NLM_cas:coden">ABBIA4</span>;
        ISSN:<span class="NLM_cas:issn">0003-9861</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Copper amine oxidases (CAOs) are a class of enzymes that contain Cu2+ and a tyrosine-derived quinone cofactor, and catalyze the conversion of a primary amine functional group to an aldehyde, generating H2O2 and NH3 as byproducts.  These enzymes can be classified into 2 non-homologous families: 2,4,5-trihydroxyphenylalanine quinone (TPQ)-dependent CAOs and the lysine tyrosylquinone (LTQ)-dependent lysyl oxidase (LOX) family of proteins.  Here, the authors focus on recent developments in the field of research concerning human CAOs and the LOX family of proteins.  The aberrant expression of these enzymes is linked to inflammation, fibrosis, tumor metastasis/invasion, and other diseases.  Consequently, there is a crit. need to understand the functions of these proteins at the mol. level, so that strategies targeting these enzymes can be developed to combat human diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoxp8xJQhX_qLVg90H21EOLACvtfcHk0ljXEPomAZFmFg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXksFaisbs%253D&md5=f7ecc08c322917ac6c9bf96636b49575</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1016%2Fj.abb.2013.12.022&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.abb.2013.12.022%26sid%3Dliteratum%253Aachs%26aulast%3DFinney%26aufirst%3DJ.%26aulast%3DMoon%26aufirst%3DH.-J.%26aulast%3DRonnebaum%26aufirst%3DT.%26aulast%3DLantz%26aufirst%3DM.%26aulast%3DMure%26aufirst%3DM.%26atitle%3DHuman%2520copper-dependent%2520amine%2520oxidases%26jtitle%3DArch.%2520Biochem.%2520Biophys.%26date%3D2014%26volume%3D546%26spage%3D19%26epage%3D32%26doi%3D10.1016%2Fj.abb.2013.12.022" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bieganski, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kusche, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lorenz, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hesterberg, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stahlknecht, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feussner, K.</span></span> <span> </span><span class="NLM_article-title">Distribution and properties of human intestinal diamine oxidase and its relevance for the histamine catabolism</span>. <i>Biochim. Biophys. Acta</i> <span class="NLM_year" style="font-weight: bold;">1983</span>,  <span class="NLM_volume"><i>756</i></span>,  <span class="NLM_fpage">196</span>– <span class="NLM_lpage">203</span>, <span class="refDoi"> DOI: 10.1016/0304-4165(83)90092-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=10.1016%2F0304-4165%2883%2990092-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=6403048" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=1%3ACAS%3A528%3ADyaL3sXhsFKqtr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=756&publication_year=1983&pages=196-203&author=T.+Bieganskiauthor=J.+Kuscheauthor=W.+Lorenzauthor=R.+Hesterbergauthor=C.+Stahlknechtauthor=K.+Feussner&title=Distribution+and+properties+of+human+intestinal+diamine+oxidase+and+its+relevance+for+the+histamine+catabolism&doi=10.1016%2F0304-4165%2883%2990092-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Distribution and properties of human intestinal diamine oxidase and its relevance for the histamine catabolism</span></div><div class="casAuthors">Bieganski, Tadeusz; Kusche, Juergen; Lorenz, Wilfried; Hesterberg, Rudolf; Stahlknecht, Carl Detmar; Feussner, Klaus Dieter</div><div class="citationInfo"><span class="NLM_cas:title">Biochimica et Biophysica Acta, General Subjects</span>
        (<span class="NLM_cas:date">1983</span>),
    <span class="NLM_cas:volume">756</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">196-203</span>CODEN:
                <span class="NLM_cas:coden">BBGSB3</span>;
        ISSN:<span class="NLM_cas:issn">0304-4165</span>.
    </div><div class="casAbstract">High activities of diamine oxidase (EC 1.4.3.6) (I) were measured in the intestinal tract of human subjects and of several mammalian species.  I was localized in the mucosa and was distributed primarily in the cytoplasm; the only exception being the guinea pig, where it was located in the particulate fraction.  Despite its instability, I from human colonic mucosa was purified 80-fold.  During the purifn., a sol. monoamine oxidase (EC 1.4.3.4) was sepd. from I.  The pH optima of I for putrescine and histamine were 6.6-7.0 and 6.4-6.6, resp.  Short-chain aliph. diamines were deaminated with the highest reaction velocity, but histamine and Nτ-methylhistamine were also excellent substrates.  The Km for putrescine was 8.3 × 10-5M, for histamine 1.9 × 10-5M, and for Nτ-methylhistamine 9.7 × 10-5M.  Typical substrates of monoamine oxidase were not deaminated by the enzyme.  Aminoguanidine strongly inhibited human intestinal I (IC50 = 1.1 × 10-8M).  Because of its properties, intestinal I is considered to play a protective role against histamine in diseases, such as ischemic bowel syndrome, mesenteric infarction, and ulcerative colitis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrE0FYj-GaaXrVg90H21EOLACvtfcHk0lgjp3hCqugz6A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL3sXhsFKqtr8%253D&md5=f8a04658ccca6efcbd2e9e4344b1aa01</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1016%2F0304-4165%2883%2990092-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0304-4165%252883%252990092-2%26sid%3Dliteratum%253Aachs%26aulast%3DBieganski%26aufirst%3DT.%26aulast%3DKusche%26aufirst%3DJ.%26aulast%3DLorenz%26aufirst%3DW.%26aulast%3DHesterberg%26aufirst%3DR.%26aulast%3DStahlknecht%26aufirst%3DC.%26aulast%3DFeussner%26aufirst%3DK.%26atitle%3DDistribution%2520and%2520properties%2520of%2520human%2520intestinal%2520diamine%2520oxidase%2520and%2520its%2520relevance%2520for%2520the%2520histamine%2520catabolism%26jtitle%3DBiochim.%2520Biophys.%2520Acta%26date%3D1983%26volume%3D756%26spage%3D196%26epage%3D203%26doi%3D10.1016%2F0304-4165%2883%2990092-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kaitaniemi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elovaara, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grön, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kidron, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liukkonen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salminen, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salmi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jalkanen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elima, K.</span></span> <span> </span><span class="NLM_article-title">The unique substrate specificity of human AOC2, a semicarbazide-sensitive amine oxidase</span>. <i>Cell. Mol. Life Sci.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>66</i></span>,  <span class="NLM_fpage">2743</span>– <span class="NLM_lpage">2757</span>, <span class="refDoi"> DOI: 10.1007/s00018-009-0076-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=10.1007%2Fs00018-009-0076-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=19588076" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=1%3ACAS%3A528%3ADC%252BD1MXovFOks7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2009&pages=2743-2757&author=S.+Kaitaniemiauthor=H.+Elovaaraauthor=K.+Gr%C3%B6nauthor=H.+Kidronauthor=J.+Liukkonenauthor=T.+Salminenauthor=M.+Salmiauthor=S.+Jalkanenauthor=K.+Elima&title=The+unique+substrate+specificity+of+human+AOC2%2C+a+semicarbazide-sensitive+amine+oxidase&doi=10.1007%2Fs00018-009-0076-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">The unique substrate specificity of human AOC2, a semicarbazide-sensitive amine oxidase</span></div><div class="casAuthors">Kaitaniemi, Sam; Elovaara, Heli; Gron, Kirsi; Kidron, Heidi; Liukkonen, Janne; Salminen, Tiina; Salmi, Marko; Jalkanen, Sirpa; Elima, Kati</div><div class="citationInfo"><span class="NLM_cas:title">Cellular and Molecular Life Sciences</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">2743-2757</span>CODEN:
                <span class="NLM_cas:coden">CMLSFI</span>;
        ISSN:<span class="NLM_cas:issn">1420-682X</span>.
    
            (<span class="NLM_cas:orgname">Birkhaeuser Verlag</span>)
        </div><div class="casAbstract">Semicarbazide-sensitive amine oxidases (SSAOs) catalyze oxidative deamination of primary amines, but the true physiol. function of these enzymes is still poorly understood.  Here, we have studied the functional and structural characteristics of a human cell-surface SSAO, AOC2, which is homologous to the better characterized family member, AOC3.  The preferred in vitro substrates of AOC2 were found to be 2-phenylethylamine, tryptamine and p-tyramine instead of methylamine and benzylamine, the favored substrates of AOC3.  Mol. modeling suggested structural differences between AOC2 and AOC3, which provide AOC2 with the capability to use the larger monoamines as substrates.  Even though AOC2 mRNA was expressed in many tissues, the only tissues with detectable AOC2-like enzyme activity were found in the eye.  Characterization of AOC2 will help in evaluating the contribution of this enzyme to the pathol. processes attributed to the SSAO activity and in designing specific inhibitors for the individual members of the SSAO family.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoGlTVwhsB7jbVg90H21EOLACvtfcHk0lgjp3hCqugz6A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXovFOks7k%253D&md5=9d060e7ed40263731d903fbb1463083b</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1007%2Fs00018-009-0076-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00018-009-0076-5%26sid%3Dliteratum%253Aachs%26aulast%3DKaitaniemi%26aufirst%3DS.%26aulast%3DElovaara%26aufirst%3DH.%26aulast%3DGr%25C3%25B6n%26aufirst%3DK.%26aulast%3DKidron%26aufirst%3DH.%26aulast%3DLiukkonen%26aufirst%3DJ.%26aulast%3DSalminen%26aufirst%3DT.%26aulast%3DSalmi%26aufirst%3DM.%26aulast%3DJalkanen%26aufirst%3DS.%26aulast%3DElima%26aufirst%3DK.%26atitle%3DThe%2520unique%2520substrate%2520specificity%2520of%2520human%2520AOC2%252C%2520a%2520semicarbazide-sensitive%2520amine%2520oxidase%26jtitle%3DCell.%2520Mol.%2520Life%2520Sci.%26date%3D2009%26volume%3D66%26spage%3D2743%26epage%3D2757%26doi%3D10.1007%2Fs00018-009-0076-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Salmi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jalkanen, S.</span></span> <span> </span><span class="NLM_article-title">Vascular Adhesion Protein-1: A cell surface amine oxidase in translation</span>. <i>Antioxid. Redox Signaling</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">314</span>– <span class="NLM_lpage">332</span>, <span class="refDoi"> DOI: 10.1089/ars.2017.7418</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=10.1089%2Fars.2017.7418" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=29065711" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisFSmsrjM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2019&pages=314-332&author=M.+Salmiauthor=S.+Jalkanen&title=Vascular+Adhesion+Protein-1%3A+A+cell+surface+amine+oxidase+in+translation&doi=10.1089%2Fars.2017.7418"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7aR"><div class="casContent"><span class="casTitleNuber">7a</span><div class="casTitle"><span class="NLM_cas:atitle">Vascular Adhesion Protein-1: A Cell Surface Amine Oxidase in Translation</span></div><div class="casAuthors">Salmi, Marko; Jalkanen, Sirpa</div><div class="citationInfo"><span class="NLM_cas:title">Antioxidants & Redox Signaling</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">314-332</span>CODEN:
                <span class="NLM_cas:coden">ARSIF2</span>;
        ISSN:<span class="NLM_cas:issn">1523-0864</span>.
    
            (<span class="NLM_cas:orgname">Mary Ann Liebert, Inc.</span>)
        </div><div class="casAbstract">Significance: Vascular adhesion protein-1 (VAP-1) is an ectoenzyme that oxidates primary amines in a reaction producing also hydrogen peroxide.  VAP-1 on the blood vessel endothelium regulates leukocyte extravasation from the blood into tissues under physiol. and pathol. conditions.  Recent Advances: Inhibition of VAP-1 by neutralizing antibodies and by several novel small-mol. enzyme inhibitors interferes with leukocyte trafficking and alleviates inflammation in many exptl. models.  Targeting of VAP-1 also shows beneficial effects in several other diseases, such as ischemia/reperfusion, fibrosis, and cancer.  Moreover, sol. VAP-1 levels may serve as a new prognostic biomarker in selected diseases.  Crit. Issues: Understanding the contribution of the enzyme activity-independent and enzyme activity-dependent functions, which often appear to be mediated by the hydrogen peroxide prodn., in the VAP-1 biol. will be crucial.  Similarly, there is a pressing need to understand which of the VAP-1 functions are regulated through the modulation of leukocyte trafficking, and what is the role of VAP-1 synthesized in adipose and smooth muscle cells.  Future Directions: The specificity and selectivity of new VAP-1 inhibitors, and their value in animal models under therapeutic settings need to be addressed.  Results from several programs studying the therapeutic potential of VAP-1 inhibition, which now are in clin. trials, will reveal the relevance of this amine oxidase in humans.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqzT3nhTaWvqLVg90H21EOLACvtfcHk0lgjp3hCqugz6A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisFSmsrjM&md5=5fe646b1e851f3e4e2c25e14cb32dec7</span></div><a href="/servlet/linkout?suffix=cit7a&amp;dbid=16384&amp;doi=10.1089%2Fars.2017.7418&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1089%252Fars.2017.7418%26sid%3Dliteratum%253Aachs%26aulast%3DSalmi%26aufirst%3DM.%26aulast%3DJalkanen%26aufirst%3DS.%26atitle%3DVascular%2520Adhesion%2520Protein-1%253A%2520A%2520cell%2520surface%2520amine%2520oxidase%2520in%2520translation%26jtitle%3DAntioxid.%2520Redox%2520Signaling%26date%3D2019%26volume%3D30%26spage%3D314%26epage%3D332%26doi%3D10.1089%2Fars.2017.7418" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit7b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Jarnicki, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schilter, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wheeldon, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Essilfie, A.-T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foot, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yow, T. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jarolimek, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hansbro, P. M.</span></span> <span> </span><span class="NLM_article-title">The inhibitor of semicarbazide-sensitive amine oxidase, PXS-4728A, ameliorates key features of chronic obstructive pulmonary disease in a mouse model</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>173</i></span>,  <span class="NLM_fpage">3161</span>– <span class="NLM_lpage">3175</span>, <span class="refDoi"> DOI: 10.1111/bph.13573</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=10.1111%2Fbph.13573" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=27495192" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht12nt7bP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=173&publication_year=2016&pages=3161-3175&author=A.+G.+Jarnickiauthor=H.+Schilterauthor=G.+Liuauthor=K.+Wheeldonauthor=A.-T.+Essilfieauthor=J.+S.+Footauthor=T.+T.+Yowauthor=W.+Jarolimekauthor=P.+M.+Hansbro&title=The+inhibitor+of+semicarbazide-sensitive+amine+oxidase%2C+PXS-4728A%2C+ameliorates+key+features+of+chronic+obstructive+pulmonary+disease+in+a+mouse+model&doi=10.1111%2Fbph.13573"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7bR"><div class="casContent"><span class="casTitleNuber">7b</span><div class="casTitle"><span class="NLM_cas:atitle">A novel SSAO inhibitor PXS-4728A suppresses inflammation and fibrosis and improves lung function in experimental chronic obstructive pulmonary disease</span></div><div class="casAuthors">Jarnicki, A. G.; Schilter, H.; Liu, G.; Wheeldon, K.; Essilfie, A-T.; Foot, J. S.; Yow, T. T.; Jarolimek, W.; Hansbro, P. M.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">173</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">3161-3175</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Background and Purpose : Chronic obstructive pulmonary disease (COPD) is a major cause of illness and death that is often induced by cigarette smoking (CS).  It is characterised by pulmonary inflammation and fibrosis that impairs lung function.  Existing pharmaceuticals aim to control symptoms but have low efficacy, and there are no broadly effective treatments.  A potential new therapeutic target is ectoenzyme semicarbazide-sensitive mono-amine oxidase (SSAO, or vascular adhesion protein-1, VAP-1).  SSAO is elevated in smokers serum, and is a pro-inflammatory enzyme that facilitates the adhesion and transmigration of leukocytes from the vasculature to sites of inflammation.  Exptl. Approach : PXS-4728A has been developed as a small mol. inhibitor of SSAO.  We tested its ability to suppress SSAO activity and ameliorate inflammation and hallmark features of human disease in a mouse model of CS-induced exptl. COPD.  The model replicates key aspects of human COPD, including chronic airway inflammation, fibrosis and impaired lung function.  Key Results : PXS-4728A treatment completely inhibited lung and systemic SSAO activity induced by acute and chronic CS exposure.  Daily oral treatment inhibited airway inflammation (immune cell influx and inflammatory factors) induced by acute CS exposure.  Therapeutic treatment during chronic CS-exposure, when the key features of exptl. COPD develop and progress, substantially suppressed inflammatory cell influx and fibrosis in the airways and improved lung function.  Conclusions and Implications : Treatment with the SSAO small mol. inhibitor, PXS-4728A, suppresses airway inflammation and fibrosis and improves lung function in exptl. COPD.  This study demonstrates the therapeutic potential of PXS-4728A for this debilitating disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpKWBKDI9C0ibVg90H21EOLACvtfcHk0lgjp3hCqugz6A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht12nt7bP&md5=f0d0b1edba9246169d2584d3ceabf881</span></div><a href="/servlet/linkout?suffix=cit7b&amp;dbid=16384&amp;doi=10.1111%2Fbph.13573&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbph.13573%26sid%3Dliteratum%253Aachs%26aulast%3DJarnicki%26aufirst%3DA.%2BG.%26aulast%3DSchilter%26aufirst%3DH.%26aulast%3DLiu%26aufirst%3DG.%26aulast%3DWheeldon%26aufirst%3DK.%26aulast%3DEssilfie%26aufirst%3DA.-T.%26aulast%3DFoot%26aufirst%3DJ.%2BS.%26aulast%3DYow%26aufirst%3DT.%2BT.%26aulast%3DJarolimek%26aufirst%3DW.%26aulast%3DHansbro%26aufirst%3DP.%2BM.%26atitle%3DThe%2520inhibitor%2520of%2520semicarbazide-sensitive%2520amine%2520oxidase%252C%2520PXS-4728A%252C%2520ameliorates%2520key%2520features%2520of%2520chronic%2520obstructive%2520pulmonary%2520disease%2520in%2520a%2520mouse%2520model%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2016%26volume%3D173%26spage%3D3161%26epage%3D3175%26doi%3D10.1111%2Fbph.13573" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schwelberger, H. G.</span></span> <span> </span><span class="NLM_article-title">The origin of mammalian plasma amine oxidases</span>. <i>J. Neural Transm.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>114</i></span>,  <span class="NLM_fpage">757</span>– <span class="NLM_lpage">762</span>, <span class="refDoi"> DOI: 10.1007/s00702-007-0684-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=10.1007%2Fs00702-007-0684-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=17385066" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=1%3ACAS%3A528%3ADC%252BD2sXls1Sgt74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=114&publication_year=2007&pages=757-762&author=H.+G.+Schwelberger&title=The+origin+of+mammalian+plasma+amine+oxidases&doi=10.1007%2Fs00702-007-0684-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">The origin of mammalian plasma amine oxidases</span></div><div class="casAuthors">Schwelberger, H. G.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neural Transmission</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">114</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">757-762</span>CODEN:
                <span class="NLM_cas:coden">JNTRF3</span>;
        ISSN:<span class="NLM_cas:issn">0300-9564</span>.
    
            (<span class="NLM_cas:orgname">Springer Wien</span>)
        </div><div class="casAbstract">Mammalian blood plasma contains considerable activity of sol. copper-contg. amine oxidase (AOC) referred to as plasma or serum amine oxidase (SAO).  The identity and origin of SAO was investigated based on the recent characterization of four porcine AOC genes with AOC1 encoding diamine oxidase (DAO), AOC2 retina-specific amine oxidase (RAO), AOC3 vascular adhesion protein-1 (VAP-1), and AOC4 a VAP-1 homolog that is expressed mainly in the liver and has a signal peptide sequence instead of a transmembrane domain at its N-terminus.  Purifn. and characterization of the major amine oxidase activity from porcine serum showed that it is the product of the AOC4 gene.  Intriguingly, all mammals possessing a functional AOC4 gene exhibit high plasma amine oxidase activity.  Humans and rodents lack a functional AOC4 gene and have comparably low plasma amine oxidase activity that is probably derived from partial proteolytic release of the membrane-assocd. AOC3 gene product VAP-1.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpGIWSRKZtvl7Vg90H21EOLACvtfcHk0liMQ6iJWrWkRw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXls1Sgt74%253D&md5=d59b572685cd7ca5ebd7945551fc3278</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1007%2Fs00702-007-0684-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00702-007-0684-x%26sid%3Dliteratum%253Aachs%26aulast%3DSchwelberger%26aufirst%3DH.%2BG.%26atitle%3DThe%2520origin%2520of%2520mammalian%2520plasma%2520amine%2520oxidases%26jtitle%3DJ.%2520Neural%2520Transm.%26date%3D2007%26volume%3D114%26spage%3D757%26epage%3D762%26doi%3D10.1007%2Fs00702-007-0684-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Barker, H. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cox, T. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erler, J. T.</span></span> <span> </span><span class="NLM_article-title">The rationale for targeting the LOX family in cancer</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">540</span>– <span class="NLM_lpage">552</span>, <span class="refDoi"> DOI: 10.1038/nrc3319</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=10.1038%2Fnrc3319" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=22810810" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtVCltLfE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2012&pages=540-552&author=H.+E.+Barkerauthor=T.+R.+Coxauthor=J.+T.+Erler&title=The+rationale+for+targeting+the+LOX+family+in+cancer&doi=10.1038%2Fnrc3319"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">The rationale for targeting the LOX family in cancer</span></div><div class="casAuthors">Barker, Holly E.; Cox, Thomas R.; Erler, Janine T.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">540-552</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The therapeutic targeting of extracellular proteins is becoming hugely attractive in light of evidence implicating the tumor microenvironment as pivotal in all aspects of tumor initiation and progression.  Members of the lysyl oxidase (LOX) family of proteins are secreted by tumors and are the subject of much effort to understand their roles in cancer.  In this Review we discuss the roles of members of this family in the remodelling of the tumor microenvironment and their paradoxical roles in tumorigenesis and metastasis.  We also discuss how targeting this family of proteins might lead to a new avenue of cancer therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrZcLr3Y7rPKLVg90H21EOLACvtfcHk0liMQ6iJWrWkRw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtVCltLfE&md5=455064ea8d5332b43fa6490a1aaa0c8f</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1038%2Fnrc3319&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc3319%26sid%3Dliteratum%253Aachs%26aulast%3DBarker%26aufirst%3DH.%2BE.%26aulast%3DCox%26aufirst%3DT.%2BR.%26aulast%3DErler%26aufirst%3DJ.%2BT.%26atitle%3DThe%2520rationale%2520for%2520targeting%2520the%2520LOX%2520family%2520in%2520cancer%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2012%26volume%3D12%26spage%3D540%26epage%3D552%26doi%3D10.1038%2Fnrc3319" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Grau-Bové, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruiz-Trillo, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodriguez-Pascual, F.</span></span> <span> </span><span class="NLM_article-title">Origin and evolution of lysyl oxidases</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">10568</span>, <span class="refDoi"> DOI: 10.1038/srep10568</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=10.1038%2Fsrep10568" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=26024311" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=1%3ACAS%3A280%3ADC%252BC2MfovFyksw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2015&pages=10568&author=X.+Grau-Bov%C3%A9author=I.+Ruiz-Trilloauthor=F.+Rodriguez-Pascual&title=Origin+and+evolution+of+lysyl+oxidases&doi=10.1038%2Fsrep10568"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Origin and evolution of lysyl oxidases</span></div><div class="casAuthors">Grau-Bove Xavier; Ruiz-Trillo Inaki; Rodriguez-Pascual Fernando</div><div class="citationInfo"><span class="NLM_cas:title">Scientific reports</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">10568</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Lysyl oxidases (LOX) are copper-dependent enzymes that oxidize primary amine substrates to reactive aldehydes.  The best-studied role of LOX enzymes is the remodeling of the extracellular matrix (ECM) in animals by cross-linking collagens and elastin, although intracellular functions have been reported as well.  Five different LOX enzymes have been identified in mammals, LOX and LOX-like (LOXL) 1 to 4, showing a highly conserved catalytic carboxy terminal domain and more divergence in the rest of the sequence.  Here we have surveyed a wide selection of genomes in order to infer the evolutionary history of LOX.  We identified LOX proteins not only in animals, but also in many other eukaryotes, as well as in bacteria and archaea - which reveals a pre-metazoan origin for this gene family.  LOX genes expanded during metazoan evolution resulting in two superfamilies, LOXL2/L3/L4 and LOX/L1/L5.  Considering the current knowledge on the function of mammalian LOX isoforms in ECM remodeling, we propose that LOXL2/L3/L4 members might have preferentially been involved in making cross-linked collagen IV-based basement membrane, whereas the diversification of LOX/L1/L5 forms contributed to chordate/vertebrate-specific ECM innovations, such as elastin and fibronectin.  Our work provides a novel view on the evolution of this family of enzymes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTHiDw73o3Ogn6oPH0mYWL1fW6udTcc2eaufUqyNcn0n7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2MfovFyksw%253D%253D&md5=ca8f3e5364edb3e5d19742d09d78b82a</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1038%2Fsrep10568&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsrep10568%26sid%3Dliteratum%253Aachs%26aulast%3DGrau-Bov%25C3%25A9%26aufirst%3DX.%26aulast%3DRuiz-Trillo%26aufirst%3DI.%26aulast%3DRodriguez-Pascual%26aufirst%3DF.%26atitle%3DOrigin%2520and%2520evolution%2520of%2520lysyl%2520oxidases%26jtitle%3DSci.%2520Rep.%26date%3D2015%26volume%3D5%26spage%3D10568%26doi%3D10.1038%2Fsrep10568" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Ricard-Blum, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ville, G.</span></span> <span> </span><span class="NLM_article-title">Collagen cross-linking</span>. <i>Int. J. Biochem.</i> <span class="NLM_year" style="font-weight: bold;">1989</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">1185</span>– <span class="NLM_lpage">1189</span>, <span class="refDoi"> DOI: 10.1016/0020-711x(89)90001-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=10.1016%2F0020-711x%2889%2990001-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=2575544" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=1%3ACAS%3A528%3ADyaK3cXnt1enuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=1989&pages=1185-1189&author=S.+Ricard-Blumauthor=G.+Ville&title=Collagen+cross-linking&doi=10.1016%2F0020-711x%2889%2990001-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11aR"><div class="casContent"><span class="casTitleNuber">11a</span><div class="casTitle"><span class="NLM_cas:atitle">Collagen cross-linking</span></div><div class="casAuthors">Ricard-Blum, S.; Ville, G.</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Biochemistry</span>
        (<span class="NLM_cas:date">1989</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1185-9</span>CODEN:
                <span class="NLM_cas:coden">IJBOBV</span>;
        ISSN:<span class="NLM_cas:issn">0020-711X</span>.
    </div><div class="casAbstract">A review, with 16 refs., on collagen crosslink formation, structure, and function in various tissues.  Metabolic and pathol. aspects of collagen crosslinking are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpY7IcRU8v0gLVg90H21EOLACvtfcHk0lj83ZBNaKUjFw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3cXnt1enuw%253D%253D&md5=8745eca7bdba7a42504283b5e28002af</span></div><a href="/servlet/linkout?suffix=cit11a&amp;dbid=16384&amp;doi=10.1016%2F0020-711x%2889%2990001-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0020-711x%252889%252990001-3%26sid%3Dliteratum%253Aachs%26aulast%3DRicard-Blum%26aufirst%3DS.%26aulast%3DVille%26aufirst%3DG.%26atitle%3DCollagen%2520cross-linking%26jtitle%3DInt.%2520J.%2520Biochem.%26date%3D1989%26volume%3D21%26spage%3D1185%26epage%3D1189%26doi%3D10.1016%2F0020-711x%2889%2990001-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit11b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Yamauchi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sricholpech, M.</span></span> <span> </span><span class="NLM_article-title">Lysine post-translational modifications of collagen</span>. <i>Essays Biochem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">113</span>– <span class="NLM_lpage">133</span>, <span class="refDoi"> DOI: 10.1042/bse0520113</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=10.1042%2Fbse0520113" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=22708567" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht1ShurrK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2012&pages=113-133&author=M.+Yamauchiauthor=M.+Sricholpech&title=Lysine+post-translational+modifications+of+collagen&doi=10.1042%2Fbse0520113"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11bR"><div class="casContent"><span class="casTitleNuber">11b</span><div class="casTitle"><span class="NLM_cas:atitle">Lysine post-translational modifications of collagen</span></div><div class="casAuthors">Yamauchi, Mitsuo; Sricholpech, Marnisa</div><div class="citationInfo"><span class="NLM_cas:title">Essays in Biochemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">Lysine-Based Post-Translational Modification of Proteins</span>),
    <span class="NLM_cas:pages">113-133</span>CODEN:
                <span class="NLM_cas:coden">ESBIAV</span>;
        ISSN:<span class="NLM_cas:issn">0071-1365</span>.
    
            (<span class="NLM_cas:orgname">Portland Press Ltd.</span>)
        </div><div class="casAbstract">A review.  Type I collagen is the most abundant structural protein in vertebrates.  It is a heterotrimeric mol. composed of two α1 chains and one α2 chain, forming a long uninterrupted triple helical structure with short non-triple helical telopeptides at both the N- and C-termini.  During biosynthesis, collagen acquires a no. of post-translational modifications, including lysine modifications, that are crit. to the structure and biol. functions of this protein.  Lysine modifications of collagen are highly complicated sequential processes catalyzed by several groups of enzymes leading to the final step of biosynthesis, covalent intermol. crosslinking.  In the cell, specific lysine residues are hydroxylated to form hydroxylysine.  Then specific hydroxylysine residues located in the helical domain of the mol. are glycosylated by the addn. of galactose or glucose-galactose.  Outside the cell, lysine and hydroxylysine residues in the N- and C-telopeptides can be oxidatively deaminated to produce reactive aldehydes that undergo a series of non-enzymic condensation reactions to form covalent intra- and inter-mol. cross-links.  Owing to the recent advances in mol. and cellular biol., and anal. technologies, the biol. significance and mol. mechanisms of these modifications have been gradually elucidated.  This chapter provides an overview on these enzymic lysine modifications and subsequent crosslinking.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoAZ1dEKotSOLVg90H21EOLACvtfcHk0lj83ZBNaKUjFw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht1ShurrK&md5=2aa838a0513d3ed1a8ea6e8ab579f56e</span></div><a href="/servlet/linkout?suffix=cit11b&amp;dbid=16384&amp;doi=10.1042%2Fbse0520113&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1042%252Fbse0520113%26sid%3Dliteratum%253Aachs%26aulast%3DYamauchi%26aufirst%3DM.%26aulast%3DSricholpech%26aufirst%3DM.%26atitle%3DLysine%2520post-translational%2520modifications%2520of%2520collagen%26jtitle%3DEssays%2520Biochem.%26date%3D2012%26volume%3D52%26spage%3D113%26epage%3D133%26doi%3D10.1042%2Fbse0520113" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Starcher, B. C.</span></span> <span> </span><span class="NLM_article-title">Elastin and the lung</span>. <i>Thorax</i> <span class="NLM_year" style="font-weight: bold;">1986</span>,  <span class="NLM_volume"><i>41</i></span>,  <span class="NLM_fpage">577</span>– <span class="NLM_lpage">585</span>, <span class="refDoi"> DOI: 10.1136/thx.41.8.577</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=10.1136%2Fthx.41.8.577" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=3538485" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=1%3ACAS%3A528%3ADyaL28Xls12nsb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=1986&pages=577-585&author=B.+C.+Starcher&title=Elastin+and+the+lung&doi=10.1136%2Fthx.41.8.577"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12aR"><div class="casContent"><span class="casTitleNuber">12a</span><div class="casTitle"><span class="NLM_cas:atitle">Elastin and the lung</span></div><div class="casAuthors">Starcher, B. C.</div><div class="citationInfo"><span class="NLM_cas:title">Thorax</span>
        (<span class="NLM_cas:date">1986</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">577-85</span>CODEN:
                <span class="NLM_cas:coden">THORA7</span>;
        ISSN:<span class="NLM_cas:issn">0040-6376</span>.
    </div><div class="casAbstract">A review, with 71 refs.  Topics include the isolation, structure, formation, and degrdn. of elastin, elastases and their inhibitors, elastin fiber structure and function, exptl. disruption of elastin in the lung, repair of lung damage, and the effects of tobacco smoke and infection and nutrition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpUR73B-lphPLVg90H21EOLACvtfcHk0lj83ZBNaKUjFw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL28Xls12nsb8%253D&md5=85ebfcfebab5bd54817350ca4a934230</span></div><a href="/servlet/linkout?suffix=cit12a&amp;dbid=16384&amp;doi=10.1136%2Fthx.41.8.577&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1136%252Fthx.41.8.577%26sid%3Dliteratum%253Aachs%26aulast%3DStarcher%26aufirst%3DB.%2BC.%26atitle%3DElastin%2520and%2520the%2520lung%26jtitle%3DThorax%26date%3D1986%26volume%3D41%26spage%3D577%26epage%3D585%26doi%3D10.1136%2Fthx.41.8.577" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit12b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Herchenhan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uhlenbrock, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eliasson, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weis, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eyre, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kadler, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magnusson, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kjaer, M.</span></span> <span> </span><span class="NLM_article-title">Lysyl oxidase activity is required for ordered collagen fibrillogenesis by tendon cells</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>290</i></span>,  <span class="NLM_fpage">16440</span>– <span class="NLM_lpage">16450</span>, <span class="refDoi"> DOI: 10.1074/jbc.m115.641670</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=10.1074%2Fjbc.m115.641670" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=25979340" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=1%3ACAS%3A528%3ADC%252BC2MXht1amur3F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=290&publication_year=2015&pages=16440-16450&author=A.+Herchenhanauthor=F.+Uhlenbrockauthor=P.+Eliassonauthor=M.+Weisauthor=D.+Eyreauthor=K.+E.+Kadlerauthor=S.+P.+Magnussonauthor=M.+Kjaer&title=Lysyl+oxidase+activity+is+required+for+ordered+collagen+fibrillogenesis+by+tendon+cells&doi=10.1074%2Fjbc.m115.641670"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12bR"><div class="casContent"><span class="casTitleNuber">12b</span><div class="casTitle"><span class="NLM_cas:atitle">Lysyl Oxidase Activity Is Required for Ordered Collagen Fibrillogenesis by Tendon Cells</span></div><div class="casAuthors">Herchenhan, Andreas; Uhlenbrock, Franziska; Eliasson, Pernilla; Weis, MaryAnn; Eyre, David; Kadler, Karl E.; Magnusson, S. Peter; Kjaer, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">290</span>
        (<span class="NLM_cas:issue">26</span>),
    <span class="NLM_cas:pages">16440-16450</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Lysyl oxidases (LOXs) are a family of copper-dependent oxido-deaminases that can modify the side chain of lysyl residues in collagen and elastin, thereby leading to the spontaneous formation of non-reducible aldehyde-derived interpolypeptide chain cross-links.  The consequences of LOX inhibition in producing lathyrism are well documented, but the consequences on collagen fibril formation are less clear.  Here we used β-aminoproprionitrile (BAPN) to inhibit LOX in tendon-like constructs (prepd. from human tenocytes), which are an exptl. model of cell-mediated collagen fibril formation.  The improvement in structure and strength seen with time in control constructs was absent in constructs treated with BAPN.  As expected, BAPN inhibited the formation of aldimine-derived cross-links in collagen, and the constructs were mech. weak.  However, an unexpected finding was that BAPN treatment led to structurally abnormal collagen fibrils with irregular profiles and widely dispersed diams.  Of special interest, the abnormal fibril profiles resembled those seen in some Ehlers-Danlos Syndrome phenotypes.  Importantly, the total collagen content developed normally, and there was no difference in COL1A1 gene expression.  Collagen type V, decorin, fibromodulin, and tenascin-X proteins were unaffected by the cross-link inhibition, suggesting that LOX regulates fibrillogenesis independently of these mols.  Collectively, the data show the importance of LOX for the mech. development of early collagenous tissues and that LOX is essential for correct collagen fibril shape formation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqWM9x9JgC8O7Vg90H21EOLACvtfcHk0lj83ZBNaKUjFw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXht1amur3F&md5=724abdfe7e2e6b993199828e94f35460</span></div><a href="/servlet/linkout?suffix=cit12b&amp;dbid=16384&amp;doi=10.1074%2Fjbc.m115.641670&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.m115.641670%26sid%3Dliteratum%253Aachs%26aulast%3DHerchenhan%26aufirst%3DA.%26aulast%3DUhlenbrock%26aufirst%3DF.%26aulast%3DEliasson%26aufirst%3DP.%26aulast%3DWeis%26aufirst%3DM.%26aulast%3DEyre%26aufirst%3DD.%26aulast%3DKadler%26aufirst%3DK.%2BE.%26aulast%3DMagnusson%26aufirst%3DS.%2BP.%26aulast%3DKjaer%26aufirst%3DM.%26atitle%3DLysyl%2520oxidase%2520activity%2520is%2520required%2520for%2520ordered%2520collagen%2520fibrillogenesis%2520by%2520tendon%2520cells%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2015%26volume%3D290%26spage%3D16440%26epage%3D16450%26doi%3D10.1074%2Fjbc.m115.641670" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">He, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Y.</span></span> <span> </span><span class="NLM_article-title">Mechanisms of fibrosis in acute liver failure</span>. <i>Liver Int.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>35</i></span>,  <span class="NLM_fpage">1877</span>– <span class="NLM_lpage">1885</span>, <span class="refDoi"> DOI: 10.1111/liv.12731</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=10.1111%2Fliv.12731" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=25388426" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtVaju7nN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2015&pages=1877-1885&author=Y.+Heauthor=L.+Jinauthor=J.+Wangauthor=Z.+Yanauthor=T.+Chenauthor=Y.+Zhao&title=Mechanisms+of+fibrosis+in+acute+liver+failure&doi=10.1111%2Fliv.12731"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13aR"><div class="casContent"><span class="casTitleNuber">13a</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanisms of fibrosis in acute liver failure</span></div><div class="casAuthors">He, Yingli; Jin, Li; Wang, Jing; Yan, Zhi; Chen, Tianyan; Zhao, Yingren</div><div class="citationInfo"><span class="NLM_cas:title">Liver International</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1877-1885</span>CODEN:
                <span class="NLM_cas:coden">LIINCM</span>;
        ISSN:<span class="NLM_cas:issn">1478-3223</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Background & Aims : Acute liver failure (ALF) is a condition with high mortality and morbidity.  Fibrosis in chronic liver disease was extensively researched, whereas fibrosis and underlying mechanism in acute liver failure remains unclear.  Methods : Hepatitis B virus related ALF patients were recruited to investigate if there was ongoing fibrosis by liver histol. and liver stiffness measurement(LSM) anal. as well as fibrosis markers assay.  Sera HMGB1 were kinetically detected in progression and remission stage of ALF.  Hepatic stellate cell(HSC) activation by HMGB1 was explored by testing mRNA and protein level of α-SMA and collagen 1a1 by using qPCR and western blot.  Autophagy induction by HMGB1 was explored by LC3-II conversion, autophagy flux and fluorescence.  Results : Firstly, ongoing fibrosis in progression stage of ALF was confirmed by histol. anal., LS measurement as well as fibrosis markers detection.  HSC activation and autophagy induction in explanted liver tissue also revealed.  Next, kinetic monitoring sera HMGB1 revealed elevated HMGB1 in progression stage of ALF vs HBsAg carrier, and drop back to base level in remission stage.  Thirdly, rHMGB1 dose dependently activated HSCs, as indicated by increased mRNA and proteins level in α-SMA and collagen 1a1.  Moreover, autophagy was induced in HSC treated with rHMGB1, as illustrated by increased LC3 lipidation, elevated autophagy flux and GFP-LC3 puncta.  Conclusions : Acute liver failure is accompanied by ongoing fibrosis, HSC activation and autophagy induction.  Increased HMGB1 activates HSC via autophagy induction.  Those findings integrate HMGB1, HSCs activation, autophagy into a common framework that underlies the fibrosis in ALF.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpX7zL7tKJHYLVg90H21EOLACvtfcHk0liv6yFm4MC26A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtVaju7nN&md5=eef5d447b92ff6fafb2e0f3ea8c1d00d</span></div><a href="/servlet/linkout?suffix=cit13a&amp;dbid=16384&amp;doi=10.1111%2Fliv.12731&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fliv.12731%26sid%3Dliteratum%253Aachs%26aulast%3DHe%26aufirst%3DY.%26aulast%3DJin%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DYan%26aufirst%3DZ.%26aulast%3DChen%26aufirst%3DT.%26aulast%3DZhao%26aufirst%3DY.%26atitle%3DMechanisms%2520of%2520fibrosis%2520in%2520acute%2520liver%2520failure%26jtitle%3DLiver%2520Int.%26date%3D2015%26volume%3D35%26spage%3D1877%26epage%3D1885%26doi%3D10.1111%2Fliv.12731" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit13b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Boor, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sebekova, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ostendorf, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Floege, J.</span></span> <span> </span><span class="NLM_article-title">Treatment targets in renal fibrosis</span>. <i>Nephrol., Dial., Transplant.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">3391</span>– <span class="NLM_lpage">3407</span>, <span class="refDoi"> DOI: 10.1093/ndt/gfm393</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=10.1093%2Fndt%2Fgfm393" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=17890247" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtlOqtr7J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2007&pages=3391-3407&author=P.+Boorauthor=K.+Sebekovaauthor=T.+Ostendorfauthor=J.+Floege&title=Treatment+targets+in+renal+fibrosis&doi=10.1093%2Fndt%2Fgfm393"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13bR"><div class="casContent"><span class="casTitleNuber">13b</span><div class="casTitle"><span class="NLM_cas:atitle">Treatment targets in renal fibrosis</span></div><div class="casAuthors">Boor, Peter; Sebekova, Katarina; Ostendorf, Tammo; Floege, Juergen</div><div class="citationInfo"><span class="NLM_cas:title">Nephrology, Dialysis, Transplantation</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">3391-3407</span>CODEN:
                <span class="NLM_cas:coden">NDTREA</span>;
        ISSN:<span class="NLM_cas:issn">0931-0509</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">A review on new, promising targets for the treatment of renal fibrosis, the principal process underlying the progression of chronic kidney disease to end-stage renal disease.  It first discusses antifibrotic approaches, that are clin. available or close to being so, and then describes potential new targets in fibrosis therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrpXEVIuwK0c7Vg90H21EOLACvtfcHk0liv6yFm4MC26A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtlOqtr7J&md5=04e21b221eec2e52416d603d6382e9a5</span></div><a href="/servlet/linkout?suffix=cit13b&amp;dbid=16384&amp;doi=10.1093%2Fndt%2Fgfm393&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fndt%252Fgfm393%26sid%3Dliteratum%253Aachs%26aulast%3DBoor%26aufirst%3DP.%26aulast%3DSebekova%26aufirst%3DK.%26aulast%3DOstendorf%26aufirst%3DT.%26aulast%3DFloege%26aufirst%3DJ.%26atitle%3DTreatment%2520targets%2520in%2520renal%2520fibrosis%26jtitle%3DNephrol.%252C%2520Dial.%252C%2520Transplant.%26date%3D2007%26volume%3D22%26spage%3D3391%26epage%3D3407%26doi%3D10.1093%2Fndt%2Fgfm393" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pischon, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mäki, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weisshaupt, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heng, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palamakumbura, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">N’Guessan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Radlanski, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Renz, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bronckers, T. A. L. J.
J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Myllyharju, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kielbassa, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kleber, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bernimoulin, J.-P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trackman, P. C.</span></span> <span> </span><span class="NLM_article-title">Lysyl oxidase (lox) gene deficiency affects osteoblastic phenotype</span>. <i>Calcif. Tissue Int.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>85</i></span>,  <span class="NLM_fpage">119</span>– <span class="NLM_lpage">126</span>, <span class="refDoi"> DOI: 10.1007/s00223-009-9252-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=10.1007%2Fs00223-009-9252-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=19458888" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtVait7%252FI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=85&publication_year=2009&pages=119-126&author=N.+Pischonauthor=J.+M.+M%C3%A4kiauthor=P.+Weisshauptauthor=N.+Hengauthor=A.+H.+Palamakumburaauthor=P.+N%E2%80%99Guessanauthor=A.+Dingauthor=R.+Radlanskiauthor=H.+Renzauthor=T.+A.+L.+J.%0AJ.+Bronckersauthor=J.+Myllyharjuauthor=A.+M.+Kielbassaauthor=B.+M.+Kleberauthor=J.-P.+Bernimoulinauthor=P.+C.+Trackman&title=Lysyl+oxidase+%28lox%29+gene+deficiency+affects+osteoblastic+phenotype&doi=10.1007%2Fs00223-009-9252-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Lysyl Oxidase (Lox) Gene Deficiency Affects Osteoblastic Phenotype</span></div><div class="casAuthors">Pischon, N.; Maeki, J. M.; Weisshaupt, P.; Heng, N.; Palamakumbura, A. H.; N'Guessan, P.; Ding, A.; Radlanski, R.; Renz, H.; Bronckers, T. A. L. J. J.; Myllyharju, J.; Kielbassa, A. M.; Kleber, B. M.; Bernimoulin, J.-P.; Trackman, P. C.</div><div class="citationInfo"><span class="NLM_cas:title">Calcified Tissue International</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">85</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">119-126</span>CODEN:
                <span class="NLM_cas:coden">CTINDZ</span>;
        ISSN:<span class="NLM_cas:issn">0171-967X</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Lysyl oxidase (LOX) catalyzes crosslinking of elastin and collagen, which is essential for the structural integrity and function of bone tissue.  The present study examd. the role of Lox gene deficiency for the osteoblast phenotype in primary calvarial osteoblasts from E18.5 Lox knockout (Lox -/- ) and wild type (wt) (C57BL/6) mice.  Next to Lox gene depletion, mRNA expression of Lox isoforms, LOXL1-4, was significantly downregulated in Lox -/- bone tissue.  A significant decrease of DNA synthesis of Lox -/- osteoblasts compared to wt was found.  Early stages of osteoblastic apoptosis studied by annexin-V binding as well as later stages of DNA fragmentation were not affected.  However, mineral nodule formation and osteoblastic differentiation were markedly decreased, as revealed by significant downregulation of osteoblastic markers, type I collagen, bone sialoprotein, and Runx2/Cbfa1.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpj0YC3msIvIbVg90H21EOLACvtfcHk0liv6yFm4MC26A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtVait7%252FI&md5=fab4300b8ff8b116247836bdf6aae915</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1007%2Fs00223-009-9252-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00223-009-9252-8%26sid%3Dliteratum%253Aachs%26aulast%3DPischon%26aufirst%3DN.%26aulast%3DM%25C3%25A4ki%26aufirst%3DJ.%2BM.%26aulast%3DWeisshaupt%26aufirst%3DP.%26aulast%3DHeng%26aufirst%3DN.%26aulast%3DPalamakumbura%26aufirst%3DA.%2BH.%26aulast%3DN%25E2%2580%2599Guessan%26aufirst%3DP.%26aulast%3DDing%26aufirst%3DA.%26aulast%3DRadlanski%26aufirst%3DR.%26aulast%3DRenz%26aufirst%3DH.%26aulast%3DBronckers%26aufirst%3DT.%2BA.%2BL.%2BJ.%2BJ.%26aulast%3DMyllyharju%26aufirst%3DJ.%26aulast%3DKielbassa%26aufirst%3DA.%2BM.%26aulast%3DKleber%26aufirst%3DB.%2BM.%26aulast%3DBernimoulin%26aufirst%3DJ.-P.%26aulast%3DTrackman%26aufirst%3DP.%2BC.%26atitle%3DLysyl%2520oxidase%2520%2528lox%2529%2520gene%2520deficiency%2520affects%2520osteoblastic%2520phenotype%26jtitle%3DCalcif.%2520Tissue%2520Int.%26date%3D2009%26volume%3D85%26spage%3D119%26epage%3D126%26doi%3D10.1007%2Fs00223-009-9252-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mäki, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sormunen, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lippo, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaarteenaho-Wiik, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soininen, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Myllyharju, J.</span></span> <span> </span><span class="NLM_article-title">Lysyl oxidase is essential for normal development and function of the respiratory system and for the integrity of elastic and collagen fibers in various tissues</span>. <i>Am. J. Pathol.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>167</i></span>,  <span class="NLM_fpage">927</span>– <span class="NLM_lpage">936</span>, <span class="refDoi"> DOI: 10.1016/s0002-9440(10)61183-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=10.1016%2Fs0002-9440%2810%2961183-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=16192629" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtFKqtLrF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=167&publication_year=2005&pages=927-936&author=J.+M.+M%C3%A4kiauthor=R.+Sormunenauthor=S.+Lippoauthor=R.+Kaarteenaho-Wiikauthor=R.+Soininenauthor=J.+Myllyharju&title=Lysyl+oxidase+is+essential+for+normal+development+and+function+of+the+respiratory+system+and+for+the+integrity+of+elastic+and+collagen+fibers+in+various+tissues&doi=10.1016%2Fs0002-9440%2810%2961183-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Lysyl oxidase is essential for normal development and function of the respiratory system and for the integrity of elastic and collagen fibers in various tissues</span></div><div class="casAuthors">Maki, Joni M.; Sormunen, Raija; Lippo, Sari; Kaarteenaho-Wiik, Riitta; Soininen, Raija; Myllyharju, Johanna</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Pathology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">167</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">927-936</span>CODEN:
                <span class="NLM_cas:coden">AJPAA4</span>;
        ISSN:<span class="NLM_cas:issn">0002-9440</span>.
    
            (<span class="NLM_cas:orgname">American Society for Investigative Pathology</span>)
        </div><div class="casAbstract">Lysyl oxidases, a family comprising LOX and four LOX-like enzymes, catalyze crosslinking of elastin and collagens.  Mouse Lox was recently shown to be crucial for development of the cardiovascular system because null mice died perinatally of aortic aneurysms and cardiovascular dysfunction.  We show here that Lox is also essential for development of the respiratory system and the integrity of elastic and collagen fibers in the lungs and skin.  The lungs of E18.5 Lox-/- embryos showed impaired development of the distal and proximal airways.  Elastic fibers in E18.5 Lox-/- lungs were markedly less intensely stained and more disperse than in the wild type, esp. in the mesenchyme surrounding the distal airways, bronchioles, bronchi, and trachea, and were fragmented in pulmonary arterial walls.  The organization of individual collagen fibers into tight bundles was likewise abnormal.  Similar elastic and collagen fiber abnormalities were seen in the skin.  Lysyl oxidase activity in cultured Lox-/- skin fibroblasts and aortic smooth muscle cells was reduced by ∼80%, indicating that Lox is the main isoenzyme in these cells.  LOX abnormalities may thus be crit. for the pathogenesis of several common diseases, including pulmonary, skin, and cardiovascular disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoEURMo0Cxd2rVg90H21EOLACvtfcHk0lj3CE2Vyb3aWw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtFKqtLrF&md5=f7add91e597d1658ae97c6ad455234f1</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1016%2Fs0002-9440%2810%2961183-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fs0002-9440%252810%252961183-2%26sid%3Dliteratum%253Aachs%26aulast%3DM%25C3%25A4ki%26aufirst%3DJ.%2BM.%26aulast%3DSormunen%26aufirst%3DR.%26aulast%3DLippo%26aufirst%3DS.%26aulast%3DKaarteenaho-Wiik%26aufirst%3DR.%26aulast%3DSoininen%26aufirst%3DR.%26aulast%3DMyllyharju%26aufirst%3DJ.%26atitle%3DLysyl%2520oxidase%2520is%2520essential%2520for%2520normal%2520development%2520and%2520function%2520of%2520the%2520respiratory%2520system%2520and%2520for%2520the%2520integrity%2520of%2520elastic%2520and%2520collagen%2520fibers%2520in%2520various%2520tissues%26jtitle%3DAm.%2520J.%2520Pathol.%26date%3D2005%26volume%3D167%26spage%3D927%26epage%3D936%26doi%3D10.1016%2Fs0002-9440%2810%2961183-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rodriguez, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinez-Gonzalez, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raposo, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alcudia, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guadall, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Badimon, L.</span></span> <span> </span><span class="NLM_article-title">Regulation of lysyl oxidase in vascular cells: lysyl oxidase as a new player in cardiovascular diseases</span>. <i>Cardiovasc. Res.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>79</i></span>,  <span class="NLM_fpage">7</span>– <span class="NLM_lpage">13</span>, <span class="refDoi"> DOI: 10.1093/cvr/cvn102</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=10.1093%2Fcvr%2Fcvn102" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=18469024" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=1%3ACAS%3A528%3ADC%252BD1cXnt1Sksbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79&publication_year=2008&pages=7-13&author=C.+Rodriguezauthor=J.+Martinez-Gonzalezauthor=B.+Raposoauthor=J.+F.+Alcudiaauthor=A.+Guadallauthor=L.+Badimon&title=Regulation+of+lysyl+oxidase+in+vascular+cells%3A+lysyl+oxidase+as+a+new+player+in+cardiovascular+diseases&doi=10.1093%2Fcvr%2Fcvn102"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Regulation of lysyl oxidase in vascular cells: lysyl oxidase as a new player in cardiovascular diseases</span></div><div class="casAuthors">Rodriguez, Cristina; Martinez-Gonzalez, Jose; Raposo, Berta; Alcudia, Javier F.; Guadall, Anna; Badimon, Lina</div><div class="citationInfo"><span class="NLM_cas:title">Cardiovascular Research</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">79</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">7-13</span>CODEN:
                <span class="NLM_cas:coden">CVREAU</span>;
        ISSN:<span class="NLM_cas:issn">0008-6363</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">A review.  Lysyl oxidase (LOX) plays a crucial role in the maintenance of extracellular matrix stability and could participate in vascular remodelling assocd. with cardiovascular diseases.  Evidence from in vitro and in vivo studies shows that LOX downregulation is assocd. with the endothelial dysfunction characteristic of earlier stages of the atherosclerotic process.  Conversely, upregulation of this enzyme in vascular cells could induce neointimal thickening in atherosclerosis and restenosis.  In fact, LOX is chemotactic for vascular smooth muscle cells and monocytes, is modulated by proliferative stimulus in these cells, and could control other cellular processes such as gene expression and cell transformation.  Furthermore, it is conceivable that LOX downregulation could underlie plaque instability and contribute to the destructive remodelling that takes place during aneurysm development.  Overall, LOX could play a key role in vascular homeostasis and, hence, it emerges as a new player in cardiovascular diseases.  This review addresses the exptl. evidence related to the role of LOX in vascular disorders and the potential benefits of controlling its expression and function.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr5WNMYo-ebGbVg90H21EOLACvtfcHk0lj3CE2Vyb3aWw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXnt1Sksbc%253D&md5=8bbbfe60f2936b1cca799a14c6213c0d</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1093%2Fcvr%2Fcvn102&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fcvr%252Fcvn102%26sid%3Dliteratum%253Aachs%26aulast%3DRodriguez%26aufirst%3DC.%26aulast%3DMartinez-Gonzalez%26aufirst%3DJ.%26aulast%3DRaposo%26aufirst%3DB.%26aulast%3DAlcudia%26aufirst%3DJ.%2BF.%26aulast%3DGuadall%26aufirst%3DA.%26aulast%3DBadimon%26aufirst%3DL.%26atitle%3DRegulation%2520of%2520lysyl%2520oxidase%2520in%2520vascular%2520cells%253A%2520lysyl%2520oxidase%2520as%2520a%2520new%2520player%2520in%2520cardiovascular%2520diseases%26jtitle%3DCardiovasc.%2520Res.%26date%3D2008%26volume%3D79%26spage%3D7%26epage%3D13%26doi%3D10.1093%2Fcvr%2Fcvn102" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Barry-Hamilton, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spangler, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marshall, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCauley, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodriguez, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oyasu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mikels, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vaysberg, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghermazien, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wai, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Velayo, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jorgensen, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biermann, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsai, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Green, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zaffryar-Eilot, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holzer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogg, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thai, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neufeld, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Vlasselaer, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, V.</span></span> <span> </span><span class="NLM_article-title">Allosteric inhibition of lysyl oxidase-like-2 impedes the development of a pathologic microenvironment</span>. <i>Nat. Med.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">1009</span>– <span class="NLM_lpage">1017</span>, <span class="refDoi"> DOI: 10.1038/nm.2208</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=10.1038%2Fnm.2208" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=20818376" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtFWksrvF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2010&pages=1009-1017&author=V.+Barry-Hamiltonauthor=R.+Spanglerauthor=D.+Marshallauthor=S.+McCauleyauthor=H.+M.+Rodriguezauthor=M.+Oyasuauthor=A.+Mikelsauthor=M.+Vaysbergauthor=H.+Ghermazienauthor=C.+Waiauthor=C.+A.+Garciaauthor=A.+C.+Velayoauthor=B.+Jorgensenauthor=D.+Biermannauthor=D.+Tsaiauthor=J.+Greenauthor=S.+Zaffryar-Eilotauthor=A.+Holzerauthor=S.+Oggauthor=D.+Thaiauthor=G.+Neufeldauthor=P.+Van+Vlasselaerauthor=V.+Smith&title=Allosteric+inhibition+of+lysyl+oxidase-like-2+impedes+the+development+of+a+pathologic+microenvironment&doi=10.1038%2Fnm.2208"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17aR"><div class="casContent"><span class="casTitleNuber">17a</span><div class="casTitle"><span class="NLM_cas:atitle">Allosteric inhibition of lysyl oxidase-like-2 impedes the development of a pathologic microenvironment</span></div><div class="casAuthors">Barry-Hamilton, Vivian; Spangler, Rhyannon; Marshall, Derek; McCauley, Scott; Rodriguez, Hector M.; Oyasu, Miho; Mikels, Amanda; Vaysberg, Maria; Ghermazien, Haben; Wai, Carol; Garcia, Carlos A.; Velayo, Arleene C.; Jorgensen, Brett; Biermann, Donna; Tsai, Daniel; Green, Jennifer; Zaffryar-Eilot, Shelly; Holzer, Alison; Ogg, Scott; Thai, Dung; Neufeld, Gera; Van Vlasselaer, Peter; Smith, Victoria</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1009-1017</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">We have identified a new role for the matrix enzyme lysyl oxidase-like-2 (LOXL2) in the creation and maintenance of the pathol. microenvironment of cancer and fibrotic disease.  Our anal. of biopsies from human tumors and fibrotic lung and liver tissues revealed an increase in LOXL2 in disease-assocd. stroma and limited expression in healthy tissues.  Targeting LOXL2 with an inhibitory monoclonal antibody (AB0023) was efficacious in both primary and metastatic xenograft models of cancer, as well as in liver and lung fibrosis models.  Inhibition of LOXL2 resulted in a marked redn. in activated fibroblasts, desmoplasia and endothelial cells, decreased prodn. of growth factors and cytokines and decreased transforming growth factor-β (TGF-β) pathway signaling.  AB0023 outperformed the small-mol. lysyl oxidase inhibitor β-aminopropionitrile.  The efficacy and safety of LOXL2-specific AB0023 represents a new therapeutic approach with broad applicability in oncol. and fibrotic diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpkE52VQCvcZrVg90H21EOLACvtfcHk0lj3CE2Vyb3aWw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtFWksrvF&md5=7e69cbf26c2985ad03fbb620538a5f04</span></div><a href="/servlet/linkout?suffix=cit17a&amp;dbid=16384&amp;doi=10.1038%2Fnm.2208&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm.2208%26sid%3Dliteratum%253Aachs%26aulast%3DBarry-Hamilton%26aufirst%3DV.%26aulast%3DSpangler%26aufirst%3DR.%26aulast%3DMarshall%26aufirst%3DD.%26aulast%3DMcCauley%26aufirst%3DS.%26aulast%3DRodriguez%26aufirst%3DH.%2BM.%26aulast%3DOyasu%26aufirst%3DM.%26aulast%3DMikels%26aufirst%3DA.%26aulast%3DVaysberg%26aufirst%3DM.%26aulast%3DGhermazien%26aufirst%3DH.%26aulast%3DWai%26aufirst%3DC.%26aulast%3DGarcia%26aufirst%3DC.%2BA.%26aulast%3DVelayo%26aufirst%3DA.%2BC.%26aulast%3DJorgensen%26aufirst%3DB.%26aulast%3DBiermann%26aufirst%3DD.%26aulast%3DTsai%26aufirst%3DD.%26aulast%3DGreen%26aufirst%3DJ.%26aulast%3DZaffryar-Eilot%26aufirst%3DS.%26aulast%3DHolzer%26aufirst%3DA.%26aulast%3DOgg%26aufirst%3DS.%26aulast%3DThai%26aufirst%3DD.%26aulast%3DNeufeld%26aufirst%3DG.%26aulast%3DVan%2BVlasselaer%26aufirst%3DP.%26aulast%3DSmith%26aufirst%3DV.%26atitle%3DAllosteric%2520inhibition%2520of%2520lysyl%2520oxidase-like-2%2520impedes%2520the%2520development%2520of%2520a%2520pathologic%2520microenvironment%26jtitle%3DNat.%2520Med.%26date%3D2010%26volume%3D16%26spage%3D1009%26epage%3D1017%26doi%3D10.1038%2Fnm.2208" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit17b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Schilter, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Findlay, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perryman, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yow, T. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moses, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zahoor, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turner, C. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deodhar, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foot, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greco, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joshi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rayner, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Townsend, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jarolimek, W.</span></span> <span> </span><span class="NLM_article-title">The lysyl oxidase like 2/3 enzymatic inhibitor, PXS-5153A, reduces crosslinks and ameliorates fibrosis</span>. <i>J. Cell Mol. Med.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">1759</span>– <span class="NLM_lpage">1770</span>, <span class="refDoi"> DOI: 10.1111/jcmm.14074</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=10.1111%2Fjcmm.14074" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=30536539" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=1%3ACAS%3A528%3ADC%252BC1MXjtVOmt7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2019&pages=1759-1770&author=H.+Schilterauthor=A.+D.+Findlayauthor=L.+Perrymanauthor=T.+T.+Yowauthor=J.+Mosesauthor=A.+Zahoorauthor=C.+I.+Turnerauthor=M.+Deodharauthor=J.+S.+Footauthor=W.+Zhouauthor=A.+Grecoauthor=A.+Joshiauthor=B.+Raynerauthor=S.+Townsendauthor=A.+Busonauthor=W.+Jarolimek&title=The+lysyl+oxidase+like+2%2F3+enzymatic+inhibitor%2C+PXS-5153A%2C+reduces+crosslinks+and+ameliorates+fibrosis&doi=10.1111%2Fjcmm.14074"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17bR"><div class="casContent"><span class="casTitleNuber">17b</span><div class="casTitle"><span class="NLM_cas:atitle">The lysyl oxidase like 2/3 enzymatic inhibitor, PXS-5153A, reduces crosslinks and ameliorates fibrosis</span></div><div class="casAuthors">Schilter, Heidi; Findlay, Alison D.; Perryman, Lara; Yow, Tin T.; Moses, Joshua; Zahoor, Amna; Turner, Craig I.; Deodhar, Mandar; Foot, Jonathan S.; Zhou, Wenbin; Greco, Angelique; Joshi, Amar; Rayner, Benjamin; Townsend, Sarah; Buson, Alberto; Jarolimek, Wolfgang</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cellular and Molecular Medicine</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1759-1770</span>CODEN:
                <span class="NLM_cas:coden">JCMMC9</span>;
        ISSN:<span class="NLM_cas:issn">1582-4934</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Fibrosis is characterized by the excessive deposition of extracellular matrix and crosslinked proteins, in particular collagen and elastin, leading to tissue stiffening and disrupted organ function.  Lysyl oxidases are key players during this process, as they initiate collagen crosslinking through the oxidn. of the ε-amino group of lysine or hydroxylysine on collagen side-chains, which subsequently dimerize to form immature, or trimerize to form mature, collagen crosslinks.  The role of LOXL2 in fibrosis and cancer is well documented, however the specific enzymic function of LOXL2 and LOXL3 during disease is less clear.  Herein, we describe the development of PXS-5153A, a novel mechanism based, fast-acting, dual LOXL2/LOXL3 inhibitor, which was used to interrogate the role of these enzymes in models of collagen crosslinking and fibrosis.  PXS-5153A dose-dependently reduced LOXL2-mediated collagen oxidn. and collagen crosslinking in vitro.  In two liver fibrosis models, carbon tetrachloride or streptozotocin/high fat diet-induced, PXS-5153A reduced disease severity and improved liver function by diminishing collagen content and collagen crosslinks.  In myocardial infarction, PXS-5153A improved cardiac output.  Taken together these results demonstrate that, due to their crucial role in collagen crosslinking, inhibition of the enzymic activities of LOXL2/LOXL3 represents an innovative therapeutic approach for the treatment of fibrosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrQ5kd2ThTrybVg90H21EOLACvtfcHk0lgcLUNknqNiMQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXjtVOmt7k%253D&md5=f92defd2aada3c8b32bfc1fbdcc9efc9</span></div><a href="/servlet/linkout?suffix=cit17b&amp;dbid=16384&amp;doi=10.1111%2Fjcmm.14074&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fjcmm.14074%26sid%3Dliteratum%253Aachs%26aulast%3DSchilter%26aufirst%3DH.%26aulast%3DFindlay%26aufirst%3DA.%2BD.%26aulast%3DPerryman%26aufirst%3DL.%26aulast%3DYow%26aufirst%3DT.%2BT.%26aulast%3DMoses%26aufirst%3DJ.%26aulast%3DZahoor%26aufirst%3DA.%26aulast%3DTurner%26aufirst%3DC.%2BI.%26aulast%3DDeodhar%26aufirst%3DM.%26aulast%3DFoot%26aufirst%3DJ.%2BS.%26aulast%3DZhou%26aufirst%3DW.%26aulast%3DGreco%26aufirst%3DA.%26aulast%3DJoshi%26aufirst%3DA.%26aulast%3DRayner%26aufirst%3DB.%26aulast%3DTownsend%26aufirst%3DS.%26aulast%3DBuson%26aufirst%3DA.%26aulast%3DJarolimek%26aufirst%3DW.%26atitle%3DThe%2520lysyl%2520oxidase%2520like%25202%252F3%2520enzymatic%2520inhibitor%252C%2520PXS-5153A%252C%2520reduces%2520crosslinks%2520and%2520ameliorates%2520fibrosis%26jtitle%3DJ.%2520Cell%2520Mol.%2520Med.%26date%3D2019%26volume%3D23%26spage%3D1759%26epage%3D1770%26doi%3D10.1111%2Fjcmm.14074" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Vadasz, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kessler, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akiri, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gengrinovitch, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kagan, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baruch, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Izhak, O. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neufeld, G.</span></span> <span> </span><span class="NLM_article-title">Abnormal deposition of collagen around hepatocytes in Wilson’s disease is associated with hepatocyte specific expression of lysyl oxidase and lysyl oxidase like protein-2</span>. <i>J. Hepatol.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>43</i></span>,  <span class="NLM_fpage">499</span>– <span class="NLM_lpage">507</span>, <span class="refDoi"> DOI: 10.1016/j.jhep.2005.02.052</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=10.1016%2Fj.jhep.2005.02.052" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=16023247" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=1%3ACAS%3A528%3ADC%252BD2MXntVCku7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2005&pages=499-507&author=Z.+Vadaszauthor=O.+Kesslerauthor=G.+Akiriauthor=S.+Gengrinovitchauthor=H.+M.+Kaganauthor=Y.+Baruchauthor=O.+B.+Izhakauthor=G.+Neufeld&title=Abnormal+deposition+of+collagen+around+hepatocytes+in+Wilson%E2%80%99s+disease+is+associated+with+hepatocyte+specific+expression+of+lysyl+oxidase+and+lysyl+oxidase+like+protein-2&doi=10.1016%2Fj.jhep.2005.02.052"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18aR"><div class="casContent"><span class="casTitleNuber">18a</span><div class="casTitle"><span class="NLM_cas:atitle">Abnormal deposition of collagen around hepatocytes in Wilson's disease is associated with hepatocyte specific expression of lysyl oxidase and lysyl oxidase like protein-2</span></div><div class="casAuthors">Vadasz, Zehava; Kessler, Ofra; Akiri, Gal; Gengrinovitch, Stela; Kagan, Herbert M.; Baruch, Yaacov; Ben Izhak, Ofer; Neufeld, Gera</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Hepatology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">499-507</span>CODEN:
                <span class="NLM_cas:coden">JOHEEC</span>;
        ISSN:<span class="NLM_cas:issn">0168-8278</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Lysyl-oxidases catalyze the oxidn. of lysine residues in collagen and elastin thereby promoting their polymn.  We have studied here the expression of four lysyl-oxidases in normal and diseased human liver.  The expression of the different lysyl-oxidases in paraffin embedded liver sections was studied using in-situ hybridization and immunohistochem.  The enzymic activity of lysyl-oxidase like protein-2 (Loxl2 or LOR-1) using a previously described lysyl-oxidase assay.  We have found that the four lysyl-oxidases which we examd. are not significantly expressed in the normal liver.  By contrast, Wilson's disease and primary biliary cirrhosis (PBC) patients express lysyl-oxidase (Lox) and lysyl-oxidase like protein-2 (Loxl2 or LOR-1) in hepatocytes, and the expression is accompanied by collagen deposition around the hepatocytes.  Lysyl-oxidases are also expressed in addnl. fibrotic liver diseases such as hepatitis B and C but in these diseases the expression is confined to the fibrotic lesions and collagen does not accumulate around hepatocytes.  We have found that Loxl2 is able to oxidize lysine residues of collagen, and behaves in that respect similarly to Lox.  The copper chelator D-penicillamine inhibits Loxl2 induced oxidn. of collagen but the Lox inhibitor β-aminopropionitrile did not inhibit the oxidn. using a BAPN concn. at which Lox activity was completely inhibited.  Loxl2 also catalyzed the oxidn. of cell surface proteins on HepG2 hepatoblastoma cells and inhibited their proliferation.  Upregulation of Lox and Loxl2 in hepatocytes of Wilson's disease and PBC patients may contribute to liver damage by various mechanisms.  The upregulation of Lox and Loxl2 in Wilson's disease could perhaps be utilized for diagnostic purposes since their expression is up-regulated in hepatocytes even before the onset of fibrosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGquJY1mygQQD7Vg90H21EOLACvtfcHk0lgcLUNknqNiMQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXntVCku7Y%253D&md5=e7bdaa18a58921c64db0eda33285ec80</span></div><a href="/servlet/linkout?suffix=cit18a&amp;dbid=16384&amp;doi=10.1016%2Fj.jhep.2005.02.052&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jhep.2005.02.052%26sid%3Dliteratum%253Aachs%26aulast%3DVadasz%26aufirst%3DZ.%26aulast%3DKessler%26aufirst%3DO.%26aulast%3DAkiri%26aufirst%3DG.%26aulast%3DGengrinovitch%26aufirst%3DS.%26aulast%3DKagan%26aufirst%3DH.%2BM.%26aulast%3DBaruch%26aufirst%3DY.%26aulast%3DIzhak%26aufirst%3DO.%2BB.%26aulast%3DNeufeld%26aufirst%3DG.%26atitle%3DAbnormal%2520deposition%2520of%2520collagen%2520around%2520hepatocytes%2520in%2520Wilson%25E2%2580%2599s%2520disease%2520is%2520associated%2520with%2520hepatocyte%2520specific%2520expression%2520of%2520lysyl%2520oxidase%2520and%2520lysyl%2520oxidase%2520like%2520protein-2%26jtitle%3DJ.%2520Hepatol.%26date%3D2005%26volume%3D43%26spage%3D499%26epage%3D507%26doi%3D10.1016%2Fj.jhep.2005.02.052" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit18b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Dongiovanni, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meroni, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baselli, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bassani, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rametta, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pietrelli, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maggioni, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Facciotti, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trunzo, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Badiali, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fargion, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gatti, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valenti, L.</span></span> <span> </span><span class="NLM_article-title">Insulin resistance promotes lysyl oxidase like 2 induction and fibrosis accumulation in non-alcoholic fatty liver disease</span>. <i>Clin. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>131</i></span>,  <span class="NLM_fpage">1301</span>– <span class="NLM_lpage">1315</span>, <span class="refDoi"> DOI: 10.1042/cs20170175</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=10.1042%2Fcs20170175" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=28468951" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhslCntbfM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=131&publication_year=2017&pages=1301-1315&author=P.+Dongiovanniauthor=M.+Meroniauthor=G.+A.+Baselliauthor=G.+A.+Bassaniauthor=R.+Ramettaauthor=A.+Pietrelliauthor=M.+Maggioniauthor=F.+Facciottiauthor=V.+Trunzoauthor=S.+Badialiauthor=S.+Fargionauthor=S.+Gattiauthor=L.+Valenti&title=Insulin+resistance+promotes+lysyl+oxidase+like+2+induction+and+fibrosis+accumulation+in+non-alcoholic+fatty+liver+disease&doi=10.1042%2Fcs20170175"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18bR"><div class="casContent"><span class="casTitleNuber">18b</span><div class="casTitle"><span class="NLM_cas:atitle">Insulin resistance promotes Lysyl Oxidase Like 2 induction and fibrosis accumulation in non-alcoholic fatty liver disease</span></div><div class="casAuthors">Dongiovanni, Paola; Meroni, Marica; Baselli, Guido Alessandro; Bassani, Giulia Alessandra; Rametta, Raffaela; Pietrelli, Alessandro; Maggioni, Marco; Facciotti, Federica; Trunzo, Valentina; Badiali, Sara; Fargion, Silvia; Gatti, Stefano; Valenti, Luca</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Science</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">131</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1301-1315</span>CODEN:
                <span class="NLM_cas:coden">CSCIAE</span>;
        ISSN:<span class="NLM_cas:issn">1470-8736</span>.
    
            (<span class="NLM_cas:orgname">Portland Press Ltd.</span>)
        </div><div class="casAbstract">In patients with non-alc. fatty liver disease (NAFLD), insulin resistance (IR) assocs. with fibrosis progression independently of the hepatic inflammation, but the mechanisms are still unclear.  We modeled the independent contribution of inflammation (non-alc. steatohepatitis: NASH) by exploiting the methionine-choline deficient (MCD) diet, and that of IR by insulin receptor (InsR) haploinsufficieny (InsR+/-) in the pathogenesis of liver fibrosis in C57BL/6 mice.  We confirmed the study findings in 96 patients with NAFLD.  InsR+/- enhanced hepatic fat content and impaired hepatic insulin signaling leading to Forkhead box protein O1 (FoxO1) accumulation in MCD-fed mice.  Remarkably, despite reduced inflammation and hampered transdifferentiation of hepatic stellate cells (HSCs), InsR+/- promoted hepatic fibrosis accumulation, which correlated with the induction of the Lysyl Oxidase Like 2 (Loxl2), involved in matrix stabilization.  Loxl2 up-regulation was not a cell autonomous property of insulin resistant HSCs, but was dependent on microparticles (MPs) released specifically by insulin resistant hepatocytes (HEPs) exposed to fatty acids.  The mechanism entailed FoxO1 up-regulation, as FoxO1 silencing normalized Loxl2 expression reversing fibrosis in InsR+/- MCD-fed mice.  Loxl2 up-regulation was similarly detected during IR induced by obesity, but not by lipogenic stimuli (fructose feeding).  Most importantly, LOXL2 up-regulation was obsd. in NAFLD patients with type 2 diabetes (T2D) and LOXL2 hepatic and circulating levels correlated with histol. fibrosis progression.  IR favors fibrosis deposition independently of the classic 'inflammation - HSC transdifferentiation' pathway.  The mechanism entails a cross-talk between enhanced lipotoxicity in insulin resistant HEPs and Loxl2 prodn. by HSCs, which was confirmed in patients with diabetes, thereby facilitating extracellular matrix (ECM) stabilization.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpS5cO1t-WtPrVg90H21EOLACvtfcHk0lgLhK_rdTbgEA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhslCntbfM&md5=74cbc48dee07ec615eb22e2342d1a77c</span></div><a href="/servlet/linkout?suffix=cit18b&amp;dbid=16384&amp;doi=10.1042%2Fcs20170175&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1042%252Fcs20170175%26sid%3Dliteratum%253Aachs%26aulast%3DDongiovanni%26aufirst%3DP.%26aulast%3DMeroni%26aufirst%3DM.%26aulast%3DBaselli%26aufirst%3DG.%2BA.%26aulast%3DBassani%26aufirst%3DG.%2BA.%26aulast%3DRametta%26aufirst%3DR.%26aulast%3DPietrelli%26aufirst%3DA.%26aulast%3DMaggioni%26aufirst%3DM.%26aulast%3DFacciotti%26aufirst%3DF.%26aulast%3DTrunzo%26aufirst%3DV.%26aulast%3DBadiali%26aufirst%3DS.%26aulast%3DFargion%26aufirst%3DS.%26aulast%3DGatti%26aufirst%3DS.%26aulast%3DValenti%26aufirst%3DL.%26atitle%3DInsulin%2520resistance%2520promotes%2520lysyl%2520oxidase%2520like%25202%2520induction%2520and%2520fibrosis%2520accumulation%2520in%2520non-alcoholic%2520fatty%2520liver%2520disease%26jtitle%3DClin.%2520Sci.%26date%3D2017%26volume%3D131%26spage%3D1301%26epage%3D1315%26doi%3D10.1042%2Fcs20170175" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chien, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richards, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gibson, K. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindell, K. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lyman, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adamkewicz, J. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaminski, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Riordan, T.</span></span> <span> </span><span class="NLM_article-title">Serum lysyl oxidase-like 2 levels and idiopathic pulmonary fibrosis disease progression</span>. <i>Eur. Respir. J.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>43</i></span>,  <span class="NLM_fpage">1430</span>– <span class="NLM_lpage">1438</span>, <span class="refDoi"> DOI: 10.1183/09031936.00141013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=10.1183%2F09031936.00141013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=24177001" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtVKnu73I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2014&pages=1430-1438&author=J.+W.+Chienauthor=T.+J.+Richardsauthor=K.+F.+Gibsonauthor=Y.+Zhangauthor=K.+O.+Lindellauthor=L.+Shaoauthor=S.+K.+Lymanauthor=J.+I.+Adamkewiczauthor=V.+Smithauthor=N.+Kaminskiauthor=T.+O%E2%80%99Riordan&title=Serum+lysyl+oxidase-like+2+levels+and+idiopathic+pulmonary+fibrosis+disease+progression&doi=10.1183%2F09031936.00141013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Serum lysyl, oxidase-like 2 levels and idiopathic pulmonary fibrosis disease progression</span></div><div class="casAuthors">Chien, Jason W.; Richards, Thomas J.; Gibson, Kevin F.; Zhang, Yingze; Lindell, Kathleen O.; Shao, Lixin; Lyman, Susan K.; Adamkewicz, Joanne I.; Smith, Victoria; Kaminski, Naftali; O'Riordan, Thomas</div><div class="citationInfo"><span class="NLM_cas:title">European Respiratory Journal</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1430-1438</span>CODEN:
                <span class="NLM_cas:coden">ERJOEI</span>;
        ISSN:<span class="NLM_cas:issn">0903-1936</span>.
    
            (<span class="NLM_cas:orgname">European Respiratory Society</span>)
        </div><div class="casAbstract">We evaluated whether lysyl oxidase-like 2 (LOXL2), which promotes crosslinking of collagen in pathol. stroma, was detectable in serum from idiopathic pulmonary fibrosis (IPF) patients, and assessed its relationship with IPF disease progression.  Patients from the ARTEMIS-IPF (n=69) and the Genomic and Proteomic Anal. of Disease Progression in IPF (GAP) (n=104) studies were analyzed.  Baseline serum LOXL2 (sLOXL2) levels were compared with baseline clin. and physiol. surrogates of disease severity, and the assocn. with IPF disease progression was assessed using a classification and regression tree (CART) method.  SLOXL2 correlated weakly with forced vital capacity and carbon monoxide diffusion capacity (r -0.24-0.05) in both cohorts.  CART-detd. thresholds were similar: ARTEMIS-IPF 800 pg·mL-1 and GAP 700 pg·mL-1.  In ARTEMIS-IPF, higher sLOXL2 (>800 pg·mL-1) was assocd. with increased risk for disease progression (hazard ratio (HR) 5.41, 95% CI 1.65-17.73).  Among GAP subjects with baseline spirometric data (n=70), higher sLOXL2 levels (>700 pg·mL-1) were assocd. with more disease progression events (HR 1.78, 95% CI 1.01-3.11).  Among all GAP subjects, higher sLOXL2 levels were assocd. with increased risk for mortality (HR 2.28, 95% CI 1.18-4.38).  These results suggest that higher sLOXL2 levels are assocd. with increased risk for IPF disease progression.  However, due to multiple limitations, these results require validation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr8WyURMNVsBLVg90H21EOLACvtfcHk0lgLhK_rdTbgEA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtVKnu73I&md5=60faa18c94ef9c37937579571a905faa</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1183%2F09031936.00141013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1183%252F09031936.00141013%26sid%3Dliteratum%253Aachs%26aulast%3DChien%26aufirst%3DJ.%2BW.%26aulast%3DRichards%26aufirst%3DT.%2BJ.%26aulast%3DGibson%26aufirst%3DK.%2BF.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DLindell%26aufirst%3DK.%2BO.%26aulast%3DShao%26aufirst%3DL.%26aulast%3DLyman%26aufirst%3DS.%2BK.%26aulast%3DAdamkewicz%26aufirst%3DJ.%2BI.%26aulast%3DSmith%26aufirst%3DV.%26aulast%3DKaminski%26aufirst%3DN.%26aulast%3DO%25E2%2580%2599Riordan%26aufirst%3DT.%26atitle%3DSerum%2520lysyl%2520oxidase-like%25202%2520levels%2520and%2520idiopathic%2520pulmonary%2520fibrosis%2520disease%2520progression%26jtitle%3DEur.%2520Respir.%2520J.%26date%3D2014%26volume%3D43%26spage%3D1430%26epage%3D1438%26doi%3D10.1183%2F09031936.00141013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span> <span> </span><span class="NLM_article-title">Comparison of Loxl-2 expression between active systematic scleroderma and active mixed connective tissue disease</span>. <i>J. China Med. Univ.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>45</i></span>,  <span class="NLM_fpage">414</span>– <span class="NLM_lpage">416</span>, <span class="refDoi"> DOI: 10.12007/j.issn.0258-4646.2016.05.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=10.12007%2Fj.issn.0258-4646.2016.05.008" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2016&pages=414-416&author=Y.+Chengauthor=X.+Wangauthor=X.+Zhangauthor=N.+Zhangauthor=X.+Zhang&title=Comparison+of+Loxl-2+expression+between+active+systematic+scleroderma+and+active+mixed+connective+tissue+disease&doi=10.12007%2Fj.issn.0258-4646.2016.05.008"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.12007%2Fj.issn.0258-4646.2016.05.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.12007%252Fj.issn.0258-4646.2016.05.008%26sid%3Dliteratum%253Aachs%26aulast%3DCheng%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DN.%26aulast%3DZhang%26aufirst%3DX.%26atitle%3DComparison%2520of%2520Loxl-2%2520expression%2520between%2520active%2520systematic%2520scleroderma%2520and%2520active%2520mixed%2520connective%2520tissue%2520disease%26jtitle%3DJ.%2520China%2520Med.%2520Univ.%26date%3D2016%26volume%3D45%26spage%3D414%26epage%3D416%26doi%3D10.12007%2Fj.issn.0258-4646.2016.05.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Janyasupab, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, Y. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Popa, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Samia, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wendt, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schiemann, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schiemann, W. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, C. C.</span></span> <span> </span><span class="NLM_article-title">Detection of lysyl oxidase-like 2 (LOXL2), a biomarker of metastasis from breast cancers using human blood samples</span>. <i>Recent Pat. Biomarkers</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">93</span>– <span class="NLM_lpage">100</span>, <span class="refDoi"> DOI: 10.2174/2210309005666150804195033</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=10.2174%2F2210309005666150804195033" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=28670509" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=1%3ACAS%3A528%3ADC%252BC28XnvFyhug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2015&pages=93-100&author=M.+Janyasupabauthor=Y.+H.+Leeauthor=Y.+Zhangauthor=C.+W.+Liuauthor=J.+Caiauthor=A.+Popaauthor=A.+Samiaauthor=K.+W.+Wangauthor=J.+Xuauthor=C.+C.+Huauthor=M.+K.+Wendtauthor=B.+J.+Schiemannauthor=C.+L.+Thompsonauthor=Y.+Yenauthor=W.+P.+Schiemannauthor=C.+C.+Liu&title=Detection+of+lysyl+oxidase-like+2+%28LOXL2%29%2C+a+biomarker+of+metastasis+from+breast+cancers+using+human+blood+samples&doi=10.2174%2F2210309005666150804195033"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21aR"><div class="casContent"><span class="casTitleNuber">21a</span><div class="casTitle"><span class="NLM_cas:atitle">detection of lysyl oxidase-like 2 (LOXL2), a biomarker of metastasis from breast cancers using human blood samples</span></div><div class="casAuthors">Janyasupab, Metini; Lee, Ying-Hui; Zhang, Yuan; Liu, Chen W.; Cai, Jieyi; Popa, Adriana; Samia, Anna C.; Wang, Kuan W.; Xu, Jiaqiang; Hu, Chi-Chang; Wendt, Michael K.; Schiemann, Barbara J.; Thompson, Cheryl L.; Yen, Yun; Schiemann, William P.; Liu, Chung C.</div><div class="citationInfo"><span class="NLM_cas:title">Recent Patents on Biomarkers</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">93-100</span>CODEN:
                <span class="NLM_cas:coden">RPBEE9</span>;
        ISSN:<span class="NLM_cas:issn">2210-3090</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">Metastasis accounts for 90% of the mortality assocd. with breast cancer.  Upregulated expression of members of the lysyl oxidase (LOX) family of secreted copper amine oxidases catalyzes the crosslinking of collagens and elastin in the extracellular matrix.  LOXs are linked to the development and metastatic progression of breast cancers.  Accordingly, aberrant expression of LOX-like 2 (LOXL2) is obsd. in poorly differentiated, high-grade tumors and is predictive of diseases recurrence, and for decreased overall patient survival.  Therefore, LOXL2 expression may serve as a biomarker for breast cancer.  Mechanistically, hydrogen peroxide is produced as a byproduct of LOXL2 when using an appropriate substrate, lysine.  We exploited this chem. to generate a revolutionary gold-based electrochem. biosensor capable of accurately detecting nanomolar quantities of LOXL2 in mouse blood, and in human blood samples.  Two different sources of the blood samples obtained from breast cancer patients were used in this study indicating the applicability of detecting LOXL2 in breast cancers patients.  Limited nos. of urine specimens from breast cancer patients were also tested.  Collectively, all of these tests show the promise and potential of this biosensor for detecting LOXL2 as a surrogate biomarker of breast cancer.  This work is described in patent no. WO2014052962 (2014).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqVBL7B7w1T4rVg90H21EOLACvtfcHk0lgLhK_rdTbgEA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XnvFyhug%253D%253D&md5=562b9bd70fa572df92227ee2d10f7de0</span></div><a href="/servlet/linkout?suffix=cit21a&amp;dbid=16384&amp;doi=10.2174%2F2210309005666150804195033&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F2210309005666150804195033%26sid%3Dliteratum%253Aachs%26aulast%3DJanyasupab%26aufirst%3DM.%26aulast%3DLee%26aufirst%3DY.%2BH.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DC.%2BW.%26aulast%3DCai%26aufirst%3DJ.%26aulast%3DPopa%26aufirst%3DA.%26aulast%3DSamia%26aufirst%3DA.%26aulast%3DWang%26aufirst%3DK.%2BW.%26aulast%3DXu%26aufirst%3DJ.%26aulast%3DHu%26aufirst%3DC.%2BC.%26aulast%3DWendt%26aufirst%3DM.%2BK.%26aulast%3DSchiemann%26aufirst%3DB.%2BJ.%26aulast%3DThompson%26aufirst%3DC.%2BL.%26aulast%3DYen%26aufirst%3DY.%26aulast%3DSchiemann%26aufirst%3DW.%2BP.%26aulast%3DLiu%26aufirst%3DC.%2BC.%26atitle%3DDetection%2520of%2520lysyl%2520oxidase-like%25202%2520%2528LOXL2%2529%252C%2520a%2520biomarker%2520of%2520metastasis%2520from%2520breast%2520cancers%2520using%2520human%2520blood%2520samples%26jtitle%3DRecent%2520Pat.%2520Biomarkers%26date%3D2015%26volume%3D5%26spage%3D93%26epage%3D100%26doi%3D10.2174%2F2210309005666150804195033" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit21b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Torres, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia-Palmero, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herrera, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bartolome, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pena, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernandez-Acenero, M.
J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Padilla, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pelaez-Garcia, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lopez-Lucendo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodriguez-Merlo, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Herreros, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonilla, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casal, J. I.</span></span> <span> </span><span class="NLM_article-title">LOXL2 is highly expressed in cancer-associated fibroblasts and associates to poor colon cancer survival</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">4892</span>– <span class="NLM_lpage">4902</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.ccr-14-3096</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=10.1158%2F1078-0432.ccr-14-3096" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=26206869" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvVWqsrjL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2015&pages=4892-4902&author=S.+Torresauthor=I.+Garcia-Palmeroauthor=M.+Herreraauthor=R.+A.+Bartolomeauthor=C.+Penaauthor=M.%0AJ.+Fernandez-Aceneroauthor=G.+Padillaauthor=A.+Pelaez-Garciaauthor=M.+Lopez-Lucendoauthor=R.+Rodriguez-Merloauthor=A.+G.+de+Herrerosauthor=F.+Bonillaauthor=J.+I.+Casal&title=LOXL2+is+highly+expressed+in+cancer-associated+fibroblasts+and+associates+to+poor+colon+cancer+survival&doi=10.1158%2F1078-0432.ccr-14-3096"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21bR"><div class="casContent"><span class="casTitleNuber">21b</span><div class="casTitle"><span class="NLM_cas:atitle">LOXL2 Is Highly Expressed in Cancer-Associated Fibroblasts and Associates to Poor Colon Cancer Survival</span></div><div class="casAuthors">Torres, Sofia; Garcia-Palmero, Irene; Herrera, Mercedes; Bartolome, Ruben A.; Pena, Cristina; Fernandez-Acenero, M. Jesus; Padilla, Guillermo; Pelaez-Garcia, Alberto; Lopez-Lucendo, Maria; Rodriguez-Merlo, Rufo; de Herreros, Antonio Garcia; Bonilla, Felix; Casal, J. Ignacio</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">4892-4902</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: Cancer-assocd. fibroblasts (CAF) are major mediators in tumor microenvironment.  We investigated the changes in protein expression in colon cancer-assocd. fibroblasts compared with normal fibroblasts (NF) in the context of searching for prognostic biomarkers, particularly for stage II patients.  Exptl. Design: CAFs and NFs isolated from colon cancer patients were used to identify differentially expressed proteins using quant. proteomics.  Stromal expression of deregulated proteins was analyzed by IHC.  Prognostic impact was studied using external gene-expression datasets for training, then quant. PCR and IHC for validation in different cohorts of patients.  Combined datasets were used for prediction of risk assessment at stages II and III.  Results: A desmoplastic signature composed of 32 proteins, highly specific for stromal components in colon cancer, was identified.  These proteins were enriched for extracellular matrix organization components, TGFβ signaling pathway, fibrosis, and wound-healing proteins.  The expression in CAFs of 11 upregulated proteins and four downregulated proteins, selected for biomarker validation, was verified by orthogonal techniques.  LOXL2 displayed a high prognostic impact by using external independent datasets and further validation in two different cohorts of patients.  High expression of LOXL2 was assocd. with higher recurrence P = 0.001 HR, 5.38 [95% confidence interval (CI), 1.70-17.01] and overall survival P = 0.001 HR, 8.52 (95% CI, 1.90-38.29).  IHC anal. revealed a prognostic value for LOXL2 in stage II patients.  Conclusions: We identified LOXL2 to be assocd. with the outcome of colon cancer patients.  Furthermore, it can be used to stratify patients at stages II and III for further therapeutic decisions.  Clin Cancer Res; 21(21); 4892-902. ©2015 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqpODhjbmk7hLVg90H21EOLACvtfcHk0lhDrkMwmdJcug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvVWqsrjL&md5=e66ea1a97471e80cb5f7f13804afd7b3</span></div><a href="/servlet/linkout?suffix=cit21b&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.ccr-14-3096&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.ccr-14-3096%26sid%3Dliteratum%253Aachs%26aulast%3DTorres%26aufirst%3DS.%26aulast%3DGarcia-Palmero%26aufirst%3DI.%26aulast%3DHerrera%26aufirst%3DM.%26aulast%3DBartolome%26aufirst%3DR.%2BA.%26aulast%3DPena%26aufirst%3DC.%26aulast%3DFernandez-Acenero%26aufirst%3DM.%2BJ.%26aulast%3DPadilla%26aufirst%3DG.%26aulast%3DPelaez-Garcia%26aufirst%3DA.%26aulast%3DLopez-Lucendo%26aufirst%3DM.%26aulast%3DRodriguez-Merlo%26aufirst%3DR.%26aulast%3Dde%2BHerreros%26aufirst%3DA.%2BG.%26aulast%3DBonilla%26aufirst%3DF.%26aulast%3DCasal%26aufirst%3DJ.%2BI.%26atitle%3DLOXL2%2520is%2520highly%2520expressed%2520in%2520cancer-associated%2520fibroblasts%2520and%2520associates%2520to%2520poor%2520colon%2520cancer%2520survival%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2015%26volume%3D21%26spage%3D4892%26epage%3D4902%26doi%3D10.1158%2F1078-0432.ccr-14-3096" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pollheimer, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Racedo, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mikels-Vigdal, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marshall, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bowlus, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lackner, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Madl, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karlsen, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hov, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lyman, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adamkewicz, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moreau, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zollner, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eide, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stojakovic, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scharnagl, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gruber, H.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stauber, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trauner, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fickert, P.</span></span> <span> </span><span class="NLM_article-title">Lysyl oxidase-like protein 2 (LOXL2) modulates barrier function in cholangiocytes in cholestasis</span>. <i>J. Hepatol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>69</i></span>,  <span class="NLM_fpage">368</span>– <span class="NLM_lpage">377</span>, <span class="refDoi"> DOI: 10.1016/j.jhep.2018.04.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=10.1016%2Fj.jhep.2018.04.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=29709678" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=1%3ACAS%3A528%3ADC%252BC1cXptlaqt7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2018&pages=368-377&author=M.+J.+Pollheimerauthor=S.+Racedoauthor=A.+Mikels-Vigdalauthor=D.+Marshallauthor=C.+Bowlusauthor=C.+Lacknerauthor=T.+Madlauthor=T.+H.+Karlsenauthor=J.+R.+Hovauthor=S.+K.+Lymanauthor=J.+Adamkewiczauthor=V.+Smithauthor=E.+Moreauauthor=G.+Zollnerauthor=T.+J.+Eideauthor=T.+Stojakovicauthor=H.+Scharnaglauthor=H.-J.+Gruberauthor=R.+E.+Stauberauthor=M.+Traunerauthor=P.+Fickert&title=Lysyl+oxidase-like+protein+2+%28LOXL2%29+modulates+barrier+function+in+cholangiocytes+in+cholestasis&doi=10.1016%2Fj.jhep.2018.04.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Lysyl oxidase-like protein 2 (LOXL2) modulates barrier function in cholangiocytes in cholestasis</span></div><div class="casAuthors">Pollheimer, Marion J.; Racedo, Silvia; Mikels-Vigdal, Amanda; Marshall, Derek; Bowlus, Christopher; Lackner, Carolin; Madl, Tobias; Karlsen, Tom H.; Hov, Johannes R.; Lyman, Susan K.; Adamkewicz, Joanne; Smith, Victoria; Moreau, Emmanuel; Zollner, Gernot; Eide, Tor Jacob; Stojakovic, Tatjana; Scharnagl, Hubert; Gruber, Hans-Juergen; Stauber, Rudolf E.; Trauner, Michael; Fickert, Peter</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Hepatology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">69</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">368-377</span>CODEN:
                <span class="NLM_cas:coden">JOHEEC</span>;
        ISSN:<span class="NLM_cas:issn">0168-8278</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The lysyl oxidase-like protein 2 (LOXL2) promotes stabilization of the extracellular matrix, chemotaxis, cell growth and cell mobility.  We aimed to (i) identify stimuli of LOXL2 in cholangiopathies, (ii) characterize the effects of LOXL2 on biliary epithelial cells' (BECs) barrier function, (iii) compare LOXL2 expression in primary sclerosing cholangitis (PSC), primary biliary cholangitis, and disease controls, and (iv) to det. LOXL2 expression and its cellular sources in four mouse models of cholangiopathies.  Cultured murine BECs were challenged with well-known triggers of cellular senescence, hypoxia, phospholipid-deficient Abcb4-/- mouse bile and chenodeoxycholic acid and investigated for LOXL2, SNAIL1 and E-cadherin expression and transepithelial elec. resistance with and without LOX-inhibition.  In vivo, LOXL2 expression was studied in PSC livers, and controls and mouse models.  We compared LOXL2 serum levels in patients with PSC, secondary SC, primary biliary cholangitis, and controls.  Cellular senescence, hypoxia, Abcb4-/- bile and chenodeoxycholic acid induced LOXL2 and SNAIL1 expression, repressed E-cadherin expression, and significantly reduced transepithelial elec. resistance in BECs.  Notably, all of the pathol. changes could be recovered via pharmacol. LOX-inhibition.  Mouse models showed induced LOXL2 expression in the portal region and in assocn. with ductular reaction.  LOXL2 serum levels were significantly elevated in patients with cholangiopathies.  In PSC, LOXL2 expression was located to characteristic periductal onion skin-type fibrosis, ductular reaction, Kupffer cells, and fibrotic septa.  Importantly, in PSC, LOXL2 overexpression was paralleled by E-cadherin loss in BECs from medium-sized bile ducts.Reactive BECs produce LOXL2, resulting in increased tight junction permeability, which can be ameliorated by pharmacol. LOX-inhibition in vitro.  Reactive BECs, portal myofibroblasts, and Kupffer cells are the main sources of LOXL2 in cholangiopathies.  In this study, we investigate the role of lysyl oxidase-like protein 2 (LOXL2), an enzyme pivotal in the development of organ fibrosis, in the pathogenesis of cholangiopathies (diseases of bile ducts), such as primary sclerosing cholangitis.  We found LOXL2 to be expressed in assocn. with bile duct epithelial injury and uncovered mechanisms for its upregulation and the subsequent effects in vitro and in vivo.  Our findings support testing of anti-LOXL2 treatment strategies for patients with primary sclerosing cholangitis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrd9j53GNHPxrVg90H21EOLACvtfcHk0lhDrkMwmdJcug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXptlaqt7o%253D&md5=eed5fe5e82dd7a0eecfaa896cdc7ff2b</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1016%2Fj.jhep.2018.04.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jhep.2018.04.009%26sid%3Dliteratum%253Aachs%26aulast%3DPollheimer%26aufirst%3DM.%2BJ.%26aulast%3DRacedo%26aufirst%3DS.%26aulast%3DMikels-Vigdal%26aufirst%3DA.%26aulast%3DMarshall%26aufirst%3DD.%26aulast%3DBowlus%26aufirst%3DC.%26aulast%3DLackner%26aufirst%3DC.%26aulast%3DMadl%26aufirst%3DT.%26aulast%3DKarlsen%26aufirst%3DT.%2BH.%26aulast%3DHov%26aufirst%3DJ.%2BR.%26aulast%3DLyman%26aufirst%3DS.%2BK.%26aulast%3DAdamkewicz%26aufirst%3DJ.%26aulast%3DSmith%26aufirst%3DV.%26aulast%3DMoreau%26aufirst%3DE.%26aulast%3DZollner%26aufirst%3DG.%26aulast%3DEide%26aufirst%3DT.%2BJ.%26aulast%3DStojakovic%26aufirst%3DT.%26aulast%3DScharnagl%26aufirst%3DH.%26aulast%3DGruber%26aufirst%3DH.-J.%26aulast%3DStauber%26aufirst%3DR.%2BE.%26aulast%3DTrauner%26aufirst%3DM.%26aulast%3DFickert%26aufirst%3DP.%26atitle%3DLysyl%2520oxidase-like%2520protein%25202%2520%2528LOXL2%2529%2520modulates%2520barrier%2520function%2520in%2520cholangiocytes%2520in%2520cholestasis%26jtitle%3DJ.%2520Hepatol.%26date%3D2018%26volume%3D69%26spage%3D368%26epage%3D377%26doi%3D10.1016%2Fj.jhep.2018.04.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ikenaga, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, Z.-W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vaid, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshida, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sverdlov, D. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mikels-Vigdal, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schuppan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Popov, Y. V.</span></span> <span> </span><span class="NLM_article-title">Selective targeting of lysyl oxidase-like 2 (LOXL2) suppresses hepatic fibrosis progression and accelerates its reversal</span>. <i>Gut</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>66</i></span>,  <span class="NLM_fpage">1697</span>– <span class="NLM_lpage">1708</span>, <span class="refDoi"> DOI: 10.1136/gutjnl-2016-312473</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=10.1136%2Fgutjnl-2016-312473" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=28073888" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitVShurvP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2017&pages=1697-1708&author=N.+Ikenagaauthor=Z.-W.+Pengauthor=K.+A.+Vaidauthor=S.+B.+Liuauthor=S.+Yoshidaauthor=D.+Y.+Sverdlovauthor=A.+Mikels-Vigdalauthor=V.+Smithauthor=D.+Schuppanauthor=Y.+V.+Popov&title=Selective+targeting+of+lysyl+oxidase-like+2+%28LOXL2%29+suppresses+hepatic+fibrosis+progression+and+accelerates+its+reversal&doi=10.1136%2Fgutjnl-2016-312473"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Selective targeting of lysyl oxidase-like 2 (LOXL2) suppresses hepatic fibrosis progression and accelerates its reversal</span></div><div class="casAuthors">Ikenaga, Naoki; Peng, Zhen-Wei; Vaid, Kahini A.; Liu, Susan B.; Yoshida, Shuhei; Sverdlov, Deanna Y.; Mikels-Vigdal, Amanda; Smith, Victoria; Schuppan, Detlef; Popov, Yury V.</div><div class="citationInfo"><span class="NLM_cas:title">Gut</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1697-1709</span>CODEN:
                <span class="NLM_cas:coden">GUTTAK</span>;
        ISSN:<span class="NLM_cas:issn">0017-5749</span>.
    
            (<span class="NLM_cas:orgname">BMJ Publishing Group</span>)
        </div><div class="casAbstract">Background/Aims: We studied the role of lysyl oxidase-like 2 (LOXL2) in collagen crosslinking and hepatic progenitor cell (HPC) differentiation, and the therapeutic efficacy of a LOXL2-blocking monoclonal antibody on liver fibrosis progression/reversal in mice.  Methods: Anti-LOXL2 antibody, control antilysyl oxidase antibody or placebo was administered during thioacetamide (TAA)-induced fibrosis progression or during recovery.  Therapeutic efficacy in biliary fibrosis was tested in BALB/c.Mdr2-/- and 3,5-diethoxycarbonyl-1,4-dihydrocollidine (DDC)-fed mice.  Collagen crosslinking, fibrosis progression and reversal were assessed histol. and biochem.  HPC differentiation was studied in primary EpCAM(+)liver cells in vitro.  Results: LOXL2 was virtually absent from healthy but strongly induced in fibrotic liver, with predominant localization within fibrotic septa.  Delayed anti-LOXL2 treatment of active TAA fibrosis significantly reduced collagen crosslinking and histol. signs of bridging fibrosis, with a 53% redn. in morphometric collagen deposition.  In established TAA fibrosis, LOXL2 inhibition promoted fibrosis reversal, with enhanced splitting and thinning of fibrotic septa, and a 45% decrease in collagen area at 4 wk of recovery.  In the Mdr2-/- and DDC-induced models of biliary fibrosis, anti-LOXL2 antibody similarly achieved significant antifibrotic efficacy and suppressed the ductular reaction, while hepatocyte replication increased.  Blocking LOXL2 had a profound direct effect on primary EpCAM(+)HPC behavior in vitro, promoting their differentiation towards hepatocytes, while inhibiting ductal cell lineage commitment.  Conclusions: LOXL2 mediates collagen crosslinking and fibrotic matrix stabilization during liver fibrosis, and independently promotes fibrogenic HPC differentiation.  By blocking these two convergent profibrotic pathways, therapeutic LOXL2 inhibition attenuates both parenchymal and biliary fibrosis and promotes fibrosis reversal.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq6NPFSjhoMLbVg90H21EOLACvtfcHk0ljs3hWOR3jt3w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitVShurvP&md5=1af0e332c38eb1850cf1fa9d613fb6be</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1136%2Fgutjnl-2016-312473&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1136%252Fgutjnl-2016-312473%26sid%3Dliteratum%253Aachs%26aulast%3DIkenaga%26aufirst%3DN.%26aulast%3DPeng%26aufirst%3DZ.-W.%26aulast%3DVaid%26aufirst%3DK.%2BA.%26aulast%3DLiu%26aufirst%3DS.%2BB.%26aulast%3DYoshida%26aufirst%3DS.%26aulast%3DSverdlov%26aufirst%3DD.%2BY.%26aulast%3DMikels-Vigdal%26aufirst%3DA.%26aulast%3DSmith%26aufirst%3DV.%26aulast%3DSchuppan%26aufirst%3DD.%26aulast%3DPopov%26aufirst%3DY.%2BV.%26atitle%3DSelective%2520targeting%2520of%2520lysyl%2520oxidase-like%25202%2520%2528LOXL2%2529%2520suppresses%2520hepatic%2520fibrosis%2520progression%2520and%2520accelerates%2520its%2520reversal%26jtitle%3DGut%26date%3D2017%26volume%3D66%26spage%3D1697%26epage%3D1708%26doi%3D10.1136%2Fgutjnl-2016-312473" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rodriguez, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vaysberg, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mikels, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCauley, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Velayo, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, V.</span></span> <span> </span><span class="NLM_article-title">Modulation of lysyl oxidase-like 2 enzymatic activity by an allosteric antibody inhibitor</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>285</i></span>,  <span class="NLM_fpage">20964</span>– <span class="NLM_lpage">20974</span>, <span class="refDoi"> DOI: 10.1074/jbc.m109.094136</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=10.1074%2Fjbc.m109.094136" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=20439985" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=1%3ACAS%3A528%3ADC%252BC3cXnvFSiur0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=285&publication_year=2010&pages=20964-20974&author=H.+M.+Rodriguezauthor=M.+Vaysbergauthor=A.+Mikelsauthor=S.+McCauleyauthor=A.+C.+Velayoauthor=C.+Garciaauthor=V.+Smith&title=Modulation+of+lysyl+oxidase-like+2+enzymatic+activity+by+an+allosteric+antibody+inhibitor&doi=10.1074%2Fjbc.m109.094136"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Modulation of Lysyl Oxidase-like 2 Enzymatic Activity by an Allosteric Antibody Inhibitor</span></div><div class="casAuthors">Rodriguez, Hector M.; Vaysberg, Maria; Mikels, Amanda; McCauley, Scott; Velayo, Arleene C.; Garcia, Carlos; Smith, Victoria</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">285</span>
        (<span class="NLM_cas:issue">27</span>),
    <span class="NLM_cas:pages">20964-20974</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">In this report, we assessed the steady-state enzymic activity of lysyl oxidase-like 2 (LOXL2) against the substrates 1,5-diaminopentane (DAP), spermine, and fibrillar type I collagen.  We find that both DAP and spermine are capable of activating LOXL2 to the same extent and have similar Michaelis consts. (Km ∼ 1 mM) and catalytic rates (kcat ∼ 0.02 s-1).  We also show that LOXL2 is capable of being inhibited by a known suicide inhibitor of lysyl oxidase (LOX), β-aminopropionitrile, which we find is a potent inhibitor of LOXL2 activity.  The modality of inhibition of β-aminopropionitrile was also examd. and found to be competitive with respect to the substrates DAP and spermine.  In addn., we identified an antibody inhibitor (AB0023) of LOXL2 enzymic function and have found that the inhibition occurs in a non-competitive manner with respect to both spermine and DAP.  The binding epitope of AB0023 was mapped to the scavenger receptor cysteine-rich domain four of human LOXL2.  AB0023 binds to a region remote from the catalytic domain making AB0023 an allosteric inhibitor of LOXL2.  This affords AB0023 several advantages, because it is specific for LOXL2 and inhibits the enzymic function of LOXL2 in a non-competitive manner thereby allowing inhibition of LOXL2 regardless of substrate concn.  These results suggest that antibody allosteric modulators of enzymic function represent a novel drug development strategy and, in the context of LOXL2, suggest that inhibitors such as these might be useful therapeutics in oncol., fibrosis, and inflammation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqFGtBWNkyY-rVg90H21EOLACvtfcHk0ljs3hWOR3jt3w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXnvFSiur0%253D&md5=d5c4074fdf77bd122feb5345e801e885</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1074%2Fjbc.m109.094136&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.m109.094136%26sid%3Dliteratum%253Aachs%26aulast%3DRodriguez%26aufirst%3DH.%2BM.%26aulast%3DVaysberg%26aufirst%3DM.%26aulast%3DMikels%26aufirst%3DA.%26aulast%3DMcCauley%26aufirst%3DS.%26aulast%3DVelayo%26aufirst%3DA.%2BC.%26aulast%3DGarcia%26aufirst%3DC.%26aulast%3DSmith%26aufirst%3DV.%26atitle%3DModulation%2520of%2520lysyl%2520oxidase-like%25202%2520enzymatic%2520activity%2520by%2520an%2520allosteric%2520antibody%2520inhibitor%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2010%26volume%3D285%26spage%3D20964%26epage%3D20974%26doi%3D10.1074%2Fjbc.m109.094136" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Puente, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fortea, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cabezas, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arias Loste, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iruzubieta, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Llerena, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huelin, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fábrega, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crespo, J.</span></span> <span> </span><span class="NLM_article-title">LOXL2-A new target in antifibrogenic therapy?</span>. <i>Int. J. Mol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">1634</span>, <span class="refDoi"> DOI: 10.3390/ijms20071634</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=10.3390%2Fijms20071634" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=1%3ACAS%3A528%3ADC%252BB3cXosVOksg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2019&pages=1634&author=A.+Puenteauthor=J.+Forteaauthor=J.+Cabezasauthor=M.+Arias+Losteauthor=P.+Iruzubietaauthor=S.+Llerenaauthor=P.+Huelinauthor=E.+F%C3%A1bregaauthor=J.+Crespo&title=LOXL2-A+new+target+in+antifibrogenic+therapy%3F&doi=10.3390%2Fijms20071634"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">LOXL2-a new target in antifibrogenic therapy?</span></div><div class="casAuthors">Puente, Angela; Fortea, Jose Ignacio; Cabezas, Joaquin; Loste, Maria Teresa Arias; Iruzubieta, Paula; Llerena, Susana; Huelin, Patricia; Fabrega, Emilio; Crespo, Javier</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Molecular Sciences</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1634</span>CODEN:
                <span class="NLM_cas:coden">IJMCFK</span>;
        ISSN:<span class="NLM_cas:issn">1422-0067</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">A review.  The concept of liver fibrosis and cirrhosis being static and therefore irreversible is outdated.  Indeed, both human and animal studies have shown that fibrogenesis is a dynamic and potentially reversible process that can be modulated either by stopping its progression and/or by promoting its resoln.  Therefore, the study of the mol. mechanisms involved in the pathogenesis of liver fibrosis is crit. for the development of future antifibrotic therapies.  The fibrogenesis process, common to all forms of liver injury, is characterized by the increased deposition of extracellular matrix components (EMCs), including collagen, proteoglycans, and glycoproteins (laminin and fibronectin 2).  These changes in the compn. of the extracellular matrix components alter their interaction with cell adhesion mols., influencing the modulation of cell functions (growth, migration, and gene expression).  Hepatic stellate cells and Kupffer cells (liver macrophages) are the key fibrogenic effectors.  The antifibrogenic mechanism starts with the activation of Ly6Chigh macrophages, which can differentiate into macrophages with antifibrogenic action.  The research of biochem. changes affecting fibrosis irreversibility has identified lysyl oxidase-like 2 (LOXL2), an enzyme that promotes the network of collagen fibers of the extracellular matrix.  LOXL2 inhibition can decrease cell nos., proliferation, colony formations, and cell growth, and it can induce cell cycle arrest and increase apoptosis.  The development of a new humanized IgG4 monoclonal antibody against LOXL2 could open the window of a new antifibrogenic treatment.  The current therapeutic target in patients with liver cirrhosis should focus (after the eradication of the causal agent) on the development of new antifibrogenic drugs.  The development of these drugs must meet three premises: Patient safety, in non-cirrhotic phases, down-staging or at least stabilization and slowing the progression to cirrhosis must be achieved; whereas in the cirrhotic stage, the objective should be to reduce fibrosis and portal pressure.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpwkSiBNrg_1LVg90H21EOLACvtfcHk0ljs3hWOR3jt3w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXosVOksg%253D%253D&md5=11468a9417073b0b2a2cf46086f9b436</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.3390%2Fijms20071634&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fijms20071634%26sid%3Dliteratum%253Aachs%26aulast%3DPuente%26aufirst%3DA.%26aulast%3DFortea%26aufirst%3DJ.%26aulast%3DCabezas%26aufirst%3DJ.%26aulast%3DArias%2BLoste%26aufirst%3DM.%26aulast%3DIruzubieta%26aufirst%3DP.%26aulast%3DLlerena%26aufirst%3DS.%26aulast%3DHuelin%26aufirst%3DP.%26aulast%3DF%25C3%25A1brega%26aufirst%3DE.%26aulast%3DCrespo%26aufirst%3DJ.%26atitle%3DLOXL2-A%2520new%2520target%2520in%2520antifibrogenic%2520therapy%253F%26jtitle%3DInt.%2520J.%2520Mol.%2520Sci.%26date%3D2019%26volume%3D20%26spage%3D1634%26doi%3D10.3390%2Fijms20071634" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mesarwi, O. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shin, M.-K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drager, L. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bevans-Fonti, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jun, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Putcha, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Torbenson, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pedrosa, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lorenzi-Filho, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steele, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schweitzer, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magnuson, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lidor, A. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwartz, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Polotsky, V. Y.</span></span> <span> </span><span class="NLM_article-title">Lysyl oxidase as a serum biomarker of liver fibrosis in patients with severe obesity and obstructive sleep apnea</span>. <i>Sleep</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>38</i></span>,  <span class="NLM_fpage">1583</span>– <span class="NLM_lpage">1591</span>, <span class="refDoi"> DOI: 10.5665/sleep.5052</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=10.5665%2Fsleep.5052" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=26085300" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=1%3ACAS%3A280%3ADC%252BC2MbksFSlsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2015&pages=1583-1591&author=O.+A.+Mesarwiauthor=M.-K.+Shinauthor=L.+F.+Dragerauthor=S.+Bevans-Fontiauthor=J.+C.+Junauthor=N.+Putchaauthor=M.+S.+Torbensonauthor=R.+P.+Pedrosaauthor=G.+Lorenzi-Filhoauthor=K.+E.+Steeleauthor=M.+A.+Schweitzerauthor=T.+H.+Magnusonauthor=A.+O.+Lidorauthor=A.+R.+Schwartzauthor=V.+Y.+Polotsky&title=Lysyl+oxidase+as+a+serum+biomarker+of+liver+fibrosis+in+patients+with+severe+obesity+and+obstructive+sleep+apnea&doi=10.5665%2Fsleep.5052"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Lysyl Oxidase as a Serum Biomarker of Liver Fibrosis in Patients with Severe Obesity and Obstructive Sleep Apnea</span></div><div class="casAuthors">Mesarwi Omar A; Shin Mi-Kyung; Bevans-Fonti Shannon; Jun Jonathan C; Putcha Nirupama; Schwartz Alan R; Polotsky Vsevolod Y; Drager Luciano F; Torbenson Michael S; Pedrosa Rodrigo P; Lorenzi-Filho Geraldo; Steele Kimberley E; Schweitzer Michael A; Magnuson Thomas H; Lidor Anne O</div><div class="citationInfo"><span class="NLM_cas:title">Sleep</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1583-91</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">STUDY OBJECTIVES:  Obstructive sleep apnea (OSA) is associated with the progression of nonalcoholic fatty liver disease (NAFLD).  We hypothesized that the hypoxia of OSA increases hepatic production of lysyl oxidase (LOX), an enzyme that cross-links collagen, and that LOX may serve as a biomarker of hepatic fibrosis.  DESIGN:  Thirty-five patients with severe obesity underwent liver biopsy, polysomnography, and serum LOX testing.  A separate group with severe OSA had serum LOX measured before and after 3 mo of CPAP or no therapy, as did age-matched controls.  LOX expression and secretion were measured in mouse hepatocytes following exposure to hypoxia.  SETTING:  The Johns Hopkins Bayview Sleep Disorders Center, and the Hypertension Unit of the Heart Institute at the University of Sao Paulo Medical School.  MEASUREMENTS AND RESULTS:  In the bariatric cohort, the apnea-hypopnea index was higher in patients with hepatic fibrosis than in those without fibrosis (42.7 ± 30.2 events/h, versus 16.2 ± 15.5 events/h; P = 0.002), as was serum LOX (84.64 ± 29.71 ng/mL, versus 45.46 ± 17.16 ng/mL; P < 0.001).  In the sleep clinic sample, patients with severe OSA had higher baseline LOX than healthy controls (70.75 ng/mL versus 52.36 ng/mL, P = 0.046), and serum LOX decreased in patients with OSA on CPAP (mean decrease 20.49 ng/mL) but not in untreated patients (mean decrease 0.19 ng/mL).  Hypoxic mouse hepatocytes demonstrated 5.9-fold increased LOX transcription (P = 0.046), and enhanced LOX protein secretion.  CONCLUSIONS:  The hypoxic stress of obstructive sleep apnea may increase circulating lysyl oxidase (LOX) levels.  LOX may serve as a biomarker of liver fibrosis in patients with severe obesity and nonalcoholic fatty liver disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTFKuhUvr3mbGZyxfu64m4ffW6udTcc2eZAGH6EATksrLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2MbksFSlsQ%253D%253D&md5=81878be58b7fd243d2fe56ca7816b706</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.5665%2Fsleep.5052&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.5665%252Fsleep.5052%26sid%3Dliteratum%253Aachs%26aulast%3DMesarwi%26aufirst%3DO.%2BA.%26aulast%3DShin%26aufirst%3DM.-K.%26aulast%3DDrager%26aufirst%3DL.%2BF.%26aulast%3DBevans-Fonti%26aufirst%3DS.%26aulast%3DJun%26aufirst%3DJ.%2BC.%26aulast%3DPutcha%26aufirst%3DN.%26aulast%3DTorbenson%26aufirst%3DM.%2BS.%26aulast%3DPedrosa%26aufirst%3DR.%2BP.%26aulast%3DLorenzi-Filho%26aufirst%3DG.%26aulast%3DSteele%26aufirst%3DK.%2BE.%26aulast%3DSchweitzer%26aufirst%3DM.%2BA.%26aulast%3DMagnuson%26aufirst%3DT.%2BH.%26aulast%3DLidor%26aufirst%3DA.%2BO.%26aulast%3DSchwartz%26aufirst%3DA.%2BR.%26aulast%3DPolotsky%26aufirst%3DV.%2BY.%26atitle%3DLysyl%2520oxidase%2520as%2520a%2520serum%2520biomarker%2520of%2520liver%2520fibrosis%2520in%2520patients%2520with%2520severe%2520obesity%2520and%2520obstructive%2520sleep%2520apnea%26jtitle%3DSleep%26date%3D2015%26volume%3D38%26spage%3D1583%26epage%3D1591%26doi%3D10.5665%2Fsleep.5052" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Aumiller, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strobel, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romeike, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schuler, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stierstorfer, B. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kreuz, S.</span></span> <span> </span><span class="NLM_article-title">Comparative analysis of lysyl oxidase (like) family members in pulmonary fibrosis</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">149</span>, <span class="refDoi"> DOI: 10.1038/s41598-017-00270-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=10.1038%2Fs41598-017-00270-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=28273952" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=1%3ACAS%3A280%3ADC%252BC1czkt1Gjsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2017&pages=149&author=V.+Aumillerauthor=B.+Strobelauthor=M.+Romeikeauthor=M.+Schulerauthor=B.+E.+Stierstorferauthor=S.+Kreuz&title=Comparative+analysis+of+lysyl+oxidase+%28like%29+family+members+in+pulmonary+fibrosis&doi=10.1038%2Fs41598-017-00270-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27aR"><div class="casContent"><span class="casTitleNuber">27a</span><div class="casTitle"><span class="NLM_cas:atitle">Comparative analysis of lysyl oxidase (like) family members in pulmonary fibrosis</span></div><div class="casAuthors">Aumiller Verena; Romeike Merrit; Kreuz Sebastian; Strobel Benjamin; Schuler Michael; Stierstorfer Birgit E</div><div class="citationInfo"><span class="NLM_cas:title">Scientific reports</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">149</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Extracellular matrix (ECM) composition and stiffness are major driving forces for the development and persistence of fibrotic diseases.  Lysyl oxidase (LOX) and LOX-like (LOXL) proteins play crucial roles in ECM remodeling due to their collagen crosslinking and intracellular functions.  Here, we systematically investigated LOX/L expression in primary fibroblasts and epithelial cells under fibrotic conditions, Bleomycin (BLM) induced lung fibrosis and in human IPF tissue.  Basal expression of all LOX/L family members was detected in epithelial cells and at higher levels in fibroblasts.  Various pro-fibrotic stimuli broadly induced LOX/L expression in fibroblasts, whereas specific induction of LOXL2 and partially LOX was observed in epithelial cells.  Immunohistochemical analysis of lung tissue from 14 IPF patients and healthy donors revealed strong induction of LOX and LOXL2 in bronchial and alveolar epithelium as well as fibroblastic foci.  Using siRNA experiments we observed that LOXL2 and LOXL3 were crucial for fibroblast-to-myofibroblast transition (FMT).  As FMT could only be reconstituted with an enzymatically active LOXL2 variant, we conclude that LOXL2 enzymatic function is crucial for fibroblast transdifferentiation.  In summary, our study provides a comprehensive analysis of the LOX/L family in fibrotic lung disease and indicates prominent roles for LOXL2/3 in fibroblast activation and LOX/LOXL2 in IPF.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSZXzPVcMeOd0h5eUSa2oe_fW6udTcc2eZAGH6EATksrLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1czkt1Gjsw%253D%253D&md5=626ced24d6605e4be98f4e97a10d9123</span></div><a href="/servlet/linkout?suffix=cit27a&amp;dbid=16384&amp;doi=10.1038%2Fs41598-017-00270-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41598-017-00270-0%26sid%3Dliteratum%253Aachs%26aulast%3DAumiller%26aufirst%3DV.%26aulast%3DStrobel%26aufirst%3DB.%26aulast%3DRomeike%26aufirst%3DM.%26aulast%3DSchuler%26aufirst%3DM.%26aulast%3DStierstorfer%26aufirst%3DB.%2BE.%26aulast%3DKreuz%26aufirst%3DS.%26atitle%3DComparative%2520analysis%2520of%2520lysyl%2520oxidase%2520%2528like%2529%2520family%2520members%2520in%2520pulmonary%2520fibrosis%26jtitle%3DSci.%2520Rep.%26date%3D2017%26volume%3D7%26spage%3D149%26doi%3D10.1038%2Fs41598-017-00270-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit27b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, W.</span></span> <span> </span><span class="NLM_article-title">LOX/LOXL in pulmonary fibrosis: potential therapeutic targets</span>. <i>J. Drug Targeting</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">790</span>, <span class="refDoi"> DOI: 10.1080/1061186x.2018.1550649</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=10.1080%2F1061186x.2018.1550649" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=30457362" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2018&pages=790&author=L.+Chenauthor=S.+Liauthor=W.+Li&title=LOX%2FLOXL+in+pulmonary+fibrosis%3A+potential+therapeutic+targets&doi=10.1080%2F1061186x.2018.1550649"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27b&amp;dbid=16384&amp;doi=10.1080%2F1061186x.2018.1550649&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F1061186x.2018.1550649%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DL.%26aulast%3DLi%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DW.%26atitle%3DLOX%252FLOXL%2520in%2520pulmonary%2520fibrosis%253A%2520potential%2520therapeutic%2520targets%26jtitle%3DJ.%2520Drug%2520Targeting%26date%3D2018%26volume%3D27%26spage%3D790%26doi%3D10.1080%2F1061186x.2018.1550649" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Kamikawaji, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seki, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watanabe, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mataki, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumamoto, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takagi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mizuno, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inoue, H.</span></span> <span> </span><span class="NLM_article-title">Regulation of LOXL2 and SERPINH1 by antitumor microRNA-29a in lung cancer with idiopathic pulmonary fibrosis</span>. <i>J. Hum. Genet.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">985</span>– <span class="NLM_lpage">993</span>, <span class="refDoi"> DOI: 10.1038/jhg.2016.99</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=10.1038%2Fjhg.2016.99" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=27488440" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=1%3ACAS%3A528%3ADC%252BC28XitFCmsL%252FE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2016&pages=985-993&author=K.+Kamikawajiauthor=N.+Sekiauthor=M.+Watanabeauthor=H.+Matakiauthor=T.+Kumamotoauthor=K.+Takagiauthor=K.+Mizunoauthor=H.+Inoue&title=Regulation+of+LOXL2+and+SERPINH1+by+antitumor+microRNA-29a+in+lung+cancer+with+idiopathic+pulmonary+fibrosis&doi=10.1038%2Fjhg.2016.99"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28aR"><div class="casContent"><span class="casTitleNuber">28a</span><div class="casTitle"><span class="NLM_cas:atitle">Regulation of LOXL2 and SERPINH1 by antitumor microRNA-29a in lung cancer with idiopathic pulmonary fibrosis</span></div><div class="casAuthors">Kamikawaji, Kazuto; Seki, Naohiko; Watanabe, Masaki; Mataki, Hiroko; Kumamoto, Tomohiro; Takagi, Koichiro; Mizuno, Keiko; Inoue, Hiromasa</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Human Genetics</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">985-993</span>CODEN:
                <span class="NLM_cas:coden">JHGEFR</span>;
        ISSN:<span class="NLM_cas:issn">1434-5161</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive lung disease that is refractory to treatment and carries a high mortality rate.  IPF is frequently assocd. with lung cancer.  Identification of mol. targets involved in both diseases may elucidate novel mol. mechanisms contributing to their pathol.  Recent studies of microRNA (miRNA) expression signatures showed that microRNA-29a (miR-29a) was downregulated in IPF and lung cancer.  The aim of this study was to investigate the functional significance of miR-29a in lung cancer cells (A549 and EBC-1) and lung fibroblasts (MRC-5) and to identify mol. targets modulated by miR-29a in these cells.  We confirmed the downregulation of miR-29a in clin. specimens of IPF and lung cancer.  Restoration of miR-29a suppressed cancer cell aggressiveness and fibroblast migration.  A combination of gene expression data and in silico anal. showed that a total of 24 genes were putative targets of miR-29a.  Among them, lysyl oxidase-like 2 (LOXL2) and serpin peptidase inhibitor clade H, member 1 (SERPINH1) were direct targets of miR-29a by luciferase reporter assays.  The functions of LOXL2 and SERPINH1 contribute significantly to collagen biosynthesis.  Overexpression of LOXL2 and SERPINH1 was obsd. in clin. specimens of lung cancer and fibrotic lesions.  Downregulation of miR-29a caused overexpression of LOXL2 and SERPINH1 in lung cancer and IPF, suggesting that these genes are involved in the pathogenesis of these two diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrb2zDp-N7psrVg90H21EOLACvtfcHk0ljxFMwHwSlITA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XitFCmsL%252FE&md5=5f34265dbac7bb03237d23dc5d2135fa</span></div><a href="/servlet/linkout?suffix=cit28a&amp;dbid=16384&amp;doi=10.1038%2Fjhg.2016.99&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fjhg.2016.99%26sid%3Dliteratum%253Aachs%26aulast%3DKamikawaji%26aufirst%3DK.%26aulast%3DSeki%26aufirst%3DN.%26aulast%3DWatanabe%26aufirst%3DM.%26aulast%3DMataki%26aufirst%3DH.%26aulast%3DKumamoto%26aufirst%3DT.%26aulast%3DTakagi%26aufirst%3DK.%26aulast%3DMizuno%26aufirst%3DK.%26aulast%3DInoue%26aufirst%3DH.%26atitle%3DRegulation%2520of%2520LOXL2%2520and%2520SERPINH1%2520by%2520antitumor%2520microRNA-29a%2520in%2520lung%2520cancer%2520with%2520idiopathic%2520pulmonary%2520fibrosis%26jtitle%3DJ.%2520Hum.%2520Genet.%26date%3D2016%26volume%3D61%26spage%3D985%26epage%3D993%26doi%3D10.1038%2Fjhg.2016.99" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit28b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Leeming, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willumsen, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sand, J. M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holm
Nielsen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dasgupta, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brodmerkel, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Curran, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bager, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karsdal, M. A.</span></span> <span> </span><span class="NLM_article-title">A serological marker of the N-terminal neoepitope generated during LOXL2 maturation is elevated in patients with cancer or idiopathic pulmonary fibrosis</span>. <i>Biochem. Biophys. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">38</span>– <span class="NLM_lpage">43</span>, <span class="refDoi"> DOI: 10.1016/j.bbrep.2018.11.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=10.1016%2Fj.bbrep.2018.11.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=30555938" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=1%3ACAS%3A280%3ADC%252BB3cnis1Crsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2019&pages=38-43&author=D.+J.+Leemingauthor=N.+Willumsenauthor=J.+M.+B.+Sandauthor=S.+Holm%0ANielsenauthor=B.+Dasguptaauthor=C.+Brodmerkelauthor=M.+Curranauthor=C.+L.+Bagerauthor=M.+A.+Karsdal&title=A+serological+marker+of+the+N-terminal+neoepitope+generated+during+LOXL2+maturation+is+elevated+in+patients+with+cancer+or+idiopathic+pulmonary+fibrosis&doi=10.1016%2Fj.bbrep.2018.11.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28bR"><div class="casContent"><span class="casTitleNuber">28b</span><div class="casTitle"><span class="NLM_cas:atitle">A serological marker of the N-terminal neoepitope generated during LOXL2 maturation is elevated in patients with cancer or idiopathic pulmonary fibrosis</span></div><div class="casAuthors">Leeming D J; Willumsen N; Sand J M B; Holm Nielsen S; Karsdal M A; Dasgupta B; Brodmerkel C; Curran M; Bager C L</div><div class="citationInfo"><span class="NLM_cas:title">Biochemistry and biophysics reports</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">38-43</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Objectives:  Lysyl oxidase like 2 (LOXL2) is associated with poor prognosis in idiopathic pulmonary disease (IPF) and cancer.  We developed an Enzyme-linked immunosorbent assay (ELISA) targeting the LOXL2 neo-epitope generated through the release of the signal peptide during LOXL2 maturation.  Design and methods:  An ELISA targeting the N-terminal site of the human LOXL2 was developed including technical optimization and validation steps.  Serum LOXL2 was measured in patients with breast, colorectal, lung, ovarian, pancreatic and prostate cancer, melanoma, IPF and in healthy controls (n = 16).  Results:  A technically robust and specific assay was developed.  LOXL2 was detectable in serum from healthy controls and showed reactivity towards recombinant LOXL2.  Compared to controls, LOXL2 levels were significantly (p < 0.001-0.05) elevated in serum from patients with breast, colerectal, lung, ovarian and pancreatic cancer (mean range: 49-84 ng/mL), but not in prostate cancer (mean: 36 ng/mL) and malignant melanoma patients (41 ng/mL).  Serum LOXL2 was elevated in IPF patients compared to healthy controls (mean: 76.5 vs 46.8 ng/mL; p > 0.001).  Conclusions:  A specific ELISA towards the N-terminal neo-epitope site in LOXL2 was developed which detected significantly elevated serum levels from patients with above-mentioned cancer types or IPF compared to healthy controls.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSL2FMWTRh-Atj_Vg2vObihfW6udTcc2eYHPkarqn9F6rntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3cnis1Crsw%253D%253D&md5=0a71f3cfc448dd6d8c1778215f63abc8</span></div><a href="/servlet/linkout?suffix=cit28b&amp;dbid=16384&amp;doi=10.1016%2Fj.bbrep.2018.11.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbrep.2018.11.002%26sid%3Dliteratum%253Aachs%26aulast%3DLeeming%26aufirst%3DD.%2BJ.%26aulast%3DWillumsen%26aufirst%3DN.%26aulast%3DSand%26aufirst%3DJ.%2BM.%2BB.%26aulast%3DHolm%2BNielsen%26aufirst%3DS.%26aulast%3DDasgupta%26aufirst%3DB.%26aulast%3DBrodmerkel%26aufirst%3DC.%26aulast%3DCurran%26aufirst%3DM.%26aulast%3DBager%26aufirst%3DC.%2BL.%26aulast%3DKarsdal%26aufirst%3DM.%2BA.%26atitle%3DA%2520serological%2520marker%2520of%2520the%2520N-terminal%2520neoepitope%2520generated%2520during%2520LOXL2%2520maturation%2520is%2520elevated%2520in%2520patients%2520with%2520cancer%2520or%2520idiopathic%2520pulmonary%2520fibrosis%26jtitle%3DBiochem.%2520Biophys.%2520Rep.%26date%3D2019%26volume%3D17%26spage%3D38%26epage%3D43%26doi%3D10.1016%2Fj.bbrep.2018.11.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wei, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gibbons, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamauchi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jackson, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le Saux, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calhoun, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peters, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Derynck, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Backes, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chapman, H. A.</span></span> <span> </span><span class="NLM_article-title">Fibroblast-specific inhibition of TGF-β1 signaling attenuates lung and tumor fibrosis</span>. <i>J. Clin. Invest.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>127</i></span>,  <span class="NLM_fpage">3675</span>– <span class="NLM_lpage">3688</span>, <span class="refDoi"> DOI: 10.1172/jci94624</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=10.1172%2Fjci94624" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=28872461" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=1%3ACAS%3A280%3ADC%252BC1cbkslOrtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=127&publication_year=2017&pages=3675-3688&author=Y.+Weiauthor=T.+J.+Kimauthor=D.+H.+Pengauthor=D.+Duanauthor=D.+L.+Gibbonsauthor=M.+Yamauchiauthor=J.+R.+Jacksonauthor=C.+J.+Le+Sauxauthor=C.+Calhounauthor=J.+Petersauthor=R.+Derynckauthor=B.+J.+Backesauthor=H.+A.+Chapman&title=Fibroblast-specific+inhibition+of+TGF-%CE%B21+signaling+attenuates+lung+and+tumor+fibrosis&doi=10.1172%2Fjci94624"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Fibroblast-specific inhibition of TGF-β1 signaling attenuates lung and tumor fibrosis</span></div><div class="casAuthors">Wei Ying; Kim Thomas J; Jackson Julia R; Le Saux Claude J; Backes Bradley J; Chapman Harold A; Peng David H; Gibbons Don L; Duan Dana; Derynck Rik; Yamauchi Mitsuo; Le Saux Claude J; Calhoun Cheresa; Peters Jay</div><div class="citationInfo"><span class="NLM_cas:title">The Journal of clinical investigation</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">127</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">3675-3688</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">TGF-β1 signaling is a critical driver of collagen accumulation and fibrotic disease but also a vital suppressor of inflammation and epithelial cell proliferation.  The nature of this multifunctional cytokine has limited the development of global TGF-β1 signaling inhibitors as therapeutic agents.  We conducted phenotypic screens for small molecules that inhibit TGF-β1-induced epithelial-mesenchymal transition without immediate TGF-β1 receptor (TβR) kinase inhibition.  We identified trihydroxyphenolic compounds as potent blockers of TGF-β1 responses (IC50 ~50 nM), Snail1 expression, and collagen deposition in vivo in models of pulmonary fibrosis and collagen-dependent lung cancer metastasis.  Remarkably, the functional effects of trihydroxyphenolics required the presence of active lysyl oxidase-like 2 (LOXL2), thereby limiting effects to fibroblasts or cancer cells, the major LOXL2 producers.  Mechanistic studies revealed that trihydroxyphenolics induce auto-oxidation of a LOXL2/3-specific lysine (K731) in a time-dependent reaction that irreversibly inhibits LOXL2 and converts the trihydrophenolic to a previously undescribed metabolite that directly inhibits TβRI kinase.  Combined inhibition of LOXL2 and TβRI activities by trihydrophenolics resulted in potent blockade of pathological collagen accumulation in vivo without the toxicities associated with global inhibitors.  These findings elucidate a therapeutic approach to attenuate fibrosis and the disease-promoting effects of tissue stiffness by specifically targeting TβRI kinase in LOXL2-expressing cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTVn_FfOxm__-3MPKNEWB5RfW6udTcc2eYHPkarqn9F6rntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1cbkslOrtw%253D%253D&md5=312867b1853f0053fdd1004b387ddf7d</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1172%2Fjci94624&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252Fjci94624%26sid%3Dliteratum%253Aachs%26aulast%3DWei%26aufirst%3DY.%26aulast%3DKim%26aufirst%3DT.%2BJ.%26aulast%3DPeng%26aufirst%3DD.%2BH.%26aulast%3DDuan%26aufirst%3DD.%26aulast%3DGibbons%26aufirst%3DD.%2BL.%26aulast%3DYamauchi%26aufirst%3DM.%26aulast%3DJackson%26aufirst%3DJ.%2BR.%26aulast%3DLe%2BSaux%26aufirst%3DC.%2BJ.%26aulast%3DCalhoun%26aufirst%3DC.%26aulast%3DPeters%26aufirst%3DJ.%26aulast%3DDerynck%26aufirst%3DR.%26aulast%3DBackes%26aufirst%3DB.%2BJ.%26aulast%3DChapman%26aufirst%3DH.%2BA.%26atitle%3DFibroblast-specific%2520inhibition%2520of%2520TGF-%25CE%25B21%2520signaling%2520attenuates%2520lung%2520and%2520tumor%2520fibrosis%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2017%26volume%3D127%26spage%3D3675%26epage%3D3688%26doi%3D10.1172%2Fjci94624" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit29b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Wen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bai, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, Y.</span></span> <span> </span><span class="NLM_article-title">LOXL2, a copper-dependent monoamine oxidase, activates lung fibroblasts through the TGF-β/Smad pathway</span>. <i>Int. J. Mol. Med.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>42</i></span>,  <span class="NLM_fpage">3530</span>– <span class="NLM_lpage">3541</span>, <span class="refDoi"> DOI: 10.3892/ijmm.2018.3927</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=10.3892%2Fijmm.2018.3927" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=30320382" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=1%3ACAS%3A528%3ADC%252BC1MXktVOrur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2018&pages=3530-3541&author=X.+Wenauthor=Y.+Liuauthor=Y.+Baiauthor=M.+Liauthor=Q.+Fuauthor=Y.+Zheng&title=LOXL2%2C+a+copper-dependent+monoamine+oxidase%2C+activates+lung+fibroblasts+through+the+TGF-%CE%B2%2FSmad+pathway&doi=10.3892%2Fijmm.2018.3927"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29bR"><div class="casContent"><span class="casTitleNuber">29b</span><div class="casTitle"><span class="NLM_cas:atitle">LOXL2, a copper-dependent monoamine oxidase, activates lung fibroblasts through the TGF-β/Smad pathway</span></div><div class="casAuthors">Wen, Xiaohong; Liu, Yuan; Bai, Yu; Li, Mingwei; Fu, Qiang; Zheng, Yi</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Molecular Medicine</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">42</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">3530-3541</span>CODEN:
                <span class="NLM_cas:coden">IJMMFG</span>;
        ISSN:<span class="NLM_cas:issn">1791-244X</span>.
    
            (<span class="NLM_cas:orgname">Spandidos Publications Ltd.</span>)
        </div><div class="casAbstract">A previous study demonstrated that Lysyl oxidase-like 2 (LOXL2) serves an essential role in matrix remodeling and fibrogenesis, thus indicating its involvement in fibrosis-assocd. diseases.  Our previous studies revealed a novel assocn. between LOXL2 expression and pulmonary fibrosis in mice.  However, the exact role and mechanisms of LOXL2 in interstitial lung disease remain poorly understood.  The present study aimed to detect LOXL2 expression in mice with bleomycin (BLM)-induced pulmonary fibrosis, and explore the effects of silencing LOXL2 on the proliferation, activation and fibrosis process of mouse lung fibroblasts (MLFs).  In addn., the present study investigated the assocn. between LOXL2 and the transforming growth factor-β (TGF-β)/Smad signaling pathway to identify the mechanism underlying the role of LOXL2 in fibrosis progression.  An animal model of pulmonary fibrosis was established by administering an intratracheal injection of 5 mg/kg BLM to C57BL/6 mice.  ELISA and immunohistochem. examn. were used to detect the LOXL2 level in the serum, lung homogenate and pulmonary tissues in mice.  Pulmonary tissues of mice were extd. to culture primary MLFs, and a LOXL2 small interfering RNA adenovirus vector was established to silence LOXL2 in MLFs.  Cell proliferation was detected using the cell counting kit-8 assay.  Reverse transcription-quant. polymerase chain reaction and western blotting were used to measure the expression of LOXL2, TGF-β1, Smad2/3, phosphorylated (p)Smad2/3, Smad4, and Smad7 and Snail in cells.  Interleukin-6 (IL-6) and type 1 collagen a1 (COL1A1) in the supernatant of cells were analyzed by ELISA.  It was demonstrated that LOXL2 expression was significantly increased in serum, lung homogenate and pulmonary tissues of mice with BLM-induced pulmonary fibrosis compared with control mice.  Furthermore, silencing LOXL2 significantly decreased MLF proliferation, and the levels of IL-6 and COL1A1 in the supernatant of cells.  Furthermore, silencing LOXL2 inhibited the expression of pSmad2/3, Smad4 and Snail, while it promoted Smad7 expression.  The present data provides a comprehensive anal. of the LOXL2 in pulmonary fibrosis and indicates prominent roles for LOXL2 in fibrogenesis via regulation of the TGF-β/Smad signaling pathway.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq65IUQGrYZ7LVg90H21EOLACvtfcHk0ljDvZIhftOcMw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXktVOrur8%253D&md5=44bfc5cc79d331e52067d31ca3c53e32</span></div><a href="/servlet/linkout?suffix=cit29b&amp;dbid=16384&amp;doi=10.3892%2Fijmm.2018.3927&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3892%252Fijmm.2018.3927%26sid%3Dliteratum%253Aachs%26aulast%3DWen%26aufirst%3DX.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DBai%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DM.%26aulast%3DFu%26aufirst%3DQ.%26aulast%3DZheng%26aufirst%3DY.%26atitle%3DLOXL2%252C%2520a%2520copper-dependent%2520monoamine%2520oxidase%252C%2520activates%2520lung%2520fibroblasts%2520through%2520the%2520TGF-%25CE%25B2%252FSmad%2520pathway%26jtitle%3DInt.%2520J.%2520Mol.%2520Med.%26date%3D2018%26volume%3D42%26spage%3D3530%26epage%3D3541%26doi%3D10.3892%2Fijmm.2018.3927" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Raghu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collard, H. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cottin, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gibson, K. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaner, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lederer, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinez, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noble, P. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wells, A. U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whelan, T. P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wuyts, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moreau, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patterson, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bayly, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chien, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gong, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Riordan, T. G.</span></span> <span> </span><span class="NLM_article-title">Efficacy of simtuzumab versus placebo in patients with idiopathic pulmonary fibrosis: a randomised, double-blind, controlled, phase 2 trial</span>. <i>Lancet Respir. Med.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">22</span>– <span class="NLM_lpage">32</span>, <span class="refDoi"> DOI: 10.1016/s2213-2600(16)30421-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=10.1016%2Fs2213-2600%2816%2930421-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=27939076" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=1%3ACAS%3A528%3ADC%252BC28XitVegu7vK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2017&pages=22-32&author=G.+Raghuauthor=K.+K.+Brownauthor=H.+R.+Collardauthor=V.+Cottinauthor=K.+F.+Gibsonauthor=R.+J.+Kanerauthor=D.+J.+Ledererauthor=F.+J.+Martinezauthor=P.+W.+Nobleauthor=J.+W.+Songauthor=A.+U.+Wellsauthor=T.+P.+M.+Whelanauthor=W.+Wuytsauthor=E.+Moreauauthor=S.+D.+Pattersonauthor=V.+Smithauthor=S.+Baylyauthor=J.+W.+Chienauthor=Q.+Gongauthor=J.+J.+Zhangauthor=T.+G.+O%E2%80%99Riordan&title=Efficacy+of+simtuzumab+versus+placebo+in+patients+with+idiopathic+pulmonary+fibrosis%3A+a+randomised%2C+double-blind%2C+controlled%2C+phase+2+trial&doi=10.1016%2Fs2213-2600%2816%2930421-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy of simtuzumab versus placebo in patients with idiopathic pulmonary fibrosis: a randomised, double-blind, controlled, phase 2 trial</span></div><div class="casAuthors">Raghu, Ganesh; Brown, Kevin K.; Collard, Harold R.; Cottin, Vincent; Gibson, Kevin F.; Kaner, Robert J.; Lederer, David J.; Martinez, Fernando J.; Noble, Paul W.; Song, Jin Woo; Wells, Athol U.; Whelan, Timothy P. M.; Wuyts, Wim; Moreau, Emmanuel; Patterson, Scott D.; Smith, Victoria; Bayly, Selina; Chien, Jason W.; Gong, Qi; Zhang, Jenny J.; O'Riordan, Thomas G.</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Respiratory Medicine</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">22-32</span>CODEN:
                <span class="NLM_cas:coden">LRMAAU</span>;
        ISSN:<span class="NLM_cas:issn">2213-2600</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Lysyl oxidase-like 2 (LOXL2) catalyzes collagen crosslinking and is implicated in the pathogenesis of idiopathic pulmonary fibrosis (IPF).  The aim of this study was to investigate the efficacy and safety of simtuzumab, a monoclonal antibody against LOXL2, in patients with IPF.  In this randomised, double-blind, phase 2 trial, we recruited patients aged 45-85 years with definite IPF diagnosed prior to 3 years of screening from 183 hospitals and respiratory clinics in 14 countries.  Eligible patients, stratified by baseline forced vital capacity (FVC), serum LOXL2 (sLOXL2) concns., and pirfenidone and nintedanib use, were randomly assigned (1:1) to inject 125 mg/mL simtuzumab or placebo s.c. once a week.  The primary endpoints were progression-free survival, defined as time to all-cause death or a categorical decrease from baseline in FVC % predicted, in the intention-to-treat population, in patients with sLOXL2 concns. in the 50th percentile or higher, and in patients with sLOXL2 concns. in the 75th percentile or higher.  Treatment duration was event-driven, and interim analyses were planned and conducted after approx. 120 and 200 progression-free survival events, resp., occurred.  We compared treatment groups with the stratified log-rank test.  This study is registered with ClinicalTrials.gov, no. NCT01769196.  Patients with IPF were recruited between Jan 31, 2013, and June 1, 2015.  The intention-to-treat population included 544 randomly assigned patients (272 patients in both groups), and the safety population included 543 randomly assigned patients who received at least one dose of study medication.  The study was terminated when the second interim anal. met the prespecified futility stopping criteria in the intention-to-treat population.  We noted no difference in progression-free survival between simtuzumab and placebo in the intention-to-treat population (median progression free survival times of 12·6 mo and 15·4 mo for simtuzumab and placebo, resp.; stratified HR 1·13, 95% CI 0·88-1·45; p=0·329) and in patients with baseline sLOXL2 in the 50th percentile or higher (median progression-free survival 11·7 mo and 14·3 mo for simtuzumab and placebo, resp.; stratified HR 1·03, 95% CI 0·74-1·43; p=0·851), or in the 75th percentile or higher (median progression-free survival 11·6 mo and 16·9 mo for simtuzumab and placebo, resp.; stratified HR 1·20, 95% CI 0·72-2·00; p=0·475).  The incidence of adverse events and serious adverse events was similar between treatment groups.  The most common adverse events in both the simtuzumab and placebo groups were dyspnoea, cough, upper respiratory tract infection, and worsening of IPF; and the most common grade 3 or 4 adverse events were worsening of IPF, dyspnoea, and pneumonia.  Simtuzumab did not improve progression-free survival in a well-defined population of patients with IPF.  Our data do not support the use of simtuzumab for patients with IPF.Gilead Sciences Inc.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGogXyb2IAh397Vg90H21EOLACvtfcHk0lhG9YGeyk-WYg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XitVegu7vK&md5=9ba5c10f1fc48f971010f7ed09fd3b62</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1016%2Fs2213-2600%2816%2930421-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fs2213-2600%252816%252930421-0%26sid%3Dliteratum%253Aachs%26aulast%3DRaghu%26aufirst%3DG.%26aulast%3DBrown%26aufirst%3DK.%2BK.%26aulast%3DCollard%26aufirst%3DH.%2BR.%26aulast%3DCottin%26aufirst%3DV.%26aulast%3DGibson%26aufirst%3DK.%2BF.%26aulast%3DKaner%26aufirst%3DR.%2BJ.%26aulast%3DLederer%26aufirst%3DD.%2BJ.%26aulast%3DMartinez%26aufirst%3DF.%2BJ.%26aulast%3DNoble%26aufirst%3DP.%2BW.%26aulast%3DSong%26aufirst%3DJ.%2BW.%26aulast%3DWells%26aufirst%3DA.%2BU.%26aulast%3DWhelan%26aufirst%3DT.%2BP.%2BM.%26aulast%3DWuyts%26aufirst%3DW.%26aulast%3DMoreau%26aufirst%3DE.%26aulast%3DPatterson%26aufirst%3DS.%2BD.%26aulast%3DSmith%26aufirst%3DV.%26aulast%3DBayly%26aufirst%3DS.%26aulast%3DChien%26aufirst%3DJ.%2BW.%26aulast%3DGong%26aufirst%3DQ.%26aulast%3DZhang%26aufirst%3DJ.%2BJ.%26aulast%3DO%25E2%2580%2599Riordan%26aufirst%3DT.%2BG.%26atitle%3DEfficacy%2520of%2520simtuzumab%2520versus%2520placebo%2520in%2520patients%2520with%2520idiopathic%2520pulmonary%2520fibrosis%253A%2520a%2520randomised%252C%2520double-blind%252C%2520controlled%252C%2520phase%25202%2520trial%26jtitle%3DLancet%2520Respir.%2520Med.%26date%3D2017%26volume%3D5%26spage%3D22%26epage%3D32%26doi%3D10.1016%2Fs2213-2600%2816%2930421-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Meissner, E. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McLaughlin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matthews, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gharib, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levy, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sinkus, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Virtaneva, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sturdevant, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martens, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Porcella, S. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goodman, Z. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kanwar, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Myers, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Subramanian, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hadigan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masur, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kleiner, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heller, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kottilil, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kovacs, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morse, C. G.</span></span> <span> </span><span class="NLM_article-title">Simtuzumab treatment of advanced liver fibrosis in HIV and HCV-infected adults: results of a 6-month open-label safety trial</span>. <i>Liver Int.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>36</i></span>,  <span class="NLM_fpage">1783</span>– <span class="NLM_lpage">1792</span>, <span class="refDoi"> DOI: 10.1111/liv.13177</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=10.1111%2Fliv.13177" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=27232579" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvFelsr3O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2016&pages=1783-1792&author=E.+G.+Meissnerauthor=M.+McLaughlinauthor=L.+Matthewsauthor=A.+M.+Gharibauthor=B.+J.+Woodauthor=E.+Levyauthor=R.+Sinkusauthor=K.+Virtanevaauthor=D.+Sturdevantauthor=C.+Martensauthor=S.+F.+Porcellaauthor=Z.+D.+Goodmanauthor=B.+Kanwarauthor=R.+P.+Myersauthor=M.+Subramanianauthor=C.+Hadiganauthor=H.+Masurauthor=D.+E.+Kleinerauthor=T.+Hellerauthor=S.+Kottililauthor=J.+A.+Kovacsauthor=C.+G.+Morse&title=Simtuzumab+treatment+of+advanced+liver+fibrosis+in+HIV+and+HCV-infected+adults%3A+results+of+a+6-month+open-label+safety+trial&doi=10.1111%2Fliv.13177"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Simtuzumab treatment of advanced liver fibrosis in HIV and HCV-infected adults: results of a 6-month open-label safety trial</span></div><div class="casAuthors">Meissner, Eric G.; McLaughlin, Mary; Matthews, Lindsay; Gharib, Ahmed M.; Wood, Bradford J.; Levy, Elliot; Sinkus, Ralph; Virtaneva, Kimmo; Sturdevant, Dan; Martens, Craig; Porcella, Stephen F.; Goodman, Zachary D.; Kanwar, Bittoo; Myers, Robert P.; Subramanian, Mani; Hadigan, Colleen; Masur, Henry; Kleiner, David E.; Heller, Theo; Kottilil, Shyam; Kovacs, Joseph A.; Morse, Caryn G.</div><div class="citationInfo"><span class="NLM_cas:title">Liver International</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1783-1792</span>CODEN:
                <span class="NLM_cas:coden">LIINCM</span>;
        ISSN:<span class="NLM_cas:issn">1478-3223</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Background : Chronic liver injury can result in fibrosis that may progress over years to end-stage liver disease.  The most effective anti-fibrotic therapy is treatment of the underlying disease, however when not possible, interventions to reverse or slow fibrosis progression are needed.  Aim : The aim of this study was to study the safety and tolerability of simtuzumab, a monoclonal antibody directed against lysyl oxidase-like 2 (LOXL2) enzyme, in subjects with hepatitis C virus (HCV), human immunodeficiency virus (HIV), or HCV-HIV co-infection and advanced liver disease.  Methods : Eighteen subjects with advanced liver fibrosis received simtuzumab 700 mg i.v. every 2 wk for 22 wk.  Transjugular liver biopsies were performed during screening and at the end of treatment to measure hepatic venous pressure gradient (HVPG) and to stage fibrosis.  Results : Treatment was well-tolerated with no discontinuations due to adverse events.  No significant changes were seen in HVPG or liver biopsy fibrosis score after treatment.  Exploratory transcriptional and protein profiling using paired pre- and post-treatment liver biopsy and serum samples suggested up-regulation of TGF-β3 and IL-10 pathways with treatment.  Conclusion : In this open-label, pilot clin. trial, simtuzumab treatment was well-tolerated in HCV- and HIV-infected subjects with advanced liver disease.  Putative modulation of TGF-β3 and IL-10 pathways during simtuzumab treatment merits investigation in future trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoh_oC46Qw8xrVg90H21EOLACvtfcHk0lhG9YGeyk-WYg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvFelsr3O&md5=3531ad0273e5e77dd501b2db201794a5</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1111%2Fliv.13177&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fliv.13177%26sid%3Dliteratum%253Aachs%26aulast%3DMeissner%26aufirst%3DE.%2BG.%26aulast%3DMcLaughlin%26aufirst%3DM.%26aulast%3DMatthews%26aufirst%3DL.%26aulast%3DGharib%26aufirst%3DA.%2BM.%26aulast%3DWood%26aufirst%3DB.%2BJ.%26aulast%3DLevy%26aufirst%3DE.%26aulast%3DSinkus%26aufirst%3DR.%26aulast%3DVirtaneva%26aufirst%3DK.%26aulast%3DSturdevant%26aufirst%3DD.%26aulast%3DMartens%26aufirst%3DC.%26aulast%3DPorcella%26aufirst%3DS.%2BF.%26aulast%3DGoodman%26aufirst%3DZ.%2BD.%26aulast%3DKanwar%26aufirst%3DB.%26aulast%3DMyers%26aufirst%3DR.%2BP.%26aulast%3DSubramanian%26aufirst%3DM.%26aulast%3DHadigan%26aufirst%3DC.%26aulast%3DMasur%26aufirst%3DH.%26aulast%3DKleiner%26aufirst%3DD.%2BE.%26aulast%3DHeller%26aufirst%3DT.%26aulast%3DKottilil%26aufirst%3DS.%26aulast%3DKovacs%26aufirst%3DJ.%2BA.%26aulast%3DMorse%26aufirst%3DC.%2BG.%26atitle%3DSimtuzumab%2520treatment%2520of%2520advanced%2520liver%2520fibrosis%2520in%2520HIV%2520and%2520HCV-infected%2520adults%253A%2520results%2520of%2520a%25206-month%2520open-label%2520safety%2520trial%26jtitle%3DLiver%2520Int.%26date%3D2016%26volume%3D36%26spage%3D1783%26epage%3D1792%26doi%3D10.1111%2Fliv.13177" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tang, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trackman, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kagan, H. M.</span></span> <span> </span><span class="NLM_article-title">Reaction of aortic lysyl oxidase with β- aminopropionitrile</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1983</span>,  <span class="NLM_volume"><i>258</i></span>,  <span class="NLM_fpage">4331</span>– <span class="NLM_lpage">4338</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=6131892" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=1%3ACAS%3A528%3ADyaL3sXhslGmsr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=258&publication_year=1983&pages=4331-4338&author=S.+S.+Tangauthor=P.+C.+Trackmanauthor=H.+M.+Kagan&title=Reaction+of+aortic+lysyl+oxidase+with+%CE%B2-+aminopropionitrile"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Reaction of aortic lysyl oxidase with β-aminopropionitrile</span></div><div class="casAuthors">Tang, Shiow Shih; Trackman, Philip C.; Kagan, Herbert M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">1983</span>),
    <span class="NLM_cas:volume">258</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">4331-8</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    </div><div class="casAbstract">β-Aminopropionitrile (I) is a potent irreversible inhibitor of lysyl oxidase (II), which initiates crosslinkage formation in elastin and collagen.  The initial interaction of I with aortic II is competitive with elastin or alkyl amine substrates.  Irreversible inhibition develops in a time- and temp.-dependent fashion upon incubation of II with I in the absence of substrate with a limiting inactivation rate const. of 0.16 min-1 and a Ki of 6 μM at 37°.  The labeled C atoms of [1,2-14C]I and [3-14C]I covalently bind to II to equiv. extents and in parallel with the development of inactivation, negating the possibility that the nitrile moiety is eliminated from I by enzymic action.  The Cu content of II is not significantly altered upon interaction with I.  The extent of labeling by [14C]I is reduced by prior treatment of II with carbonyl-modifying reagents, suggesting the possibility of I-II Schiff base formation.  However, I is not processed to a free aldehyde product upon incubation with II.  A mechanism of inhibition is postulated which involves the formation of a covalent bond between an enzyme nucleophile and a ketenimine formed from I by II-assisted β-proton abstraction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr6R41H2SgQY7Vg90H21EOLACvtfcHk0lhtEcp_2OX-2w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL3sXhslGmsr4%253D&md5=b64e1c85d58fb8c2c47d8beb939fa59a</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DTang%26aufirst%3DS.%2BS.%26aulast%3DTrackman%26aufirst%3DP.%2BC.%26aulast%3DKagan%26aufirst%3DH.%2BM.%26atitle%3DReaction%2520of%2520aortic%2520lysyl%2520oxidase%2520with%2520%25CE%25B2-%2520aminopropionitrile%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1983%26volume%3D258%26spage%3D4331%26epage%3D4338" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leung, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saturno, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Viros, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Leva, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morrison, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niculescu-Duvaz, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lopes, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dhomen, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Springer, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marais, R.</span></span> <span> </span><span class="NLM_article-title">Lysyl oxidase drives tumour progression by trapping EGF receptors at the cell surface</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">14909</span>, <span class="refDoi"> DOI: 10.1038/ncomms14909</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=10.1038%2Fncomms14909" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=28416796" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=1%3ACAS%3A528%3ADC%252BC2sXmtFKgtbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=14909&author=H.+Tangauthor=L.+Leungauthor=G.+Saturnoauthor=A.+Virosauthor=D.+Smithauthor=G.+Di+Levaauthor=E.+Morrisonauthor=D.+Niculescu-Duvazauthor=F.+Lopesauthor=L.+Johnsonauthor=N.+Dhomenauthor=C.+Springerauthor=R.+Marais&title=Lysyl+oxidase+drives+tumour+progression+by+trapping+EGF+receptors+at+the+cell+surface&doi=10.1038%2Fncomms14909"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33aR"><div class="casContent"><span class="casTitleNuber">33a</span><div class="casTitle"><span class="NLM_cas:atitle">Lysyl oxidase drives tumour progression by trapping EGF receptors at the cell surface</span></div><div class="casAuthors">Tang, Hao Ran; Leung, Leo; Saturno, Grazia; Viros, Amaya; Smith, Duncan; Di Leva, Gianpiero; Morrison, Eamonn; Niculescu-Duvaz, Dan; Lopes, Filipa; Johnson, Louise; Dhomen, Nathalie; Springer, Caroline; Marais, Richard</div><div class="citationInfo"><span class="NLM_cas:title">Nature Communications</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">14909</span>CODEN:
                <span class="NLM_cas:coden">NCAOBW</span>;
        ISSN:<span class="NLM_cas:issn">2041-1723</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Lysyl oxidase (LOX) remodels the tumor microenvironment by crosslinking the extracellular matrix.  LOX overexpression is assocd. with poor cancer outcomes.  Here, we find that LOX regulates the epidermal growth factor receptor (EGFR) to drive tumor progression.  We show that LOX regulates EGFR by suppressing TGFβ1 signalling through the secreted protease HTRA1.  This increases the expression of Matrilin2 (MATN2), an EGF-like domain-contg. protein that traps EGFR at the cell surface to facilitate its activation by EGF.  We describe a pharmacol. inhibitor of LOX, CCT365623, which disrupts EGFR cell surface retention and delays the growth of primary and metastatic tumor cells in vivo.  Thus, we show that LOX regulates EGFR cell surface retention to drive tumor progression, and we validate the therapeutic potential of inhibiting this pathway with the small mol. inhibitor CCT365623.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqjI8odBCa4OLVg90H21EOLACvtfcHk0lhtEcp_2OX-2w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXmtFKgtbw%253D&md5=d0db599dc8344c8685196f6d289fd3cf</span></div><a href="/servlet/linkout?suffix=cit33a&amp;dbid=16384&amp;doi=10.1038%2Fncomms14909&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fncomms14909%26sid%3Dliteratum%253Aachs%26aulast%3DTang%26aufirst%3DH.%26aulast%3DLeung%26aufirst%3DL.%26aulast%3DSaturno%26aufirst%3DG.%26aulast%3DViros%26aufirst%3DA.%26aulast%3DSmith%26aufirst%3DD.%26aulast%3DDi%2BLeva%26aufirst%3DG.%26aulast%3DMorrison%26aufirst%3DE.%26aulast%3DNiculescu-Duvaz%26aufirst%3DD.%26aulast%3DLopes%26aufirst%3DF.%26aulast%3DJohnson%26aufirst%3DL.%26aulast%3DDhomen%26aufirst%3DN.%26aulast%3DSpringer%26aufirst%3DC.%26aulast%3DMarais%26aufirst%3DR.%26atitle%3DLysyl%2520oxidase%2520drives%2520tumour%2520progression%2520by%2520trapping%2520EGF%2520receptors%2520at%2520the%2520cell%2520surface%26jtitle%3DNat.%2520Commun.%26date%3D2017%26volume%3D8%26spage%3D14909%26doi%3D10.1038%2Fncomms14909" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit33b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Springer, C.</span>; <span class="NLM_string-name">Marais, R.</span>; <span class="NLM_string-name">Niculescu-Duvaz, D.</span>; <span class="NLM_string-name">Leung, L.</span>; <span class="NLM_string-name">Smithen, D.</span>; <span class="NLM_string-name">Callens, C.</span>; <span class="NLM_string-name">Tang, H.</span></span> <span> </span><span class="NLM_article-title">Methylamine Derivatives as Lysyl Oxidase Inhibitors for the Treatment of Cancer</span>. <span class="NLM_patent">WO2017141049A1</span>, <span class="NLM_year">2017</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&author=C.+Springer&author=R.+Marais&author=D.+Niculescu-Duvaz&author=L.+Leung&author=D.+Smithen&author=C.+Callens&author=H.+Tang&title=Methylamine+Derivatives+as+Lysyl+Oxidase+Inhibitors+for+the+Treatment+of+Cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit33b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DSpringer%26aufirst%3DC.%26atitle%3DMethylamine%2520Derivatives%2520as%2520Lysyl%2520Oxidase%2520Inhibitors%2520for%2520the%2520Treatment%2520of%2520Cancer%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit33c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Leung, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niculescu-Duvaz, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smithen, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lopes, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Callens, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McLeary, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saturno, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aljarah, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zambon, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chambers, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ménard, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bayliss, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knight, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fish, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lawrence, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Challinor, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marais, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Springer, C.</span></span> <span> </span><span class="NLM_article-title">Anti-metastatic inhibitors of lysyl oxidase (LOX): Design and structure-activity relationships</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">5863</span>– <span class="NLM_lpage">5884</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b00335</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b00335" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref33/cit33c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=1%3ACAS%3A528%3ADC%252BC1MXptFymur0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=5863-5884&author=L.+Leungauthor=D.+Niculescu-Duvazauthor=D.+Smithenauthor=F.+Lopesauthor=C.+Callensauthor=R.+McLearyauthor=G.+Saturnoauthor=L.+Daviesauthor=M.+Aljarahauthor=M.+Brownauthor=L.+Johnsonauthor=A.+Zambonauthor=T.+Chambersauthor=D.+M%C3%A9nardauthor=N.+Baylissauthor=R.+Knightauthor=L.+Fishauthor=R.+Lawrenceauthor=M.+Challinorauthor=H.+Tangauthor=R.+Maraisauthor=C.+Springer&title=Anti-metastatic+inhibitors+of+lysyl+oxidase+%28LOX%29%3A+Design+and+structure-activity+relationships&doi=10.1021%2Facs.jmedchem.9b00335"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33cR"><div class="casContent"><span class="casTitleNuber">33c</span><div class="casTitle"><span class="NLM_cas:atitle">Anti-metastatic Inhibitors of Lysyl Oxidase (LOX): Design and Structure-Activity Relationships</span></div><div class="casAuthors">Leung, Leo; Niculescu-Duvaz, Dan; Smithen, Deborah; Lopes, Filipa; Callens, Cedric; McLeary, Robert; Saturno, Grazia; Davies, Lawrence; Aljarah, Mohammed; Brown, Michael; Johnson, Louise; Zambon, Alfonso; Chambers, Tim; Menard, Delphine; Bayliss, Natasha; Knight, Ruth; Fish, Laura; Lawrence, Rae; Challinor, Mairi; Tang, HaoRan; Marais, Richard; Springer, Caroline</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">5863-5884</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Lysyl oxidase (LOX) is a secreted copper-dependent amine oxidase that cross-links collagens and elastin in the extracellular matrix and is a crit. mediator of tumor growth and metastatic spread.  LOX is a target for cancer therapy, and thus the search for therapeutic agents against LOX has been widely sought.  We report herein the medicinal chem. discovery of a series of LOX inhibitors bearing an aminomethylenethiophene (AMT) scaffold.  High-throughput screening provided the initial hits.  Structure-activity relationship (SAR) studies led to the discovery of AMT inhibitors with sub-micromolar half-maximal inhibitory concns. (IC50) in a LOX enzyme activity assay.  Further SAR optimization yielded the orally bioavailable LOX inhibitor CCT365623 (I) with good anti-LOX potency, selectivity, pharmacokinetic properties, as well as anti-metastatic efficacy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrnOAYiFZQNe7Vg90H21EOLACvtfcHk0lhtEcp_2OX-2w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXptFymur0%253D&md5=a3318ce21ba6b8fac450b12f4e4e30aa</span></div><a href="/servlet/linkout?suffix=cit33c&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b00335&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b00335%26sid%3Dliteratum%253Aachs%26aulast%3DLeung%26aufirst%3DL.%26aulast%3DNiculescu-Duvaz%26aufirst%3DD.%26aulast%3DSmithen%26aufirst%3DD.%26aulast%3DLopes%26aufirst%3DF.%26aulast%3DCallens%26aufirst%3DC.%26aulast%3DMcLeary%26aufirst%3DR.%26aulast%3DSaturno%26aufirst%3DG.%26aulast%3DDavies%26aufirst%3DL.%26aulast%3DAljarah%26aufirst%3DM.%26aulast%3DBrown%26aufirst%3DM.%26aulast%3DJohnson%26aufirst%3DL.%26aulast%3DZambon%26aufirst%3DA.%26aulast%3DChambers%26aufirst%3DT.%26aulast%3DM%25C3%25A9nard%26aufirst%3DD.%26aulast%3DBayliss%26aufirst%3DN.%26aulast%3DKnight%26aufirst%3DR.%26aulast%3DFish%26aufirst%3DL.%26aulast%3DLawrence%26aufirst%3DR.%26aulast%3DChallinor%26aufirst%3DM.%26aulast%3DTang%26aufirst%3DH.%26aulast%3DMarais%26aufirst%3DR.%26aulast%3DSpringer%26aufirst%3DC.%26atitle%3DAnti-metastatic%2520inhibitors%2520of%2520lysyl%2520oxidase%2520%2528LOX%2529%253A%2520Design%2520and%2520structure-activity%2520relationships%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D5863%26epage%3D5884%26doi%3D10.1021%2Facs.jmedchem.9b00335" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rowbottom, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bain, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calderon, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lasof, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lonergan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Darlington, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prodanovich, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santini, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">King, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goulet, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shannon, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MacKenna, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evans, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hutchinson, J. H.</span></span> <span> </span><span class="NLM_article-title">Identification of 4-(aminomethyl)-6-(trifluoromethyl)-2-(phenoxy)pyridine derivatives as potent, selective, and orally efficacious inhibitors of the copper-dependent amine oxidase, lysyl oxidase-like 2 (LOXL2)</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">4403</span>– <span class="NLM_lpage">4423</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b00345</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00345" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=1%3ACAS%3A528%3ADC%252BC2sXntFSksrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=4403-4423&author=M.+W.+Rowbottomauthor=G.+Bainauthor=I.+Calderonauthor=T.+Lasofauthor=D.+Lonerganauthor=A.+Laiauthor=F.+Huangauthor=J.+Darlingtonauthor=P.+Prodanovichauthor=A.+M.+Santiniauthor=C.+D.+Kingauthor=L.+Gouletauthor=K.+E.+Shannonauthor=G.+L.+Maauthor=K.+Nguyenauthor=D.+A.+MacKennaauthor=J.+F.+Evansauthor=J.+H.+Hutchinson&title=Identification+of+4-%28aminomethyl%29-6-%28trifluoromethyl%29-2-%28phenoxy%29pyridine+derivatives+as+potent%2C+selective%2C+and+orally+efficacious+inhibitors+of+the+copper-dependent+amine+oxidase%2C+lysyl+oxidase-like+2+%28LOXL2%29&doi=10.1021%2Facs.jmedchem.7b00345"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of 4-(Aminomethyl)-6-(trifluoromethyl)-2-(phenoxy)pyridine Derivatives as Potent, Selective, and Orally Efficacious Inhibitors of the Copper-Dependent Amine Oxidase, Lysyl Oxidase-Like 2 (LOXL2)</span></div><div class="casAuthors">Rowbottom, Martin W.; Bain, Gretchen; Calderon, Imelda; Lasof, Taylor; Lonergan, David; Lai, Andiliy; Huang, Fei; Darlington, Janice; Prodanovich, Patricia; Santini, Angelina M.; King, Christopher D.; Goulet, Lance; Shannon, Kristen E.; Ma, Gina L.; Nguyen, Katherine; MacKenna, Deidre A.; Evans, Jilly F.; Hutchinson, John H.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">4403-4423</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">LOXL2 catalyzes the oxidative deamination of ε-amines of lysine and hydroxylysine residues within collagen and elastin, generating reactive aldehydes (allysine).  Condensation with other allysines or lysines drives the formation of inter- and intramol. cross-linkages, a process crit. for the remodeling of the ECM.  Dysregulation of this process can lead to fibrosis, and LOXL2 is known to be upregulated in fibrotic tissue.  Small-mols. that directly inhibit LOXL2 catalytic activity represent a useful option for the treatment of fibrosis.  Herein, the authors describe optimization of an initial hit, resulting in identification of racemic I, a potent irreversible inhibitor of LOXL2 that is highly selective over LOX and other amine oxidases.  Oral administration of I significantly reduced fibrosis in a 14-day mouse lung bleomycin model.  The (R,R)-enantiomer of I (PAT-1251) was selected as the clin. compd. which has progressed into healthy volunteer Phase 1 trials, making it the "first-in-class" small-mol. LOXL2 inhibitor to enter clin. development. KEY LOXL2 inhibitor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrX-yiHL-BRUrVg90H21EOLACvtfcHk0ljgomuM1glB8A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXntFSksrs%253D&md5=c71db3046b5ed711043b39181fdf87c9</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00345&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00345%26sid%3Dliteratum%253Aachs%26aulast%3DRowbottom%26aufirst%3DM.%2BW.%26aulast%3DBain%26aufirst%3DG.%26aulast%3DCalderon%26aufirst%3DI.%26aulast%3DLasof%26aufirst%3DT.%26aulast%3DLonergan%26aufirst%3DD.%26aulast%3DLai%26aufirst%3DA.%26aulast%3DHuang%26aufirst%3DF.%26aulast%3DDarlington%26aufirst%3DJ.%26aulast%3DProdanovich%26aufirst%3DP.%26aulast%3DSantini%26aufirst%3DA.%2BM.%26aulast%3DKing%26aufirst%3DC.%2BD.%26aulast%3DGoulet%26aufirst%3DL.%26aulast%3DShannon%26aufirst%3DK.%2BE.%26aulast%3DMa%26aufirst%3DG.%2BL.%26aulast%3DNguyen%26aufirst%3DK.%26aulast%3DMacKenna%26aufirst%3DD.%2BA.%26aulast%3DEvans%26aufirst%3DJ.%2BF.%26aulast%3DHutchinson%26aufirst%3DJ.%2BH.%26atitle%3DIdentification%2520of%25204-%2528aminomethyl%2529-6-%2528trifluoromethyl%2529-2-%2528phenoxy%2529pyridine%2520derivatives%2520as%2520potent%252C%2520selective%252C%2520and%2520orally%2520efficacious%2520inhibitors%2520of%2520the%2520copper-dependent%2520amine%2520oxidase%252C%2520lysyl%2520oxidase-like%25202%2520%2528LOXL2%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D4403%26epage%3D4423%26doi%3D10.1021%2Facs.jmedchem.7b00345" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span> <i>Single and Multiple
Dose Safety, Tolerability, PK and Food Effect
Study of PAT-1251 in Healthy Adult Subjects, NCT02852551</i>,
Nov <span class="NLM_year">2016</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+Single+and+Multiple%0ADose+Safety%2C+Tolerability%2C+PK+and+Food+Effect%0AStudy+of+PAT-1251+in+Healthy+Adult+Subjects%2C+NCT02852551%2C%0ANov+2016."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dreport%26sid%3Dliteratum%253Aachs%26jtitle%3DSingle%2520and%2520Multiple%250ADose%2520Safety%252C%2520Tolerability%252C%2520PK%2520and%2520Food%2520Effect%250AStudy%2520of%2520PAT-1251%2520in%2520Healthy%2520Adult%2520Subjects%252C%2520NCT02852551%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rowbottom, M. W.</span>; <span class="NLM_string-name">Hutchinson, J. H.</span>; <span class="NLM_string-name">Evans, J. F.</span>; <span class="NLM_string-name">Bain, G.</span></span> <span> </span><span class="NLM_article-title">Chemical Probes of Lysyl Oxidase-Like 2 and Uses Thereof</span>. <span class="NLM_patent">WO2018048928A1</span>, <span class="NLM_year">2018</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&author=M.+W.+Rowbottom&author=J.+H.+Hutchinson&author=J.+F.+Evans&author=G.+Bain&title=Chemical+Probes+of+Lysyl+Oxidase-Like+2+and+Uses+Thereof"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DRowbottom%26aufirst%3DM.%2BW.%26atitle%3DChemical%2520Probes%2520of%2520Lysyl%2520Oxidase-Like%25202%2520and%2520Uses%2520Thereof%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stangenberg, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saad, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schilter, H. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zaky, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gill, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pollock, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, M. G.</span></span> <span> </span><span class="NLM_article-title">Lysyl oxidase-like 2 inhibition ameliorates glomerulosclerosis and albuminuria in diabetic nephropathy</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">9423</span>, <span class="refDoi"> DOI: 10.1038/s41598-018-27462-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=10.1038%2Fs41598-018-27462-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=29930330" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=1%3ACAS%3A280%3ADC%252BB3c%252FgsF2msw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2018&pages=9423&author=S.+Stangenbergauthor=S.+Saadauthor=H.+C.+Schilterauthor=A.+Zakyauthor=A.+Gillauthor=C.+A.+Pollockauthor=M.+G.+Wong&title=Lysyl+oxidase-like+2+inhibition+ameliorates+glomerulosclerosis+and+albuminuria+in+diabetic+nephropathy&doi=10.1038%2Fs41598-018-27462-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Lysyl oxidase-like 2 inhibition ameliorates glomerulosclerosis and albuminuria in diabetic nephropathy</span></div><div class="casAuthors">Stangenberg Stefanie; Saad Sonia; Zaky Amgad; Pollock Carol A; Wong Muh Geot; Stangenberg Stefanie; Pollock Carol A; Schilter Heidi C; Gill Anthony</div><div class="citationInfo"><span class="NLM_cas:title">Scientific reports</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">9423</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Diabetic nephropathy is characterised by the excessive amount of extracellular matrix in glomeruli and tubulointerstitial space.  Lysyl oxidase-like 2 (LOXL2) is elevated in renal fibrosis and known to play key roles in ECM stabilisation by facilitating collagen cross-links, epithelial to mesenchymal transition and myofibroblast activation.  Thus, targeting LOXL2 may prove to be a useful strategy to prevent diabetic nephropathy.  We explored the renoprotective effect of a selective small molecule LOXL2 inhibitor (PXS-S2B) in a streptozotocin-induced diabetes model.  Diabetic mice were treated with PXS-S2B for 24 weeks and outcomes compared with untreated diabetic mice and with telmisartan treated animals as comparator of current standard of care.  Diabetic mice had albuminuria, higher glomerulosclerosis scores, upregulation of fibrosis markers and increased renal cortical LOXL2 expression.  Treatment with PXS-S2B reduced albuminuria and ameliorated glomerulosclerosis.  This was associated with reduced expression of glomerular fibronectin and tubulointerstitial collagen I.  The renoprotective effects of both PXS-S2B and telmisartan were more marked in the glomerular compartment than in the tubulointerstitial space.  The study reveals that LOXL2 inhibition was beneficial in preserving glomerular structure and function.  Thus, LOXL2 may be a potential therapeutic target in diabetic nephropathy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTqtRzP_i5UFnT4ugvCDgnZfW6udTcc2ebm31-ge6c0Rbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3c%252FgsF2msw%253D%253D&md5=eebbe97c2915983c009e575ec6e76a04</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1038%2Fs41598-018-27462-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41598-018-27462-6%26sid%3Dliteratum%253Aachs%26aulast%3DStangenberg%26aufirst%3DS.%26aulast%3DSaad%26aufirst%3DS.%26aulast%3DSchilter%26aufirst%3DH.%2BC.%26aulast%3DZaky%26aufirst%3DA.%26aulast%3DGill%26aufirst%3DA.%26aulast%3DPollock%26aufirst%3DC.%2BA.%26aulast%3DWong%26aufirst%3DM.%2BG.%26atitle%3DLysyl%2520oxidase-like%25202%2520inhibition%2520ameliorates%2520glomerulosclerosis%2520and%2520albuminuria%2520in%2520diabetic%2520nephropathy%26jtitle%3DSci.%2520Rep.%26date%3D2018%26volume%3D8%26spage%3D9423%26doi%3D10.1038%2Fs41598-018-27462-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yu, P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zuo, D.-M.</span></span> <span> </span><span class="NLM_article-title">Inhibition of a type B monoamine oxidase inhibitor, (E)-2-(4-fluorophenethyl)-3-fluoroallylamine (MDL-72974A), on semicarbazide-sensitive amine oxidases isolated from vascular tissues and sera of different species</span>. <i>Biochem. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1992</span>,  <span class="NLM_volume"><i>43</i></span>,  <span class="NLM_fpage">307</span>– <span class="NLM_lpage">312</span>, <span class="refDoi"> DOI: 10.1016/0006-2952(92)90293-r</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=10.1016%2F0006-2952%2892%2990293-r" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=1739419" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=1%3ACAS%3A528%3ADyaK38XhsVersrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=1992&pages=307-312&author=P.+H.+Yuauthor=D.-M.+Zuo&title=Inhibition+of+a+type+B+monoamine+oxidase+inhibitor%2C+%28E%29-2-%284-fluorophenethyl%29-3-fluoroallylamine+%28MDL-72974A%29%2C+on+semicarbazide-sensitive+amine+oxidases+isolated+from+vascular+tissues+and+sera+of+different+species&doi=10.1016%2F0006-2952%2892%2990293-r"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of a type B monoamine oxidase inhibitor, (E)-2-(4-fluorophenethyl)-3-fluoroallylamine (MDL-72974A), on semicarbazide-sensitive amine oxidases isolated from vascular tissues and sera of different species</span></div><div class="casAuthors">Yu, Peter H.; Zuo, Dong Mei</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Pharmacology</span>
        (<span class="NLM_cas:date">1992</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">307-12</span>CODEN:
                <span class="NLM_cas:coden">BCPCA6</span>;
        ISSN:<span class="NLM_cas:issn">0006-2952</span>.
    </div><div class="casAbstract">(E)-2-(4-Fluorophenethyl)-3-fluoroallylamine hydrochloride (MDL-72974A) has been discovered recently to be a very potent and highly selective type B monoamine oxidase inhibitor.  The authors found that this inhibitor is also capable of inhibiting semicarbazide-sensitive amine oxidases (SSAOs) obtained from vascular tissues and sera of different species.  The inhibition of SSAO by MDL-72974A was irreversible and time-dependent.  It was competitive without preincubation of the enzyme with the inhibitor and demonstrated a mixed-type of inhibition when the enzyme was preincubated with the inhibitor.  The IC50 values were estd. to be 2 × 10-9 M, 5 × 10-9 M, 8 × 10-8 M and 2 × 10-8 M for SSAO for dog aorta, rat aorta, bovine aorta and human umbilical artery, resp.  SSAO obtained from bovine serum was relatively insensitive to MDL-72974A (IC50 = 3 × 10-7 M).  Following i.p. administration of MDL-72974A, rat brain MAO-B was inhibited with the ED50 value being about 0.2 mg/kg.  Rat aorta SSAO was also inhibited and to a similar extent by the same dose.  MDL-72974A is the most potent SSAO inhibitor that has been described thus far.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqd8gbzL_F8zrVg90H21EOLACvtfcHk0lhN3ufO3zM6Uw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK38XhsVersrg%253D&md5=8f558adce9f09f7218139ce873de4b92</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1016%2F0006-2952%2892%2990293-r&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0006-2952%252892%252990293-r%26sid%3Dliteratum%253Aachs%26aulast%3DYu%26aufirst%3DP.%2BH.%26aulast%3DZuo%26aufirst%3DD.-M.%26atitle%3DInhibition%2520of%2520a%2520type%2520B%2520monoamine%2520oxidase%2520inhibitor%252C%2520%2528E%2529-2-%25284-fluorophenethyl%2529-3-fluoroallylamine%2520%2528MDL-72974A%2529%252C%2520on%2520semicarbazide-sensitive%2520amine%2520oxidases%2520isolated%2520from%2520vascular%2520tissues%2520and%2520sera%2520of%2520different%2520species%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D1992%26volume%3D43%26spage%3D307%26epage%3D312%26doi%3D10.1016%2F0006-2952%2892%2990293-r" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Foot, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deodhar, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turner, C. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yin, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Dam, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silva, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olivieri, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holt, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDonald, I. A.</span></span> <span> </span><span class="NLM_article-title">The discovery and development of selective 3-fluoro-4-aryloxyallylamine inhibitors of the amine oxidase activity of semicarbazide-sensitive amine oxidase/vascular adhesion protein-1 (SSAO/VAP-1)</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">3935</span>– <span class="NLM_lpage">3940</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2012.04.111</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=10.1016%2Fj.bmcl.2012.04.111" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=22595173" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=1%3ACAS%3A528%3ADC%252BC38XntVyrtLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2012&pages=3935-3940&author=J.+S.+Footauthor=M.+Deodharauthor=C.+I.+Turnerauthor=P.+Yinauthor=E.+M.+van+Damauthor=D.+G.+Silvaauthor=A.+Olivieriauthor=A.+Holtauthor=I.+A.+McDonald&title=The+discovery+and+development+of+selective+3-fluoro-4-aryloxyallylamine+inhibitors+of+the+amine+oxidase+activity+of+semicarbazide-sensitive+amine+oxidase%2Fvascular+adhesion+protein-1+%28SSAO%2FVAP-1%29&doi=10.1016%2Fj.bmcl.2012.04.111"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">The discovery and development of selective 3-fluoro-4-aryloxyallylamine inhibitors of the amine oxidase activity of semicarbazide-sensitive amine oxidase/vascular adhesion protein-1 (SSAO/VAP-1)</span></div><div class="casAuthors">Foot, Jonathan S.; Deodhar, Mandar; Turner, Craig I.; Yin, Ping; van Dam, Ellen M.; Silva, Diego G.; Olivieri, Aldo; Holt, Andrew; McDonald, Ian A.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">3935-3940</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A new class of 3-fluoroallyl amine-based SSAO/VAP-1 inhibitors is reported.  These compds. have excellent selectivity over diamine oxidase, MAO-A and MAO-B.  Synthesis and SAR studies leading to compd. 28 (PXS-4159A, I) are reported.  The pharmacokinetic profile of 28 in the rat, together with activity in a murine model of lung inflammation are also disclosed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrFPi3_tFawXLVg90H21EOLACvtfcHk0lhN3ufO3zM6Uw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XntVyrtLg%253D&md5=cb02b80379ec2a2a6323b158f2297944</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2012.04.111&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2012.04.111%26sid%3Dliteratum%253Aachs%26aulast%3DFoot%26aufirst%3DJ.%2BS.%26aulast%3DDeodhar%26aufirst%3DM.%26aulast%3DTurner%26aufirst%3DC.%2BI.%26aulast%3DYin%26aufirst%3DP.%26aulast%3Dvan%2BDam%26aufirst%3DE.%2BM.%26aulast%3DSilva%26aufirst%3DD.%2BG.%26aulast%3DOlivieri%26aufirst%3DA.%26aulast%3DHolt%26aufirst%3DA.%26aulast%3DMcDonald%26aufirst%3DI.%2BA.%26atitle%3DThe%2520discovery%2520and%2520development%2520of%2520selective%25203-fluoro-4-aryloxyallylamine%2520inhibitors%2520of%2520the%2520amine%2520oxidase%2520activity%2520of%2520semicarbazide-sensitive%2520amine%2520oxidase%252Fvascular%2520adhesion%2520protein-1%2520%2528SSAO%252FVAP-1%2529%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D22%26spage%3D3935%26epage%3D3940%26doi%3D10.1016%2Fj.bmcl.2012.04.111" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">O’Rourke, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, E. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Podar, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scheyhing, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kessler, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ton-Nu, H. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macdonald, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Linnik, M. D.</span></span> <span> </span><span class="NLM_article-title">Anti-inflammatory effects of LJP 1586 [Z-3-fluoro-2-(4-methoxybenzyl)allylamine hydrochloride], an amine-based inhibitor of semicarbazide-sensitive amine oxidase activity</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>324</i></span>,  <span class="NLM_fpage">867</span>– <span class="NLM_lpage">875</span>, <span class="refDoi"> DOI: 10.1124/jpet.107.131672</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=10.1124%2Fjpet.107.131672" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=17993604" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsFShurY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=324&publication_year=2008&pages=867-875&author=A.+M.+O%E2%80%99Rourkeauthor=E.+Y.+Wangauthor=A.+Millerauthor=E.+M.+Podarauthor=K.+Scheyhingauthor=L.+Huangauthor=C.+Kesslerauthor=H.+Gaoauthor=H.+T.+Ton-Nuauthor=M.+T.+Macdonaldauthor=D.+S.+Jonesauthor=M.+D.+Linnik&title=Anti-inflammatory+effects+of+LJP+1586+%5BZ-3-fluoro-2-%284-methoxybenzyl%29allylamine+hydrochloride%5D%2C+an+amine-based+inhibitor+of+semicarbazide-sensitive+amine+oxidase+activity&doi=10.1124%2Fjpet.107.131672"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Anti-inflammatory effects of LJP 1586 [Z-3-fluoro-2-(4-methoxybenzyl)allylamine hydrochloride], an amine-based inhibitor of semicarbazide-sensitive amine oxidase activity</span></div><div class="casAuthors">O'Rourke, Anne M.; Wang, Eric Y.; Miller, Andrew; Podar, Erika M.; Scheyhing, Kelly; Huang, Li; Kessler, Christina; Gao, Hongfeng; Ton-Nu, Huong-Thu; MacDonald, Mary T.; Jones, David S.; Linnik, Matthew D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">324</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">867-875</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Semicarbazide-sensitive amine oxidase (SSAO, amine oxidase, copper-contg. 3, and vascular adhesion protein-1) is a copper-contg. enzyme that catalyzes the oxidative deamination of primary amines to an aldehyde, ammonia, and hydrogen peroxide.  SSAO is also involved in leukocyte migration to sites of inflammation, and the enzymic activity of SSAO is essential to this role.  Thus, inhibition of SSAO enzyme activity represents a target for the development of small mol. anti-inflammatory compds.  Here, we have characterized the novel SSAO inhibitor, Z-3-fluoro-2-(4-methoxybenzyl)allylamine hydrochloride (LJP 1586), and assessed its anti-inflammatory activity.  LJP 1586 is a potent inhibitor of rodent and human SSAO activity, with IC50 values between 4 and 43 nM.  The selectivity of LJP 1586 was confirmed with a broad panel of receptors and enzymes that included the monoamine oxidases A and B.  Oral administration of LJP 1586 resulted in complete inhibition of rat lung SSAO, with an ED50 between 0.1 and 1 mg/kg, and a pharmacodynamic half-life of greater than 24 h.  In a mouse model of inflammatory leukocyte trafficking oral dosing with LJP 1586 resulted in significant dose-dependent inhibition of neutrophil accumulation, with an effect comparable to that of anti-leukocyte function-assocd. antigen-1 antibody.  In a rat model of LPS-induced lung inflammation, administration of 10 mg/kg LJP 1586 resulted in a 55% significant redn. in transmigrated cells recovered by bronchoalveolar lavage.  The results demonstrate that a selective, orally active small mol. inhibitor of SSAO is an effective anti-inflammatory compd. in vivo and provide further support for SSAO as a therapeutic anti-inflammatory target.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrg6t1pTM6ntbVg90H21EOLACvtfcHk0lhN3ufO3zM6Uw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsFShurY%253D&md5=488fa2c75c5488de6cb038c1a253c72e</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1124%2Fjpet.107.131672&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.107.131672%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Rourke%26aufirst%3DA.%2BM.%26aulast%3DWang%26aufirst%3DE.%2BY.%26aulast%3DMiller%26aufirst%3DA.%26aulast%3DPodar%26aufirst%3DE.%2BM.%26aulast%3DScheyhing%26aufirst%3DK.%26aulast%3DHuang%26aufirst%3DL.%26aulast%3DKessler%26aufirst%3DC.%26aulast%3DGao%26aufirst%3DH.%26aulast%3DTon-Nu%26aufirst%3DH.%2BT.%26aulast%3DMacdonald%26aufirst%3DM.%2BT.%26aulast%3DJones%26aufirst%3DD.%2BS.%26aulast%3DLinnik%26aufirst%3DM.%2BD.%26atitle%3DAnti-inflammatory%2520effects%2520of%2520LJP%25201586%2520%255BZ-3-fluoro-2-%25284-methoxybenzyl%2529allylamine%2520hydrochloride%255D%252C%2520an%2520amine-based%2520inhibitor%2520of%2520semicarbazide-sensitive%2520amine%2520oxidase%2520activity%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2008%26volume%3D324%26spage%3D867%26epage%3D875%26doi%3D10.1124%2Fjpet.107.131672" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Foot, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yow, T. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schilter, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deodhar, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Findlay, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDonald, I. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turner, C. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jarolimek, W.</span></span> <span> </span><span class="NLM_article-title">PXS-4681A, a potent and selective mechanism-based inhibitor of SSAO/VAP-1 with anti-inflammatory effects in vivo</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>347</i></span>,  <span class="NLM_fpage">365</span>– <span class="NLM_lpage">374</span>, <span class="refDoi"> DOI: 10.1124/jpet.113.207613</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=10.1124%2Fjpet.113.207613" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=23943052" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhslSqsL3L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=347&publication_year=2013&pages=365-374&author=J.+S.+Footauthor=T.+T.+Yowauthor=H.+Schilterauthor=A.+Busonauthor=M.+Deodharauthor=A.+D.+Findlayauthor=L.+Guoauthor=I.+A.+McDonaldauthor=C.+I.+Turnerauthor=W.+Zhouauthor=W.+Jarolimek&title=PXS-4681A%2C+a+potent+and+selective+mechanism-based+inhibitor+of+SSAO%2FVAP-1+with+anti-inflammatory+effects+in+vivo&doi=10.1124%2Fjpet.113.207613"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">PXS-4681A, a potent and selective mechanism-based inhibitor of SSAO/VAP-1 with anti-inflammatory effects in vivo</span></div><div class="casAuthors">Foot, Jonathan S.; Yow, Tin T.; Schilter, Heidi; Buson, Alberto; Deodhar, Mandar; Findlay, Alison D.; Guo, Lily; McDonald, Ian A.; Turner, Craig I.; Zhou, Wenbin; Jarolimek, Wolfgang</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">347</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">365-374</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Semicarbazide-sensitive amine oxidase (SSAO), also known as vascular adhesion protein-1 (VAP-1), is a member of the copper-dependent amine oxidase family that is assocd. with various forms of inflammation and fibrosis.  To investigate the therapeutic potential of SSAO/VAP-1 inhibition, potent and selective inhibitors with drug-like properties are required.  PXS-4681A [(Z)-4-(2-(aminomethyl)-3-fluoroallyloxy)benzenesulfonamide hydrochloride] is a mechanism-based inhibitor of enzyme function with a pharmacokinetic and pharmacodynamic profile that ensures complete, long-lasting inhibition of the enzyme after a single low dose in vivo.  PXS-4681A irreversibly inhibits the enzyme with an apparent Ki of 37 nM and a kinact of 0.26 min-1 with no obsd. turnover in vitro.  It is highly selective for SSAO/VAP-1 when profiled against related amine oxidases, ion channels, and seven-transmembrane domain receptors, and is superior to previously reported inhibitors.  In mouse models of lung inflammation and localized inflammation, dosing of this mol. at 2 mg/kg attenuates neutrophil migration, tumor necrosis factor-α, and interleukin-6 levels.  These results demonstrate the drug-like properties of PXS-4681A and its potential use in the treatment of inflammation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqhUjl7gonLQrVg90H21EOLACvtfcHk0lg8Zto5Qmoeew"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhslSqsL3L&md5=d3c24925c4b717c9405d46be9a82f2d9</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1124%2Fjpet.113.207613&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.113.207613%26sid%3Dliteratum%253Aachs%26aulast%3DFoot%26aufirst%3DJ.%2BS.%26aulast%3DYow%26aufirst%3DT.%2BT.%26aulast%3DSchilter%26aufirst%3DH.%26aulast%3DBuson%26aufirst%3DA.%26aulast%3DDeodhar%26aufirst%3DM.%26aulast%3DFindlay%26aufirst%3DA.%2BD.%26aulast%3DGuo%26aufirst%3DL.%26aulast%3DMcDonald%26aufirst%3DI.%2BA.%26aulast%3DTurner%26aufirst%3DC.%2BI.%26aulast%3DZhou%26aufirst%3DW.%26aulast%3DJarolimek%26aufirst%3DW.%26atitle%3DPXS-4681A%252C%2520a%2520potent%2520and%2520selective%2520mechanism-based%2520inhibitor%2520of%2520SSAO%252FVAP-1%2520with%2520anti-inflammatory%2520effects%2520in%2520vivo%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2013%26volume%3D347%26spage%3D365%26epage%3D374%26doi%3D10.1124%2Fjpet.113.207613" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span> A similar mechanism
has been reported for the related vinyl fluoride, mofegiline;<span class="NLM_contrib-group"><span class="NLM_string-name">Milczek, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonivento, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Binda, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mattevi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDonald, I. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edmondson, D. E.</span></span> <span> </span><span class="NLM_article-title">Structural and Mechanistic Studies of Mofegiline Inhibition of Recombinant Human Monoamine Oxidase B</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">8019</span>– <span class="NLM_lpage">8026</span>, <span class="refDoi"> DOI: 10.1021/jm8011867</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm8011867" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsVKlu73L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=8019-8026&author=E.+M.+Milczekauthor=D.+Boniventoauthor=C.+Bindaauthor=A.+Matteviauthor=I.+A.+McDonaldauthor=D.+E.+Edmondson&title=Structural+and+Mechanistic+Studies+of+Mofegiline+Inhibition+of+Recombinant+Human+Monoamine+Oxidase+B&doi=10.1021%2Fjm8011867"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Structural and Mechanistic Studies of Mofegiline Inhibition of Recombinant Human Monoamine Oxidase B</span></div><div class="casAuthors">Milczek, Erika M.; Bonivento, Daniele; Binda, Claudia; Mattevi, Andrea; McDonald, Ian A.; Edmondson, Dale E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">8019-8026</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Mechanistic and structural studies have been carried out to investigate the mol. basis for the irreversible inhibition of human MAO-B by mofegiline.  Competitive inhibition with substrate shows an apparent Ki of 28 nM.  Irreversible inhibition of MAO-B occurs with a 1:1 M stoichiometry with no observable catalytic turnover.  The absorption spectral properties of mofegiline inhibited MAO-B show features (λmax ≃ 450 nm) unlike those of traditional flavin N(5) or C(4a) adducts.  Visible and near-UV CD spectra of the mofegiline-MAO-B adduct shows a neg. peak at 340 nm with an intensity similar to that of N(5) flavocyanine adducts.  The x-ray crystal structure of the mofegiline-MAO-B adduct shows a covalent bond between the flavin cofactor N(5) with the distal allylamine carbon atom as well as the absence of the fluorine atom.  A mechanism to explain these structural and spectral data is proposed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoyyHGVkF0PcbVg90H21EOLACvtfcHk0lg8Zto5Qmoeew"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsVKlu73L&md5=a2155647066b1e971ecc2b7680ee7bee</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1021%2Fjm8011867&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm8011867%26sid%3Dliteratum%253Aachs%26aulast%3DMilczek%26aufirst%3DE.%2BM.%26aulast%3DBonivento%26aufirst%3DD.%26aulast%3DBinda%26aufirst%3DC.%26aulast%3DMattevi%26aufirst%3DA.%26aulast%3DMcDonald%26aufirst%3DI.%2BA.%26aulast%3DEdmondson%26aufirst%3DD.%2BE.%26atitle%3DStructural%2520and%2520Mechanistic%2520Studies%2520of%2520Mofegiline%2520Inhibition%2520of%2520Recombinant%2520Human%2520Monoamine%2520Oxidase%2520B%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D8019%26epage%3D8026%26doi%3D10.1021%2Fjm8011867" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span> A crystal structure
of LOXL2 in a precursor state, with the copper atom missing, was published
recently. Given the conformational changes needed to form the active
LTQ cofactor, this structure is likely unsuitable for future structure
based design efforts;<span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, M.</span></span> <span> </span><span class="NLM_article-title">Crystal structure of human lysyl oxidase-like 2 (hLOXL2) in a precursor state</span>. <i>Proc. Natl. Acad. Sci. U.S.A.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>115</i></span>,  <span class="NLM_fpage">3828</span>– <span class="NLM_lpage">3833</span>, <span class="refDoi"> DOI: 10.1073/pnas.1720859115</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=10.1073%2Fpnas.1720859115" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=29581294" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=1%3ACAS%3A528%3ADC%252BC1cXht1Gqtr%252FM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=115&publication_year=2018&pages=3828-3833&author=X.+Zhangauthor=Q.+Wangauthor=J.+Wuauthor=J.+Wangauthor=Y.+Shiauthor=M.+Liu&title=Crystal+structure+of+human+lysyl+oxidase-like+2+%28hLOXL2%29+in+a+precursor+state&doi=10.1073%2Fpnas.1720859115"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal structure of human lysyl oxidase-like 2 (hLOXL2) in a precursor state</span></div><div class="casAuthors">Zhang, Xi; Wang, Qifan; Wu, Jianping; Wang, Jiawei; Shi, Yigong; Liu, Minhao</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">115</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">3828-3833</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Lysyl oxidases (LOXs), a type of copper- and lysyl tyrosylquinone (LTQ) -dependent amine oxidase, catalyze the oxidative deamination of lysine residues of extracellular matrix (ECM) proteins such as elastins and collagens and generate aldehyde groups.  The oxidative deamination of lysine represents the foundational step for the crosslinking of elastin and collagen and thus is crucial for ECM modeling.  Despite their physiol. significance, the structure of this important family of enzymes remains elusive.  Here we report the crystal structure of human lysyl oxidase-like 2 (hLOXL2) at 2.4-Å resoln.  Unexpectedly, the copper-binding site of hLOXL2 is occupied by zinc, which blocks LTQ generation and the enzymic activity of hLOXL2 in our in vitro assay.  Biochem. anal. confirms that copper loading robustly activates hLOXL2 and supports LTQ formation.  Furthermore, the LTQ precursor residues in the structure are distanced by 16.6 Å, corroborating the notion that the present structure may represent a precursor state and that pronounced conformational rearrangements would be required for protein activation.  The structure presented here establishes an important foundation for understanding the structure-function relationship of LOX proteins and will facilitate LOX-targeting drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrAQtLUIP5TKrVg90H21EOLACvtfcHk0lg8Zto5Qmoeew"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXht1Gqtr%252FM&md5=c2b32a9187d289a5b1cc2f7ef485d813</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1720859115&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1720859115%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DQ.%26aulast%3DWu%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DShi%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DM.%26atitle%3DCrystal%2520structure%2520of%2520human%2520lysyl%2520oxidase-like%25202%2520%2528hLOXL2%2529%2520in%2520a%2520precursor%2520state%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2018%26volume%3D115%26spage%3D3828%26epage%3D3833%26doi%3D10.1073%2Fpnas.1720859115" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McDonald, I. A.</span>; <span class="NLM_string-name">Turner, C. I.</span>; <span class="NLM_string-name">Deodhar, M.</span>; <span class="NLM_string-name">Foot, J.
S.</span></span> <span> </span><span class="NLM_article-title">Haloallylamine Inhibitors of SSAO/VAP-1 and Uses Therefor</span>. <span class="NLM_patent">WO2009066152A2</span>, <span class="NLM_year">2009</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2009&author=I.+A.+McDonald&author=C.+I.+Turner&author=M.+Deodhar&author=J.%0AS.+Foot&title=Haloallylamine+Inhibitors+of+SSAO%2FVAP-1+and+Uses+Therefor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DMcDonald%26aufirst%3DI.%2BA.%26atitle%3DHaloallylamine%2520Inhibitors%2520of%2520SSAO%252FVAP-1%2520and%2520Uses%2520Therefor%26date%3D2009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rostovtsev, V. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Green, L. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fokin, V. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharpless, K. B.</span></span> <span> </span><span class="NLM_article-title">A Stepwise Huisgen Cycloaddition Process: Copper(I)-Catalyzed Regioselective “Ligation” of Azides and Terminal Alkynes</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>41</i></span>,  <span class="NLM_fpage">2596</span>– <span class="NLM_lpage">2599</span>, <span class="refDoi"> DOI: 10.1002/1521-3773(20020715)41:14<2596::aid-anie2596>3.0.co;2-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=10.1002%2F1521-3773%2820020715%2941%3A14%3C2596%3A%3AAID-ANIE2596%3E3.0.CO%3B2-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=12203546" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=1%3ACAS%3A528%3ADC%252BD38Xls1Ohsr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2002&pages=2596-2599&author=V.+V.+Rostovtsevauthor=L.+G.+Greenauthor=V.+V.+Fokinauthor=K.+B.+Sharpless&title=A+Stepwise+Huisgen+Cycloaddition+Process%3A+Copper%28I%29-Catalyzed+Regioselective+%E2%80%9CLigation%E2%80%9D+of+Azides+and+Terminal+Alkynes&doi=10.1002%2F1521-3773%2820020715%2941%3A14%3C2596%3A%3Aaid-anie2596%3E3.0.co%3B2-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">A stepwise Huisgen cycloaddition process: copper(I)-catalyzed regioselective "ligation" of azides and terminal alkynes</span></div><div class="casAuthors">Rostovtsev, Vsevolod V.; Green, Luke G.; Fokin, Valery V.; Sharpless, K. Barry</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">2596-2599</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH</span>)
        </div><div class="casAbstract">1,4-Disubstituted 1,2,3-triazoles I (R1 = PhCH2, PhCH2OCH2, 1-adamantyl, etc.; R2 = HO2C, Ph, PhOCH2, Et2NCH2, etc.) were readily and cleanly prepd. via highly efficient and regioselective copper(I)-catalyzed cycloaddn. of azides R1N3 with terminal alkynes R2C≡CH in 82-93% yields.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGptcW2JUNM1r7Vg90H21EOLACvtfcHk0lhPLwfqkDREHQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xls1Ohsr4%253D&md5=4603664be6639353b5e70f19b9f8d59f</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1002%2F1521-3773%2820020715%2941%3A14%3C2596%3A%3AAID-ANIE2596%3E3.0.CO%3B2-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252F1521-3773%252820020715%252941%253A14%253C2596%253A%253AAID-ANIE2596%253E3.0.CO%253B2-4%26sid%3Dliteratum%253Aachs%26aulast%3DRostovtsev%26aufirst%3DV.%2BV.%26aulast%3DGreen%26aufirst%3DL.%2BG.%26aulast%3DFokin%26aufirst%3DV.%2BV.%26aulast%3DSharpless%26aufirst%3DK.%2BB.%26atitle%3DA%2520Stepwise%2520Huisgen%2520Cycloaddition%2520Process%253A%2520Copper%2528I%2529-Catalyzed%2520Regioselective%2520%25E2%2580%259CLigation%25E2%2580%259D%2520of%2520Azides%2520and%2520Terminal%2520Alkynes%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2002%26volume%3D41%26spage%3D2596%26epage%3D2599%26doi%3D10.1002%2F1521-3773%2820020715%2941%3A14%3C2596%3A%3Aaid-anie2596%3E3.0.co%3B2-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diwu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Panchuk-Voloshina, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haugland, R. P.</span></span> <span> </span><span class="NLM_article-title">A Stable Nonfluorescent Derivative of Resorufin for the Fluorometric Determination of Trace Hydrogen Peroxide: Applications in Detecting the Activity of Phagocyte NADPH Oxidase and Other Oxidases</span>. <i>Anal. Biochem.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>253</i></span>,  <span class="NLM_fpage">162</span>– <span class="NLM_lpage">168</span>, <span class="refDoi"> DOI: 10.1006/abio.1997.2391</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=10.1006%2Fabio.1997.2391" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=9367498" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=1%3ACAS%3A528%3ADyaK2sXnsFahsr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=253&publication_year=1997&pages=162-168&author=M.+Zhouauthor=Z.+Diwuauthor=N.+Panchuk-Voloshinaauthor=R.+P.+Haugland&title=A+Stable+Nonfluorescent+Derivative+of+Resorufin+for+the+Fluorometric+Determination+of+Trace+Hydrogen+Peroxide%3A+Applications+in+Detecting+the+Activity+of+Phagocyte+NADPH+Oxidase+and+Other+Oxidases&doi=10.1006%2Fabio.1997.2391"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">A stable nonfluorescent derivative of resorufin for the fluorometric determination of trace hydrogen peroxide: applications in detecting the activity of phagocyte NADPH oxidase and other oxidase spectrochemical analysis fluorometrics</span></div><div class="casAuthors">Zhou, Mingjie; Diwu, Zhenjun; Panchuk-Voloshina, Nataliya; Haugland, Richard P.</div><div class="citationInfo"><span class="NLM_cas:title">Analytical Biochemistry</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">253</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">162-168</span>CODEN:
                <span class="NLM_cas:coden">ANBCA2</span>;
        ISSN:<span class="NLM_cas:issn">0003-2697</span>.
    
            (<span class="NLM_cas:orgname">Academic Press</span>)
        </div><div class="casAbstract">The enzymic detn. of hydrogen peroxide can be accomplished with high sensitivity and specificity using N-acetyl-3,7-dihydroxyphenoxazine (Amplex Red), a highly sensitive and chem. stable fluorogenic probe for the enzymic detn. of H2O2.  Enzyme-catalyzed oxidn. of Amplex Red, which is a colorless and nonfluorescent deriv. of dihydroresorufin, produces highly fluorescent resorufin, which has an excitation max. at 563 nm and emission max. at 587 nm.  The reaction stoichiometry of Amplex Red and H2O2 was detd. to be 1:1.  This probe allows detection of 5 pmol H2O2 in a 96-well fluorescence microplate assay.  When applied to the measurement of NADPH oxidase activation, the Amplex Red assay can detect H2O2 release from as few as 2000 phorbol myristate acetate-stimulated neutrophils with a sensitivity 5- to 20-fold greater than that attained in the scopoletin assay under the same exptl. conditions.  Furthermore, the oxidase-catalyzed assay using Amplex Red results in an increase in fluorescence on oxidn. rather than a decrease in fluorescence as in the scopoletin assay.  In comparison with other fluorometric and spectrophotometric assays for the detection of monoamine oxidase and glucose oxidase, this probe is also found to be more sensitive.  Given its high sensitivity and specificity, Amplex Red should have a broad application for the measurement of H2O2 in a variety of oxidase-mediated reactions and very low levels of H2O2 in food, environmental waters, and consumer products.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo-7MWSaM2nZLVg90H21EOLACvtfcHk0lhPLwfqkDREHQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXnsFahsr4%253D&md5=56ad0d7f78ede7a6fc0c6a9208dec947</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1006%2Fabio.1997.2391&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1006%252Fabio.1997.2391%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DM.%26aulast%3DDiwu%26aufirst%3DZ.%26aulast%3DPanchuk-Voloshina%26aufirst%3DN.%26aulast%3DHaugland%26aufirst%3DR.%2BP.%26atitle%3DA%2520Stable%2520Nonfluorescent%2520Derivative%2520of%2520Resorufin%2520for%2520the%2520Fluorometric%2520Determination%2520of%2520Trace%2520Hydrogen%2520Peroxide%253A%2520Applications%2520in%2520Detecting%2520the%2520Activity%2520of%2520Phagocyte%2520NADPH%2520Oxidase%2520and%2520Other%2520Oxidases%26jtitle%3DAnal.%2520Biochem.%26date%3D1997%26volume%3D253%26spage%3D162%26epage%3D168%26doi%3D10.1006%2Fabio.1997.2391" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kuo, W.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, M.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsai, C.-N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, T.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, M.-F.</span></span> <span> </span><span class="NLM_article-title">Imatinib Mesylate Improves Liver Regeneration and Attenuates Liver Fibrogenesis in CCL4-Treated Mice</span>. <i>J. Gastrointest. Surg.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">361</span>– <span class="NLM_lpage">369</span>, <span class="refDoi"> DOI: 10.1007/s11605-011-1764-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=10.1007%2Fs11605-011-1764-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=22068968" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=1%3ACAS%3A280%3ADC%252BC387mvFajtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2012&pages=361-369&author=W.-L.+Kuoauthor=M.-C.+Yuauthor=J.-F.+Leeauthor=C.-N.+Tsaiauthor=T.-C.+Chenauthor=M.-F.+Chen&title=Imatinib+Mesylate+Improves+Liver+Regeneration+and+Attenuates+Liver+Fibrogenesis+in+CCL4-Treated+Mice&doi=10.1007%2Fs11605-011-1764-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Imatinib mesylate improves liver regeneration and attenuates liver fibrogenesis in CCL4-treated mice</span></div><div class="casAuthors">Kuo Wen-Ling; Yu Ming-Chin; Lee Ju-Fang; Tsai Chi-Neu; Chen Tse-Ching; Chen Miin-Fu</div><div class="citationInfo"><span class="NLM_cas:title">Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">361-9</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUNDS:  Imatinib mesylate (STI-571), a tyrosine kinase inhibitor, has previously been demonstrated to attenuate liver fibrogenesis through inhibition of the activation of hepatic stellate cells (HSCs) in CCL(4)-treated rat models.  AIMS:  This study aimed to further evaluate the role of STI-571 in liver regeneration.  MATERIALS AND METHODS:  All animals were divided into four groups, and mice were treated with or without CCL(4) and STI-571 (n = 6 for each group).  RESULTS:  Activated cultured HSCs in vitro with STI-571 administration showed increased apoptosis and reduced proliferation, as determined by flow cytometric analysis, 3-(4, 5-cimethylthiazol-2-yl)-2, 5-diphenyl tetrazolium bromide assay, and confocal microscopy.  STI-571 treatment attenuated liver fibrosis in vivo, as was evident in the results of histology, mRNA level, and expression analysis of smooth muscle actin and type I collagen.  Mice treated with STI-571 had increased liver weight ratio and the improvement in liver regeneration was compatible with the change of serum interleukin 6 levels (p < 0.05).  Further, increased apoptosis and a reduced proliferation were observed in the CCL(4)-treated mice after STI-571 treatment based on the immunohistochemical staining of Annexin V, phosphorylated STAT3, and PCNA.  CONCLUSION:  STI-571 treatment effectively attenuated liver fibrogenesis and improved in liver regeneration in vivo and induced apoptosis in HSCs both in vitro and in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRQPWxRp6ppkxe4jJGKT5N0fW6udTcc2ebuHw0vJD9f57ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC387mvFajtQ%253D%253D&md5=53541b37647f583777a5b725240d649e</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1007%2Fs11605-011-1764-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11605-011-1764-7%26sid%3Dliteratum%253Aachs%26aulast%3DKuo%26aufirst%3DW.-L.%26aulast%3DYu%26aufirst%3DM.-C.%26aulast%3DLee%26aufirst%3DJ.-F.%26aulast%3DTsai%26aufirst%3DC.-N.%26aulast%3DChen%26aufirst%3DT.-C.%26aulast%3DChen%26aufirst%3DM.-F.%26atitle%3DImatinib%2520Mesylate%2520Improves%2520Liver%2520Regeneration%2520and%2520Attenuates%2520Liver%2520Fibrogenesis%2520in%2520CCL4-Treated%2520Mice%26jtitle%3DJ.%2520Gastrointest.%2520Surg.%26date%3D2012%26volume%3D16%26spage%3D361%26epage%3D369%26doi%3D10.1007%2Fs11605-011-1764-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Aono, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nishioka, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inayama, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ugai, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kishi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uehara, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Izumi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sone, S.</span></span> <span> </span><span class="NLM_article-title">Imatinib as a novel antifibrotic agent in bleomycin-induced pulmonary fibrosis in mice</span>. <i>Am. J. Respir. Crit. Care Med.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>171</i></span>,  <span class="NLM_fpage">1279</span>– <span class="NLM_lpage">1285</span>, <span class="refDoi"> DOI: 10.1164/rccm.200404-531oc</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=10.1164%2Frccm.200404-531oc" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=15735062" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=1%3ACAS%3A280%3ADC%252BD2M3ntFWmtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=171&publication_year=2005&pages=1279-1285&author=Y.+Aonoauthor=Y.+Nishiokaauthor=M.+Inayamaauthor=M.+Ugaiauthor=J.+Kishiauthor=H.+Ueharaauthor=K.+Izumiauthor=S.+Sone&title=Imatinib+as+a+novel+antifibrotic+agent+in+bleomycin-induced+pulmonary+fibrosis+in+mice&doi=10.1164%2Frccm.200404-531oc"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Imatinib as a novel antifibrotic agent in bleomycin-induced pulmonary fibrosis in mice</span></div><div class="casAuthors">Aono Yoshinori; Nishioka Yasuhiko; Inayama Mami; Ugai Momoyo; Kishi Jun; Uehara Hisanori; Izumi Keisuke; Sone Saburo</div><div class="citationInfo"><span class="NLM_cas:title">American journal of respiratory and critical care medicine</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">171</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1279-85</span>
        ISSN:<span class="NLM_cas:issn">1073-449X</span>.
    </div><div class="casAbstract">Imatinib mesylate is a potent and specific tyrosine kinase inhibitor against c-ABL, BCR-ABL, and c-KIT, and has been demonstrated to be highly active in chronic myeloid leukemia and gastrointestinal stromal tumors.  We examined the antifibrotic effects of imatinib using a bleomycin-induced lung fibrosis model in mice because imatinib also inhibits tyrosine kinase of platelet-derived growth factor receptors (PDGFRs).  Imatinib inhibited the growth of primary murine lung fibroblasts and the autophosphorylation of PDGFR-beta induced by PDGF.  Administration of imatinib significantly prevented bleomycin-induced pulmonary fibrosis in mice, partly by reducing the number of mesenchymal cells incorporating bromodeoxyuridine.  Analysis of bronchoalveolar lavage cells demonstrated that imatinib did not suppress early inflammation on Days 7 and 14 caused by bleomycin.  These results suggest that imatinib has the potential to prevent pulmonary fibrosis by inhibiting the proliferation of mesenchymal cells, and that imatinib might be useful for the treatment of pulmonary fibrosis in humans.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT6Hl7Y7MSGmVZoq0fPSOTvfW6udTcc2ebuHw0vJD9f57ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2M3ntFWmtw%253D%253D&md5=998232993f5ca1d46769358d0ac73cb1</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1164%2Frccm.200404-531oc&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1164%252Frccm.200404-531oc%26sid%3Dliteratum%253Aachs%26aulast%3DAono%26aufirst%3DY.%26aulast%3DNishioka%26aufirst%3DY.%26aulast%3DInayama%26aufirst%3DM.%26aulast%3DUgai%26aufirst%3DM.%26aulast%3DKishi%26aufirst%3DJ.%26aulast%3DUehara%26aufirst%3DH.%26aulast%3DIzumi%26aufirst%3DK.%26aulast%3DSone%26aufirst%3DS.%26atitle%3DImatinib%2520as%2520a%2520novel%2520antifibrotic%2520agent%2520in%2520bleomycin-induced%2520pulmonary%2520fibrosis%2520in%2520mice%26jtitle%3DAm.%2520J.%2520Respir.%2520Crit.%2520Care%2520Med.%26date%3D2005%26volume%3D171%26spage%3D1279%26epage%3D1285%26doi%3D10.1164%2Frccm.200404-531oc" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ashcroft, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simpson, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Timbrell, V.</span></span> <span> </span><span class="NLM_article-title">Simple method of estimating severity of pulmonary fibrosis on a numerical scale</span>. <i>J. Clin. Pathol.</i> <span class="NLM_year" style="font-weight: bold;">1988</span>,  <span class="NLM_volume"><i>41</i></span>,  <span class="NLM_fpage">467</span>– <span class="NLM_lpage">470</span>, <span class="refDoi"> DOI: 10.1136/jcp.41.4.467</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=10.1136%2Fjcp.41.4.467" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=3366935" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=1%3ACAS%3A280%3ADyaL1c3htlOltg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=1988&pages=467-470&author=T.+Ashcroftauthor=J.+M.+Simpsonauthor=V.+Timbrell&title=Simple+method+of+estimating+severity+of+pulmonary+fibrosis+on+a+numerical+scale&doi=10.1136%2Fjcp.41.4.467"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Simple method of estimating severity of pulmonary fibrosis on a numerical scale</span></div><div class="casAuthors">Ashcroft T; Simpson J M; Timbrell V</div><div class="citationInfo"><span class="NLM_cas:title">Journal of clinical pathology</span>
        (<span class="NLM_cas:date">1988</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">467-70</span>
        ISSN:<span class="NLM_cas:issn">0021-9746</span>.
    </div><div class="casAbstract">A continuous numerical scale for determining the degree of fibrosis in lung specimens was devised for correlation with other pulmonary variables such as lung function tests or mineral burden.  Grading was scored on a scale from 0 to 8, using the average of microscope field scores.  The system allows fibrosis to be measured in small samples of tissue (1 cm) which can provide a detailed description of the changes in a lung, currently not possible with most existing methods.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT5mGFCkDKSIzUE-swuRqsHfW6udTcc2ebnjifnvRbr_Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaL1c3htlOltg%253D%253D&md5=d1da07e3ba735d309aa78d3955474bfd</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1136%2Fjcp.41.4.467&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1136%252Fjcp.41.4.467%26sid%3Dliteratum%253Aachs%26aulast%3DAshcroft%26aufirst%3DT.%26aulast%3DSimpson%26aufirst%3DJ.%2BM.%26aulast%3DTimbrell%26aufirst%3DV.%26atitle%3DSimple%2520method%2520of%2520estimating%2520severity%2520of%2520pulmonary%2520fibrosis%2520on%2520a%2520numerical%2520scale%26jtitle%3DJ.%2520Clin.%2520Pathol.%26date%3D1988%26volume%3D41%26spage%3D467%26epage%3D470%26doi%3D10.1136%2Fjcp.41.4.467" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Balle, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perregaard, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramirez, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larsen, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Søby, K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liljefors, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andersen, K.</span></span> <span> </span><span class="NLM_article-title">Synthesis and Structure–Affinity Relationship Investigations of 5-Heteroaryl-Substituted Analogues of the Antipsychotic Sertindole. A New Class of Highly Selective α1Adrenoceptor Antagonists</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>46</i></span>,  <span class="NLM_fpage">265</span>– <span class="NLM_lpage">283</span>, <span class="refDoi"> DOI: 10.1021/jm020938y</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm020938y" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=1%3ACAS%3A528%3ADC%252BD38XpsVegtLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2003&pages=265-283&author=T.+Balleauthor=J.+Perregaardauthor=M.+T.+Ramirezauthor=A.+K.+Larsenauthor=K.+K.+S%C3%B8byauthor=T.+Liljeforsauthor=K.+Andersen&title=Synthesis+and+Structure%E2%80%93Affinity+Relationship+Investigations+of+5-Heteroaryl-Substituted+Analogues+of+the+Antipsychotic+Sertindole.+A+New+Class+of+Highly+Selective+%CE%B11Adrenoceptor+Antagonists&doi=10.1021%2Fjm020938y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and Structure-Affinity Relationship Investigations of 5-Heteroaryl-Substituted Analogues of the Antipsychotic Sertindole. A New Class of Highly Selective α1 Adrenoceptor Antagonists</span></div><div class="casAuthors">Balle, Thomas; Perregaard, Jens; Ramirez, Martha Teresa; Larsen, Anna Kirstine; Soby, Karina Krojer; Liljefors, Tommy; Andersen, Kim</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">265-283</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A new class of 5-heteroaryl-substituted 1-(4-fluorophenyl)-3-(4-piperidinyl)-1H-indoles, e.g., I (X = NH, O), as highly selective and potentially CNS-active α1-adrenoceptor antagonists is described.  The compds. are derived from the antipsychotic sertindole.  The structure-affinity relationships of the 5-heteroaryl substituents, and the substituents on the piperidine nitrogen atom were optimized with respect to affinity for α1 adrenoceptors and selectivity in respect to dopamine (D1-4) and serotonin (5-HT1A-1B and 5-HT2A,2C) receptors.  The most selective compd. obtained, 3-{4-[1-(4-fluorophenyl)-5-(1-methyl-1,2,4-triazol-3-yl)-1H-indol-3-yl]-1-piperidinyl}propionitrile (II), has affinities of 0.99, 3.2, and 9.0 nM for the α1a, α1b, and α1d adrenoceptor subtypes, resp., and a selectivity for adrenergic α1a receptors in respect to dopamine D2, D3, and D4 and serotonin 5-HT2A and 5-HT2C higher than 900, comparable to the selectivity of prazosin.  Compd. II is more than 150-fold selective in respect to serotonin 5-HT1A and 5-HT1B receptors.  A new basic pharmacophore for α1-adrenoceptor antagonists based on a previously reported pharmacophore model for dopamine D2 antagonist is suggested.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp7ipwqVAJLKrVg90H21EOLACvtfcHk0ljncuvsmUEDPw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XpsVegtLY%253D&md5=518924c375dc409bb74dd1d3f682681f</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1021%2Fjm020938y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm020938y%26sid%3Dliteratum%253Aachs%26aulast%3DBalle%26aufirst%3DT.%26aulast%3DPerregaard%26aufirst%3DJ.%26aulast%3DRamirez%26aufirst%3DM.%2BT.%26aulast%3DLarsen%26aufirst%3DA.%2BK.%26aulast%3DS%25C3%25B8by%26aufirst%3DK.%2BK.%26aulast%3DLiljefors%26aufirst%3DT.%26aulast%3DAndersen%26aufirst%3DK.%26atitle%3DSynthesis%2520and%2520Structure%25E2%2580%2593Affinity%2520Relationship%2520Investigations%2520of%25205-Heteroaryl-Substituted%2520Analogues%2520of%2520the%2520Antipsychotic%2520Sertindole.%2520A%2520New%2520Class%2520of%2520Highly%2520Selective%2520%25CE%25B11Adrenoceptor%2520Antagonists%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2003%26volume%3D46%26spage%3D265%26epage%3D283%26doi%3D10.1021%2Fjm020938y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">de
Bruin, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Rooden, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ward, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wesseling, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van den Nieuwendijk, A. M. C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Boeckel, C. A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Driessen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kisselev, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Florea, B. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van der
Stelt, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Overkleeft, H. S.</span></span> <span> </span><span class="NLM_article-title">Asymmetric synthesis of lysine analogues with reduced basicity, and their incorporation into proteasome inhibitors</span>. <i>Eur. J. Org. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_fpage">5921</span>– <span class="NLM_lpage">5934</span>, <span class="refDoi"> DOI: 10.1002/ejoc.201701174</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=10.1002%2Fejoc.201701174" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhslagsbvL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&pages=5921-5934&author=G.+de%0ABruinauthor=E.+J.+van+Roodenauthor=D.+Wardauthor=C.+Wesselingauthor=A.+M.+C.+H.+van+den+Nieuwendijkauthor=C.+A.+A.+van+Boeckelauthor=C.+Driessenauthor=A.+F.+Kisselevauthor=B.+I.+Floreaauthor=M.+van+der%0ASteltauthor=H.+S.+Overkleeft&title=Asymmetric+synthesis+of+lysine+analogues+with+reduced+basicity%2C+and+their+incorporation+into+proteasome+inhibitors&doi=10.1002%2Fejoc.201701174"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Asymmetric synthesis of lysine analogues with reduced basicity, and their incorporation into proteasome inhibitors</span></div><div class="casAuthors">de Bruin, Gerjan; van Rooden, Eva J.; Ward, David; Wesseling, Charlotte; van den Nieuwendijk, Adrianus M. C. H.; van Boeckel, Constant A. A.; Driessen, Christoph; Kisselev, Alexei F.; Florea, Bogdan I.; van der Stelt, Mario; Overkleeft, Herman S.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Organic Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">2017</span>
        (<span class="NLM_cas:issue">39</span>),
    <span class="NLM_cas:pages">5921-5934</span>CODEN:
                <span class="NLM_cas:coden">EJOCFK</span>;
        ISSN:<span class="NLM_cas:issn">1099-0690</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Most known β2-selective proteasome inhibitors suffer from relatively poor cell permeability as the result of a net pos. charge caused by the basic moiety at P1.  In this paper, we describe the synthesis of oligopeptide vinyl sulfones that contain different amino acids bearing amino groups with reduced basicity at P1 and/or P3.  For this, we developed the first enantioselective synthesis of lysine(4-ene) and lysine(4-yne).  These amino acids, as well as histidine and diaminopropionic-acid-glycine, were incorporated at the P1 and/or P3 positions of oligopeptide vinyl sulfones.  All inhibitors were found to inhibit β2, but with a loss of potency compared to our most potent and selective β2 inhibitor, LU-102.  These results notwithstanding, our results provide important insights for the future design of β2-selective proteasome inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqxdaoHyPyG27Vg90H21EOLACvtfcHk0ljncuvsmUEDPw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhslagsbvL&md5=cc4321236acb824cca3af6708d16736f</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1002%2Fejoc.201701174&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fejoc.201701174%26sid%3Dliteratum%253Aachs%26aulast%3Dde%2BBruin%26aufirst%3DG.%26aulast%3Dvan%2BRooden%26aufirst%3DE.%2BJ.%26aulast%3DWard%26aufirst%3DD.%26aulast%3DWesseling%26aufirst%3DC.%26aulast%3Dvan%2Bden%2BNieuwendijk%26aufirst%3DA.%2BM.%2BC.%2BH.%26aulast%3Dvan%2BBoeckel%26aufirst%3DC.%2BA.%2BA.%26aulast%3DDriessen%26aufirst%3DC.%26aulast%3DKisselev%26aufirst%3DA.%2BF.%26aulast%3DFlorea%26aufirst%3DB.%2BI.%26aulast%3Dvan%2Bder%2BStelt%26aufirst%3DM.%26aulast%3DOverkleeft%26aufirst%3DH.%2BS.%26atitle%3DAsymmetric%2520synthesis%2520of%2520lysine%2520analogues%2520with%2520reduced%2520basicity%252C%2520and%2520their%2520incorporation%2520into%2520proteasome%2520inhibitors%26jtitle%3DEur.%2520J.%2520Org.%2520Chem.%26date%3D2017%26spage%3D5921%26epage%3D5934%26doi%3D10.1002%2Fejoc.201701174" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref52"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref52'); return false;" data-citation="" class="refNumLink">52</a></strong><div class="NLM_citation" id="cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shieh, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tamaye, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yasunobu, K. T.</span></span> <span> </span><span class="NLM_article-title">A purification procedure for the isolation of homogeneous preparations of bovine aorta amine oxidase and a study of its lysyl oxidase activity</span>. <i>Biochim. Biophys. Acta</i> <span class="NLM_year" style="font-weight: bold;">1975</span>,  <span class="NLM_volume"><i>377</i></span>,  <span class="NLM_fpage">229</span>– <span class="NLM_lpage">238</span>, <span class="refDoi"> DOI: 10.1016/0005-2744(75)90305-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=10.1016%2F0005-2744%2875%2990305-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=235299" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=1%3ACAS%3A528%3ADyaE2MXht1Slt7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=377&publication_year=1975&pages=229-238&author=J.+J.+Shiehauthor=R.+Tamayeauthor=K.+T.+Yasunobu&title=A+purification+procedure+for+the+isolation+of+homogeneous+preparations+of+bovine+aorta+amine+oxidase+and+a+study+of+its+lysyl+oxidase+activity&doi=10.1016%2F0005-2744%2875%2990305-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Purification procedure for the isolation of homogeneous preparations of bovine aorta amine oxidase and a study of its lysyl oxidase activity</span></div><div class="casAuthors">Shieh, James J.; Tamaye, Randolph; Yasunobu, Kerry T.</div><div class="citationInfo"><span class="NLM_cas:title">Biochimica et Biophysica Acta, Enzymology</span>
        (<span class="NLM_cas:date">1975</span>),
    <span class="NLM_cas:volume">377</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">229-38</span>CODEN:
                <span class="NLM_cas:coden">BBEZAD</span>;
        ISSN:<span class="NLM_cas:issn">0924-1086</span>.
    </div><div class="casAbstract">It was reported that bovine aorta amine oxidase oxidizes lysine residues in tropoelastin to allylsine (R. B. Rucker and B. L. O'Dell (1971)).  Pure bovine aorta amine oxidase was isolated by DEAE-cellulose, hydroxylapatite, Bio-Gel A-1.5 m and concanavalin A-Sepharose 4B chromatog.  Enzymic, chromatog., and immunochem. tests disclosed that pure bovine aorta amine oxidase was not a lysyl oxidase capable of oxidizing the lysine residues of tropoelastin to allylsine.  The bovine aorta amine oxidase prepn. used by Rucker and O'Dell was apparently contaminated with lysyl oxidase.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrZAUhL5XTEPbVg90H21EOLACvtfcHk0ljh8O2aPuyamA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaE2MXht1Slt7g%253D&md5=d5fc9ef0d26f35af273bb349a1cd8aaa</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1016%2F0005-2744%2875%2990305-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0005-2744%252875%252990305-8%26sid%3Dliteratum%253Aachs%26aulast%3DShieh%26aufirst%3DJ.%2BJ.%26aulast%3DTamaye%26aufirst%3DR.%26aulast%3DYasunobu%26aufirst%3DK.%2BT.%26atitle%3DA%2520purification%2520procedure%2520for%2520the%2520isolation%2520of%2520homogeneous%2520preparations%2520of%2520bovine%2520aorta%2520amine%2520oxidase%2520and%2520a%2520study%2520of%2520its%2520lysyl%2520oxidase%2520activity%26jtitle%3DBiochim.%2520Biophys.%2520Acta%26date%3D1975%26volume%3D377%26spage%3D229%26epage%3D238%26doi%3D10.1016%2F0005-2744%2875%2990305-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref53"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref53'); return false;" data-citation="" class="refNumLink">53</a></strong><div class="NLM_citation" id="cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schilter, H. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collison, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Russo, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foot, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yow, T. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vieira, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tavares, L. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mattes, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teixeira, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jarolimek, W.</span></span> <span> </span><span class="NLM_article-title">Effects of an anti-inflammatory VAP-1/SSAO inhibitor, PXS-4728A, on pulmonary neutrophil migration</span>. <i>Respir. Res.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">42</span>– <span class="NLM_lpage">49</span>, <span class="refDoi"> DOI: 10.1186/s12931-015-0200-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=10.1186%2Fs12931-015-0200-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=25889951" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=1%3ACAS%3A280%3ADC%252BC2MjlvVehug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2015&pages=42-49&author=H.+C.+Schilterauthor=A.+Collisonauthor=R.+C.+Russoauthor=J.+S.+Footauthor=T.+T.+Yowauthor=A.+T.+Vieiraauthor=L.+D.+Tavaresauthor=J.+Mattesauthor=M.+M.+Teixeiraauthor=W.+Jarolimek&title=Effects+of+an+anti-inflammatory+VAP-1%2FSSAO+inhibitor%2C+PXS-4728A%2C+on+pulmonary+neutrophil+migration&doi=10.1186%2Fs12931-015-0200-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Effects of an anti-inflammatory VAP-1/SSAO inhibitor, PXS-4728A, on pulmonary neutrophil migration</span></div><div class="casAuthors">Schilter Heidi C; Foot Jonathan S; Yow Tin T; Jarolimek Wolfgang; Collison Adam; Mattes Joerg; Russo Remo C; Russo Remo C; Vieira Angelica T; Tavares Livia D; Teixeira Mauro M; Jarolimek Wolfgang</div><div class="citationInfo"><span class="NLM_cas:title">Respiratory research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">42</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND AND PURPOSE:  The persistent influx of neutrophils into the lung and subsequent tissue damage are characteristics of COPD, cystic fibrosis and acute lung inflammation.  VAP-1/SSAO is an endothelial bound adhesion molecule with amine oxidase activity that is reported to be involved in neutrophil egress from the microvasculature during inflammation.  This study explored the role of VAP-1/SSAO in neutrophilic lung mediated diseases and examined the therapeutic potential of the selective inhibitor PXS-4728A.  METHODS:  Mice treated with PXS-4728A underwent intra-vital microscopy visualization of the cremaster muscle upon CXCL1/KC stimulation.  LPS inflammation, Klebsiella pneumoniae infection, cecal ligation and puncture as well as rhinovirus exacerbated asthma models were also assessed using PXS-4728A.  RESULTS:  Selective VAP-1/SSAO inhibition by PXS-4728A diminished leukocyte rolling and adherence induced by CXCL1/KC.  Inhibition of VAP-1/SSAO also dampened the migration of neutrophils to the lungs in response to LPS, Klebsiella pneumoniae lung infection and CLP induced sepsis; whilst still allowing for normal neutrophil defense function, resulting in increased survival.  The functional effects of this inhibition were demonstrated in the RV exacerbated asthma model, with a reduction in cellular infiltrate correlating with a reduction in airways hyperractivity.  CONCLUSIONS AND IMPLICATIONS:  This study demonstrates that the endothelial cell ligand VAP-1/SSAO contributes to the migration of neutrophils during acute lung inflammation, pulmonary infection and airway hyperractivity.  These results highlight the potential of inhibiting of VAP-1/SSAO enzymatic function, by PXS-4728A, as a novel therapeutic approach in lung diseases that are characterized by neutrophilic pattern of inflammation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ0DDPb95t7V9K0qsdY6Nc1fW6udTcc2eYimf_eHHq6d7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2MjlvVehug%253D%253D&md5=8a1e21dcc37596356424720fd11bcc1d</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1186%2Fs12931-015-0200-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs12931-015-0200-z%26sid%3Dliteratum%253Aachs%26aulast%3DSchilter%26aufirst%3DH.%2BC.%26aulast%3DCollison%26aufirst%3DA.%26aulast%3DRusso%26aufirst%3DR.%2BC.%26aulast%3DFoot%26aufirst%3DJ.%2BS.%26aulast%3DYow%26aufirst%3DT.%2BT.%26aulast%3DVieira%26aufirst%3DA.%2BT.%26aulast%3DTavares%26aufirst%3DL.%2BD.%26aulast%3DMattes%26aufirst%3DJ.%26aulast%3DTeixeira%26aufirst%3DM.%2BM.%26aulast%3DJarolimek%26aufirst%3DW.%26atitle%3DEffects%2520of%2520an%2520anti-inflammatory%2520VAP-1%252FSSAO%2520inhibitor%252C%2520PXS-4728A%252C%2520on%2520pulmonary%2520neutrophil%2520migration%26jtitle%3DRespir.%2520Res.%26date%3D2015%26volume%3D16%26spage%3D42%26epage%3D49%26doi%3D10.1186%2Fs12931-015-0200-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref54"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref54'); return false;" data-citation="" class="refNumLink">54</a></strong><div class="NLM_citation" id="cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kitz, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, I. B.</span></span> <span> </span><span class="NLM_article-title">Esters of methanesulfonic acid as irreversible inhibitors of acetylcholinesterase</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1962</span>,  <span class="NLM_volume"><i>237</i></span>,  <span class="NLM_fpage">3245</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=14033211" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=1%3ACAS%3A528%3ADyaF38Xks1Cmsrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=237&publication_year=1962&pages=3245&author=R.+Kitzauthor=I.+B.+Wilson&title=Esters+of+methanesulfonic+acid+as+irreversible+inhibitors+of+acetylcholinesterase"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Esters of methanesulfonic acid as irreversible inhibitors of acetylcholinesterase</span></div><div class="casAuthors">Kitz, R.; Wilson, Irwin B.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">1962</span>),
    <span class="NLM_cas:volume">237</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">3245-49</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    </div><div class="casAbstract">Nine esters (anhydrides) of methanesulfonic acid, analogs to well known carbamate (e.g. neostigmine) and phosphate (e.g. paraoxon) inhibitors, were examd. as possible irreversible inhibitors of acetylcholinesterase.  Five were active.  Of these, 4 formed initial reversible complexes.  The progressive development of irreversible inhibition was slowed by reversible inhibitors, indicating that the active site is involved.  The inhibited enzyme is not reactivated by water or by hydroxylamine, hydrazine, acetate, or pyridine-2-aldoxime methiodide.  It is reactivated by pyridine-3-aldoxime methiodide.  On the basis of the evidence presented, it may be concluded safely that the active methanesulfonates form methanesulfonyl enzyme derivs. and, therefore, belong to the class of acid-transferring or oxydiaphoric inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoXvcQevCYwCbVg90H21EOLACvtfcHk0ljh8O2aPuyamA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaF38Xks1Cmsrg%253D&md5=f3993cf79ebb66299fada0ad04b15860</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKitz%26aufirst%3DR.%26aulast%3DWilson%26aufirst%3DI.%2BB.%26atitle%3DEsters%2520of%2520methanesulfonic%2520acid%2520as%2520irreversible%2520inhibitors%2520of%2520acetylcholinesterase%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1962%26volume%3D237%26spage%3D3245" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref55"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref55'); return false;" data-citation="" class="refNumLink">55</a></strong><div class="NLM_citation" id="cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Holt, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cendron, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zanotti, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rigo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Paolo, M. L.</span></span> <span> </span><span class="NLM_article-title">Multiple binding sites for substrates and modulators of semicarbazide-sensitive amine oxidases: kinetic consequences</span>. <i>Mol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>73</i></span>,  <span class="NLM_fpage">525</span>– <span class="NLM_lpage">538</span>, <span class="refDoi"> DOI: 10.1124/mol.107.040964</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=10.1124%2Fmol.107.040964" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=17989349" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=1%3ACAS%3A528%3ADC%252BD1cXht1ymtrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=2008&pages=525-538&author=A.+Holtauthor=D.+J.+Smithauthor=L.+Cendronauthor=G.+Zanottiauthor=A.+Rigoauthor=M.+L.+Di+Paolo&title=Multiple+binding+sites+for+substrates+and+modulators+of+semicarbazide-sensitive+amine+oxidases%3A+kinetic+consequences&doi=10.1124%2Fmol.107.040964"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Multiple binding sites for substrates and modulators of semicarbazide-sensitive amine oxidases: kinetic consequences</span></div><div class="casAuthors">Holt, Andrew; Smith, David J.; Cendron, Laura; Zanotti, Giuseppe; Rigo, Adelio; Di Paolo, Maria Luisa</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmacology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">73</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">525-538</span>CODEN:
                <span class="NLM_cas:coden">MOPMA3</span>;
        ISSN:<span class="NLM_cas:issn">0026-895X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Human semicarbazide-sensitive amine oxidase (SSAO) is a target for novel anti-inflammatory drugs that inhibit enzymic activity.  However, progress in developing such drugs has been hampered by an incomplete understanding of mechanisms involved in substrate turnover.  We report here results of a comparative study of human and bovine SSAO enzymes that reveal binding of substrates and other ligands to at least two (human) and up to four (bovine) distinct sites on enzyme monomers.  Anaerobic spectroscopy reveals binding of substrates (spermidine and benzylamine) and of an imidazoline site ligand (clonidine) to the reduced active site of bovine SSAO, whereas interactions with oxidized enzyme are evident in kinetic assays and crystn. studies.  Radioligand binding expts. with [3H]tetraphenylphosphonium, an inhibitor of bovine SSAO that binds to an anionic cavity outside the active site, reveal competition with spermidine, benzylamine, and clonidine, indicating that these ligands also bind to this second anionic region.  Kinetic models of bovine SSAO are consistent with one spermidine mol. straddling the active and secondary sites on both oxidized and reduced enzyme, whereas these sites are occupied by two individual mols. of smaller substrates such as benzylamine.  Clonidine and other imidazoline site ligands enhance or inhibit activity as a result of differing affinities for both sites on oxidized and reduced enzyme.  In contrast, although analyses of kinetic data obtained with human SSAO are also consistent with ligands binding to oxidized and reduced enzyme, we obsd. no apparent requirement for substrate or modulator binding to any secondary site to model enzyme behavior.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp9kU0mAyme37Vg90H21EOLACvtfcHk0livN5ta92URCw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXht1ymtrY%253D&md5=2cc605a9cb13c427a8654fd2f14851d0</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1124%2Fmol.107.040964&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fmol.107.040964%26sid%3Dliteratum%253Aachs%26aulast%3DHolt%26aufirst%3DA.%26aulast%3DSmith%26aufirst%3DD.%2BJ.%26aulast%3DCendron%26aufirst%3DL.%26aulast%3DZanotti%26aufirst%3DG.%26aulast%3DRigo%26aufirst%3DA.%26aulast%3DDi%2BPaolo%26aufirst%3DM.%2BL.%26atitle%3DMultiple%2520binding%2520sites%2520for%2520substrates%2520and%2520modulators%2520of%2520semicarbazide-sensitive%2520amine%2520oxidases%253A%2520kinetic%2520consequences%26jtitle%3DMol.%2520Pharmacol.%26date%3D2008%26volume%3D73%26spage%3D525%26epage%3D538%26doi%3D10.1124%2Fmol.107.040964" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref56"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref56'); return false;" data-citation="" class="refNumLink">56</a></strong><div class="NLM_citation" id="cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Holt, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palcic, M. M.</span></span> <span> </span><span class="NLM_article-title">A peroxidase-coupled continuous absorbance plate-reader assay for flavin monoamine oxidases, copper-containing amine oxidases and related enzymes</span>. <i>Nat. Protoc.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">2498</span>– <span class="NLM_lpage">2505</span>, <span class="refDoi"> DOI: 10.1038/nprot.2006.402</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=10.1038%2Fnprot.2006.402" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=17406497" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtFGjtLrJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2006&pages=2498-2505&author=A.+Holtauthor=M.+M.+Palcic&title=A+peroxidase-coupled+continuous+absorbance+plate-reader+assay+for+flavin+monoamine+oxidases%2C+copper-containing+amine+oxidases+and+related+enzymes&doi=10.1038%2Fnprot.2006.402"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">A peroxidase-coupled continuous absorbance plate-reader assay for flavin monoamine oxidases, copper-containing amine oxidases and related enzymes</span></div><div class="casAuthors">Holt, Andrew; Palcic, Monica M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Protocols</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2498-2505</span>CODEN:
                <span class="NLM_cas:coden">NPARDW</span>;
        ISSN:<span class="NLM_cas:issn">1750-2799</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">This absorbance plate-reader-based assay is suitable for the examn. of monoamine oxidase and copper amine oxidase activities vs. numerous substrates.  The assay is robust, continuous, rapid, highly quant., reasonably sensitive, inexpensive and suitable for automation.  In the presence of a suitable amine substrate, amine oxidase enzymes generate hydrogen peroxide, which then drives the peroxidase-dependent oxidn. of 4-aminoantipyrine.  A subsequent interaction with vanillic acid generates stoichiometric amts. of a red quinoneimine dye, the appearance of which is monitored at 498 nm.  An alternative procedure in which vanillic acid is replaced by 2,4-dichlorophenol enhances sensitivity but precludes the measurement of monoamine oxidases due to inhibition of these enzymes by dichlorophenol.  Some substrates with low redox potentials, such as catecholamines, are not suitable for inclusion in this assay.  A researcher familiar with the procedure can manually generate data for 30 full kinetic curves, composed of ten triplicate points, in 8 h.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrM4Zljfb0I57Vg90H21EOLACvtfcHk0livN5ta92URCw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtFGjtLrJ&md5=e226ec15739a0cadb733639303e35609</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1038%2Fnprot.2006.402&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnprot.2006.402%26sid%3Dliteratum%253Aachs%26aulast%3DHolt%26aufirst%3DA.%26aulast%3DPalcic%26aufirst%3DM.%2BM.%26atitle%3DA%2520peroxidase-coupled%2520continuous%2520absorbance%2520plate-reader%2520assay%2520for%2520flavin%2520monoamine%2520oxidases%252C%2520copper-containing%2520amine%2520oxidases%2520and%2520related%2520enzymes%26jtitle%3DNat.%2520Protoc.%26date%3D2006%26volume%3D1%26spage%3D2498%26epage%3D2505%26doi%3D10.1038%2Fnprot.2006.402" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref57"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref57'); return false;" data-citation="" class="refNumLink">57</a></strong><div class="NLM_citation" id="cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Copeland, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Basavapathruni, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moyer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scott, M. P.</span></span> <span> </span><span class="NLM_article-title">Impact of enzyme concentration and residence time on apparent activity recovery in jump dilution analysis</span>. <i>Anal. Biochem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>416</i></span>,  <span class="NLM_fpage">206</span>– <span class="NLM_lpage">210</span>, <span class="refDoi"> DOI: 10.1016/j.ab.2011.05.029</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=10.1016%2Fj.ab.2011.05.029" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=21669181" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=1%3ACAS%3A528%3ADC%252BC3MXptVakurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=416&publication_year=2011&pages=206-210&author=R.+A.+Copelandauthor=A.+Basavapathruniauthor=M.+Moyerauthor=M.+P.+Scott&title=Impact+of+enzyme+concentration+and+residence+time+on+apparent+activity+recovery+in+jump+dilution+analysis&doi=10.1016%2Fj.ab.2011.05.029"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">Impact of enzyme concentration and residence time on apparent activity recovery in jump dilution analysis</span></div><div class="casAuthors">Copeland, Robert A.; Basavapathruni, Aravind; Moyer, Mikel; Scott, Margaret Porter</div><div class="citationInfo"><span class="NLM_cas:title">Analytical Biochemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">416</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">206-210</span>CODEN:
                <span class="NLM_cas:coden">ANBCA2</span>;
        ISSN:<span class="NLM_cas:issn">0003-2697</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Jump diln. anal. is commonly used to evaluate the reversibility of inhibition and to quantify the residence time of the inhibitor-enzyme complex.  During hit and lead characterization, one sometimes observes apparently linear progress curves after jump diln. that display activity recoveries that are intermediate between those expected for fully reversible and irreversible inhibition.  Computer simulations of progress curves after jump diln. indicate that seemingly linear progress curves can result when dealing with tight-binding inhibitors if substoichiometric concns. of inhibitor are preincubated with enzyme.  In this situation, the activity recovered is comparable to that expected for instantaneously reversible inhibitors.  In addn., simulations demonstrate that intermediate values of activity recovery may be obsd. for compds. with modestly slow dissocn. rates (i.e., residence times >0 min but ≤20 min) when the attending curvature of the data is not accounted for.  The observation of intermediate values of recovery can, thus, serve as an indication of either modest residence time or a contaminating inactivator within an inhibitor sample, in either case prompting greater scrutiny of the test compd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpMe9Zt5K_fKrVg90H21EOLACvtfcHk0li8jV3rCudtbg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXptVakurk%253D&md5=4bb34803356e35d7a2de0de4d50bd90a</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1016%2Fj.ab.2011.05.029&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ab.2011.05.029%26sid%3Dliteratum%253Aachs%26aulast%3DCopeland%26aufirst%3DR.%2BA.%26aulast%3DBasavapathruni%26aufirst%3DA.%26aulast%3DMoyer%26aufirst%3DM.%26aulast%3DScott%26aufirst%3DM.%2BP.%26atitle%3DImpact%2520of%2520enzyme%2520concentration%2520and%2520residence%2520time%2520on%2520apparent%2520activity%2520recovery%2520in%2520jump%2520dilution%2520analysis%26jtitle%3DAnal.%2520Biochem.%26date%3D2011%26volume%3D416%26spage%3D206%26epage%3D210%26doi%3D10.1016%2Fj.ab.2011.05.029" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref58"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref58'); return false;" data-citation="" class="refNumLink">58</a></strong><div class="NLM_citation" id="cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">O’Donoghue, R. J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knight, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richards, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prêle, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lau, H. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jarnicki, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bozinovski, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vlahos, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thiem, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKenzie, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stumbles, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laurent, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McAnulty, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rose-John, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, G. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ernst, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mutsaers, S. E.</span></span> <span> </span><span class="NLM_article-title">Genetic partitioning of interleukin-6 signalling in mice dissociates Stat3 from Smad3-mediated lung fibrosis</span>. <i>EMBO Mol. Med.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">939</span>– <span class="NLM_lpage">951</span>, <span class="refDoi"> DOI: 10.1002/emmm.201100604</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=10.1002%2Femmm.201100604" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=22684844" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht1ylurzF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2012&pages=939-951&author=R.+J.+J.+O%E2%80%99Donoghueauthor=D.+A.+Knightauthor=C.+D.+Richardsauthor=C.+M.+Pr%C3%AAleauthor=H.+L.+Lauauthor=A.+G.+Jarnickiauthor=J.+Jonesauthor=S.+Bozinovskiauthor=R.+Vlahosauthor=S.+Thiemauthor=B.+S.+McKenzieauthor=B.+Wangauthor=P.+Stumblesauthor=G.+J.+Laurentauthor=R.+J.+McAnultyauthor=S.+Rose-Johnauthor=H.+J.+Zhuauthor=G.+P.+Andersonauthor=M.+R.+Ernstauthor=S.+E.+Mutsaers&title=Genetic+partitioning+of+interleukin-6+signalling+in+mice+dissociates+Stat3+from+Smad3-mediated+lung+fibrosis&doi=10.1002%2Femmm.201100604"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">Genetic partitioning of interleukin-6 signalling in mice dissociates Stat3 from Smad3-mediated lung fibrosis</span></div><div class="casAuthors">O'Donoghue, Robert J. J.; Knight, Darryl A.; Richards, Carl D.; Prele, Cecilia M.; Lau, Hui Ling; Jarnicki, Andrew G.; Jones, Jessica; Bozinovski, Steven; Vlahos, Ross; Thiem, Stefan; McKenzie, Brent S.; Wang, Bo; Stumbles, Philip; Laurent, Geoffrey J.; McAnulty, Robin J.; Rose-John, Stefan; Zhu, Hong Jian; Anderson, Gary P.; Ernst, Matthias R.; Mutsaers, Steven E.</div><div class="citationInfo"><span class="NLM_cas:title">EMBO Molecular Medicine</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">939-951</span>CODEN:
                <span class="NLM_cas:coden">EMMMAM</span>;
        ISSN:<span class="NLM_cas:issn">1757-4684</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Idiopathic pulmonary fibrosis (IPF) is a fatal disease that is unresponsive to current therapies and characterized by excessive collagen deposition and subsequent fibrosis.  While inflammatory cytokines, including interleukin (IL)-6, are elevated in IPF, the mol. mechanisms that underlie this disease are incompletely understood, although the development of fibrosis is believed to depend on canonical transforming growth factor (TGF)-β signalling.  We examd. bleomycin-induced inflammation and fibrosis in mice carrying a mutation in the shared IL-6 family receptor gp130.  Using genetic complementation, we directly correlate the extent of IL-6-mediated, excessive Stat3 activity with inflammatory infiltrates in the lung and the severity of fibrosis in corresponding gp130757F mice.  The extent of fibrosis was attenuated in B lymphocyte-deficient gp130757F;μMT-/- compd. mutant mice, but fibrosis still occurred in their Smad3-/- counterparts consistent with the capacity of excessive Stat3 activity to induce collagen 1α1 gene transcription independently of canonical TGF-β/Smad3 signalling.  These findings are of therapeutic relevance, since we confirmed abundant STAT3 activation in fibrotic lungs from IPF patients and showed that genetic redn. of Stat3 protected mice from bleomycin-induced lung fibrosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoXc6SZBKl3w7Vg90H21EOLACvtfcHk0li8jV3rCudtbg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht1ylurzF&md5=2906a89576dfc4a7caccb1df7bd5cd66</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1002%2Femmm.201100604&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Femmm.201100604%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Donoghue%26aufirst%3DR.%2BJ.%2BJ.%26aulast%3DKnight%26aufirst%3DD.%2BA.%26aulast%3DRichards%26aufirst%3DC.%2BD.%26aulast%3DPr%25C3%25AAle%26aufirst%3DC.%2BM.%26aulast%3DLau%26aufirst%3DH.%2BL.%26aulast%3DJarnicki%26aufirst%3DA.%2BG.%26aulast%3DJones%26aufirst%3DJ.%26aulast%3DBozinovski%26aufirst%3DS.%26aulast%3DVlahos%26aufirst%3DR.%26aulast%3DThiem%26aufirst%3DS.%26aulast%3DMcKenzie%26aufirst%3DB.%2BS.%26aulast%3DWang%26aufirst%3DB.%26aulast%3DStumbles%26aufirst%3DP.%26aulast%3DLaurent%26aufirst%3DG.%2BJ.%26aulast%3DMcAnulty%26aufirst%3DR.%2BJ.%26aulast%3DRose-John%26aufirst%3DS.%26aulast%3DZhu%26aufirst%3DH.%2BJ.%26aulast%3DAnderson%26aufirst%3DG.%2BP.%26aulast%3DErnst%26aufirst%3DM.%2BR.%26aulast%3DMutsaers%26aufirst%3DS.%2BE.%26atitle%3DGenetic%2520partitioning%2520of%2520interleukin-6%2520signalling%2520in%2520mice%2520dissociates%2520Stat3%2520from%2520Smad3-mediated%2520lung%2520fibrosis%26jtitle%3DEMBO%2520Mol.%2520Med.%26date%3D2012%26volume%3D4%26spage%3D939%26epage%3D951%26doi%3D10.1002%2Femmm.201100604" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7a','cit7b'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11a','cit11b'],'ref12':['cit12a','cit12b'],'ref13':['cit13a','cit13b'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17a','cit17b'],'ref18':['cit18a','cit18b'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21a','cit21b'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27a','cit27b'],'ref28':['cit28a','cit28b'],'ref29':['cit29','cit29b'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33a','cit33b','cit33c'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50'],'ref51':['cit51'],'ref52':['cit52'],'ref53':['cit53'],'ref54':['cit54'],'ref55':['cit55'],'ref56':['cit56'],'ref57':['cit57'],'ref58':['cit58']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 8 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Wenfang Xiong, Fuxing Shi, Ruixiang Cheng, Baiyao Zhu, Lu Wang, Pengquan Chen, Hongming Lou, Wanqing Wu, Chaorong Qi, Ming Lei, <span class="NLM_string-name hlFld-ContribAuthor">Huanfeng Jiang</span>. </span><span class="cited-content_cbyCitation_article-title">Palladium-Catalyzed Highly Regioselective Hydrocarboxylation of Alkynes with Carbon Dioxide. </span><span class="cited-content_cbyCitation_journal-name">ACS Catalysis</span><span> <strong>2020,</strong> <em>10 </em>
                                    (14)
                                     , 7968-7978. <a href="https://doi.org/10.1021/acscatal.0c01687" title="DOI URL">https://doi.org/10.1021/acscatal.0c01687</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acscatal.0c01687&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facscatal.0c01687%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Catalysis%26atitle%3DPalladium-Catalyzed%252BHighly%252BRegioselective%252BHydrocarboxylation%252Bof%252BAlkynes%252Bwith%252BCarbon%252BDioxide%26aulast%3DXiong%26aufirst%3DWenfang%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D14042020%26date%3D24062020%26date%3D07072020%26date%3D25062020%26volume%3D10%26issue%3D14%26spage%3D7968%26epage%3D7978" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">F. Anthony Romero, Christopher T. Jones, Yingzi Xu, Martijn Fenaux, <span class="NLM_string-name hlFld-ContribAuthor">Randall L. Halcomb</span>. </span><span class="cited-content_cbyCitation_article-title">The Race to Bash NASH: Emerging Targets and Drug Development in a Complex Liver Disease. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (10)
                                     , 5031-5073. <a href="https://doi.org/10.1021/acs.jmedchem.9b01701" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b01701</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b01701&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.9b01701%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DThe%252BRace%252Bto%252BBash%252BNASH%25253A%252BEmerging%252BTargets%252Band%252BDrug%252BDevelopment%252Bin%252Ba%252BComplex%252BLiver%252BDisease%26aulast%3DRomero%26aufirst%3DF.%2BAnthony%26date%3D2020%26date%3D2020%26date%3D2019%26date%3D14102019%26date%3D29012020%26date%3D13012020%26volume%3D63%26issue%3D10%26spage%3D5031%26epage%3D5073" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Simion C.  Dinca</span>, <span class="hlFld-ContribAuthor ">Daniel  Greiner</span>, <span class="hlFld-ContribAuthor ">Keren  Weidenfeld</span>, <span class="hlFld-ContribAuthor ">Laura  Bond</span>, <span class="hlFld-ContribAuthor ">Dalit  Barkan</span>, <span class="hlFld-ContribAuthor ">Cheryl L.  Jorcyk</span>. </span><span class="cited-content_cbyCitation_article-title">Novel mechanism for OSM-promoted extracellular matrix remodeling in breast cancer: LOXL2 upregulation and subsequent ECM alignment. </span><span class="cited-content_cbyCitation_journal-name">Breast Cancer Research</span><span> <strong>2021,</strong> <em>23 </em>
                                    (1)
                                     <a href="https://doi.org/10.1186/s13058-021-01430-x" title="DOI URL">https://doi.org/10.1186/s13058-021-01430-x</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1186/s13058-021-01430-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1186%2Fs13058-021-01430-x%26sid%3Dliteratum%253Aachs%26jtitle%3DBreast%2520Cancer%2520Research%26atitle%3DNovel%252Bmechanism%252Bfor%252BOSM-promoted%252Bextracellular%252Bmatrix%252Bremodeling%252Bin%252Bbreast%252Bcancer%25253A%252BLOXL2%252Bupregulation%252Band%252Bsubsequent%252BECM%252Balignment%26aulast%3DDinca%26aufirst%3DSimion%2BC.%26date%3D2021%26date%3D2021%26volume%3D23%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Gang  Liu</span>, <span class="hlFld-ContribAuthor ">Ashleigh M.  Philp</span>, <span class="hlFld-ContribAuthor ">Tamera  Corte</span>, <span class="hlFld-ContribAuthor ">Mark A.  Travis</span>, <span class="hlFld-ContribAuthor ">Heidi  Schilter</span>, <span class="hlFld-ContribAuthor ">Nicole G.  Hansbro</span>, <span class="hlFld-ContribAuthor ">Chris J.  Burns</span>, <span class="hlFld-ContribAuthor ">Mathew S.  Eapen</span>, <span class="hlFld-ContribAuthor ">Sukhwinder S.  Sohal</span>, <span class="hlFld-ContribAuthor ">Janette K.  Burgess</span>, <span class="hlFld-ContribAuthor ">Philip M.  Hansbro</span>. </span><span class="cited-content_cbyCitation_article-title">Therapeutic targets in lung tissue remodelling and fibrosis. </span><span class="cited-content_cbyCitation_journal-name">Pharmacology & Therapeutics</span><span> <strong>2021,</strong> <em>225 </em>, 107839. <a href="https://doi.org/10.1016/j.pharmthera.2021.107839" title="DOI URL">https://doi.org/10.1016/j.pharmthera.2021.107839</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.pharmthera.2021.107839&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.pharmthera.2021.107839%26sid%3Dliteratum%253Aachs%26jtitle%3DPharmacology%2520%2526%2520Therapeutics%26atitle%3DTherapeutic%252Btargets%252Bin%252Blung%252Btissue%252Bremodelling%252Band%252Bfibrosis%26aulast%3DLiu%26aufirst%3DGang%26date%3D2021%26volume%3D225%26spage%3D107839" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Da-Yun  Luo</span>, <span class="hlFld-ContribAuthor ">Xing-Mei  Hu</span>, <span class="hlFld-ContribAuthor ">Rong  Huang</span>, <span class="hlFld-ContribAuthor ">Shi-Sheng  Cui</span>, <span class="hlFld-ContribAuthor ">Sheng-Jiao  Yan</span>. </span><span class="cited-content_cbyCitation_article-title">Base-promoted relay reaction of heterocyclic ketene aminals with o-difluorobenzene derivatives for the highly site-selective synthesis of functionalized indoles. </span><span class="cited-content_cbyCitation_journal-name">Tetrahedron</span><span> <strong>2021,</strong> <em>92 </em>, 132275. <a href="https://doi.org/10.1016/j.tet.2021.132275" title="DOI URL">https://doi.org/10.1016/j.tet.2021.132275</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.tet.2021.132275&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.tet.2021.132275%26sid%3Dliteratum%253Aachs%26jtitle%3DTetrahedron%26atitle%3DBase-promoted%252Brelay%252Breaction%252Bof%252Bheterocyclic%252Bketene%252Baminals%252Bwith%252Bo-difluorobenzene%252Bderivatives%252Bfor%252Bthe%252Bhighly%252Bsite-selective%252Bsynthesis%252Bof%252Bfunctionalized%252Bindoles%26aulast%3DLuo%26aufirst%3DDa-Yun%26date%3D2021%26volume%3D92%26spage%3D132275" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yordanos F.I.  Setargew</span>, <span class="hlFld-ContribAuthor ">Kaitlin  Wyllie</span>, <span class="hlFld-ContribAuthor ">Rhiannon D.  Grant</span>, <span class="hlFld-ContribAuthor ">Jessica L.  Chitty</span>, <span class="hlFld-ContribAuthor ">Thomas R.  Cox</span>. </span><span class="cited-content_cbyCitation_article-title">Targeting Lysyl Oxidase Family Meditated Matrix Cross-Linking as an Anti-Stromal Therapy in Solid Tumours. </span><span class="cited-content_cbyCitation_journal-name">Cancers</span><span> <strong>2021,</strong> <em>13 </em>
                                    (3)
                                     , 491. <a href="https://doi.org/10.3390/cancers13030491" title="DOI URL">https://doi.org/10.3390/cancers13030491</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/cancers13030491&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fcancers13030491%26sid%3Dliteratum%253Aachs%26jtitle%3DCancers%26atitle%3DTargeting%252BLysyl%252BOxidase%252BFamily%252BMeditated%252BMatrix%252BCross-Linking%252Bas%252Ban%252BAnti-Stromal%252BTherapy%252Bin%252BSolid%252BTumours%26aulast%3DSetargew%26aufirst%3DYordanos%2BF.I.%26date%3D2021%26date%3D2021%26volume%3D13%26issue%3D3%26spage%3D491" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Zhenjun  Deng</span>, <span class="hlFld-ContribAuthor ">Mark W.  Fear</span>, <span class="hlFld-ContribAuthor ">Yu  Suk Choi</span>, <span class="hlFld-ContribAuthor ">Fiona M.  Wood</span>, <span class="hlFld-ContribAuthor ">Amira  Allahham</span>, <span class="hlFld-ContribAuthor ">Steven E.  Mutsaers</span>, <span class="hlFld-ContribAuthor ">Cecilia M.  Prêle</span>. </span><span class="cited-content_cbyCitation_article-title">The extracellular matrix and mechanotransduction in pulmonary fibrosis. </span><span class="cited-content_cbyCitation_journal-name">The International Journal of Biochemistry & Cell Biology</span><span> <strong>2020,</strong> <em>126 </em>, 105802. <a href="https://doi.org/10.1016/j.biocel.2020.105802" title="DOI URL">https://doi.org/10.1016/j.biocel.2020.105802</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.biocel.2020.105802&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.biocel.2020.105802%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520International%2520Journal%2520of%2520Biochemistry%2520%2526%2520Cell%2520Biology%26atitle%3DThe%252Bextracellular%252Bmatrix%252Band%252Bmechanotransduction%252Bin%252Bpulmonary%252Bfibrosis%26aulast%3DDeng%26aufirst%3DZhenjun%26date%3D2020%26volume%3D126%26spage%3D105802" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jessica L.  Chitty</span>, <span class="hlFld-ContribAuthor ">Yordanos F.I.  Setargew</span>, <span class="hlFld-ContribAuthor ">Thomas R.  Cox</span>. </span><span class="cited-content_cbyCitation_article-title">Targeting the lysyl oxidases in tumour desmoplasia. </span><span class="cited-content_cbyCitation_journal-name">Biochemical Society Transactions</span><span> <strong>2019,</strong> <em>47 </em>
                                    (6)
                                     , 1661-1678. <a href="https://doi.org/10.1042/BST20190098" title="DOI URL">https://doi.org/10.1042/BST20190098</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1042/BST20190098&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1042%2FBST20190098%26sid%3Dliteratum%253Aachs%26jtitle%3DBiochemical%2520Society%2520Transactions%26atitle%3DTargeting%252Bthe%252Blysyl%252Boxidases%252Bin%252Btumour%252Bdesmoplasia%26aulast%3DChitty%26aufirst%3DJessica%2BL.%26date%3D2019%26date%3D2019%26volume%3D47%26issue%3D6%26spage%3D1661%26epage%3D1678" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-21/acs.jmedchem.9b01283/20191108/images/medium/jm9b01283_0012.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-21/acs.jmedchem.9b01283/20191108/images/large/jm9b01283_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01283&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-21/acs.jmedchem.9b01283/20191108/images/medium/jm9b01283_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-21/acs.jmedchem.9b01283/20191108/images/large/jm9b01283_0001.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Chemical structures of BAPN, CCT365623 (<b>1</b>), PAT-1251 (<b>2</b>), and <b>PXS-5153A</b> (<b>3</b>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-21/acs.jmedchem.9b01283/20191108/images/large/jm9b01283_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01283&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-21/acs.jmedchem.9b01283/20191108/images/medium/jm9b01283_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-21/acs.jmedchem.9b01283/20191108/images/large/jm9b01283_0008.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Proposed Mechanism of Inhibition of SSAO/VAP-1 by Fluoroallylamine-Based compounds<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-21/acs.jmedchem.9b01283/20191108/images/large/jm9b01283_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01283&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Scheme shows the proposed mechanism of inhibition of SSAO by fluoroallylamine-based inhibitors. Black arrows portray the normal catalytic turnover of amine substrates, and the red arrows show how the installation of a vinyl fluoride into the molecule can redirect the pathway, resulting in the covalent alkylation of the protein active site. “Nu”: nucleophilic amino acid residue in the active site.</p></p></figure><figure data-id="fig2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-21/acs.jmedchem.9b01283/20191108/images/medium/jm9b01283_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-21/acs.jmedchem.9b01283/20191108/images/large/jm9b01283_0002.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Identification of a suitable fluoroallylamine configuration.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-21/acs.jmedchem.9b01283/20191108/images/large/jm9b01283_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01283&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-21/acs.jmedchem.9b01283/20191108/images/medium/jm9b01283_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-21/acs.jmedchem.9b01283/20191108/images/large/jm9b01283_0009.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of 1,2,3-Triazole-Based Inhibitors <b>10a–h</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-21/acs.jmedchem.9b01283/20191108/images/large/jm9b01283_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01283&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) propargyl bromide, K<sub>2</sub>CO<sub>3</sub>, MeCN, rt; (b) MsCl, Et<sub>3</sub>N, acetone, then LiBr, 0 °C to rt; (c) NaN<sub>3</sub>, DMF, rt; (d) CuSO<sub>4</sub>(H<sub>2</sub>O)<sub>5</sub>, sodium ascorbate, <i>t</i>-BuOH, rt; (e) (i) TFA, DCM, rt; (ii) HCl, Et<sub>2</sub>O/EtOAc, rt.</p></p></figure><figure data-id="fig3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-21/acs.jmedchem.9b01283/20191108/images/medium/jm9b01283_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-21/acs.jmedchem.9b01283/20191108/images/large/jm9b01283_0003.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Variation of the linker and core regions.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-21/acs.jmedchem.9b01283/20191108/images/large/jm9b01283_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01283&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-21/acs.jmedchem.9b01283/20191108/images/medium/jm9b01283_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-21/acs.jmedchem.9b01283/20191108/images/large/jm9b01283_0004.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Mechanistic studies on <b>4</b> (<b>PXS-5120A</b>). (A) LOXL2 inhibition by <b>PXS-5120A</b>, which is time-dependent. (B) Substrate competition; rising concentrations of the substrate putrescine compete with LOXL2 inhibition by <b>PXS-5120A</b>, suggesting that <b>PXS-5120A</b> acts directly through interacting with the catalytic cofactor. (C) Jump dilution; 1 h soak with an inhibitor (at a concentration equivalent to 30 × IC<sub>50</sub>) followed by a 100-fold dilution, before addition of putrescine. Assay readout at 30 min after substrate addition. No significant return of activity was observed for either BAPN or <b>PXS-5120A</b>. (D) Washout experiment using bound LOXL2; time course of substrate turnover post washout showing the return of enzyme activity over time after exposure to the inhibitor. Neither <b>PXS-5120A</b> nor BAPN (plots overlapping) showed any return of activity over background after 30 min. <i>des</i>-Fluoro <b>PXS-5120A</b>, <b>12n</b>, shows a return of enzyme activity to a level of ∼75% of that observed where no inhibitor was present pre-washout.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-21/acs.jmedchem.9b01283/20191108/images/large/jm9b01283_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01283&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch3" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-21/acs.jmedchem.9b01283/20191108/images/medium/jm9b01283_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-21/acs.jmedchem.9b01283/20191108/images/large/jm9b01283_0010.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of 2-Methyl, 3-Aryl Indole-Based Inhibitors <b>12b–12o</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-21/acs.jmedchem.9b01283/20191108/images/large/jm9b01283_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01283&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) NBS, then DMAP, Boc<sub>2</sub>O, CH<sub>2</sub>Cl<sub>2</sub>, rt; (b) aryl boronic acid/ester, Pd(PPh<sub>3</sub>)<sub>4</sub>, K<sub>2</sub>CO<sub>3</sub> (aq), dioxane, 80 °C, then TFA, CH<sub>2</sub>Cl<sub>2</sub>, rt; (c) Cs<sub>2</sub>CO<sub>3</sub>, DMF, rt; (d) LiOH, MeOH, THF, H<sub>2</sub>O, rt; (e) if R = CONMe<sub>2</sub> group, then Me<sub>2</sub>NH, HATU, DIPEA, DMF, rt; (f) either 2 M HCl (in Et<sub>2</sub>O), MeOH, or TFA, CH<sub>2</sub>Cl<sub>2</sub>, then HCl (in Et<sub>2</sub>O).</p></p></figure><figure data-id="fig5" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-21/acs.jmedchem.9b01283/20191108/images/medium/jm9b01283_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-21/acs.jmedchem.9b01283/20191108/images/large/jm9b01283_0005.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Mouse plasma profile of <b>PXS-5120</b> (free base of <b>PXS-5120A</b>) after oral (20 mg/kg) administration of the corresponding ethyl ester, <b>PXS-5129A</b>. Pharmacokinetic analysis of <b>PXS-5129A</b> and <b>PXS-5120</b> in BALB/c mice, showing the hydrolysis of <b>PXS-5129A</b> in vivo to afford therapeutically relevant plasma concentrations of <b>PXS-5120</b>. The plasma concentrations of both <b>PXS-5129A</b> and <b>PXS-5120</b> were quantified by LCMS/MS. Each data point represents an average of 3 animals.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-21/acs.jmedchem.9b01283/20191108/images/large/jm9b01283_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01283&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-21/acs.jmedchem.9b01283/20191108/images/medium/jm9b01283_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-21/acs.jmedchem.9b01283/20191108/images/large/jm9b01283_0006.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Inhibition of CCl<sub>4</sub>-induced liver fibrosis by <b>PXS-5120A</b>/<b>PXS-5129A</b>. Quantitative measurement of fibrosis in a 6 week model of CCl<sub>4</sub>-induced liver fibrosis in BALB/c mice, and the anti-fibrotic effects of <b>PXS-5129A</b>, BAPN, and imatinib. The area of fibrosis was quantified by staining for α-SMA and is measured as a percentage of the total liver area. <b>PXS-5129A</b> reduces fibrosis when dosed both prophylactically at 15 mg/kg (6 weeks, blue bar) and therapeutically at 5 and 15 mg/kg (weeks 4–6, green bars). Results are expressed as mean ± SEM. #<i>p</i> < 0.05, ##<i>p</i> < 0.01 and ###<i>p</i> < 0.001, vs group 2 (CCl<sub>4</sub> + vehicle); data analysis was performed by one-way ANOVA followed by Dunnett’s multiple comparison test.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-21/acs.jmedchem.9b01283/20191108/images/large/jm9b01283_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01283&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-21/acs.jmedchem.9b01283/20191108/images/medium/jm9b01283_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-21/acs.jmedchem.9b01283/20191108/images/large/jm9b01283_0007.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Inhibition of bleomycin-induced lung fibrosis by <b>PXS-5120A</b>/<b>PXS-5129A</b>. Determination of the anti-fibrotic effects of <b>PXS-5129A</b> and imatinib in a 28 day bleomycin-induced lung fibrosis in C57BL/6 mice. Analysis of the amount of fibrosis as measured by the Ashcroft score.<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a><b>PXS-5129A</b> reduces fibrosis when dosed therapeutically at 15 mg/kg (from day 7 onwards, blue bars). Results are expressed as mean ± SEM. #<i>p</i> < 0.05, ##<i>p</i> < 0.01 and ###<i>p</i> < 0.001, vs group 2 (bleo + vehicle); data analysis was performed by one-way ANOVA followed by Dunnett’s multiple comparison test.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-21/acs.jmedchem.9b01283/20191108/images/large/jm9b01283_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01283&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i70">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_10175" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_10175" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 58 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dostert, P. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benedetti, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tipton, K. F.</span></span> <span> </span><span class="NLM_article-title">Interactions of monoamine oxidase with substrates and inhibitors</span>. <i>Med. Res. Rev.</i> <span class="NLM_year" style="font-weight: bold;">1989</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">45</span>– <span class="NLM_lpage">89</span>, <span class="refDoi"> DOI: 10.1002/med.2610090104</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=10.1002%2Fmed.2610090104" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=2644497" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=1%3ACAS%3A528%3ADyaL1MXhtlSrtbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=1989&pages=45-89&author=P.+L.+Dostertauthor=M.+S.+Benedettiauthor=K.+F.+Tipton&title=Interactions+of+monoamine+oxidase+with+substrates+and+inhibitors&doi=10.1002%2Fmed.2610090104"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Interactions of monoamine oxidase with substrates and inhibitors</span></div><div class="casAuthors">Dostert, Philippe L.; Strolin Benedetti, Margherita; Tipton, Keith F.</div><div class="citationInfo"><span class="NLM_cas:title">Medicinal Research Reviews</span>
        (<span class="NLM_cas:date">1989</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">45-89</span>CODEN:
                <span class="NLM_cas:coden">MRREDD</span>;
        ISSN:<span class="NLM_cas:issn">0198-6325</span>.
    </div><div class="casAbstract">A review with 312 refs. on the substrate and inhibitor interactions of the A and B forms of monoamine oxidase (MAO).  The topics discussed include mechanistic and stereochem. aspects of MAO-substrate interactions, MAO-B and MAO-A substrate specificities, and kinetic and mechanistic aspects of MAO interaction with noncovalent and mechanism-based inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqrnQPMDeH2erVg90H21EOLACvtfcHk0lga7rgT0A0Rnw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL1MXhtlSrtbs%253D&md5=784879e53b063fc1550f9b8dd9c0298d</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1002%2Fmed.2610090104&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fmed.2610090104%26sid%3Dliteratum%253Aachs%26aulast%3DDostert%26aufirst%3DP.%2BL.%26aulast%3DBenedetti%26aufirst%3DM.%2BS.%26aulast%3DTipton%26aufirst%3DK.%2BF.%26atitle%3DInteractions%2520of%2520monoamine%2520oxidase%2520with%2520substrates%2520and%2520inhibitors%26jtitle%3DMed.%2520Res.%2520Rev.%26date%3D1989%26volume%3D9%26spage%3D45%26epage%3D89%26doi%3D10.1002%2Fmed.2610090104" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Holtta, E.</span></span> <span> </span><span class="NLM_article-title">Oxidation of spermidine and spermine in rat liver: purification and properties of polyamine oxidase</span>. <i>Biochemistry</i> <span class="NLM_year" style="font-weight: bold;">1977</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">91</span>– <span class="NLM_lpage">100</span>, <span class="refDoi"> DOI: 10.1021/bi00620a015</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bi00620a015" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=1%3ACAS%3A528%3ADyaE2sXmslarsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=1977&pages=91-100&author=E.+Holtta&title=Oxidation+of+spermidine+and+spermine+in+rat+liver%3A+purification+and+properties+of+polyamine+oxidase&doi=10.1021%2Fbi00620a015"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Oxidation of spermidine and spermine in rat liver:  purification and properties of polyamine oxidase</span></div><div class="casAuthors">Holtta, Erkki</div><div class="citationInfo"><span class="NLM_cas:title">Biochemistry</span>
        (<span class="NLM_cas:date">1977</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">91-100</span>CODEN:
                <span class="NLM_cas:coden">BICHAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-2960</span>.
    </div><div class="casAbstract">A novel enzyme responsible for the oxidn. of spermidine and spermine was found in rat liver.  Spermidine is degraded to putrescine and 3-aminopropionaldehyde, and spermine is cleaved to spermidine and 3-aminopropionaldehyde.  A single enzyme catalyzing both reactions and designated as polyamine oxidase (I) was purified 4000-fold to electrophoretic homogeneity.  I appears to be a flavoprotein, contg. FAD as a prosthetic group.  H2O2 is evolved in the reaction and no other electron acceptors except mol. O were found.  The mol. wt. of I is approx. 60,000 and the sedimentation coeff. 4.5 S.  I appears to be a single polypeptide chain since no evidence for structural subunits was obtained.  I is sensitive to SH and carbonyl group reagents.  The optimum pH value for the oxidn. of polyamines was ∼10.  The reaction velocities were enhanced by various aldehydes, esp. certain arom. aldehydes.  I appears to be localized in peroxisomes of liver cells, although the existence of an isoenzyme in the cytosolic fraction was not definitively ruled out.  No marked changes were obsd. in the activity of I oxidase in rat liver after partial hepatectomy, CCl4 poisoning, and after treatment with growth hormone or thioacetamide, conditions which are known to alter profoundly the metab. and accumulation of polyamines.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq7b2EGIYg_drVg90H21EOLACvtfcHk0lgLgjhNdHlZHg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaE2sXmslarsA%253D%253D&md5=506a5112dd6ef581cab177eb07a4fd54</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1021%2Fbi00620a015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi00620a015%26sid%3Dliteratum%253Aachs%26aulast%3DHoltta%26aufirst%3DE.%26atitle%3DOxidation%2520of%2520spermidine%2520and%2520spermine%2520in%2520rat%2520liver%253A%2520purification%2520and%2520properties%2520of%2520polyamine%2520oxidase%26jtitle%3DBiochemistry%26date%3D1977%26volume%3D16%26spage%3D91%26epage%3D100%26doi%3D10.1021%2Fbi00620a015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lan, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matson, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mulligan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whetstine, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cole, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casero, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, Y.</span></span> <span> </span><span class="NLM_article-title">Histone demethylation mediated by the nuclear amine oxidase homolog LSD1</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>119</i></span>,  <span class="NLM_fpage">941</span>– <span class="NLM_lpage">953</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2004.12.012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=10.1016%2Fj.cell.2004.12.012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=15620353" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=1%3ACAS%3A528%3ADC%252BD2MXltlSitg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=119&publication_year=2004&pages=941-953&author=Y.+Shiauthor=F.+Lanauthor=C.+Matsonauthor=P.+Mulliganauthor=J.+R.+Whetstineauthor=P.+A.+Coleauthor=R.+A.+Caseroauthor=Y.+Shi&title=Histone+demethylation+mediated+by+the+nuclear+amine+oxidase+homolog+LSD1&doi=10.1016%2Fj.cell.2004.12.012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Histone demethylation mediated by the nuclear amine oxidase homolog LSD1</span></div><div class="casAuthors">Shi, Yujiang; Lan, Fei; Matson, Caitlin; Mulligan, Peter; Whetstine, Johnathan R.; Cole, Philip A.; Casero, Robert A.; Shi, Yang</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">119</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">941-953</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Posttranslational modifications of histone N-terminal tails impact chromatin structure and gene transcription.  While the extent of histone acetylation is detd. by both acetyltransferases and deacetylases, it has been unclear whether histone methylation is also regulated by enzymes with opposing activities.  Here, we provide evidence that LSD1 (KIAA0601), a nuclear homolog of amine oxidases, functions as a histone demethylase and transcriptional corepressor.  LSD1 specifically demethylates histone H3 lysine 4, which is linked to active transcription.  Lysine demethylation occurs via an oxidn. reaction that generates formaldehyde.  Importantly, RNAi inhibition of LSD1 causes an increase in H3 lysine 4 methylation and concomitant derepression of target genes, suggesting that LSD1 represses transcription via histone demethylation.  The results thus identify a histone demethylase conserved from S. pombe to human and reveal dynamic regulation of histone methylation by both histone methylases and demethylases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrXHr-8kwGdXrVg90H21EOLACvtfcHk0lgLgjhNdHlZHg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXltlSitg%253D%253D&md5=3474569204255e90a832667ba654748b</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2004.12.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2004.12.012%26sid%3Dliteratum%253Aachs%26aulast%3DShi%26aufirst%3DY.%26aulast%3DLan%26aufirst%3DF.%26aulast%3DMatson%26aufirst%3DC.%26aulast%3DMulligan%26aufirst%3DP.%26aulast%3DWhetstine%26aufirst%3DJ.%2BR.%26aulast%3DCole%26aufirst%3DP.%2BA.%26aulast%3DCasero%26aufirst%3DR.%2BA.%26aulast%3DShi%26aufirst%3DY.%26atitle%3DHistone%2520demethylation%2520mediated%2520by%2520the%2520nuclear%2520amine%2520oxidase%2520homolog%2520LSD1%26jtitle%3DCell%26date%3D2004%26volume%3D119%26spage%3D941%26epage%3D953%26doi%3D10.1016%2Fj.cell.2004.12.012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Finney, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moon, H.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ronnebaum, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lantz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mure, M.</span></span> <span> </span><span class="NLM_article-title">Human copper-dependent amine oxidases</span>. <i>Arch. Biochem. Biophys.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>546</i></span>,  <span class="NLM_fpage">19</span>– <span class="NLM_lpage">32</span>, <span class="refDoi"> DOI: 10.1016/j.abb.2013.12.022</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=10.1016%2Fj.abb.2013.12.022" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=24407025" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=1%3ACAS%3A528%3ADC%252BC2cXksFaisbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=546&publication_year=2014&pages=19-32&author=J.+Finneyauthor=H.-J.+Moonauthor=T.+Ronnebaumauthor=M.+Lantzauthor=M.+Mure&title=Human+copper-dependent+amine+oxidases&doi=10.1016%2Fj.abb.2013.12.022"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Human copper-dependent amine oxidases</span></div><div class="casAuthors">Finney, Joel; Moon, Hee-Jung; Ronnebaum, Trey; Lantz, Mason; Mure, Minae</div><div class="citationInfo"><span class="NLM_cas:title">Archives of Biochemistry and Biophysics</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">546</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">19-32</span>CODEN:
                <span class="NLM_cas:coden">ABBIA4</span>;
        ISSN:<span class="NLM_cas:issn">0003-9861</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Copper amine oxidases (CAOs) are a class of enzymes that contain Cu2+ and a tyrosine-derived quinone cofactor, and catalyze the conversion of a primary amine functional group to an aldehyde, generating H2O2 and NH3 as byproducts.  These enzymes can be classified into 2 non-homologous families: 2,4,5-trihydroxyphenylalanine quinone (TPQ)-dependent CAOs and the lysine tyrosylquinone (LTQ)-dependent lysyl oxidase (LOX) family of proteins.  Here, the authors focus on recent developments in the field of research concerning human CAOs and the LOX family of proteins.  The aberrant expression of these enzymes is linked to inflammation, fibrosis, tumor metastasis/invasion, and other diseases.  Consequently, there is a crit. need to understand the functions of these proteins at the mol. level, so that strategies targeting these enzymes can be developed to combat human diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoxp8xJQhX_qLVg90H21EOLACvtfcHk0lgLgjhNdHlZHg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXksFaisbs%253D&md5=f7ecc08c322917ac6c9bf96636b49575</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1016%2Fj.abb.2013.12.022&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.abb.2013.12.022%26sid%3Dliteratum%253Aachs%26aulast%3DFinney%26aufirst%3DJ.%26aulast%3DMoon%26aufirst%3DH.-J.%26aulast%3DRonnebaum%26aufirst%3DT.%26aulast%3DLantz%26aufirst%3DM.%26aulast%3DMure%26aufirst%3DM.%26atitle%3DHuman%2520copper-dependent%2520amine%2520oxidases%26jtitle%3DArch.%2520Biochem.%2520Biophys.%26date%3D2014%26volume%3D546%26spage%3D19%26epage%3D32%26doi%3D10.1016%2Fj.abb.2013.12.022" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bieganski, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kusche, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lorenz, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hesterberg, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stahlknecht, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feussner, K.</span></span> <span> </span><span class="NLM_article-title">Distribution and properties of human intestinal diamine oxidase and its relevance for the histamine catabolism</span>. <i>Biochim. Biophys. Acta</i> <span class="NLM_year" style="font-weight: bold;">1983</span>,  <span class="NLM_volume"><i>756</i></span>,  <span class="NLM_fpage">196</span>– <span class="NLM_lpage">203</span>, <span class="refDoi"> DOI: 10.1016/0304-4165(83)90092-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=10.1016%2F0304-4165%2883%2990092-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=6403048" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=1%3ACAS%3A528%3ADyaL3sXhsFKqtr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=756&publication_year=1983&pages=196-203&author=T.+Bieganskiauthor=J.+Kuscheauthor=W.+Lorenzauthor=R.+Hesterbergauthor=C.+Stahlknechtauthor=K.+Feussner&title=Distribution+and+properties+of+human+intestinal+diamine+oxidase+and+its+relevance+for+the+histamine+catabolism&doi=10.1016%2F0304-4165%2883%2990092-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Distribution and properties of human intestinal diamine oxidase and its relevance for the histamine catabolism</span></div><div class="casAuthors">Bieganski, Tadeusz; Kusche, Juergen; Lorenz, Wilfried; Hesterberg, Rudolf; Stahlknecht, Carl Detmar; Feussner, Klaus Dieter</div><div class="citationInfo"><span class="NLM_cas:title">Biochimica et Biophysica Acta, General Subjects</span>
        (<span class="NLM_cas:date">1983</span>),
    <span class="NLM_cas:volume">756</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">196-203</span>CODEN:
                <span class="NLM_cas:coden">BBGSB3</span>;
        ISSN:<span class="NLM_cas:issn">0304-4165</span>.
    </div><div class="casAbstract">High activities of diamine oxidase (EC 1.4.3.6) (I) were measured in the intestinal tract of human subjects and of several mammalian species.  I was localized in the mucosa and was distributed primarily in the cytoplasm; the only exception being the guinea pig, where it was located in the particulate fraction.  Despite its instability, I from human colonic mucosa was purified 80-fold.  During the purifn., a sol. monoamine oxidase (EC 1.4.3.4) was sepd. from I.  The pH optima of I for putrescine and histamine were 6.6-7.0 and 6.4-6.6, resp.  Short-chain aliph. diamines were deaminated with the highest reaction velocity, but histamine and Nτ-methylhistamine were also excellent substrates.  The Km for putrescine was 8.3 × 10-5M, for histamine 1.9 × 10-5M, and for Nτ-methylhistamine 9.7 × 10-5M.  Typical substrates of monoamine oxidase were not deaminated by the enzyme.  Aminoguanidine strongly inhibited human intestinal I (IC50 = 1.1 × 10-8M).  Because of its properties, intestinal I is considered to play a protective role against histamine in diseases, such as ischemic bowel syndrome, mesenteric infarction, and ulcerative colitis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrE0FYj-GaaXrVg90H21EOLACvtfcHk0ljj4e6PvymaLQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL3sXhsFKqtr8%253D&md5=f8a04658ccca6efcbd2e9e4344b1aa01</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1016%2F0304-4165%2883%2990092-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0304-4165%252883%252990092-2%26sid%3Dliteratum%253Aachs%26aulast%3DBieganski%26aufirst%3DT.%26aulast%3DKusche%26aufirst%3DJ.%26aulast%3DLorenz%26aufirst%3DW.%26aulast%3DHesterberg%26aufirst%3DR.%26aulast%3DStahlknecht%26aufirst%3DC.%26aulast%3DFeussner%26aufirst%3DK.%26atitle%3DDistribution%2520and%2520properties%2520of%2520human%2520intestinal%2520diamine%2520oxidase%2520and%2520its%2520relevance%2520for%2520the%2520histamine%2520catabolism%26jtitle%3DBiochim.%2520Biophys.%2520Acta%26date%3D1983%26volume%3D756%26spage%3D196%26epage%3D203%26doi%3D10.1016%2F0304-4165%2883%2990092-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kaitaniemi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elovaara, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grön, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kidron, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liukkonen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salminen, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salmi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jalkanen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elima, K.</span></span> <span> </span><span class="NLM_article-title">The unique substrate specificity of human AOC2, a semicarbazide-sensitive amine oxidase</span>. <i>Cell. Mol. Life Sci.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>66</i></span>,  <span class="NLM_fpage">2743</span>– <span class="NLM_lpage">2757</span>, <span class="refDoi"> DOI: 10.1007/s00018-009-0076-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=10.1007%2Fs00018-009-0076-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=19588076" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=1%3ACAS%3A528%3ADC%252BD1MXovFOks7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2009&pages=2743-2757&author=S.+Kaitaniemiauthor=H.+Elovaaraauthor=K.+Gr%C3%B6nauthor=H.+Kidronauthor=J.+Liukkonenauthor=T.+Salminenauthor=M.+Salmiauthor=S.+Jalkanenauthor=K.+Elima&title=The+unique+substrate+specificity+of+human+AOC2%2C+a+semicarbazide-sensitive+amine+oxidase&doi=10.1007%2Fs00018-009-0076-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">The unique substrate specificity of human AOC2, a semicarbazide-sensitive amine oxidase</span></div><div class="casAuthors">Kaitaniemi, Sam; Elovaara, Heli; Gron, Kirsi; Kidron, Heidi; Liukkonen, Janne; Salminen, Tiina; Salmi, Marko; Jalkanen, Sirpa; Elima, Kati</div><div class="citationInfo"><span class="NLM_cas:title">Cellular and Molecular Life Sciences</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">2743-2757</span>CODEN:
                <span class="NLM_cas:coden">CMLSFI</span>;
        ISSN:<span class="NLM_cas:issn">1420-682X</span>.
    
            (<span class="NLM_cas:orgname">Birkhaeuser Verlag</span>)
        </div><div class="casAbstract">Semicarbazide-sensitive amine oxidases (SSAOs) catalyze oxidative deamination of primary amines, but the true physiol. function of these enzymes is still poorly understood.  Here, we have studied the functional and structural characteristics of a human cell-surface SSAO, AOC2, which is homologous to the better characterized family member, AOC3.  The preferred in vitro substrates of AOC2 were found to be 2-phenylethylamine, tryptamine and p-tyramine instead of methylamine and benzylamine, the favored substrates of AOC3.  Mol. modeling suggested structural differences between AOC2 and AOC3, which provide AOC2 with the capability to use the larger monoamines as substrates.  Even though AOC2 mRNA was expressed in many tissues, the only tissues with detectable AOC2-like enzyme activity were found in the eye.  Characterization of AOC2 will help in evaluating the contribution of this enzyme to the pathol. processes attributed to the SSAO activity and in designing specific inhibitors for the individual members of the SSAO family.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoGlTVwhsB7jbVg90H21EOLACvtfcHk0ljj4e6PvymaLQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXovFOks7k%253D&md5=9d060e7ed40263731d903fbb1463083b</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1007%2Fs00018-009-0076-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00018-009-0076-5%26sid%3Dliteratum%253Aachs%26aulast%3DKaitaniemi%26aufirst%3DS.%26aulast%3DElovaara%26aufirst%3DH.%26aulast%3DGr%25C3%25B6n%26aufirst%3DK.%26aulast%3DKidron%26aufirst%3DH.%26aulast%3DLiukkonen%26aufirst%3DJ.%26aulast%3DSalminen%26aufirst%3DT.%26aulast%3DSalmi%26aufirst%3DM.%26aulast%3DJalkanen%26aufirst%3DS.%26aulast%3DElima%26aufirst%3DK.%26atitle%3DThe%2520unique%2520substrate%2520specificity%2520of%2520human%2520AOC2%252C%2520a%2520semicarbazide-sensitive%2520amine%2520oxidase%26jtitle%3DCell.%2520Mol.%2520Life%2520Sci.%26date%3D2009%26volume%3D66%26spage%3D2743%26epage%3D2757%26doi%3D10.1007%2Fs00018-009-0076-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Salmi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jalkanen, S.</span></span> <span> </span><span class="NLM_article-title">Vascular Adhesion Protein-1: A cell surface amine oxidase in translation</span>. <i>Antioxid. Redox Signaling</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">314</span>– <span class="NLM_lpage">332</span>, <span class="refDoi"> DOI: 10.1089/ars.2017.7418</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=10.1089%2Fars.2017.7418" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=29065711" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisFSmsrjM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2019&pages=314-332&author=M.+Salmiauthor=S.+Jalkanen&title=Vascular+Adhesion+Protein-1%3A+A+cell+surface+amine+oxidase+in+translation&doi=10.1089%2Fars.2017.7418"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7aR"><div class="casContent"><span class="casTitleNuber">7a</span><div class="casTitle"><span class="NLM_cas:atitle">Vascular Adhesion Protein-1: A Cell Surface Amine Oxidase in Translation</span></div><div class="casAuthors">Salmi, Marko; Jalkanen, Sirpa</div><div class="citationInfo"><span class="NLM_cas:title">Antioxidants & Redox Signaling</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">314-332</span>CODEN:
                <span class="NLM_cas:coden">ARSIF2</span>;
        ISSN:<span class="NLM_cas:issn">1523-0864</span>.
    
            (<span class="NLM_cas:orgname">Mary Ann Liebert, Inc.</span>)
        </div><div class="casAbstract">Significance: Vascular adhesion protein-1 (VAP-1) is an ectoenzyme that oxidates primary amines in a reaction producing also hydrogen peroxide.  VAP-1 on the blood vessel endothelium regulates leukocyte extravasation from the blood into tissues under physiol. and pathol. conditions.  Recent Advances: Inhibition of VAP-1 by neutralizing antibodies and by several novel small-mol. enzyme inhibitors interferes with leukocyte trafficking and alleviates inflammation in many exptl. models.  Targeting of VAP-1 also shows beneficial effects in several other diseases, such as ischemia/reperfusion, fibrosis, and cancer.  Moreover, sol. VAP-1 levels may serve as a new prognostic biomarker in selected diseases.  Crit. Issues: Understanding the contribution of the enzyme activity-independent and enzyme activity-dependent functions, which often appear to be mediated by the hydrogen peroxide prodn., in the VAP-1 biol. will be crucial.  Similarly, there is a pressing need to understand which of the VAP-1 functions are regulated through the modulation of leukocyte trafficking, and what is the role of VAP-1 synthesized in adipose and smooth muscle cells.  Future Directions: The specificity and selectivity of new VAP-1 inhibitors, and their value in animal models under therapeutic settings need to be addressed.  Results from several programs studying the therapeutic potential of VAP-1 inhibition, which now are in clin. trials, will reveal the relevance of this amine oxidase in humans.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqzT3nhTaWvqLVg90H21EOLACvtfcHk0ljj4e6PvymaLQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisFSmsrjM&md5=5fe646b1e851f3e4e2c25e14cb32dec7</span></div><a href="/servlet/linkout?suffix=cit7a&amp;dbid=16384&amp;doi=10.1089%2Fars.2017.7418&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1089%252Fars.2017.7418%26sid%3Dliteratum%253Aachs%26aulast%3DSalmi%26aufirst%3DM.%26aulast%3DJalkanen%26aufirst%3DS.%26atitle%3DVascular%2520Adhesion%2520Protein-1%253A%2520A%2520cell%2520surface%2520amine%2520oxidase%2520in%2520translation%26jtitle%3DAntioxid.%2520Redox%2520Signaling%26date%3D2019%26volume%3D30%26spage%3D314%26epage%3D332%26doi%3D10.1089%2Fars.2017.7418" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit7b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Jarnicki, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schilter, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wheeldon, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Essilfie, A.-T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foot, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yow, T. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jarolimek, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hansbro, P. M.</span></span> <span> </span><span class="NLM_article-title">The inhibitor of semicarbazide-sensitive amine oxidase, PXS-4728A, ameliorates key features of chronic obstructive pulmonary disease in a mouse model</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>173</i></span>,  <span class="NLM_fpage">3161</span>– <span class="NLM_lpage">3175</span>, <span class="refDoi"> DOI: 10.1111/bph.13573</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=10.1111%2Fbph.13573" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=27495192" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht12nt7bP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=173&publication_year=2016&pages=3161-3175&author=A.+G.+Jarnickiauthor=H.+Schilterauthor=G.+Liuauthor=K.+Wheeldonauthor=A.-T.+Essilfieauthor=J.+S.+Footauthor=T.+T.+Yowauthor=W.+Jarolimekauthor=P.+M.+Hansbro&title=The+inhibitor+of+semicarbazide-sensitive+amine+oxidase%2C+PXS-4728A%2C+ameliorates+key+features+of+chronic+obstructive+pulmonary+disease+in+a+mouse+model&doi=10.1111%2Fbph.13573"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7bR"><div class="casContent"><span class="casTitleNuber">7b</span><div class="casTitle"><span class="NLM_cas:atitle">A novel SSAO inhibitor PXS-4728A suppresses inflammation and fibrosis and improves lung function in experimental chronic obstructive pulmonary disease</span></div><div class="casAuthors">Jarnicki, A. G.; Schilter, H.; Liu, G.; Wheeldon, K.; Essilfie, A-T.; Foot, J. S.; Yow, T. T.; Jarolimek, W.; Hansbro, P. M.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">173</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">3161-3175</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Background and Purpose : Chronic obstructive pulmonary disease (COPD) is a major cause of illness and death that is often induced by cigarette smoking (CS).  It is characterised by pulmonary inflammation and fibrosis that impairs lung function.  Existing pharmaceuticals aim to control symptoms but have low efficacy, and there are no broadly effective treatments.  A potential new therapeutic target is ectoenzyme semicarbazide-sensitive mono-amine oxidase (SSAO, or vascular adhesion protein-1, VAP-1).  SSAO is elevated in smokers serum, and is a pro-inflammatory enzyme that facilitates the adhesion and transmigration of leukocytes from the vasculature to sites of inflammation.  Exptl. Approach : PXS-4728A has been developed as a small mol. inhibitor of SSAO.  We tested its ability to suppress SSAO activity and ameliorate inflammation and hallmark features of human disease in a mouse model of CS-induced exptl. COPD.  The model replicates key aspects of human COPD, including chronic airway inflammation, fibrosis and impaired lung function.  Key Results : PXS-4728A treatment completely inhibited lung and systemic SSAO activity induced by acute and chronic CS exposure.  Daily oral treatment inhibited airway inflammation (immune cell influx and inflammatory factors) induced by acute CS exposure.  Therapeutic treatment during chronic CS-exposure, when the key features of exptl. COPD develop and progress, substantially suppressed inflammatory cell influx and fibrosis in the airways and improved lung function.  Conclusions and Implications : Treatment with the SSAO small mol. inhibitor, PXS-4728A, suppresses airway inflammation and fibrosis and improves lung function in exptl. COPD.  This study demonstrates the therapeutic potential of PXS-4728A for this debilitating disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpKWBKDI9C0ibVg90H21EOLACvtfcHk0ljg3gb_tYiwhA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht12nt7bP&md5=f0d0b1edba9246169d2584d3ceabf881</span></div><a href="/servlet/linkout?suffix=cit7b&amp;dbid=16384&amp;doi=10.1111%2Fbph.13573&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbph.13573%26sid%3Dliteratum%253Aachs%26aulast%3DJarnicki%26aufirst%3DA.%2BG.%26aulast%3DSchilter%26aufirst%3DH.%26aulast%3DLiu%26aufirst%3DG.%26aulast%3DWheeldon%26aufirst%3DK.%26aulast%3DEssilfie%26aufirst%3DA.-T.%26aulast%3DFoot%26aufirst%3DJ.%2BS.%26aulast%3DYow%26aufirst%3DT.%2BT.%26aulast%3DJarolimek%26aufirst%3DW.%26aulast%3DHansbro%26aufirst%3DP.%2BM.%26atitle%3DThe%2520inhibitor%2520of%2520semicarbazide-sensitive%2520amine%2520oxidase%252C%2520PXS-4728A%252C%2520ameliorates%2520key%2520features%2520of%2520chronic%2520obstructive%2520pulmonary%2520disease%2520in%2520a%2520mouse%2520model%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2016%26volume%3D173%26spage%3D3161%26epage%3D3175%26doi%3D10.1111%2Fbph.13573" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schwelberger, H. G.</span></span> <span> </span><span class="NLM_article-title">The origin of mammalian plasma amine oxidases</span>. <i>J. Neural Transm.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>114</i></span>,  <span class="NLM_fpage">757</span>– <span class="NLM_lpage">762</span>, <span class="refDoi"> DOI: 10.1007/s00702-007-0684-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=10.1007%2Fs00702-007-0684-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=17385066" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=1%3ACAS%3A528%3ADC%252BD2sXls1Sgt74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=114&publication_year=2007&pages=757-762&author=H.+G.+Schwelberger&title=The+origin+of+mammalian+plasma+amine+oxidases&doi=10.1007%2Fs00702-007-0684-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">The origin of mammalian plasma amine oxidases</span></div><div class="casAuthors">Schwelberger, H. G.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neural Transmission</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">114</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">757-762</span>CODEN:
                <span class="NLM_cas:coden">JNTRF3</span>;
        ISSN:<span class="NLM_cas:issn">0300-9564</span>.
    
            (<span class="NLM_cas:orgname">Springer Wien</span>)
        </div><div class="casAbstract">Mammalian blood plasma contains considerable activity of sol. copper-contg. amine oxidase (AOC) referred to as plasma or serum amine oxidase (SAO).  The identity and origin of SAO was investigated based on the recent characterization of four porcine AOC genes with AOC1 encoding diamine oxidase (DAO), AOC2 retina-specific amine oxidase (RAO), AOC3 vascular adhesion protein-1 (VAP-1), and AOC4 a VAP-1 homolog that is expressed mainly in the liver and has a signal peptide sequence instead of a transmembrane domain at its N-terminus.  Purifn. and characterization of the major amine oxidase activity from porcine serum showed that it is the product of the AOC4 gene.  Intriguingly, all mammals possessing a functional AOC4 gene exhibit high plasma amine oxidase activity.  Humans and rodents lack a functional AOC4 gene and have comparably low plasma amine oxidase activity that is probably derived from partial proteolytic release of the membrane-assocd. AOC3 gene product VAP-1.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpGIWSRKZtvl7Vg90H21EOLACvtfcHk0ljg3gb_tYiwhA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXls1Sgt74%253D&md5=d59b572685cd7ca5ebd7945551fc3278</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1007%2Fs00702-007-0684-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00702-007-0684-x%26sid%3Dliteratum%253Aachs%26aulast%3DSchwelberger%26aufirst%3DH.%2BG.%26atitle%3DThe%2520origin%2520of%2520mammalian%2520plasma%2520amine%2520oxidases%26jtitle%3DJ.%2520Neural%2520Transm.%26date%3D2007%26volume%3D114%26spage%3D757%26epage%3D762%26doi%3D10.1007%2Fs00702-007-0684-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Barker, H. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cox, T. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erler, J. T.</span></span> <span> </span><span class="NLM_article-title">The rationale for targeting the LOX family in cancer</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">540</span>– <span class="NLM_lpage">552</span>, <span class="refDoi"> DOI: 10.1038/nrc3319</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=10.1038%2Fnrc3319" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=22810810" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtVCltLfE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2012&pages=540-552&author=H.+E.+Barkerauthor=T.+R.+Coxauthor=J.+T.+Erler&title=The+rationale+for+targeting+the+LOX+family+in+cancer&doi=10.1038%2Fnrc3319"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">The rationale for targeting the LOX family in cancer</span></div><div class="casAuthors">Barker, Holly E.; Cox, Thomas R.; Erler, Janine T.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">540-552</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The therapeutic targeting of extracellular proteins is becoming hugely attractive in light of evidence implicating the tumor microenvironment as pivotal in all aspects of tumor initiation and progression.  Members of the lysyl oxidase (LOX) family of proteins are secreted by tumors and are the subject of much effort to understand their roles in cancer.  In this Review we discuss the roles of members of this family in the remodelling of the tumor microenvironment and their paradoxical roles in tumorigenesis and metastasis.  We also discuss how targeting this family of proteins might lead to a new avenue of cancer therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrZcLr3Y7rPKLVg90H21EOLACvtfcHk0ljg3gb_tYiwhA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtVCltLfE&md5=455064ea8d5332b43fa6490a1aaa0c8f</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1038%2Fnrc3319&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc3319%26sid%3Dliteratum%253Aachs%26aulast%3DBarker%26aufirst%3DH.%2BE.%26aulast%3DCox%26aufirst%3DT.%2BR.%26aulast%3DErler%26aufirst%3DJ.%2BT.%26atitle%3DThe%2520rationale%2520for%2520targeting%2520the%2520LOX%2520family%2520in%2520cancer%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2012%26volume%3D12%26spage%3D540%26epage%3D552%26doi%3D10.1038%2Fnrc3319" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Grau-Bové, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruiz-Trillo, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodriguez-Pascual, F.</span></span> <span> </span><span class="NLM_article-title">Origin and evolution of lysyl oxidases</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">10568</span>, <span class="refDoi"> DOI: 10.1038/srep10568</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=10.1038%2Fsrep10568" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=26024311" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=1%3ACAS%3A280%3ADC%252BC2MfovFyksw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2015&pages=10568&author=X.+Grau-Bov%C3%A9author=I.+Ruiz-Trilloauthor=F.+Rodriguez-Pascual&title=Origin+and+evolution+of+lysyl+oxidases&doi=10.1038%2Fsrep10568"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Origin and evolution of lysyl oxidases</span></div><div class="casAuthors">Grau-Bove Xavier; Ruiz-Trillo Inaki; Rodriguez-Pascual Fernando</div><div class="citationInfo"><span class="NLM_cas:title">Scientific reports</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">10568</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Lysyl oxidases (LOX) are copper-dependent enzymes that oxidize primary amine substrates to reactive aldehydes.  The best-studied role of LOX enzymes is the remodeling of the extracellular matrix (ECM) in animals by cross-linking collagens and elastin, although intracellular functions have been reported as well.  Five different LOX enzymes have been identified in mammals, LOX and LOX-like (LOXL) 1 to 4, showing a highly conserved catalytic carboxy terminal domain and more divergence in the rest of the sequence.  Here we have surveyed a wide selection of genomes in order to infer the evolutionary history of LOX.  We identified LOX proteins not only in animals, but also in many other eukaryotes, as well as in bacteria and archaea - which reveals a pre-metazoan origin for this gene family.  LOX genes expanded during metazoan evolution resulting in two superfamilies, LOXL2/L3/L4 and LOX/L1/L5.  Considering the current knowledge on the function of mammalian LOX isoforms in ECM remodeling, we propose that LOXL2/L3/L4 members might have preferentially been involved in making cross-linked collagen IV-based basement membrane, whereas the diversification of LOX/L1/L5 forms contributed to chordate/vertebrate-specific ECM innovations, such as elastin and fibronectin.  Our work provides a novel view on the evolution of this family of enzymes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTHiDw73o3Ogn6oPH0mYWL1fW6udTcc2eY2pgEycspTKbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2MfovFyksw%253D%253D&md5=ca8f3e5364edb3e5d19742d09d78b82a</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1038%2Fsrep10568&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsrep10568%26sid%3Dliteratum%253Aachs%26aulast%3DGrau-Bov%25C3%25A9%26aufirst%3DX.%26aulast%3DRuiz-Trillo%26aufirst%3DI.%26aulast%3DRodriguez-Pascual%26aufirst%3DF.%26atitle%3DOrigin%2520and%2520evolution%2520of%2520lysyl%2520oxidases%26jtitle%3DSci.%2520Rep.%26date%3D2015%26volume%3D5%26spage%3D10568%26doi%3D10.1038%2Fsrep10568" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Ricard-Blum, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ville, G.</span></span> <span> </span><span class="NLM_article-title">Collagen cross-linking</span>. <i>Int. J. Biochem.</i> <span class="NLM_year" style="font-weight: bold;">1989</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">1185</span>– <span class="NLM_lpage">1189</span>, <span class="refDoi"> DOI: 10.1016/0020-711x(89)90001-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=10.1016%2F0020-711x%2889%2990001-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=2575544" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=1%3ACAS%3A528%3ADyaK3cXnt1enuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=1989&pages=1185-1189&author=S.+Ricard-Blumauthor=G.+Ville&title=Collagen+cross-linking&doi=10.1016%2F0020-711x%2889%2990001-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11aR"><div class="casContent"><span class="casTitleNuber">11a</span><div class="casTitle"><span class="NLM_cas:atitle">Collagen cross-linking</span></div><div class="casAuthors">Ricard-Blum, S.; Ville, G.</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Biochemistry</span>
        (<span class="NLM_cas:date">1989</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1185-9</span>CODEN:
                <span class="NLM_cas:coden">IJBOBV</span>;
        ISSN:<span class="NLM_cas:issn">0020-711X</span>.
    </div><div class="casAbstract">A review, with 16 refs., on collagen crosslink formation, structure, and function in various tissues.  Metabolic and pathol. aspects of collagen crosslinking are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpY7IcRU8v0gLVg90H21EOLACvtfcHk0lghDZasOjMz1Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3cXnt1enuw%253D%253D&md5=8745eca7bdba7a42504283b5e28002af</span></div><a href="/servlet/linkout?suffix=cit11a&amp;dbid=16384&amp;doi=10.1016%2F0020-711x%2889%2990001-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0020-711x%252889%252990001-3%26sid%3Dliteratum%253Aachs%26aulast%3DRicard-Blum%26aufirst%3DS.%26aulast%3DVille%26aufirst%3DG.%26atitle%3DCollagen%2520cross-linking%26jtitle%3DInt.%2520J.%2520Biochem.%26date%3D1989%26volume%3D21%26spage%3D1185%26epage%3D1189%26doi%3D10.1016%2F0020-711x%2889%2990001-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit11b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Yamauchi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sricholpech, M.</span></span> <span> </span><span class="NLM_article-title">Lysine post-translational modifications of collagen</span>. <i>Essays Biochem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">113</span>– <span class="NLM_lpage">133</span>, <span class="refDoi"> DOI: 10.1042/bse0520113</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=10.1042%2Fbse0520113" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=22708567" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht1ShurrK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2012&pages=113-133&author=M.+Yamauchiauthor=M.+Sricholpech&title=Lysine+post-translational+modifications+of+collagen&doi=10.1042%2Fbse0520113"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11bR"><div class="casContent"><span class="casTitleNuber">11b</span><div class="casTitle"><span class="NLM_cas:atitle">Lysine post-translational modifications of collagen</span></div><div class="casAuthors">Yamauchi, Mitsuo; Sricholpech, Marnisa</div><div class="citationInfo"><span class="NLM_cas:title">Essays in Biochemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">Lysine-Based Post-Translational Modification of Proteins</span>),
    <span class="NLM_cas:pages">113-133</span>CODEN:
                <span class="NLM_cas:coden">ESBIAV</span>;
        ISSN:<span class="NLM_cas:issn">0071-1365</span>.
    
            (<span class="NLM_cas:orgname">Portland Press Ltd.</span>)
        </div><div class="casAbstract">A review.  Type I collagen is the most abundant structural protein in vertebrates.  It is a heterotrimeric mol. composed of two α1 chains and one α2 chain, forming a long uninterrupted triple helical structure with short non-triple helical telopeptides at both the N- and C-termini.  During biosynthesis, collagen acquires a no. of post-translational modifications, including lysine modifications, that are crit. to the structure and biol. functions of this protein.  Lysine modifications of collagen are highly complicated sequential processes catalyzed by several groups of enzymes leading to the final step of biosynthesis, covalent intermol. crosslinking.  In the cell, specific lysine residues are hydroxylated to form hydroxylysine.  Then specific hydroxylysine residues located in the helical domain of the mol. are glycosylated by the addn. of galactose or glucose-galactose.  Outside the cell, lysine and hydroxylysine residues in the N- and C-telopeptides can be oxidatively deaminated to produce reactive aldehydes that undergo a series of non-enzymic condensation reactions to form covalent intra- and inter-mol. cross-links.  Owing to the recent advances in mol. and cellular biol., and anal. technologies, the biol. significance and mol. mechanisms of these modifications have been gradually elucidated.  This chapter provides an overview on these enzymic lysine modifications and subsequent crosslinking.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoAZ1dEKotSOLVg90H21EOLACvtfcHk0lghDZasOjMz1Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht1ShurrK&md5=2aa838a0513d3ed1a8ea6e8ab579f56e</span></div><a href="/servlet/linkout?suffix=cit11b&amp;dbid=16384&amp;doi=10.1042%2Fbse0520113&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1042%252Fbse0520113%26sid%3Dliteratum%253Aachs%26aulast%3DYamauchi%26aufirst%3DM.%26aulast%3DSricholpech%26aufirst%3DM.%26atitle%3DLysine%2520post-translational%2520modifications%2520of%2520collagen%26jtitle%3DEssays%2520Biochem.%26date%3D2012%26volume%3D52%26spage%3D113%26epage%3D133%26doi%3D10.1042%2Fbse0520113" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Starcher, B. C.</span></span> <span> </span><span class="NLM_article-title">Elastin and the lung</span>. <i>Thorax</i> <span class="NLM_year" style="font-weight: bold;">1986</span>,  <span class="NLM_volume"><i>41</i></span>,  <span class="NLM_fpage">577</span>– <span class="NLM_lpage">585</span>, <span class="refDoi"> DOI: 10.1136/thx.41.8.577</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=10.1136%2Fthx.41.8.577" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=3538485" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=1%3ACAS%3A528%3ADyaL28Xls12nsb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=1986&pages=577-585&author=B.+C.+Starcher&title=Elastin+and+the+lung&doi=10.1136%2Fthx.41.8.577"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12aR"><div class="casContent"><span class="casTitleNuber">12a</span><div class="casTitle"><span class="NLM_cas:atitle">Elastin and the lung</span></div><div class="casAuthors">Starcher, B. C.</div><div class="citationInfo"><span class="NLM_cas:title">Thorax</span>
        (<span class="NLM_cas:date">1986</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">577-85</span>CODEN:
                <span class="NLM_cas:coden">THORA7</span>;
        ISSN:<span class="NLM_cas:issn">0040-6376</span>.
    </div><div class="casAbstract">A review, with 71 refs.  Topics include the isolation, structure, formation, and degrdn. of elastin, elastases and their inhibitors, elastin fiber structure and function, exptl. disruption of elastin in the lung, repair of lung damage, and the effects of tobacco smoke and infection and nutrition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpUR73B-lphPLVg90H21EOLACvtfcHk0lghDZasOjMz1Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL28Xls12nsb8%253D&md5=85ebfcfebab5bd54817350ca4a934230</span></div><a href="/servlet/linkout?suffix=cit12a&amp;dbid=16384&amp;doi=10.1136%2Fthx.41.8.577&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1136%252Fthx.41.8.577%26sid%3Dliteratum%253Aachs%26aulast%3DStarcher%26aufirst%3DB.%2BC.%26atitle%3DElastin%2520and%2520the%2520lung%26jtitle%3DThorax%26date%3D1986%26volume%3D41%26spage%3D577%26epage%3D585%26doi%3D10.1136%2Fthx.41.8.577" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit12b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Herchenhan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uhlenbrock, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eliasson, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weis, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eyre, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kadler, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magnusson, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kjaer, M.</span></span> <span> </span><span class="NLM_article-title">Lysyl oxidase activity is required for ordered collagen fibrillogenesis by tendon cells</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>290</i></span>,  <span class="NLM_fpage">16440</span>– <span class="NLM_lpage">16450</span>, <span class="refDoi"> DOI: 10.1074/jbc.m115.641670</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=10.1074%2Fjbc.m115.641670" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=25979340" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=1%3ACAS%3A528%3ADC%252BC2MXht1amur3F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=290&publication_year=2015&pages=16440-16450&author=A.+Herchenhanauthor=F.+Uhlenbrockauthor=P.+Eliassonauthor=M.+Weisauthor=D.+Eyreauthor=K.+E.+Kadlerauthor=S.+P.+Magnussonauthor=M.+Kjaer&title=Lysyl+oxidase+activity+is+required+for+ordered+collagen+fibrillogenesis+by+tendon+cells&doi=10.1074%2Fjbc.m115.641670"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12bR"><div class="casContent"><span class="casTitleNuber">12b</span><div class="casTitle"><span class="NLM_cas:atitle">Lysyl Oxidase Activity Is Required for Ordered Collagen Fibrillogenesis by Tendon Cells</span></div><div class="casAuthors">Herchenhan, Andreas; Uhlenbrock, Franziska; Eliasson, Pernilla; Weis, MaryAnn; Eyre, David; Kadler, Karl E.; Magnusson, S. Peter; Kjaer, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">290</span>
        (<span class="NLM_cas:issue">26</span>),
    <span class="NLM_cas:pages">16440-16450</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Lysyl oxidases (LOXs) are a family of copper-dependent oxido-deaminases that can modify the side chain of lysyl residues in collagen and elastin, thereby leading to the spontaneous formation of non-reducible aldehyde-derived interpolypeptide chain cross-links.  The consequences of LOX inhibition in producing lathyrism are well documented, but the consequences on collagen fibril formation are less clear.  Here we used β-aminoproprionitrile (BAPN) to inhibit LOX in tendon-like constructs (prepd. from human tenocytes), which are an exptl. model of cell-mediated collagen fibril formation.  The improvement in structure and strength seen with time in control constructs was absent in constructs treated with BAPN.  As expected, BAPN inhibited the formation of aldimine-derived cross-links in collagen, and the constructs were mech. weak.  However, an unexpected finding was that BAPN treatment led to structurally abnormal collagen fibrils with irregular profiles and widely dispersed diams.  Of special interest, the abnormal fibril profiles resembled those seen in some Ehlers-Danlos Syndrome phenotypes.  Importantly, the total collagen content developed normally, and there was no difference in COL1A1 gene expression.  Collagen type V, decorin, fibromodulin, and tenascin-X proteins were unaffected by the cross-link inhibition, suggesting that LOX regulates fibrillogenesis independently of these mols.  Collectively, the data show the importance of LOX for the mech. development of early collagenous tissues and that LOX is essential for correct collagen fibril shape formation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqWM9x9JgC8O7Vg90H21EOLACvtfcHk0lghDZasOjMz1Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXht1amur3F&md5=724abdfe7e2e6b993199828e94f35460</span></div><a href="/servlet/linkout?suffix=cit12b&amp;dbid=16384&amp;doi=10.1074%2Fjbc.m115.641670&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.m115.641670%26sid%3Dliteratum%253Aachs%26aulast%3DHerchenhan%26aufirst%3DA.%26aulast%3DUhlenbrock%26aufirst%3DF.%26aulast%3DEliasson%26aufirst%3DP.%26aulast%3DWeis%26aufirst%3DM.%26aulast%3DEyre%26aufirst%3DD.%26aulast%3DKadler%26aufirst%3DK.%2BE.%26aulast%3DMagnusson%26aufirst%3DS.%2BP.%26aulast%3DKjaer%26aufirst%3DM.%26atitle%3DLysyl%2520oxidase%2520activity%2520is%2520required%2520for%2520ordered%2520collagen%2520fibrillogenesis%2520by%2520tendon%2520cells%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2015%26volume%3D290%26spage%3D16440%26epage%3D16450%26doi%3D10.1074%2Fjbc.m115.641670" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">He, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Y.</span></span> <span> </span><span class="NLM_article-title">Mechanisms of fibrosis in acute liver failure</span>. <i>Liver Int.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>35</i></span>,  <span class="NLM_fpage">1877</span>– <span class="NLM_lpage">1885</span>, <span class="refDoi"> DOI: 10.1111/liv.12731</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=10.1111%2Fliv.12731" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=25388426" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtVaju7nN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2015&pages=1877-1885&author=Y.+Heauthor=L.+Jinauthor=J.+Wangauthor=Z.+Yanauthor=T.+Chenauthor=Y.+Zhao&title=Mechanisms+of+fibrosis+in+acute+liver+failure&doi=10.1111%2Fliv.12731"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13aR"><div class="casContent"><span class="casTitleNuber">13a</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanisms of fibrosis in acute liver failure</span></div><div class="casAuthors">He, Yingli; Jin, Li; Wang, Jing; Yan, Zhi; Chen, Tianyan; Zhao, Yingren</div><div class="citationInfo"><span class="NLM_cas:title">Liver International</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1877-1885</span>CODEN:
                <span class="NLM_cas:coden">LIINCM</span>;
        ISSN:<span class="NLM_cas:issn">1478-3223</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Background & Aims : Acute liver failure (ALF) is a condition with high mortality and morbidity.  Fibrosis in chronic liver disease was extensively researched, whereas fibrosis and underlying mechanism in acute liver failure remains unclear.  Methods : Hepatitis B virus related ALF patients were recruited to investigate if there was ongoing fibrosis by liver histol. and liver stiffness measurement(LSM) anal. as well as fibrosis markers assay.  Sera HMGB1 were kinetically detected in progression and remission stage of ALF.  Hepatic stellate cell(HSC) activation by HMGB1 was explored by testing mRNA and protein level of α-SMA and collagen 1a1 by using qPCR and western blot.  Autophagy induction by HMGB1 was explored by LC3-II conversion, autophagy flux and fluorescence.  Results : Firstly, ongoing fibrosis in progression stage of ALF was confirmed by histol. anal., LS measurement as well as fibrosis markers detection.  HSC activation and autophagy induction in explanted liver tissue also revealed.  Next, kinetic monitoring sera HMGB1 revealed elevated HMGB1 in progression stage of ALF vs HBsAg carrier, and drop back to base level in remission stage.  Thirdly, rHMGB1 dose dependently activated HSCs, as indicated by increased mRNA and proteins level in α-SMA and collagen 1a1.  Moreover, autophagy was induced in HSC treated with rHMGB1, as illustrated by increased LC3 lipidation, elevated autophagy flux and GFP-LC3 puncta.  Conclusions : Acute liver failure is accompanied by ongoing fibrosis, HSC activation and autophagy induction.  Increased HMGB1 activates HSC via autophagy induction.  Those findings integrate HMGB1, HSCs activation, autophagy into a common framework that underlies the fibrosis in ALF.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpX7zL7tKJHYLVg90H21EOLACvtfcHk0ljYrnNDj2Eyhw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtVaju7nN&md5=eef5d447b92ff6fafb2e0f3ea8c1d00d</span></div><a href="/servlet/linkout?suffix=cit13a&amp;dbid=16384&amp;doi=10.1111%2Fliv.12731&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fliv.12731%26sid%3Dliteratum%253Aachs%26aulast%3DHe%26aufirst%3DY.%26aulast%3DJin%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DYan%26aufirst%3DZ.%26aulast%3DChen%26aufirst%3DT.%26aulast%3DZhao%26aufirst%3DY.%26atitle%3DMechanisms%2520of%2520fibrosis%2520in%2520acute%2520liver%2520failure%26jtitle%3DLiver%2520Int.%26date%3D2015%26volume%3D35%26spage%3D1877%26epage%3D1885%26doi%3D10.1111%2Fliv.12731" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit13b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Boor, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sebekova, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ostendorf, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Floege, J.</span></span> <span> </span><span class="NLM_article-title">Treatment targets in renal fibrosis</span>. <i>Nephrol., Dial., Transplant.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">3391</span>– <span class="NLM_lpage">3407</span>, <span class="refDoi"> DOI: 10.1093/ndt/gfm393</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=10.1093%2Fndt%2Fgfm393" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=17890247" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtlOqtr7J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2007&pages=3391-3407&author=P.+Boorauthor=K.+Sebekovaauthor=T.+Ostendorfauthor=J.+Floege&title=Treatment+targets+in+renal+fibrosis&doi=10.1093%2Fndt%2Fgfm393"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13bR"><div class="casContent"><span class="casTitleNuber">13b</span><div class="casTitle"><span class="NLM_cas:atitle">Treatment targets in renal fibrosis</span></div><div class="casAuthors">Boor, Peter; Sebekova, Katarina; Ostendorf, Tammo; Floege, Juergen</div><div class="citationInfo"><span class="NLM_cas:title">Nephrology, Dialysis, Transplantation</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">3391-3407</span>CODEN:
                <span class="NLM_cas:coden">NDTREA</span>;
        ISSN:<span class="NLM_cas:issn">0931-0509</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">A review on new, promising targets for the treatment of renal fibrosis, the principal process underlying the progression of chronic kidney disease to end-stage renal disease.  It first discusses antifibrotic approaches, that are clin. available or close to being so, and then describes potential new targets in fibrosis therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrpXEVIuwK0c7Vg90H21EOLACvtfcHk0ljYrnNDj2Eyhw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtlOqtr7J&md5=04e21b221eec2e52416d603d6382e9a5</span></div><a href="/servlet/linkout?suffix=cit13b&amp;dbid=16384&amp;doi=10.1093%2Fndt%2Fgfm393&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fndt%252Fgfm393%26sid%3Dliteratum%253Aachs%26aulast%3DBoor%26aufirst%3DP.%26aulast%3DSebekova%26aufirst%3DK.%26aulast%3DOstendorf%26aufirst%3DT.%26aulast%3DFloege%26aufirst%3DJ.%26atitle%3DTreatment%2520targets%2520in%2520renal%2520fibrosis%26jtitle%3DNephrol.%252C%2520Dial.%252C%2520Transplant.%26date%3D2007%26volume%3D22%26spage%3D3391%26epage%3D3407%26doi%3D10.1093%2Fndt%2Fgfm393" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pischon, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mäki, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weisshaupt, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heng, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palamakumbura, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">N’Guessan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Radlanski, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Renz, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bronckers, T. A. L. J.
J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Myllyharju, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kielbassa, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kleber, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bernimoulin, J.-P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trackman, P. C.</span></span> <span> </span><span class="NLM_article-title">Lysyl oxidase (lox) gene deficiency affects osteoblastic phenotype</span>. <i>Calcif. Tissue Int.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>85</i></span>,  <span class="NLM_fpage">119</span>– <span class="NLM_lpage">126</span>, <span class="refDoi"> DOI: 10.1007/s00223-009-9252-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=10.1007%2Fs00223-009-9252-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=19458888" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtVait7%252FI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=85&publication_year=2009&pages=119-126&author=N.+Pischonauthor=J.+M.+M%C3%A4kiauthor=P.+Weisshauptauthor=N.+Hengauthor=A.+H.+Palamakumburaauthor=P.+N%E2%80%99Guessanauthor=A.+Dingauthor=R.+Radlanskiauthor=H.+Renzauthor=T.+A.+L.+J.%0AJ.+Bronckersauthor=J.+Myllyharjuauthor=A.+M.+Kielbassaauthor=B.+M.+Kleberauthor=J.-P.+Bernimoulinauthor=P.+C.+Trackman&title=Lysyl+oxidase+%28lox%29+gene+deficiency+affects+osteoblastic+phenotype&doi=10.1007%2Fs00223-009-9252-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Lysyl Oxidase (Lox) Gene Deficiency Affects Osteoblastic Phenotype</span></div><div class="casAuthors">Pischon, N.; Maeki, J. M.; Weisshaupt, P.; Heng, N.; Palamakumbura, A. H.; N'Guessan, P.; Ding, A.; Radlanski, R.; Renz, H.; Bronckers, T. A. L. J. J.; Myllyharju, J.; Kielbassa, A. M.; Kleber, B. M.; Bernimoulin, J.-P.; Trackman, P. C.</div><div class="citationInfo"><span class="NLM_cas:title">Calcified Tissue International</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">85</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">119-126</span>CODEN:
                <span class="NLM_cas:coden">CTINDZ</span>;
        ISSN:<span class="NLM_cas:issn">0171-967X</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Lysyl oxidase (LOX) catalyzes crosslinking of elastin and collagen, which is essential for the structural integrity and function of bone tissue.  The present study examd. the role of Lox gene deficiency for the osteoblast phenotype in primary calvarial osteoblasts from E18.5 Lox knockout (Lox -/- ) and wild type (wt) (C57BL/6) mice.  Next to Lox gene depletion, mRNA expression of Lox isoforms, LOXL1-4, was significantly downregulated in Lox -/- bone tissue.  A significant decrease of DNA synthesis of Lox -/- osteoblasts compared to wt was found.  Early stages of osteoblastic apoptosis studied by annexin-V binding as well as later stages of DNA fragmentation were not affected.  However, mineral nodule formation and osteoblastic differentiation were markedly decreased, as revealed by significant downregulation of osteoblastic markers, type I collagen, bone sialoprotein, and Runx2/Cbfa1.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpj0YC3msIvIbVg90H21EOLACvtfcHk0ljYrnNDj2Eyhw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtVait7%252FI&md5=fab4300b8ff8b116247836bdf6aae915</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1007%2Fs00223-009-9252-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00223-009-9252-8%26sid%3Dliteratum%253Aachs%26aulast%3DPischon%26aufirst%3DN.%26aulast%3DM%25C3%25A4ki%26aufirst%3DJ.%2BM.%26aulast%3DWeisshaupt%26aufirst%3DP.%26aulast%3DHeng%26aufirst%3DN.%26aulast%3DPalamakumbura%26aufirst%3DA.%2BH.%26aulast%3DN%25E2%2580%2599Guessan%26aufirst%3DP.%26aulast%3DDing%26aufirst%3DA.%26aulast%3DRadlanski%26aufirst%3DR.%26aulast%3DRenz%26aufirst%3DH.%26aulast%3DBronckers%26aufirst%3DT.%2BA.%2BL.%2BJ.%2BJ.%26aulast%3DMyllyharju%26aufirst%3DJ.%26aulast%3DKielbassa%26aufirst%3DA.%2BM.%26aulast%3DKleber%26aufirst%3DB.%2BM.%26aulast%3DBernimoulin%26aufirst%3DJ.-P.%26aulast%3DTrackman%26aufirst%3DP.%2BC.%26atitle%3DLysyl%2520oxidase%2520%2528lox%2529%2520gene%2520deficiency%2520affects%2520osteoblastic%2520phenotype%26jtitle%3DCalcif.%2520Tissue%2520Int.%26date%3D2009%26volume%3D85%26spage%3D119%26epage%3D126%26doi%3D10.1007%2Fs00223-009-9252-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mäki, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sormunen, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lippo, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaarteenaho-Wiik, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soininen, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Myllyharju, J.</span></span> <span> </span><span class="NLM_article-title">Lysyl oxidase is essential for normal development and function of the respiratory system and for the integrity of elastic and collagen fibers in various tissues</span>. <i>Am. J. Pathol.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>167</i></span>,  <span class="NLM_fpage">927</span>– <span class="NLM_lpage">936</span>, <span class="refDoi"> DOI: 10.1016/s0002-9440(10)61183-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=10.1016%2Fs0002-9440%2810%2961183-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=16192629" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtFKqtLrF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=167&publication_year=2005&pages=927-936&author=J.+M.+M%C3%A4kiauthor=R.+Sormunenauthor=S.+Lippoauthor=R.+Kaarteenaho-Wiikauthor=R.+Soininenauthor=J.+Myllyharju&title=Lysyl+oxidase+is+essential+for+normal+development+and+function+of+the+respiratory+system+and+for+the+integrity+of+elastic+and+collagen+fibers+in+various+tissues&doi=10.1016%2Fs0002-9440%2810%2961183-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Lysyl oxidase is essential for normal development and function of the respiratory system and for the integrity of elastic and collagen fibers in various tissues</span></div><div class="casAuthors">Maki, Joni M.; Sormunen, Raija; Lippo, Sari; Kaarteenaho-Wiik, Riitta; Soininen, Raija; Myllyharju, Johanna</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Pathology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">167</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">927-936</span>CODEN:
                <span class="NLM_cas:coden">AJPAA4</span>;
        ISSN:<span class="NLM_cas:issn">0002-9440</span>.
    
            (<span class="NLM_cas:orgname">American Society for Investigative Pathology</span>)
        </div><div class="casAbstract">Lysyl oxidases, a family comprising LOX and four LOX-like enzymes, catalyze crosslinking of elastin and collagens.  Mouse Lox was recently shown to be crucial for development of the cardiovascular system because null mice died perinatally of aortic aneurysms and cardiovascular dysfunction.  We show here that Lox is also essential for development of the respiratory system and the integrity of elastic and collagen fibers in the lungs and skin.  The lungs of E18.5 Lox-/- embryos showed impaired development of the distal and proximal airways.  Elastic fibers in E18.5 Lox-/- lungs were markedly less intensely stained and more disperse than in the wild type, esp. in the mesenchyme surrounding the distal airways, bronchioles, bronchi, and trachea, and were fragmented in pulmonary arterial walls.  The organization of individual collagen fibers into tight bundles was likewise abnormal.  Similar elastic and collagen fiber abnormalities were seen in the skin.  Lysyl oxidase activity in cultured Lox-/- skin fibroblasts and aortic smooth muscle cells was reduced by ∼80%, indicating that Lox is the main isoenzyme in these cells.  LOX abnormalities may thus be crit. for the pathogenesis of several common diseases, including pulmonary, skin, and cardiovascular disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoEURMo0Cxd2rVg90H21EOLACvtfcHk0lgClLP4M0iXvA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtFKqtLrF&md5=f7add91e597d1658ae97c6ad455234f1</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1016%2Fs0002-9440%2810%2961183-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fs0002-9440%252810%252961183-2%26sid%3Dliteratum%253Aachs%26aulast%3DM%25C3%25A4ki%26aufirst%3DJ.%2BM.%26aulast%3DSormunen%26aufirst%3DR.%26aulast%3DLippo%26aufirst%3DS.%26aulast%3DKaarteenaho-Wiik%26aufirst%3DR.%26aulast%3DSoininen%26aufirst%3DR.%26aulast%3DMyllyharju%26aufirst%3DJ.%26atitle%3DLysyl%2520oxidase%2520is%2520essential%2520for%2520normal%2520development%2520and%2520function%2520of%2520the%2520respiratory%2520system%2520and%2520for%2520the%2520integrity%2520of%2520elastic%2520and%2520collagen%2520fibers%2520in%2520various%2520tissues%26jtitle%3DAm.%2520J.%2520Pathol.%26date%3D2005%26volume%3D167%26spage%3D927%26epage%3D936%26doi%3D10.1016%2Fs0002-9440%2810%2961183-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rodriguez, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinez-Gonzalez, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raposo, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alcudia, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guadall, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Badimon, L.</span></span> <span> </span><span class="NLM_article-title">Regulation of lysyl oxidase in vascular cells: lysyl oxidase as a new player in cardiovascular diseases</span>. <i>Cardiovasc. Res.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>79</i></span>,  <span class="NLM_fpage">7</span>– <span class="NLM_lpage">13</span>, <span class="refDoi"> DOI: 10.1093/cvr/cvn102</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=10.1093%2Fcvr%2Fcvn102" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=18469024" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=1%3ACAS%3A528%3ADC%252BD1cXnt1Sksbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79&publication_year=2008&pages=7-13&author=C.+Rodriguezauthor=J.+Martinez-Gonzalezauthor=B.+Raposoauthor=J.+F.+Alcudiaauthor=A.+Guadallauthor=L.+Badimon&title=Regulation+of+lysyl+oxidase+in+vascular+cells%3A+lysyl+oxidase+as+a+new+player+in+cardiovascular+diseases&doi=10.1093%2Fcvr%2Fcvn102"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Regulation of lysyl oxidase in vascular cells: lysyl oxidase as a new player in cardiovascular diseases</span></div><div class="casAuthors">Rodriguez, Cristina; Martinez-Gonzalez, Jose; Raposo, Berta; Alcudia, Javier F.; Guadall, Anna; Badimon, Lina</div><div class="citationInfo"><span class="NLM_cas:title">Cardiovascular Research</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">79</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">7-13</span>CODEN:
                <span class="NLM_cas:coden">CVREAU</span>;
        ISSN:<span class="NLM_cas:issn">0008-6363</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">A review.  Lysyl oxidase (LOX) plays a crucial role in the maintenance of extracellular matrix stability and could participate in vascular remodelling assocd. with cardiovascular diseases.  Evidence from in vitro and in vivo studies shows that LOX downregulation is assocd. with the endothelial dysfunction characteristic of earlier stages of the atherosclerotic process.  Conversely, upregulation of this enzyme in vascular cells could induce neointimal thickening in atherosclerosis and restenosis.  In fact, LOX is chemotactic for vascular smooth muscle cells and monocytes, is modulated by proliferative stimulus in these cells, and could control other cellular processes such as gene expression and cell transformation.  Furthermore, it is conceivable that LOX downregulation could underlie plaque instability and contribute to the destructive remodelling that takes place during aneurysm development.  Overall, LOX could play a key role in vascular homeostasis and, hence, it emerges as a new player in cardiovascular diseases.  This review addresses the exptl. evidence related to the role of LOX in vascular disorders and the potential benefits of controlling its expression and function.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr5WNMYo-ebGbVg90H21EOLACvtfcHk0lgClLP4M0iXvA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXnt1Sksbc%253D&md5=8bbbfe60f2936b1cca799a14c6213c0d</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1093%2Fcvr%2Fcvn102&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fcvr%252Fcvn102%26sid%3Dliteratum%253Aachs%26aulast%3DRodriguez%26aufirst%3DC.%26aulast%3DMartinez-Gonzalez%26aufirst%3DJ.%26aulast%3DRaposo%26aufirst%3DB.%26aulast%3DAlcudia%26aufirst%3DJ.%2BF.%26aulast%3DGuadall%26aufirst%3DA.%26aulast%3DBadimon%26aufirst%3DL.%26atitle%3DRegulation%2520of%2520lysyl%2520oxidase%2520in%2520vascular%2520cells%253A%2520lysyl%2520oxidase%2520as%2520a%2520new%2520player%2520in%2520cardiovascular%2520diseases%26jtitle%3DCardiovasc.%2520Res.%26date%3D2008%26volume%3D79%26spage%3D7%26epage%3D13%26doi%3D10.1093%2Fcvr%2Fcvn102" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Barry-Hamilton, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spangler, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marshall, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCauley, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodriguez, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oyasu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mikels, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vaysberg, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghermazien, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wai, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Velayo, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jorgensen, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biermann, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsai, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Green, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zaffryar-Eilot, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holzer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogg, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thai, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neufeld, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Vlasselaer, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, V.</span></span> <span> </span><span class="NLM_article-title">Allosteric inhibition of lysyl oxidase-like-2 impedes the development of a pathologic microenvironment</span>. <i>Nat. Med.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">1009</span>– <span class="NLM_lpage">1017</span>, <span class="refDoi"> DOI: 10.1038/nm.2208</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=10.1038%2Fnm.2208" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=20818376" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtFWksrvF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2010&pages=1009-1017&author=V.+Barry-Hamiltonauthor=R.+Spanglerauthor=D.+Marshallauthor=S.+McCauleyauthor=H.+M.+Rodriguezauthor=M.+Oyasuauthor=A.+Mikelsauthor=M.+Vaysbergauthor=H.+Ghermazienauthor=C.+Waiauthor=C.+A.+Garciaauthor=A.+C.+Velayoauthor=B.+Jorgensenauthor=D.+Biermannauthor=D.+Tsaiauthor=J.+Greenauthor=S.+Zaffryar-Eilotauthor=A.+Holzerauthor=S.+Oggauthor=D.+Thaiauthor=G.+Neufeldauthor=P.+Van+Vlasselaerauthor=V.+Smith&title=Allosteric+inhibition+of+lysyl+oxidase-like-2+impedes+the+development+of+a+pathologic+microenvironment&doi=10.1038%2Fnm.2208"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17aR"><div class="casContent"><span class="casTitleNuber">17a</span><div class="casTitle"><span class="NLM_cas:atitle">Allosteric inhibition of lysyl oxidase-like-2 impedes the development of a pathologic microenvironment</span></div><div class="casAuthors">Barry-Hamilton, Vivian; Spangler, Rhyannon; Marshall, Derek; McCauley, Scott; Rodriguez, Hector M.; Oyasu, Miho; Mikels, Amanda; Vaysberg, Maria; Ghermazien, Haben; Wai, Carol; Garcia, Carlos A.; Velayo, Arleene C.; Jorgensen, Brett; Biermann, Donna; Tsai, Daniel; Green, Jennifer; Zaffryar-Eilot, Shelly; Holzer, Alison; Ogg, Scott; Thai, Dung; Neufeld, Gera; Van Vlasselaer, Peter; Smith, Victoria</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1009-1017</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">We have identified a new role for the matrix enzyme lysyl oxidase-like-2 (LOXL2) in the creation and maintenance of the pathol. microenvironment of cancer and fibrotic disease.  Our anal. of biopsies from human tumors and fibrotic lung and liver tissues revealed an increase in LOXL2 in disease-assocd. stroma and limited expression in healthy tissues.  Targeting LOXL2 with an inhibitory monoclonal antibody (AB0023) was efficacious in both primary and metastatic xenograft models of cancer, as well as in liver and lung fibrosis models.  Inhibition of LOXL2 resulted in a marked redn. in activated fibroblasts, desmoplasia and endothelial cells, decreased prodn. of growth factors and cytokines and decreased transforming growth factor-β (TGF-β) pathway signaling.  AB0023 outperformed the small-mol. lysyl oxidase inhibitor β-aminopropionitrile.  The efficacy and safety of LOXL2-specific AB0023 represents a new therapeutic approach with broad applicability in oncol. and fibrotic diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpkE52VQCvcZrVg90H21EOLACvtfcHk0lgClLP4M0iXvA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtFWksrvF&md5=7e69cbf26c2985ad03fbb620538a5f04</span></div><a href="/servlet/linkout?suffix=cit17a&amp;dbid=16384&amp;doi=10.1038%2Fnm.2208&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm.2208%26sid%3Dliteratum%253Aachs%26aulast%3DBarry-Hamilton%26aufirst%3DV.%26aulast%3DSpangler%26aufirst%3DR.%26aulast%3DMarshall%26aufirst%3DD.%26aulast%3DMcCauley%26aufirst%3DS.%26aulast%3DRodriguez%26aufirst%3DH.%2BM.%26aulast%3DOyasu%26aufirst%3DM.%26aulast%3DMikels%26aufirst%3DA.%26aulast%3DVaysberg%26aufirst%3DM.%26aulast%3DGhermazien%26aufirst%3DH.%26aulast%3DWai%26aufirst%3DC.%26aulast%3DGarcia%26aufirst%3DC.%2BA.%26aulast%3DVelayo%26aufirst%3DA.%2BC.%26aulast%3DJorgensen%26aufirst%3DB.%26aulast%3DBiermann%26aufirst%3DD.%26aulast%3DTsai%26aufirst%3DD.%26aulast%3DGreen%26aufirst%3DJ.%26aulast%3DZaffryar-Eilot%26aufirst%3DS.%26aulast%3DHolzer%26aufirst%3DA.%26aulast%3DOgg%26aufirst%3DS.%26aulast%3DThai%26aufirst%3DD.%26aulast%3DNeufeld%26aufirst%3DG.%26aulast%3DVan%2BVlasselaer%26aufirst%3DP.%26aulast%3DSmith%26aufirst%3DV.%26atitle%3DAllosteric%2520inhibition%2520of%2520lysyl%2520oxidase-like-2%2520impedes%2520the%2520development%2520of%2520a%2520pathologic%2520microenvironment%26jtitle%3DNat.%2520Med.%26date%3D2010%26volume%3D16%26spage%3D1009%26epage%3D1017%26doi%3D10.1038%2Fnm.2208" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit17b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Schilter, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Findlay, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perryman, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yow, T. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moses, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zahoor, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turner, C. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deodhar, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foot, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greco, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joshi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rayner, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Townsend, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jarolimek, W.</span></span> <span> </span><span class="NLM_article-title">The lysyl oxidase like 2/3 enzymatic inhibitor, PXS-5153A, reduces crosslinks and ameliorates fibrosis</span>. <i>J. Cell Mol. Med.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">1759</span>– <span class="NLM_lpage">1770</span>, <span class="refDoi"> DOI: 10.1111/jcmm.14074</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=10.1111%2Fjcmm.14074" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=30536539" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=1%3ACAS%3A528%3ADC%252BC1MXjtVOmt7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2019&pages=1759-1770&author=H.+Schilterauthor=A.+D.+Findlayauthor=L.+Perrymanauthor=T.+T.+Yowauthor=J.+Mosesauthor=A.+Zahoorauthor=C.+I.+Turnerauthor=M.+Deodharauthor=J.+S.+Footauthor=W.+Zhouauthor=A.+Grecoauthor=A.+Joshiauthor=B.+Raynerauthor=S.+Townsendauthor=A.+Busonauthor=W.+Jarolimek&title=The+lysyl+oxidase+like+2%2F3+enzymatic+inhibitor%2C+PXS-5153A%2C+reduces+crosslinks+and+ameliorates+fibrosis&doi=10.1111%2Fjcmm.14074"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17bR"><div class="casContent"><span class="casTitleNuber">17b</span><div class="casTitle"><span class="NLM_cas:atitle">The lysyl oxidase like 2/3 enzymatic inhibitor, PXS-5153A, reduces crosslinks and ameliorates fibrosis</span></div><div class="casAuthors">Schilter, Heidi; Findlay, Alison D.; Perryman, Lara; Yow, Tin T.; Moses, Joshua; Zahoor, Amna; Turner, Craig I.; Deodhar, Mandar; Foot, Jonathan S.; Zhou, Wenbin; Greco, Angelique; Joshi, Amar; Rayner, Benjamin; Townsend, Sarah; Buson, Alberto; Jarolimek, Wolfgang</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cellular and Molecular Medicine</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1759-1770</span>CODEN:
                <span class="NLM_cas:coden">JCMMC9</span>;
        ISSN:<span class="NLM_cas:issn">1582-4934</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Fibrosis is characterized by the excessive deposition of extracellular matrix and crosslinked proteins, in particular collagen and elastin, leading to tissue stiffening and disrupted organ function.  Lysyl oxidases are key players during this process, as they initiate collagen crosslinking through the oxidn. of the ε-amino group of lysine or hydroxylysine on collagen side-chains, which subsequently dimerize to form immature, or trimerize to form mature, collagen crosslinks.  The role of LOXL2 in fibrosis and cancer is well documented, however the specific enzymic function of LOXL2 and LOXL3 during disease is less clear.  Herein, we describe the development of PXS-5153A, a novel mechanism based, fast-acting, dual LOXL2/LOXL3 inhibitor, which was used to interrogate the role of these enzymes in models of collagen crosslinking and fibrosis.  PXS-5153A dose-dependently reduced LOXL2-mediated collagen oxidn. and collagen crosslinking in vitro.  In two liver fibrosis models, carbon tetrachloride or streptozotocin/high fat diet-induced, PXS-5153A reduced disease severity and improved liver function by diminishing collagen content and collagen crosslinks.  In myocardial infarction, PXS-5153A improved cardiac output.  Taken together these results demonstrate that, due to their crucial role in collagen crosslinking, inhibition of the enzymic activities of LOXL2/LOXL3 represents an innovative therapeutic approach for the treatment of fibrosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrQ5kd2ThTrybVg90H21EOLACvtfcHk0lgmVvMEfmQUpw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXjtVOmt7k%253D&md5=f92defd2aada3c8b32bfc1fbdcc9efc9</span></div><a href="/servlet/linkout?suffix=cit17b&amp;dbid=16384&amp;doi=10.1111%2Fjcmm.14074&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fjcmm.14074%26sid%3Dliteratum%253Aachs%26aulast%3DSchilter%26aufirst%3DH.%26aulast%3DFindlay%26aufirst%3DA.%2BD.%26aulast%3DPerryman%26aufirst%3DL.%26aulast%3DYow%26aufirst%3DT.%2BT.%26aulast%3DMoses%26aufirst%3DJ.%26aulast%3DZahoor%26aufirst%3DA.%26aulast%3DTurner%26aufirst%3DC.%2BI.%26aulast%3DDeodhar%26aufirst%3DM.%26aulast%3DFoot%26aufirst%3DJ.%2BS.%26aulast%3DZhou%26aufirst%3DW.%26aulast%3DGreco%26aufirst%3DA.%26aulast%3DJoshi%26aufirst%3DA.%26aulast%3DRayner%26aufirst%3DB.%26aulast%3DTownsend%26aufirst%3DS.%26aulast%3DBuson%26aufirst%3DA.%26aulast%3DJarolimek%26aufirst%3DW.%26atitle%3DThe%2520lysyl%2520oxidase%2520like%25202%252F3%2520enzymatic%2520inhibitor%252C%2520PXS-5153A%252C%2520reduces%2520crosslinks%2520and%2520ameliorates%2520fibrosis%26jtitle%3DJ.%2520Cell%2520Mol.%2520Med.%26date%3D2019%26volume%3D23%26spage%3D1759%26epage%3D1770%26doi%3D10.1111%2Fjcmm.14074" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Vadasz, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kessler, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akiri, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gengrinovitch, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kagan, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baruch, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Izhak, O. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neufeld, G.</span></span> <span> </span><span class="NLM_article-title">Abnormal deposition of collagen around hepatocytes in Wilson’s disease is associated with hepatocyte specific expression of lysyl oxidase and lysyl oxidase like protein-2</span>. <i>J. Hepatol.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>43</i></span>,  <span class="NLM_fpage">499</span>– <span class="NLM_lpage">507</span>, <span class="refDoi"> DOI: 10.1016/j.jhep.2005.02.052</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=10.1016%2Fj.jhep.2005.02.052" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=16023247" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=1%3ACAS%3A528%3ADC%252BD2MXntVCku7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2005&pages=499-507&author=Z.+Vadaszauthor=O.+Kesslerauthor=G.+Akiriauthor=S.+Gengrinovitchauthor=H.+M.+Kaganauthor=Y.+Baruchauthor=O.+B.+Izhakauthor=G.+Neufeld&title=Abnormal+deposition+of+collagen+around+hepatocytes+in+Wilson%E2%80%99s+disease+is+associated+with+hepatocyte+specific+expression+of+lysyl+oxidase+and+lysyl+oxidase+like+protein-2&doi=10.1016%2Fj.jhep.2005.02.052"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18aR"><div class="casContent"><span class="casTitleNuber">18a</span><div class="casTitle"><span class="NLM_cas:atitle">Abnormal deposition of collagen around hepatocytes in Wilson's disease is associated with hepatocyte specific expression of lysyl oxidase and lysyl oxidase like protein-2</span></div><div class="casAuthors">Vadasz, Zehava; Kessler, Ofra; Akiri, Gal; Gengrinovitch, Stela; Kagan, Herbert M.; Baruch, Yaacov; Ben Izhak, Ofer; Neufeld, Gera</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Hepatology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">499-507</span>CODEN:
                <span class="NLM_cas:coden">JOHEEC</span>;
        ISSN:<span class="NLM_cas:issn">0168-8278</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Lysyl-oxidases catalyze the oxidn. of lysine residues in collagen and elastin thereby promoting their polymn.  We have studied here the expression of four lysyl-oxidases in normal and diseased human liver.  The expression of the different lysyl-oxidases in paraffin embedded liver sections was studied using in-situ hybridization and immunohistochem.  The enzymic activity of lysyl-oxidase like protein-2 (Loxl2 or LOR-1) using a previously described lysyl-oxidase assay.  We have found that the four lysyl-oxidases which we examd. are not significantly expressed in the normal liver.  By contrast, Wilson's disease and primary biliary cirrhosis (PBC) patients express lysyl-oxidase (Lox) and lysyl-oxidase like protein-2 (Loxl2 or LOR-1) in hepatocytes, and the expression is accompanied by collagen deposition around the hepatocytes.  Lysyl-oxidases are also expressed in addnl. fibrotic liver diseases such as hepatitis B and C but in these diseases the expression is confined to the fibrotic lesions and collagen does not accumulate around hepatocytes.  We have found that Loxl2 is able to oxidize lysine residues of collagen, and behaves in that respect similarly to Lox.  The copper chelator D-penicillamine inhibits Loxl2 induced oxidn. of collagen but the Lox inhibitor β-aminopropionitrile did not inhibit the oxidn. using a BAPN concn. at which Lox activity was completely inhibited.  Loxl2 also catalyzed the oxidn. of cell surface proteins on HepG2 hepatoblastoma cells and inhibited their proliferation.  Upregulation of Lox and Loxl2 in hepatocytes of Wilson's disease and PBC patients may contribute to liver damage by various mechanisms.  The upregulation of Lox and Loxl2 in Wilson's disease could perhaps be utilized for diagnostic purposes since their expression is up-regulated in hepatocytes even before the onset of fibrosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGquJY1mygQQD7Vg90H21EOLACvtfcHk0lgmVvMEfmQUpw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXntVCku7Y%253D&md5=e7bdaa18a58921c64db0eda33285ec80</span></div><a href="/servlet/linkout?suffix=cit18a&amp;dbid=16384&amp;doi=10.1016%2Fj.jhep.2005.02.052&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jhep.2005.02.052%26sid%3Dliteratum%253Aachs%26aulast%3DVadasz%26aufirst%3DZ.%26aulast%3DKessler%26aufirst%3DO.%26aulast%3DAkiri%26aufirst%3DG.%26aulast%3DGengrinovitch%26aufirst%3DS.%26aulast%3DKagan%26aufirst%3DH.%2BM.%26aulast%3DBaruch%26aufirst%3DY.%26aulast%3DIzhak%26aufirst%3DO.%2BB.%26aulast%3DNeufeld%26aufirst%3DG.%26atitle%3DAbnormal%2520deposition%2520of%2520collagen%2520around%2520hepatocytes%2520in%2520Wilson%25E2%2580%2599s%2520disease%2520is%2520associated%2520with%2520hepatocyte%2520specific%2520expression%2520of%2520lysyl%2520oxidase%2520and%2520lysyl%2520oxidase%2520like%2520protein-2%26jtitle%3DJ.%2520Hepatol.%26date%3D2005%26volume%3D43%26spage%3D499%26epage%3D507%26doi%3D10.1016%2Fj.jhep.2005.02.052" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit18b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Dongiovanni, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meroni, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baselli, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bassani, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rametta, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pietrelli, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maggioni, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Facciotti, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trunzo, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Badiali, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fargion, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gatti, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valenti, L.</span></span> <span> </span><span class="NLM_article-title">Insulin resistance promotes lysyl oxidase like 2 induction and fibrosis accumulation in non-alcoholic fatty liver disease</span>. <i>Clin. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>131</i></span>,  <span class="NLM_fpage">1301</span>– <span class="NLM_lpage">1315</span>, <span class="refDoi"> DOI: 10.1042/cs20170175</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=10.1042%2Fcs20170175" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=28468951" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhslCntbfM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=131&publication_year=2017&pages=1301-1315&author=P.+Dongiovanniauthor=M.+Meroniauthor=G.+A.+Baselliauthor=G.+A.+Bassaniauthor=R.+Ramettaauthor=A.+Pietrelliauthor=M.+Maggioniauthor=F.+Facciottiauthor=V.+Trunzoauthor=S.+Badialiauthor=S.+Fargionauthor=S.+Gattiauthor=L.+Valenti&title=Insulin+resistance+promotes+lysyl+oxidase+like+2+induction+and+fibrosis+accumulation+in+non-alcoholic+fatty+liver+disease&doi=10.1042%2Fcs20170175"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18bR"><div class="casContent"><span class="casTitleNuber">18b</span><div class="casTitle"><span class="NLM_cas:atitle">Insulin resistance promotes Lysyl Oxidase Like 2 induction and fibrosis accumulation in non-alcoholic fatty liver disease</span></div><div class="casAuthors">Dongiovanni, Paola; Meroni, Marica; Baselli, Guido Alessandro; Bassani, Giulia Alessandra; Rametta, Raffaela; Pietrelli, Alessandro; Maggioni, Marco; Facciotti, Federica; Trunzo, Valentina; Badiali, Sara; Fargion, Silvia; Gatti, Stefano; Valenti, Luca</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Science</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">131</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1301-1315</span>CODEN:
                <span class="NLM_cas:coden">CSCIAE</span>;
        ISSN:<span class="NLM_cas:issn">1470-8736</span>.
    
            (<span class="NLM_cas:orgname">Portland Press Ltd.</span>)
        </div><div class="casAbstract">In patients with non-alc. fatty liver disease (NAFLD), insulin resistance (IR) assocs. with fibrosis progression independently of the hepatic inflammation, but the mechanisms are still unclear.  We modeled the independent contribution of inflammation (non-alc. steatohepatitis: NASH) by exploiting the methionine-choline deficient (MCD) diet, and that of IR by insulin receptor (InsR) haploinsufficieny (InsR+/-) in the pathogenesis of liver fibrosis in C57BL/6 mice.  We confirmed the study findings in 96 patients with NAFLD.  InsR+/- enhanced hepatic fat content and impaired hepatic insulin signaling leading to Forkhead box protein O1 (FoxO1) accumulation in MCD-fed mice.  Remarkably, despite reduced inflammation and hampered transdifferentiation of hepatic stellate cells (HSCs), InsR+/- promoted hepatic fibrosis accumulation, which correlated with the induction of the Lysyl Oxidase Like 2 (Loxl2), involved in matrix stabilization.  Loxl2 up-regulation was not a cell autonomous property of insulin resistant HSCs, but was dependent on microparticles (MPs) released specifically by insulin resistant hepatocytes (HEPs) exposed to fatty acids.  The mechanism entailed FoxO1 up-regulation, as FoxO1 silencing normalized Loxl2 expression reversing fibrosis in InsR+/- MCD-fed mice.  Loxl2 up-regulation was similarly detected during IR induced by obesity, but not by lipogenic stimuli (fructose feeding).  Most importantly, LOXL2 up-regulation was obsd. in NAFLD patients with type 2 diabetes (T2D) and LOXL2 hepatic and circulating levels correlated with histol. fibrosis progression.  IR favors fibrosis deposition independently of the classic 'inflammation - HSC transdifferentiation' pathway.  The mechanism entails a cross-talk between enhanced lipotoxicity in insulin resistant HEPs and Loxl2 prodn. by HSCs, which was confirmed in patients with diabetes, thereby facilitating extracellular matrix (ECM) stabilization.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpS5cO1t-WtPrVg90H21EOLACvtfcHk0ljZrMBUAnFgkA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhslCntbfM&md5=74cbc48dee07ec615eb22e2342d1a77c</span></div><a href="/servlet/linkout?suffix=cit18b&amp;dbid=16384&amp;doi=10.1042%2Fcs20170175&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1042%252Fcs20170175%26sid%3Dliteratum%253Aachs%26aulast%3DDongiovanni%26aufirst%3DP.%26aulast%3DMeroni%26aufirst%3DM.%26aulast%3DBaselli%26aufirst%3DG.%2BA.%26aulast%3DBassani%26aufirst%3DG.%2BA.%26aulast%3DRametta%26aufirst%3DR.%26aulast%3DPietrelli%26aufirst%3DA.%26aulast%3DMaggioni%26aufirst%3DM.%26aulast%3DFacciotti%26aufirst%3DF.%26aulast%3DTrunzo%26aufirst%3DV.%26aulast%3DBadiali%26aufirst%3DS.%26aulast%3DFargion%26aufirst%3DS.%26aulast%3DGatti%26aufirst%3DS.%26aulast%3DValenti%26aufirst%3DL.%26atitle%3DInsulin%2520resistance%2520promotes%2520lysyl%2520oxidase%2520like%25202%2520induction%2520and%2520fibrosis%2520accumulation%2520in%2520non-alcoholic%2520fatty%2520liver%2520disease%26jtitle%3DClin.%2520Sci.%26date%3D2017%26volume%3D131%26spage%3D1301%26epage%3D1315%26doi%3D10.1042%2Fcs20170175" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chien, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richards, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gibson, K. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindell, K. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lyman, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adamkewicz, J. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaminski, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Riordan, T.</span></span> <span> </span><span class="NLM_article-title">Serum lysyl oxidase-like 2 levels and idiopathic pulmonary fibrosis disease progression</span>. <i>Eur. Respir. J.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>43</i></span>,  <span class="NLM_fpage">1430</span>– <span class="NLM_lpage">1438</span>, <span class="refDoi"> DOI: 10.1183/09031936.00141013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=10.1183%2F09031936.00141013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=24177001" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtVKnu73I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2014&pages=1430-1438&author=J.+W.+Chienauthor=T.+J.+Richardsauthor=K.+F.+Gibsonauthor=Y.+Zhangauthor=K.+O.+Lindellauthor=L.+Shaoauthor=S.+K.+Lymanauthor=J.+I.+Adamkewiczauthor=V.+Smithauthor=N.+Kaminskiauthor=T.+O%E2%80%99Riordan&title=Serum+lysyl+oxidase-like+2+levels+and+idiopathic+pulmonary+fibrosis+disease+progression&doi=10.1183%2F09031936.00141013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Serum lysyl, oxidase-like 2 levels and idiopathic pulmonary fibrosis disease progression</span></div><div class="casAuthors">Chien, Jason W.; Richards, Thomas J.; Gibson, Kevin F.; Zhang, Yingze; Lindell, Kathleen O.; Shao, Lixin; Lyman, Susan K.; Adamkewicz, Joanne I.; Smith, Victoria; Kaminski, Naftali; O'Riordan, Thomas</div><div class="citationInfo"><span class="NLM_cas:title">European Respiratory Journal</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1430-1438</span>CODEN:
                <span class="NLM_cas:coden">ERJOEI</span>;
        ISSN:<span class="NLM_cas:issn">0903-1936</span>.
    
            (<span class="NLM_cas:orgname">European Respiratory Society</span>)
        </div><div class="casAbstract">We evaluated whether lysyl oxidase-like 2 (LOXL2), which promotes crosslinking of collagen in pathol. stroma, was detectable in serum from idiopathic pulmonary fibrosis (IPF) patients, and assessed its relationship with IPF disease progression.  Patients from the ARTEMIS-IPF (n=69) and the Genomic and Proteomic Anal. of Disease Progression in IPF (GAP) (n=104) studies were analyzed.  Baseline serum LOXL2 (sLOXL2) levels were compared with baseline clin. and physiol. surrogates of disease severity, and the assocn. with IPF disease progression was assessed using a classification and regression tree (CART) method.  SLOXL2 correlated weakly with forced vital capacity and carbon monoxide diffusion capacity (r -0.24-0.05) in both cohorts.  CART-detd. thresholds were similar: ARTEMIS-IPF 800 pg·mL-1 and GAP 700 pg·mL-1.  In ARTEMIS-IPF, higher sLOXL2 (>800 pg·mL-1) was assocd. with increased risk for disease progression (hazard ratio (HR) 5.41, 95% CI 1.65-17.73).  Among GAP subjects with baseline spirometric data (n=70), higher sLOXL2 levels (>700 pg·mL-1) were assocd. with more disease progression events (HR 1.78, 95% CI 1.01-3.11).  Among all GAP subjects, higher sLOXL2 levels were assocd. with increased risk for mortality (HR 2.28, 95% CI 1.18-4.38).  These results suggest that higher sLOXL2 levels are assocd. with increased risk for IPF disease progression.  However, due to multiple limitations, these results require validation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr8WyURMNVsBLVg90H21EOLACvtfcHk0ljZrMBUAnFgkA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtVKnu73I&md5=60faa18c94ef9c37937579571a905faa</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1183%2F09031936.00141013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1183%252F09031936.00141013%26sid%3Dliteratum%253Aachs%26aulast%3DChien%26aufirst%3DJ.%2BW.%26aulast%3DRichards%26aufirst%3DT.%2BJ.%26aulast%3DGibson%26aufirst%3DK.%2BF.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DLindell%26aufirst%3DK.%2BO.%26aulast%3DShao%26aufirst%3DL.%26aulast%3DLyman%26aufirst%3DS.%2BK.%26aulast%3DAdamkewicz%26aufirst%3DJ.%2BI.%26aulast%3DSmith%26aufirst%3DV.%26aulast%3DKaminski%26aufirst%3DN.%26aulast%3DO%25E2%2580%2599Riordan%26aufirst%3DT.%26atitle%3DSerum%2520lysyl%2520oxidase-like%25202%2520levels%2520and%2520idiopathic%2520pulmonary%2520fibrosis%2520disease%2520progression%26jtitle%3DEur.%2520Respir.%2520J.%26date%3D2014%26volume%3D43%26spage%3D1430%26epage%3D1438%26doi%3D10.1183%2F09031936.00141013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span> <span> </span><span class="NLM_article-title">Comparison of Loxl-2 expression between active systematic scleroderma and active mixed connective tissue disease</span>. <i>J. China Med. Univ.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>45</i></span>,  <span class="NLM_fpage">414</span>– <span class="NLM_lpage">416</span>, <span class="refDoi"> DOI: 10.12007/j.issn.0258-4646.2016.05.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=10.12007%2Fj.issn.0258-4646.2016.05.008" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2016&pages=414-416&author=Y.+Chengauthor=X.+Wangauthor=X.+Zhangauthor=N.+Zhangauthor=X.+Zhang&title=Comparison+of+Loxl-2+expression+between+active+systematic+scleroderma+and+active+mixed+connective+tissue+disease&doi=10.12007%2Fj.issn.0258-4646.2016.05.008"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.12007%2Fj.issn.0258-4646.2016.05.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.12007%252Fj.issn.0258-4646.2016.05.008%26sid%3Dliteratum%253Aachs%26aulast%3DCheng%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DN.%26aulast%3DZhang%26aufirst%3DX.%26atitle%3DComparison%2520of%2520Loxl-2%2520expression%2520between%2520active%2520systematic%2520scleroderma%2520and%2520active%2520mixed%2520connective%2520tissue%2520disease%26jtitle%3DJ.%2520China%2520Med.%2520Univ.%26date%3D2016%26volume%3D45%26spage%3D414%26epage%3D416%26doi%3D10.12007%2Fj.issn.0258-4646.2016.05.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Janyasupab, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, Y. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Popa, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Samia, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wendt, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schiemann, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schiemann, W. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, C. C.</span></span> <span> </span><span class="NLM_article-title">Detection of lysyl oxidase-like 2 (LOXL2), a biomarker of metastasis from breast cancers using human blood samples</span>. <i>Recent Pat. Biomarkers</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">93</span>– <span class="NLM_lpage">100</span>, <span class="refDoi"> DOI: 10.2174/2210309005666150804195033</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=10.2174%2F2210309005666150804195033" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=28670509" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=1%3ACAS%3A528%3ADC%252BC28XnvFyhug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2015&pages=93-100&author=M.+Janyasupabauthor=Y.+H.+Leeauthor=Y.+Zhangauthor=C.+W.+Liuauthor=J.+Caiauthor=A.+Popaauthor=A.+Samiaauthor=K.+W.+Wangauthor=J.+Xuauthor=C.+C.+Huauthor=M.+K.+Wendtauthor=B.+J.+Schiemannauthor=C.+L.+Thompsonauthor=Y.+Yenauthor=W.+P.+Schiemannauthor=C.+C.+Liu&title=Detection+of+lysyl+oxidase-like+2+%28LOXL2%29%2C+a+biomarker+of+metastasis+from+breast+cancers+using+human+blood+samples&doi=10.2174%2F2210309005666150804195033"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21aR"><div class="casContent"><span class="casTitleNuber">21a</span><div class="casTitle"><span class="NLM_cas:atitle">detection of lysyl oxidase-like 2 (LOXL2), a biomarker of metastasis from breast cancers using human blood samples</span></div><div class="casAuthors">Janyasupab, Metini; Lee, Ying-Hui; Zhang, Yuan; Liu, Chen W.; Cai, Jieyi; Popa, Adriana; Samia, Anna C.; Wang, Kuan W.; Xu, Jiaqiang; Hu, Chi-Chang; Wendt, Michael K.; Schiemann, Barbara J.; Thompson, Cheryl L.; Yen, Yun; Schiemann, William P.; Liu, Chung C.</div><div class="citationInfo"><span class="NLM_cas:title">Recent Patents on Biomarkers</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">93-100</span>CODEN:
                <span class="NLM_cas:coden">RPBEE9</span>;
        ISSN:<span class="NLM_cas:issn">2210-3090</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">Metastasis accounts for 90% of the mortality assocd. with breast cancer.  Upregulated expression of members of the lysyl oxidase (LOX) family of secreted copper amine oxidases catalyzes the crosslinking of collagens and elastin in the extracellular matrix.  LOXs are linked to the development and metastatic progression of breast cancers.  Accordingly, aberrant expression of LOX-like 2 (LOXL2) is obsd. in poorly differentiated, high-grade tumors and is predictive of diseases recurrence, and for decreased overall patient survival.  Therefore, LOXL2 expression may serve as a biomarker for breast cancer.  Mechanistically, hydrogen peroxide is produced as a byproduct of LOXL2 when using an appropriate substrate, lysine.  We exploited this chem. to generate a revolutionary gold-based electrochem. biosensor capable of accurately detecting nanomolar quantities of LOXL2 in mouse blood, and in human blood samples.  Two different sources of the blood samples obtained from breast cancer patients were used in this study indicating the applicability of detecting LOXL2 in breast cancers patients.  Limited nos. of urine specimens from breast cancer patients were also tested.  Collectively, all of these tests show the promise and potential of this biosensor for detecting LOXL2 as a surrogate biomarker of breast cancer.  This work is described in patent no. WO2014052962 (2014).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqVBL7B7w1T4rVg90H21EOLACvtfcHk0ljZrMBUAnFgkA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XnvFyhug%253D%253D&md5=562b9bd70fa572df92227ee2d10f7de0</span></div><a href="/servlet/linkout?suffix=cit21a&amp;dbid=16384&amp;doi=10.2174%2F2210309005666150804195033&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F2210309005666150804195033%26sid%3Dliteratum%253Aachs%26aulast%3DJanyasupab%26aufirst%3DM.%26aulast%3DLee%26aufirst%3DY.%2BH.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DC.%2BW.%26aulast%3DCai%26aufirst%3DJ.%26aulast%3DPopa%26aufirst%3DA.%26aulast%3DSamia%26aufirst%3DA.%26aulast%3DWang%26aufirst%3DK.%2BW.%26aulast%3DXu%26aufirst%3DJ.%26aulast%3DHu%26aufirst%3DC.%2BC.%26aulast%3DWendt%26aufirst%3DM.%2BK.%26aulast%3DSchiemann%26aufirst%3DB.%2BJ.%26aulast%3DThompson%26aufirst%3DC.%2BL.%26aulast%3DYen%26aufirst%3DY.%26aulast%3DSchiemann%26aufirst%3DW.%2BP.%26aulast%3DLiu%26aufirst%3DC.%2BC.%26atitle%3DDetection%2520of%2520lysyl%2520oxidase-like%25202%2520%2528LOXL2%2529%252C%2520a%2520biomarker%2520of%2520metastasis%2520from%2520breast%2520cancers%2520using%2520human%2520blood%2520samples%26jtitle%3DRecent%2520Pat.%2520Biomarkers%26date%3D2015%26volume%3D5%26spage%3D93%26epage%3D100%26doi%3D10.2174%2F2210309005666150804195033" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit21b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Torres, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia-Palmero, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herrera, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bartolome, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pena, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernandez-Acenero, M.
J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Padilla, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pelaez-Garcia, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lopez-Lucendo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodriguez-Merlo, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Herreros, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonilla, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casal, J. I.</span></span> <span> </span><span class="NLM_article-title">LOXL2 is highly expressed in cancer-associated fibroblasts and associates to poor colon cancer survival</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">4892</span>– <span class="NLM_lpage">4902</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.ccr-14-3096</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=10.1158%2F1078-0432.ccr-14-3096" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=26206869" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvVWqsrjL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2015&pages=4892-4902&author=S.+Torresauthor=I.+Garcia-Palmeroauthor=M.+Herreraauthor=R.+A.+Bartolomeauthor=C.+Penaauthor=M.%0AJ.+Fernandez-Aceneroauthor=G.+Padillaauthor=A.+Pelaez-Garciaauthor=M.+Lopez-Lucendoauthor=R.+Rodriguez-Merloauthor=A.+G.+de+Herrerosauthor=F.+Bonillaauthor=J.+I.+Casal&title=LOXL2+is+highly+expressed+in+cancer-associated+fibroblasts+and+associates+to+poor+colon+cancer+survival&doi=10.1158%2F1078-0432.ccr-14-3096"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21bR"><div class="casContent"><span class="casTitleNuber">21b</span><div class="casTitle"><span class="NLM_cas:atitle">LOXL2 Is Highly Expressed in Cancer-Associated Fibroblasts and Associates to Poor Colon Cancer Survival</span></div><div class="casAuthors">Torres, Sofia; Garcia-Palmero, Irene; Herrera, Mercedes; Bartolome, Ruben A.; Pena, Cristina; Fernandez-Acenero, M. Jesus; Padilla, Guillermo; Pelaez-Garcia, Alberto; Lopez-Lucendo, Maria; Rodriguez-Merlo, Rufo; de Herreros, Antonio Garcia; Bonilla, Felix; Casal, J. Ignacio</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">4892-4902</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: Cancer-assocd. fibroblasts (CAF) are major mediators in tumor microenvironment.  We investigated the changes in protein expression in colon cancer-assocd. fibroblasts compared with normal fibroblasts (NF) in the context of searching for prognostic biomarkers, particularly for stage II patients.  Exptl. Design: CAFs and NFs isolated from colon cancer patients were used to identify differentially expressed proteins using quant. proteomics.  Stromal expression of deregulated proteins was analyzed by IHC.  Prognostic impact was studied using external gene-expression datasets for training, then quant. PCR and IHC for validation in different cohorts of patients.  Combined datasets were used for prediction of risk assessment at stages II and III.  Results: A desmoplastic signature composed of 32 proteins, highly specific for stromal components in colon cancer, was identified.  These proteins were enriched for extracellular matrix organization components, TGFβ signaling pathway, fibrosis, and wound-healing proteins.  The expression in CAFs of 11 upregulated proteins and four downregulated proteins, selected for biomarker validation, was verified by orthogonal techniques.  LOXL2 displayed a high prognostic impact by using external independent datasets and further validation in two different cohorts of patients.  High expression of LOXL2 was assocd. with higher recurrence P = 0.001 HR, 5.38 [95% confidence interval (CI), 1.70-17.01] and overall survival P = 0.001 HR, 8.52 (95% CI, 1.90-38.29).  IHC anal. revealed a prognostic value for LOXL2 in stage II patients.  Conclusions: We identified LOXL2 to be assocd. with the outcome of colon cancer patients.  Furthermore, it can be used to stratify patients at stages II and III for further therapeutic decisions.  Clin Cancer Res; 21(21); 4892-902. ©2015 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqpODhjbmk7hLVg90H21EOLACvtfcHk0lgiiLSfGyIIJw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvVWqsrjL&md5=e66ea1a97471e80cb5f7f13804afd7b3</span></div><a href="/servlet/linkout?suffix=cit21b&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.ccr-14-3096&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.ccr-14-3096%26sid%3Dliteratum%253Aachs%26aulast%3DTorres%26aufirst%3DS.%26aulast%3DGarcia-Palmero%26aufirst%3DI.%26aulast%3DHerrera%26aufirst%3DM.%26aulast%3DBartolome%26aufirst%3DR.%2BA.%26aulast%3DPena%26aufirst%3DC.%26aulast%3DFernandez-Acenero%26aufirst%3DM.%2BJ.%26aulast%3DPadilla%26aufirst%3DG.%26aulast%3DPelaez-Garcia%26aufirst%3DA.%26aulast%3DLopez-Lucendo%26aufirst%3DM.%26aulast%3DRodriguez-Merlo%26aufirst%3DR.%26aulast%3Dde%2BHerreros%26aufirst%3DA.%2BG.%26aulast%3DBonilla%26aufirst%3DF.%26aulast%3DCasal%26aufirst%3DJ.%2BI.%26atitle%3DLOXL2%2520is%2520highly%2520expressed%2520in%2520cancer-associated%2520fibroblasts%2520and%2520associates%2520to%2520poor%2520colon%2520cancer%2520survival%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2015%26volume%3D21%26spage%3D4892%26epage%3D4902%26doi%3D10.1158%2F1078-0432.ccr-14-3096" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pollheimer, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Racedo, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mikels-Vigdal, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marshall, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bowlus, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lackner, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Madl, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karlsen, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hov, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lyman, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adamkewicz, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moreau, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zollner, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eide, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stojakovic, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scharnagl, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gruber, H.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stauber, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trauner, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fickert, P.</span></span> <span> </span><span class="NLM_article-title">Lysyl oxidase-like protein 2 (LOXL2) modulates barrier function in cholangiocytes in cholestasis</span>. <i>J. Hepatol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>69</i></span>,  <span class="NLM_fpage">368</span>– <span class="NLM_lpage">377</span>, <span class="refDoi"> DOI: 10.1016/j.jhep.2018.04.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=10.1016%2Fj.jhep.2018.04.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=29709678" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=1%3ACAS%3A528%3ADC%252BC1cXptlaqt7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2018&pages=368-377&author=M.+J.+Pollheimerauthor=S.+Racedoauthor=A.+Mikels-Vigdalauthor=D.+Marshallauthor=C.+Bowlusauthor=C.+Lacknerauthor=T.+Madlauthor=T.+H.+Karlsenauthor=J.+R.+Hovauthor=S.+K.+Lymanauthor=J.+Adamkewiczauthor=V.+Smithauthor=E.+Moreauauthor=G.+Zollnerauthor=T.+J.+Eideauthor=T.+Stojakovicauthor=H.+Scharnaglauthor=H.-J.+Gruberauthor=R.+E.+Stauberauthor=M.+Traunerauthor=P.+Fickert&title=Lysyl+oxidase-like+protein+2+%28LOXL2%29+modulates+barrier+function+in+cholangiocytes+in+cholestasis&doi=10.1016%2Fj.jhep.2018.04.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Lysyl oxidase-like protein 2 (LOXL2) modulates barrier function in cholangiocytes in cholestasis</span></div><div class="casAuthors">Pollheimer, Marion J.; Racedo, Silvia; Mikels-Vigdal, Amanda; Marshall, Derek; Bowlus, Christopher; Lackner, Carolin; Madl, Tobias; Karlsen, Tom H.; Hov, Johannes R.; Lyman, Susan K.; Adamkewicz, Joanne; Smith, Victoria; Moreau, Emmanuel; Zollner, Gernot; Eide, Tor Jacob; Stojakovic, Tatjana; Scharnagl, Hubert; Gruber, Hans-Juergen; Stauber, Rudolf E.; Trauner, Michael; Fickert, Peter</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Hepatology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">69</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">368-377</span>CODEN:
                <span class="NLM_cas:coden">JOHEEC</span>;
        ISSN:<span class="NLM_cas:issn">0168-8278</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The lysyl oxidase-like protein 2 (LOXL2) promotes stabilization of the extracellular matrix, chemotaxis, cell growth and cell mobility.  We aimed to (i) identify stimuli of LOXL2 in cholangiopathies, (ii) characterize the effects of LOXL2 on biliary epithelial cells' (BECs) barrier function, (iii) compare LOXL2 expression in primary sclerosing cholangitis (PSC), primary biliary cholangitis, and disease controls, and (iv) to det. LOXL2 expression and its cellular sources in four mouse models of cholangiopathies.  Cultured murine BECs were challenged with well-known triggers of cellular senescence, hypoxia, phospholipid-deficient Abcb4-/- mouse bile and chenodeoxycholic acid and investigated for LOXL2, SNAIL1 and E-cadherin expression and transepithelial elec. resistance with and without LOX-inhibition.  In vivo, LOXL2 expression was studied in PSC livers, and controls and mouse models.  We compared LOXL2 serum levels in patients with PSC, secondary SC, primary biliary cholangitis, and controls.  Cellular senescence, hypoxia, Abcb4-/- bile and chenodeoxycholic acid induced LOXL2 and SNAIL1 expression, repressed E-cadherin expression, and significantly reduced transepithelial elec. resistance in BECs.  Notably, all of the pathol. changes could be recovered via pharmacol. LOX-inhibition.  Mouse models showed induced LOXL2 expression in the portal region and in assocn. with ductular reaction.  LOXL2 serum levels were significantly elevated in patients with cholangiopathies.  In PSC, LOXL2 expression was located to characteristic periductal onion skin-type fibrosis, ductular reaction, Kupffer cells, and fibrotic septa.  Importantly, in PSC, LOXL2 overexpression was paralleled by E-cadherin loss in BECs from medium-sized bile ducts.Reactive BECs produce LOXL2, resulting in increased tight junction permeability, which can be ameliorated by pharmacol. LOX-inhibition in vitro.  Reactive BECs, portal myofibroblasts, and Kupffer cells are the main sources of LOXL2 in cholangiopathies.  In this study, we investigate the role of lysyl oxidase-like protein 2 (LOXL2), an enzyme pivotal in the development of organ fibrosis, in the pathogenesis of cholangiopathies (diseases of bile ducts), such as primary sclerosing cholangitis.  We found LOXL2 to be expressed in assocn. with bile duct epithelial injury and uncovered mechanisms for its upregulation and the subsequent effects in vitro and in vivo.  Our findings support testing of anti-LOXL2 treatment strategies for patients with primary sclerosing cholangitis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrd9j53GNHPxrVg90H21EOLACvtfcHk0lgiiLSfGyIIJw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXptlaqt7o%253D&md5=eed5fe5e82dd7a0eecfaa896cdc7ff2b</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1016%2Fj.jhep.2018.04.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jhep.2018.04.009%26sid%3Dliteratum%253Aachs%26aulast%3DPollheimer%26aufirst%3DM.%2BJ.%26aulast%3DRacedo%26aufirst%3DS.%26aulast%3DMikels-Vigdal%26aufirst%3DA.%26aulast%3DMarshall%26aufirst%3DD.%26aulast%3DBowlus%26aufirst%3DC.%26aulast%3DLackner%26aufirst%3DC.%26aulast%3DMadl%26aufirst%3DT.%26aulast%3DKarlsen%26aufirst%3DT.%2BH.%26aulast%3DHov%26aufirst%3DJ.%2BR.%26aulast%3DLyman%26aufirst%3DS.%2BK.%26aulast%3DAdamkewicz%26aufirst%3DJ.%26aulast%3DSmith%26aufirst%3DV.%26aulast%3DMoreau%26aufirst%3DE.%26aulast%3DZollner%26aufirst%3DG.%26aulast%3DEide%26aufirst%3DT.%2BJ.%26aulast%3DStojakovic%26aufirst%3DT.%26aulast%3DScharnagl%26aufirst%3DH.%26aulast%3DGruber%26aufirst%3DH.-J.%26aulast%3DStauber%26aufirst%3DR.%2BE.%26aulast%3DTrauner%26aufirst%3DM.%26aulast%3DFickert%26aufirst%3DP.%26atitle%3DLysyl%2520oxidase-like%2520protein%25202%2520%2528LOXL2%2529%2520modulates%2520barrier%2520function%2520in%2520cholangiocytes%2520in%2520cholestasis%26jtitle%3DJ.%2520Hepatol.%26date%3D2018%26volume%3D69%26spage%3D368%26epage%3D377%26doi%3D10.1016%2Fj.jhep.2018.04.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ikenaga, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, Z.-W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vaid, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshida, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sverdlov, D. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mikels-Vigdal, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schuppan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Popov, Y. V.</span></span> <span> </span><span class="NLM_article-title">Selective targeting of lysyl oxidase-like 2 (LOXL2) suppresses hepatic fibrosis progression and accelerates its reversal</span>. <i>Gut</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>66</i></span>,  <span class="NLM_fpage">1697</span>– <span class="NLM_lpage">1708</span>, <span class="refDoi"> DOI: 10.1136/gutjnl-2016-312473</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=10.1136%2Fgutjnl-2016-312473" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=28073888" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitVShurvP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2017&pages=1697-1708&author=N.+Ikenagaauthor=Z.-W.+Pengauthor=K.+A.+Vaidauthor=S.+B.+Liuauthor=S.+Yoshidaauthor=D.+Y.+Sverdlovauthor=A.+Mikels-Vigdalauthor=V.+Smithauthor=D.+Schuppanauthor=Y.+V.+Popov&title=Selective+targeting+of+lysyl+oxidase-like+2+%28LOXL2%29+suppresses+hepatic+fibrosis+progression+and+accelerates+its+reversal&doi=10.1136%2Fgutjnl-2016-312473"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Selective targeting of lysyl oxidase-like 2 (LOXL2) suppresses hepatic fibrosis progression and accelerates its reversal</span></div><div class="casAuthors">Ikenaga, Naoki; Peng, Zhen-Wei; Vaid, Kahini A.; Liu, Susan B.; Yoshida, Shuhei; Sverdlov, Deanna Y.; Mikels-Vigdal, Amanda; Smith, Victoria; Schuppan, Detlef; Popov, Yury V.</div><div class="citationInfo"><span class="NLM_cas:title">Gut</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1697-1709</span>CODEN:
                <span class="NLM_cas:coden">GUTTAK</span>;
        ISSN:<span class="NLM_cas:issn">0017-5749</span>.
    
            (<span class="NLM_cas:orgname">BMJ Publishing Group</span>)
        </div><div class="casAbstract">Background/Aims: We studied the role of lysyl oxidase-like 2 (LOXL2) in collagen crosslinking and hepatic progenitor cell (HPC) differentiation, and the therapeutic efficacy of a LOXL2-blocking monoclonal antibody on liver fibrosis progression/reversal in mice.  Methods: Anti-LOXL2 antibody, control antilysyl oxidase antibody or placebo was administered during thioacetamide (TAA)-induced fibrosis progression or during recovery.  Therapeutic efficacy in biliary fibrosis was tested in BALB/c.Mdr2-/- and 3,5-diethoxycarbonyl-1,4-dihydrocollidine (DDC)-fed mice.  Collagen crosslinking, fibrosis progression and reversal were assessed histol. and biochem.  HPC differentiation was studied in primary EpCAM(+)liver cells in vitro.  Results: LOXL2 was virtually absent from healthy but strongly induced in fibrotic liver, with predominant localization within fibrotic septa.  Delayed anti-LOXL2 treatment of active TAA fibrosis significantly reduced collagen crosslinking and histol. signs of bridging fibrosis, with a 53% redn. in morphometric collagen deposition.  In established TAA fibrosis, LOXL2 inhibition promoted fibrosis reversal, with enhanced splitting and thinning of fibrotic septa, and a 45% decrease in collagen area at 4 wk of recovery.  In the Mdr2-/- and DDC-induced models of biliary fibrosis, anti-LOXL2 antibody similarly achieved significant antifibrotic efficacy and suppressed the ductular reaction, while hepatocyte replication increased.  Blocking LOXL2 had a profound direct effect on primary EpCAM(+)HPC behavior in vitro, promoting their differentiation towards hepatocytes, while inhibiting ductal cell lineage commitment.  Conclusions: LOXL2 mediates collagen crosslinking and fibrotic matrix stabilization during liver fibrosis, and independently promotes fibrogenic HPC differentiation.  By blocking these two convergent profibrotic pathways, therapeutic LOXL2 inhibition attenuates both parenchymal and biliary fibrosis and promotes fibrosis reversal.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq6NPFSjhoMLbVg90H21EOLACvtfcHk0liuHRYHw-4JGQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitVShurvP&md5=1af0e332c38eb1850cf1fa9d613fb6be</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1136%2Fgutjnl-2016-312473&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1136%252Fgutjnl-2016-312473%26sid%3Dliteratum%253Aachs%26aulast%3DIkenaga%26aufirst%3DN.%26aulast%3DPeng%26aufirst%3DZ.-W.%26aulast%3DVaid%26aufirst%3DK.%2BA.%26aulast%3DLiu%26aufirst%3DS.%2BB.%26aulast%3DYoshida%26aufirst%3DS.%26aulast%3DSverdlov%26aufirst%3DD.%2BY.%26aulast%3DMikels-Vigdal%26aufirst%3DA.%26aulast%3DSmith%26aufirst%3DV.%26aulast%3DSchuppan%26aufirst%3DD.%26aulast%3DPopov%26aufirst%3DY.%2BV.%26atitle%3DSelective%2520targeting%2520of%2520lysyl%2520oxidase-like%25202%2520%2528LOXL2%2529%2520suppresses%2520hepatic%2520fibrosis%2520progression%2520and%2520accelerates%2520its%2520reversal%26jtitle%3DGut%26date%3D2017%26volume%3D66%26spage%3D1697%26epage%3D1708%26doi%3D10.1136%2Fgutjnl-2016-312473" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rodriguez, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vaysberg, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mikels, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCauley, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Velayo, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, V.</span></span> <span> </span><span class="NLM_article-title">Modulation of lysyl oxidase-like 2 enzymatic activity by an allosteric antibody inhibitor</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>285</i></span>,  <span class="NLM_fpage">20964</span>– <span class="NLM_lpage">20974</span>, <span class="refDoi"> DOI: 10.1074/jbc.m109.094136</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=10.1074%2Fjbc.m109.094136" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=20439985" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=1%3ACAS%3A528%3ADC%252BC3cXnvFSiur0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=285&publication_year=2010&pages=20964-20974&author=H.+M.+Rodriguezauthor=M.+Vaysbergauthor=A.+Mikelsauthor=S.+McCauleyauthor=A.+C.+Velayoauthor=C.+Garciaauthor=V.+Smith&title=Modulation+of+lysyl+oxidase-like+2+enzymatic+activity+by+an+allosteric+antibody+inhibitor&doi=10.1074%2Fjbc.m109.094136"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Modulation of Lysyl Oxidase-like 2 Enzymatic Activity by an Allosteric Antibody Inhibitor</span></div><div class="casAuthors">Rodriguez, Hector M.; Vaysberg, Maria; Mikels, Amanda; McCauley, Scott; Velayo, Arleene C.; Garcia, Carlos; Smith, Victoria</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">285</span>
        (<span class="NLM_cas:issue">27</span>),
    <span class="NLM_cas:pages">20964-20974</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">In this report, we assessed the steady-state enzymic activity of lysyl oxidase-like 2 (LOXL2) against the substrates 1,5-diaminopentane (DAP), spermine, and fibrillar type I collagen.  We find that both DAP and spermine are capable of activating LOXL2 to the same extent and have similar Michaelis consts. (Km ∼ 1 mM) and catalytic rates (kcat ∼ 0.02 s-1).  We also show that LOXL2 is capable of being inhibited by a known suicide inhibitor of lysyl oxidase (LOX), β-aminopropionitrile, which we find is a potent inhibitor of LOXL2 activity.  The modality of inhibition of β-aminopropionitrile was also examd. and found to be competitive with respect to the substrates DAP and spermine.  In addn., we identified an antibody inhibitor (AB0023) of LOXL2 enzymic function and have found that the inhibition occurs in a non-competitive manner with respect to both spermine and DAP.  The binding epitope of AB0023 was mapped to the scavenger receptor cysteine-rich domain four of human LOXL2.  AB0023 binds to a region remote from the catalytic domain making AB0023 an allosteric inhibitor of LOXL2.  This affords AB0023 several advantages, because it is specific for LOXL2 and inhibits the enzymic function of LOXL2 in a non-competitive manner thereby allowing inhibition of LOXL2 regardless of substrate concn.  These results suggest that antibody allosteric modulators of enzymic function represent a novel drug development strategy and, in the context of LOXL2, suggest that inhibitors such as these might be useful therapeutics in oncol., fibrosis, and inflammation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqFGtBWNkyY-rVg90H21EOLACvtfcHk0liuHRYHw-4JGQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXnvFSiur0%253D&md5=d5c4074fdf77bd122feb5345e801e885</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1074%2Fjbc.m109.094136&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.m109.094136%26sid%3Dliteratum%253Aachs%26aulast%3DRodriguez%26aufirst%3DH.%2BM.%26aulast%3DVaysberg%26aufirst%3DM.%26aulast%3DMikels%26aufirst%3DA.%26aulast%3DMcCauley%26aufirst%3DS.%26aulast%3DVelayo%26aufirst%3DA.%2BC.%26aulast%3DGarcia%26aufirst%3DC.%26aulast%3DSmith%26aufirst%3DV.%26atitle%3DModulation%2520of%2520lysyl%2520oxidase-like%25202%2520enzymatic%2520activity%2520by%2520an%2520allosteric%2520antibody%2520inhibitor%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2010%26volume%3D285%26spage%3D20964%26epage%3D20974%26doi%3D10.1074%2Fjbc.m109.094136" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Puente, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fortea, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cabezas, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arias Loste, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iruzubieta, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Llerena, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huelin, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fábrega, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crespo, J.</span></span> <span> </span><span class="NLM_article-title">LOXL2-A new target in antifibrogenic therapy?</span>. <i>Int. J. Mol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">1634</span>, <span class="refDoi"> DOI: 10.3390/ijms20071634</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=10.3390%2Fijms20071634" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=1%3ACAS%3A528%3ADC%252BB3cXosVOksg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2019&pages=1634&author=A.+Puenteauthor=J.+Forteaauthor=J.+Cabezasauthor=M.+Arias+Losteauthor=P.+Iruzubietaauthor=S.+Llerenaauthor=P.+Huelinauthor=E.+F%C3%A1bregaauthor=J.+Crespo&title=LOXL2-A+new+target+in+antifibrogenic+therapy%3F&doi=10.3390%2Fijms20071634"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">LOXL2-a new target in antifibrogenic therapy?</span></div><div class="casAuthors">Puente, Angela; Fortea, Jose Ignacio; Cabezas, Joaquin; Loste, Maria Teresa Arias; Iruzubieta, Paula; Llerena, Susana; Huelin, Patricia; Fabrega, Emilio; Crespo, Javier</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Molecular Sciences</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1634</span>CODEN:
                <span class="NLM_cas:coden">IJMCFK</span>;
        ISSN:<span class="NLM_cas:issn">1422-0067</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">A review.  The concept of liver fibrosis and cirrhosis being static and therefore irreversible is outdated.  Indeed, both human and animal studies have shown that fibrogenesis is a dynamic and potentially reversible process that can be modulated either by stopping its progression and/or by promoting its resoln.  Therefore, the study of the mol. mechanisms involved in the pathogenesis of liver fibrosis is crit. for the development of future antifibrotic therapies.  The fibrogenesis process, common to all forms of liver injury, is characterized by the increased deposition of extracellular matrix components (EMCs), including collagen, proteoglycans, and glycoproteins (laminin and fibronectin 2).  These changes in the compn. of the extracellular matrix components alter their interaction with cell adhesion mols., influencing the modulation of cell functions (growth, migration, and gene expression).  Hepatic stellate cells and Kupffer cells (liver macrophages) are the key fibrogenic effectors.  The antifibrogenic mechanism starts with the activation of Ly6Chigh macrophages, which can differentiate into macrophages with antifibrogenic action.  The research of biochem. changes affecting fibrosis irreversibility has identified lysyl oxidase-like 2 (LOXL2), an enzyme that promotes the network of collagen fibers of the extracellular matrix.  LOXL2 inhibition can decrease cell nos., proliferation, colony formations, and cell growth, and it can induce cell cycle arrest and increase apoptosis.  The development of a new humanized IgG4 monoclonal antibody against LOXL2 could open the window of a new antifibrogenic treatment.  The current therapeutic target in patients with liver cirrhosis should focus (after the eradication of the causal agent) on the development of new antifibrogenic drugs.  The development of these drugs must meet three premises: Patient safety, in non-cirrhotic phases, down-staging or at least stabilization and slowing the progression to cirrhosis must be achieved; whereas in the cirrhotic stage, the objective should be to reduce fibrosis and portal pressure.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpwkSiBNrg_1LVg90H21EOLACvtfcHk0liuHRYHw-4JGQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXosVOksg%253D%253D&md5=11468a9417073b0b2a2cf46086f9b436</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.3390%2Fijms20071634&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fijms20071634%26sid%3Dliteratum%253Aachs%26aulast%3DPuente%26aufirst%3DA.%26aulast%3DFortea%26aufirst%3DJ.%26aulast%3DCabezas%26aufirst%3DJ.%26aulast%3DArias%2BLoste%26aufirst%3DM.%26aulast%3DIruzubieta%26aufirst%3DP.%26aulast%3DLlerena%26aufirst%3DS.%26aulast%3DHuelin%26aufirst%3DP.%26aulast%3DF%25C3%25A1brega%26aufirst%3DE.%26aulast%3DCrespo%26aufirst%3DJ.%26atitle%3DLOXL2-A%2520new%2520target%2520in%2520antifibrogenic%2520therapy%253F%26jtitle%3DInt.%2520J.%2520Mol.%2520Sci.%26date%3D2019%26volume%3D20%26spage%3D1634%26doi%3D10.3390%2Fijms20071634" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mesarwi, O. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shin, M.-K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drager, L. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bevans-Fonti, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jun, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Putcha, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Torbenson, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pedrosa, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lorenzi-Filho, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steele, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schweitzer, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magnuson, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lidor, A. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwartz, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Polotsky, V. Y.</span></span> <span> </span><span class="NLM_article-title">Lysyl oxidase as a serum biomarker of liver fibrosis in patients with severe obesity and obstructive sleep apnea</span>. <i>Sleep</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>38</i></span>,  <span class="NLM_fpage">1583</span>– <span class="NLM_lpage">1591</span>, <span class="refDoi"> DOI: 10.5665/sleep.5052</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=10.5665%2Fsleep.5052" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=26085300" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=1%3ACAS%3A280%3ADC%252BC2MbksFSlsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2015&pages=1583-1591&author=O.+A.+Mesarwiauthor=M.-K.+Shinauthor=L.+F.+Dragerauthor=S.+Bevans-Fontiauthor=J.+C.+Junauthor=N.+Putchaauthor=M.+S.+Torbensonauthor=R.+P.+Pedrosaauthor=G.+Lorenzi-Filhoauthor=K.+E.+Steeleauthor=M.+A.+Schweitzerauthor=T.+H.+Magnusonauthor=A.+O.+Lidorauthor=A.+R.+Schwartzauthor=V.+Y.+Polotsky&title=Lysyl+oxidase+as+a+serum+biomarker+of+liver+fibrosis+in+patients+with+severe+obesity+and+obstructive+sleep+apnea&doi=10.5665%2Fsleep.5052"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Lysyl Oxidase as a Serum Biomarker of Liver Fibrosis in Patients with Severe Obesity and Obstructive Sleep Apnea</span></div><div class="casAuthors">Mesarwi Omar A; Shin Mi-Kyung; Bevans-Fonti Shannon; Jun Jonathan C; Putcha Nirupama; Schwartz Alan R; Polotsky Vsevolod Y; Drager Luciano F; Torbenson Michael S; Pedrosa Rodrigo P; Lorenzi-Filho Geraldo; Steele Kimberley E; Schweitzer Michael A; Magnuson Thomas H; Lidor Anne O</div><div class="citationInfo"><span class="NLM_cas:title">Sleep</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1583-91</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">STUDY OBJECTIVES:  Obstructive sleep apnea (OSA) is associated with the progression of nonalcoholic fatty liver disease (NAFLD).  We hypothesized that the hypoxia of OSA increases hepatic production of lysyl oxidase (LOX), an enzyme that cross-links collagen, and that LOX may serve as a biomarker of hepatic fibrosis.  DESIGN:  Thirty-five patients with severe obesity underwent liver biopsy, polysomnography, and serum LOX testing.  A separate group with severe OSA had serum LOX measured before and after 3 mo of CPAP or no therapy, as did age-matched controls.  LOX expression and secretion were measured in mouse hepatocytes following exposure to hypoxia.  SETTING:  The Johns Hopkins Bayview Sleep Disorders Center, and the Hypertension Unit of the Heart Institute at the University of Sao Paulo Medical School.  MEASUREMENTS AND RESULTS:  In the bariatric cohort, the apnea-hypopnea index was higher in patients with hepatic fibrosis than in those without fibrosis (42.7 ± 30.2 events/h, versus 16.2 ± 15.5 events/h; P = 0.002), as was serum LOX (84.64 ± 29.71 ng/mL, versus 45.46 ± 17.16 ng/mL; P < 0.001).  In the sleep clinic sample, patients with severe OSA had higher baseline LOX than healthy controls (70.75 ng/mL versus 52.36 ng/mL, P = 0.046), and serum LOX decreased in patients with OSA on CPAP (mean decrease 20.49 ng/mL) but not in untreated patients (mean decrease 0.19 ng/mL).  Hypoxic mouse hepatocytes demonstrated 5.9-fold increased LOX transcription (P = 0.046), and enhanced LOX protein secretion.  CONCLUSIONS:  The hypoxic stress of obstructive sleep apnea may increase circulating lysyl oxidase (LOX) levels.  LOX may serve as a biomarker of liver fibrosis in patients with severe obesity and nonalcoholic fatty liver disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTFKuhUvr3mbGZyxfu64m4ffW6udTcc2eaMpzW3yRSrkLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2MbksFSlsQ%253D%253D&md5=81878be58b7fd243d2fe56ca7816b706</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.5665%2Fsleep.5052&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.5665%252Fsleep.5052%26sid%3Dliteratum%253Aachs%26aulast%3DMesarwi%26aufirst%3DO.%2BA.%26aulast%3DShin%26aufirst%3DM.-K.%26aulast%3DDrager%26aufirst%3DL.%2BF.%26aulast%3DBevans-Fonti%26aufirst%3DS.%26aulast%3DJun%26aufirst%3DJ.%2BC.%26aulast%3DPutcha%26aufirst%3DN.%26aulast%3DTorbenson%26aufirst%3DM.%2BS.%26aulast%3DPedrosa%26aufirst%3DR.%2BP.%26aulast%3DLorenzi-Filho%26aufirst%3DG.%26aulast%3DSteele%26aufirst%3DK.%2BE.%26aulast%3DSchweitzer%26aufirst%3DM.%2BA.%26aulast%3DMagnuson%26aufirst%3DT.%2BH.%26aulast%3DLidor%26aufirst%3DA.%2BO.%26aulast%3DSchwartz%26aufirst%3DA.%2BR.%26aulast%3DPolotsky%26aufirst%3DV.%2BY.%26atitle%3DLysyl%2520oxidase%2520as%2520a%2520serum%2520biomarker%2520of%2520liver%2520fibrosis%2520in%2520patients%2520with%2520severe%2520obesity%2520and%2520obstructive%2520sleep%2520apnea%26jtitle%3DSleep%26date%3D2015%26volume%3D38%26spage%3D1583%26epage%3D1591%26doi%3D10.5665%2Fsleep.5052" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Aumiller, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strobel, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romeike, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schuler, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stierstorfer, B. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kreuz, S.</span></span> <span> </span><span class="NLM_article-title">Comparative analysis of lysyl oxidase (like) family members in pulmonary fibrosis</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">149</span>, <span class="refDoi"> DOI: 10.1038/s41598-017-00270-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=10.1038%2Fs41598-017-00270-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=28273952" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=1%3ACAS%3A280%3ADC%252BC1czkt1Gjsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2017&pages=149&author=V.+Aumillerauthor=B.+Strobelauthor=M.+Romeikeauthor=M.+Schulerauthor=B.+E.+Stierstorferauthor=S.+Kreuz&title=Comparative+analysis+of+lysyl+oxidase+%28like%29+family+members+in+pulmonary+fibrosis&doi=10.1038%2Fs41598-017-00270-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27aR"><div class="casContent"><span class="casTitleNuber">27a</span><div class="casTitle"><span class="NLM_cas:atitle">Comparative analysis of lysyl oxidase (like) family members in pulmonary fibrosis</span></div><div class="casAuthors">Aumiller Verena; Romeike Merrit; Kreuz Sebastian; Strobel Benjamin; Schuler Michael; Stierstorfer Birgit E</div><div class="citationInfo"><span class="NLM_cas:title">Scientific reports</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">149</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Extracellular matrix (ECM) composition and stiffness are major driving forces for the development and persistence of fibrotic diseases.  Lysyl oxidase (LOX) and LOX-like (LOXL) proteins play crucial roles in ECM remodeling due to their collagen crosslinking and intracellular functions.  Here, we systematically investigated LOX/L expression in primary fibroblasts and epithelial cells under fibrotic conditions, Bleomycin (BLM) induced lung fibrosis and in human IPF tissue.  Basal expression of all LOX/L family members was detected in epithelial cells and at higher levels in fibroblasts.  Various pro-fibrotic stimuli broadly induced LOX/L expression in fibroblasts, whereas specific induction of LOXL2 and partially LOX was observed in epithelial cells.  Immunohistochemical analysis of lung tissue from 14 IPF patients and healthy donors revealed strong induction of LOX and LOXL2 in bronchial and alveolar epithelium as well as fibroblastic foci.  Using siRNA experiments we observed that LOXL2 and LOXL3 were crucial for fibroblast-to-myofibroblast transition (FMT).  As FMT could only be reconstituted with an enzymatically active LOXL2 variant, we conclude that LOXL2 enzymatic function is crucial for fibroblast transdifferentiation.  In summary, our study provides a comprehensive analysis of the LOX/L family in fibrotic lung disease and indicates prominent roles for LOXL2/3 in fibroblast activation and LOX/LOXL2 in IPF.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSZXzPVcMeOd0h5eUSa2oe_fW6udTcc2eaMpzW3yRSrkLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1czkt1Gjsw%253D%253D&md5=626ced24d6605e4be98f4e97a10d9123</span></div><a href="/servlet/linkout?suffix=cit27a&amp;dbid=16384&amp;doi=10.1038%2Fs41598-017-00270-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41598-017-00270-0%26sid%3Dliteratum%253Aachs%26aulast%3DAumiller%26aufirst%3DV.%26aulast%3DStrobel%26aufirst%3DB.%26aulast%3DRomeike%26aufirst%3DM.%26aulast%3DSchuler%26aufirst%3DM.%26aulast%3DStierstorfer%26aufirst%3DB.%2BE.%26aulast%3DKreuz%26aufirst%3DS.%26atitle%3DComparative%2520analysis%2520of%2520lysyl%2520oxidase%2520%2528like%2529%2520family%2520members%2520in%2520pulmonary%2520fibrosis%26jtitle%3DSci.%2520Rep.%26date%3D2017%26volume%3D7%26spage%3D149%26doi%3D10.1038%2Fs41598-017-00270-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit27b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, W.</span></span> <span> </span><span class="NLM_article-title">LOX/LOXL in pulmonary fibrosis: potential therapeutic targets</span>. <i>J. Drug Targeting</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">790</span>, <span class="refDoi"> DOI: 10.1080/1061186x.2018.1550649</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=10.1080%2F1061186x.2018.1550649" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=30457362" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2018&pages=790&author=L.+Chenauthor=S.+Liauthor=W.+Li&title=LOX%2FLOXL+in+pulmonary+fibrosis%3A+potential+therapeutic+targets&doi=10.1080%2F1061186x.2018.1550649"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27b&amp;dbid=16384&amp;doi=10.1080%2F1061186x.2018.1550649&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F1061186x.2018.1550649%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DL.%26aulast%3DLi%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DW.%26atitle%3DLOX%252FLOXL%2520in%2520pulmonary%2520fibrosis%253A%2520potential%2520therapeutic%2520targets%26jtitle%3DJ.%2520Drug%2520Targeting%26date%3D2018%26volume%3D27%26spage%3D790%26doi%3D10.1080%2F1061186x.2018.1550649" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Kamikawaji, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seki, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watanabe, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mataki, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumamoto, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takagi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mizuno, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inoue, H.</span></span> <span> </span><span class="NLM_article-title">Regulation of LOXL2 and SERPINH1 by antitumor microRNA-29a in lung cancer with idiopathic pulmonary fibrosis</span>. <i>J. Hum. Genet.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">985</span>– <span class="NLM_lpage">993</span>, <span class="refDoi"> DOI: 10.1038/jhg.2016.99</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=10.1038%2Fjhg.2016.99" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=27488440" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=1%3ACAS%3A528%3ADC%252BC28XitFCmsL%252FE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2016&pages=985-993&author=K.+Kamikawajiauthor=N.+Sekiauthor=M.+Watanabeauthor=H.+Matakiauthor=T.+Kumamotoauthor=K.+Takagiauthor=K.+Mizunoauthor=H.+Inoue&title=Regulation+of+LOXL2+and+SERPINH1+by+antitumor+microRNA-29a+in+lung+cancer+with+idiopathic+pulmonary+fibrosis&doi=10.1038%2Fjhg.2016.99"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28aR"><div class="casContent"><span class="casTitleNuber">28a</span><div class="casTitle"><span class="NLM_cas:atitle">Regulation of LOXL2 and SERPINH1 by antitumor microRNA-29a in lung cancer with idiopathic pulmonary fibrosis</span></div><div class="casAuthors">Kamikawaji, Kazuto; Seki, Naohiko; Watanabe, Masaki; Mataki, Hiroko; Kumamoto, Tomohiro; Takagi, Koichiro; Mizuno, Keiko; Inoue, Hiromasa</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Human Genetics</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">985-993</span>CODEN:
                <span class="NLM_cas:coden">JHGEFR</span>;
        ISSN:<span class="NLM_cas:issn">1434-5161</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive lung disease that is refractory to treatment and carries a high mortality rate.  IPF is frequently assocd. with lung cancer.  Identification of mol. targets involved in both diseases may elucidate novel mol. mechanisms contributing to their pathol.  Recent studies of microRNA (miRNA) expression signatures showed that microRNA-29a (miR-29a) was downregulated in IPF and lung cancer.  The aim of this study was to investigate the functional significance of miR-29a in lung cancer cells (A549 and EBC-1) and lung fibroblasts (MRC-5) and to identify mol. targets modulated by miR-29a in these cells.  We confirmed the downregulation of miR-29a in clin. specimens of IPF and lung cancer.  Restoration of miR-29a suppressed cancer cell aggressiveness and fibroblast migration.  A combination of gene expression data and in silico anal. showed that a total of 24 genes were putative targets of miR-29a.  Among them, lysyl oxidase-like 2 (LOXL2) and serpin peptidase inhibitor clade H, member 1 (SERPINH1) were direct targets of miR-29a by luciferase reporter assays.  The functions of LOXL2 and SERPINH1 contribute significantly to collagen biosynthesis.  Overexpression of LOXL2 and SERPINH1 was obsd. in clin. specimens of lung cancer and fibrotic lesions.  Downregulation of miR-29a caused overexpression of LOXL2 and SERPINH1 in lung cancer and IPF, suggesting that these genes are involved in the pathogenesis of these two diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrb2zDp-N7psrVg90H21EOLACvtfcHk0ljxj3zT1xD10w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XitFCmsL%252FE&md5=5f34265dbac7bb03237d23dc5d2135fa</span></div><a href="/servlet/linkout?suffix=cit28a&amp;dbid=16384&amp;doi=10.1038%2Fjhg.2016.99&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fjhg.2016.99%26sid%3Dliteratum%253Aachs%26aulast%3DKamikawaji%26aufirst%3DK.%26aulast%3DSeki%26aufirst%3DN.%26aulast%3DWatanabe%26aufirst%3DM.%26aulast%3DMataki%26aufirst%3DH.%26aulast%3DKumamoto%26aufirst%3DT.%26aulast%3DTakagi%26aufirst%3DK.%26aulast%3DMizuno%26aufirst%3DK.%26aulast%3DInoue%26aufirst%3DH.%26atitle%3DRegulation%2520of%2520LOXL2%2520and%2520SERPINH1%2520by%2520antitumor%2520microRNA-29a%2520in%2520lung%2520cancer%2520with%2520idiopathic%2520pulmonary%2520fibrosis%26jtitle%3DJ.%2520Hum.%2520Genet.%26date%3D2016%26volume%3D61%26spage%3D985%26epage%3D993%26doi%3D10.1038%2Fjhg.2016.99" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit28b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Leeming, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willumsen, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sand, J. M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holm
Nielsen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dasgupta, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brodmerkel, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Curran, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bager, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karsdal, M. A.</span></span> <span> </span><span class="NLM_article-title">A serological marker of the N-terminal neoepitope generated during LOXL2 maturation is elevated in patients with cancer or idiopathic pulmonary fibrosis</span>. <i>Biochem. Biophys. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">38</span>– <span class="NLM_lpage">43</span>, <span class="refDoi"> DOI: 10.1016/j.bbrep.2018.11.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=10.1016%2Fj.bbrep.2018.11.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=30555938" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=1%3ACAS%3A280%3ADC%252BB3cnis1Crsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2019&pages=38-43&author=D.+J.+Leemingauthor=N.+Willumsenauthor=J.+M.+B.+Sandauthor=S.+Holm%0ANielsenauthor=B.+Dasguptaauthor=C.+Brodmerkelauthor=M.+Curranauthor=C.+L.+Bagerauthor=M.+A.+Karsdal&title=A+serological+marker+of+the+N-terminal+neoepitope+generated+during+LOXL2+maturation+is+elevated+in+patients+with+cancer+or+idiopathic+pulmonary+fibrosis&doi=10.1016%2Fj.bbrep.2018.11.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28bR"><div class="casContent"><span class="casTitleNuber">28b</span><div class="casTitle"><span class="NLM_cas:atitle">A serological marker of the N-terminal neoepitope generated during LOXL2 maturation is elevated in patients with cancer or idiopathic pulmonary fibrosis</span></div><div class="casAuthors">Leeming D J; Willumsen N; Sand J M B; Holm Nielsen S; Karsdal M A; Dasgupta B; Brodmerkel C; Curran M; Bager C L</div><div class="citationInfo"><span class="NLM_cas:title">Biochemistry and biophysics reports</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">38-43</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Objectives:  Lysyl oxidase like 2 (LOXL2) is associated with poor prognosis in idiopathic pulmonary disease (IPF) and cancer.  We developed an Enzyme-linked immunosorbent assay (ELISA) targeting the LOXL2 neo-epitope generated through the release of the signal peptide during LOXL2 maturation.  Design and methods:  An ELISA targeting the N-terminal site of the human LOXL2 was developed including technical optimization and validation steps.  Serum LOXL2 was measured in patients with breast, colorectal, lung, ovarian, pancreatic and prostate cancer, melanoma, IPF and in healthy controls (n = 16).  Results:  A technically robust and specific assay was developed.  LOXL2 was detectable in serum from healthy controls and showed reactivity towards recombinant LOXL2.  Compared to controls, LOXL2 levels were significantly (p < 0.001-0.05) elevated in serum from patients with breast, colerectal, lung, ovarian and pancreatic cancer (mean range: 49-84 ng/mL), but not in prostate cancer (mean: 36 ng/mL) and malignant melanoma patients (41 ng/mL).  Serum LOXL2 was elevated in IPF patients compared to healthy controls (mean: 76.5 vs 46.8 ng/mL; p > 0.001).  Conclusions:  A specific ELISA towards the N-terminal neo-epitope site in LOXL2 was developed which detected significantly elevated serum levels from patients with above-mentioned cancer types or IPF compared to healthy controls.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSL2FMWTRh-Atj_Vg2vObihfW6udTcc2eYfg3pU010UF7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3cnis1Crsw%253D%253D&md5=0a71f3cfc448dd6d8c1778215f63abc8</span></div><a href="/servlet/linkout?suffix=cit28b&amp;dbid=16384&amp;doi=10.1016%2Fj.bbrep.2018.11.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbrep.2018.11.002%26sid%3Dliteratum%253Aachs%26aulast%3DLeeming%26aufirst%3DD.%2BJ.%26aulast%3DWillumsen%26aufirst%3DN.%26aulast%3DSand%26aufirst%3DJ.%2BM.%2BB.%26aulast%3DHolm%2BNielsen%26aufirst%3DS.%26aulast%3DDasgupta%26aufirst%3DB.%26aulast%3DBrodmerkel%26aufirst%3DC.%26aulast%3DCurran%26aufirst%3DM.%26aulast%3DBager%26aufirst%3DC.%2BL.%26aulast%3DKarsdal%26aufirst%3DM.%2BA.%26atitle%3DA%2520serological%2520marker%2520of%2520the%2520N-terminal%2520neoepitope%2520generated%2520during%2520LOXL2%2520maturation%2520is%2520elevated%2520in%2520patients%2520with%2520cancer%2520or%2520idiopathic%2520pulmonary%2520fibrosis%26jtitle%3DBiochem.%2520Biophys.%2520Rep.%26date%3D2019%26volume%3D17%26spage%3D38%26epage%3D43%26doi%3D10.1016%2Fj.bbrep.2018.11.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wei, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gibbons, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamauchi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jackson, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le Saux, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calhoun, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peters, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Derynck, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Backes, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chapman, H. A.</span></span> <span> </span><span class="NLM_article-title">Fibroblast-specific inhibition of TGF-β1 signaling attenuates lung and tumor fibrosis</span>. <i>J. Clin. Invest.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>127</i></span>,  <span class="NLM_fpage">3675</span>– <span class="NLM_lpage">3688</span>, <span class="refDoi"> DOI: 10.1172/jci94624</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=10.1172%2Fjci94624" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=28872461" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=1%3ACAS%3A280%3ADC%252BC1cbkslOrtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=127&publication_year=2017&pages=3675-3688&author=Y.+Weiauthor=T.+J.+Kimauthor=D.+H.+Pengauthor=D.+Duanauthor=D.+L.+Gibbonsauthor=M.+Yamauchiauthor=J.+R.+Jacksonauthor=C.+J.+Le+Sauxauthor=C.+Calhounauthor=J.+Petersauthor=R.+Derynckauthor=B.+J.+Backesauthor=H.+A.+Chapman&title=Fibroblast-specific+inhibition+of+TGF-%CE%B21+signaling+attenuates+lung+and+tumor+fibrosis&doi=10.1172%2Fjci94624"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Fibroblast-specific inhibition of TGF-β1 signaling attenuates lung and tumor fibrosis</span></div><div class="casAuthors">Wei Ying; Kim Thomas J; Jackson Julia R; Le Saux Claude J; Backes Bradley J; Chapman Harold A; Peng David H; Gibbons Don L; Duan Dana; Derynck Rik; Yamauchi Mitsuo; Le Saux Claude J; Calhoun Cheresa; Peters Jay</div><div class="citationInfo"><span class="NLM_cas:title">The Journal of clinical investigation</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">127</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">3675-3688</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">TGF-β1 signaling is a critical driver of collagen accumulation and fibrotic disease but also a vital suppressor of inflammation and epithelial cell proliferation.  The nature of this multifunctional cytokine has limited the development of global TGF-β1 signaling inhibitors as therapeutic agents.  We conducted phenotypic screens for small molecules that inhibit TGF-β1-induced epithelial-mesenchymal transition without immediate TGF-β1 receptor (TβR) kinase inhibition.  We identified trihydroxyphenolic compounds as potent blockers of TGF-β1 responses (IC50 ~50 nM), Snail1 expression, and collagen deposition in vivo in models of pulmonary fibrosis and collagen-dependent lung cancer metastasis.  Remarkably, the functional effects of trihydroxyphenolics required the presence of active lysyl oxidase-like 2 (LOXL2), thereby limiting effects to fibroblasts or cancer cells, the major LOXL2 producers.  Mechanistic studies revealed that trihydroxyphenolics induce auto-oxidation of a LOXL2/3-specific lysine (K731) in a time-dependent reaction that irreversibly inhibits LOXL2 and converts the trihydrophenolic to a previously undescribed metabolite that directly inhibits TβRI kinase.  Combined inhibition of LOXL2 and TβRI activities by trihydrophenolics resulted in potent blockade of pathological collagen accumulation in vivo without the toxicities associated with global inhibitors.  These findings elucidate a therapeutic approach to attenuate fibrosis and the disease-promoting effects of tissue stiffness by specifically targeting TβRI kinase in LOXL2-expressing cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTVn_FfOxm__-3MPKNEWB5RfW6udTcc2eYfg3pU010UF7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1cbkslOrtw%253D%253D&md5=312867b1853f0053fdd1004b387ddf7d</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1172%2Fjci94624&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252Fjci94624%26sid%3Dliteratum%253Aachs%26aulast%3DWei%26aufirst%3DY.%26aulast%3DKim%26aufirst%3DT.%2BJ.%26aulast%3DPeng%26aufirst%3DD.%2BH.%26aulast%3DDuan%26aufirst%3DD.%26aulast%3DGibbons%26aufirst%3DD.%2BL.%26aulast%3DYamauchi%26aufirst%3DM.%26aulast%3DJackson%26aufirst%3DJ.%2BR.%26aulast%3DLe%2BSaux%26aufirst%3DC.%2BJ.%26aulast%3DCalhoun%26aufirst%3DC.%26aulast%3DPeters%26aufirst%3DJ.%26aulast%3DDerynck%26aufirst%3DR.%26aulast%3DBackes%26aufirst%3DB.%2BJ.%26aulast%3DChapman%26aufirst%3DH.%2BA.%26atitle%3DFibroblast-specific%2520inhibition%2520of%2520TGF-%25CE%25B21%2520signaling%2520attenuates%2520lung%2520and%2520tumor%2520fibrosis%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2017%26volume%3D127%26spage%3D3675%26epage%3D3688%26doi%3D10.1172%2Fjci94624" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit29b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Wen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bai, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, Y.</span></span> <span> </span><span class="NLM_article-title">LOXL2, a copper-dependent monoamine oxidase, activates lung fibroblasts through the TGF-β/Smad pathway</span>. <i>Int. J. Mol. Med.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>42</i></span>,  <span class="NLM_fpage">3530</span>– <span class="NLM_lpage">3541</span>, <span class="refDoi"> DOI: 10.3892/ijmm.2018.3927</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=10.3892%2Fijmm.2018.3927" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=30320382" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=1%3ACAS%3A528%3ADC%252BC1MXktVOrur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2018&pages=3530-3541&author=X.+Wenauthor=Y.+Liuauthor=Y.+Baiauthor=M.+Liauthor=Q.+Fuauthor=Y.+Zheng&title=LOXL2%2C+a+copper-dependent+monoamine+oxidase%2C+activates+lung+fibroblasts+through+the+TGF-%CE%B2%2FSmad+pathway&doi=10.3892%2Fijmm.2018.3927"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29bR"><div class="casContent"><span class="casTitleNuber">29b</span><div class="casTitle"><span class="NLM_cas:atitle">LOXL2, a copper-dependent monoamine oxidase, activates lung fibroblasts through the TGF-β/Smad pathway</span></div><div class="casAuthors">Wen, Xiaohong; Liu, Yuan; Bai, Yu; Li, Mingwei; Fu, Qiang; Zheng, Yi</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Molecular Medicine</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">42</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">3530-3541</span>CODEN:
                <span class="NLM_cas:coden">IJMMFG</span>;
        ISSN:<span class="NLM_cas:issn">1791-244X</span>.
    
            (<span class="NLM_cas:orgname">Spandidos Publications Ltd.</span>)
        </div><div class="casAbstract">A previous study demonstrated that Lysyl oxidase-like 2 (LOXL2) serves an essential role in matrix remodeling and fibrogenesis, thus indicating its involvement in fibrosis-assocd. diseases.  Our previous studies revealed a novel assocn. between LOXL2 expression and pulmonary fibrosis in mice.  However, the exact role and mechanisms of LOXL2 in interstitial lung disease remain poorly understood.  The present study aimed to detect LOXL2 expression in mice with bleomycin (BLM)-induced pulmonary fibrosis, and explore the effects of silencing LOXL2 on the proliferation, activation and fibrosis process of mouse lung fibroblasts (MLFs).  In addn., the present study investigated the assocn. between LOXL2 and the transforming growth factor-β (TGF-β)/Smad signaling pathway to identify the mechanism underlying the role of LOXL2 in fibrosis progression.  An animal model of pulmonary fibrosis was established by administering an intratracheal injection of 5 mg/kg BLM to C57BL/6 mice.  ELISA and immunohistochem. examn. were used to detect the LOXL2 level in the serum, lung homogenate and pulmonary tissues in mice.  Pulmonary tissues of mice were extd. to culture primary MLFs, and a LOXL2 small interfering RNA adenovirus vector was established to silence LOXL2 in MLFs.  Cell proliferation was detected using the cell counting kit-8 assay.  Reverse transcription-quant. polymerase chain reaction and western blotting were used to measure the expression of LOXL2, TGF-β1, Smad2/3, phosphorylated (p)Smad2/3, Smad4, and Smad7 and Snail in cells.  Interleukin-6 (IL-6) and type 1 collagen a1 (COL1A1) in the supernatant of cells were analyzed by ELISA.  It was demonstrated that LOXL2 expression was significantly increased in serum, lung homogenate and pulmonary tissues of mice with BLM-induced pulmonary fibrosis compared with control mice.  Furthermore, silencing LOXL2 significantly decreased MLF proliferation, and the levels of IL-6 and COL1A1 in the supernatant of cells.  Furthermore, silencing LOXL2 inhibited the expression of pSmad2/3, Smad4 and Snail, while it promoted Smad7 expression.  The present data provides a comprehensive anal. of the LOXL2 in pulmonary fibrosis and indicates prominent roles for LOXL2 in fibrogenesis via regulation of the TGF-β/Smad signaling pathway.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq65IUQGrYZ7LVg90H21EOLACvtfcHk0lh7uVTmVM5Bvg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXktVOrur8%253D&md5=44bfc5cc79d331e52067d31ca3c53e32</span></div><a href="/servlet/linkout?suffix=cit29b&amp;dbid=16384&amp;doi=10.3892%2Fijmm.2018.3927&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3892%252Fijmm.2018.3927%26sid%3Dliteratum%253Aachs%26aulast%3DWen%26aufirst%3DX.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DBai%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DM.%26aulast%3DFu%26aufirst%3DQ.%26aulast%3DZheng%26aufirst%3DY.%26atitle%3DLOXL2%252C%2520a%2520copper-dependent%2520monoamine%2520oxidase%252C%2520activates%2520lung%2520fibroblasts%2520through%2520the%2520TGF-%25CE%25B2%252FSmad%2520pathway%26jtitle%3DInt.%2520J.%2520Mol.%2520Med.%26date%3D2018%26volume%3D42%26spage%3D3530%26epage%3D3541%26doi%3D10.3892%2Fijmm.2018.3927" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Raghu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collard, H. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cottin, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gibson, K. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaner, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lederer, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinez, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noble, P. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wells, A. U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whelan, T. P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wuyts, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moreau, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patterson, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bayly, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chien, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gong, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Riordan, T. G.</span></span> <span> </span><span class="NLM_article-title">Efficacy of simtuzumab versus placebo in patients with idiopathic pulmonary fibrosis: a randomised, double-blind, controlled, phase 2 trial</span>. <i>Lancet Respir. Med.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">22</span>– <span class="NLM_lpage">32</span>, <span class="refDoi"> DOI: 10.1016/s2213-2600(16)30421-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=10.1016%2Fs2213-2600%2816%2930421-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=27939076" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=1%3ACAS%3A528%3ADC%252BC28XitVegu7vK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2017&pages=22-32&author=G.+Raghuauthor=K.+K.+Brownauthor=H.+R.+Collardauthor=V.+Cottinauthor=K.+F.+Gibsonauthor=R.+J.+Kanerauthor=D.+J.+Ledererauthor=F.+J.+Martinezauthor=P.+W.+Nobleauthor=J.+W.+Songauthor=A.+U.+Wellsauthor=T.+P.+M.+Whelanauthor=W.+Wuytsauthor=E.+Moreauauthor=S.+D.+Pattersonauthor=V.+Smithauthor=S.+Baylyauthor=J.+W.+Chienauthor=Q.+Gongauthor=J.+J.+Zhangauthor=T.+G.+O%E2%80%99Riordan&title=Efficacy+of+simtuzumab+versus+placebo+in+patients+with+idiopathic+pulmonary+fibrosis%3A+a+randomised%2C+double-blind%2C+controlled%2C+phase+2+trial&doi=10.1016%2Fs2213-2600%2816%2930421-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy of simtuzumab versus placebo in patients with idiopathic pulmonary fibrosis: a randomised, double-blind, controlled, phase 2 trial</span></div><div class="casAuthors">Raghu, Ganesh; Brown, Kevin K.; Collard, Harold R.; Cottin, Vincent; Gibson, Kevin F.; Kaner, Robert J.; Lederer, David J.; Martinez, Fernando J.; Noble, Paul W.; Song, Jin Woo; Wells, Athol U.; Whelan, Timothy P. M.; Wuyts, Wim; Moreau, Emmanuel; Patterson, Scott D.; Smith, Victoria; Bayly, Selina; Chien, Jason W.; Gong, Qi; Zhang, Jenny J.; O'Riordan, Thomas G.</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Respiratory Medicine</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">22-32</span>CODEN:
                <span class="NLM_cas:coden">LRMAAU</span>;
        ISSN:<span class="NLM_cas:issn">2213-2600</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Lysyl oxidase-like 2 (LOXL2) catalyzes collagen crosslinking and is implicated in the pathogenesis of idiopathic pulmonary fibrosis (IPF).  The aim of this study was to investigate the efficacy and safety of simtuzumab, a monoclonal antibody against LOXL2, in patients with IPF.  In this randomised, double-blind, phase 2 trial, we recruited patients aged 45-85 years with definite IPF diagnosed prior to 3 years of screening from 183 hospitals and respiratory clinics in 14 countries.  Eligible patients, stratified by baseline forced vital capacity (FVC), serum LOXL2 (sLOXL2) concns., and pirfenidone and nintedanib use, were randomly assigned (1:1) to inject 125 mg/mL simtuzumab or placebo s.c. once a week.  The primary endpoints were progression-free survival, defined as time to all-cause death or a categorical decrease from baseline in FVC % predicted, in the intention-to-treat population, in patients with sLOXL2 concns. in the 50th percentile or higher, and in patients with sLOXL2 concns. in the 75th percentile or higher.  Treatment duration was event-driven, and interim analyses were planned and conducted after approx. 120 and 200 progression-free survival events, resp., occurred.  We compared treatment groups with the stratified log-rank test.  This study is registered with ClinicalTrials.gov, no. NCT01769196.  Patients with IPF were recruited between Jan 31, 2013, and June 1, 2015.  The intention-to-treat population included 544 randomly assigned patients (272 patients in both groups), and the safety population included 543 randomly assigned patients who received at least one dose of study medication.  The study was terminated when the second interim anal. met the prespecified futility stopping criteria in the intention-to-treat population.  We noted no difference in progression-free survival between simtuzumab and placebo in the intention-to-treat population (median progression free survival times of 12·6 mo and 15·4 mo for simtuzumab and placebo, resp.; stratified HR 1·13, 95% CI 0·88-1·45; p=0·329) and in patients with baseline sLOXL2 in the 50th percentile or higher (median progression-free survival 11·7 mo and 14·3 mo for simtuzumab and placebo, resp.; stratified HR 1·03, 95% CI 0·74-1·43; p=0·851), or in the 75th percentile or higher (median progression-free survival 11·6 mo and 16·9 mo for simtuzumab and placebo, resp.; stratified HR 1·20, 95% CI 0·72-2·00; p=0·475).  The incidence of adverse events and serious adverse events was similar between treatment groups.  The most common adverse events in both the simtuzumab and placebo groups were dyspnoea, cough, upper respiratory tract infection, and worsening of IPF; and the most common grade 3 or 4 adverse events were worsening of IPF, dyspnoea, and pneumonia.  Simtuzumab did not improve progression-free survival in a well-defined population of patients with IPF.  Our data do not support the use of simtuzumab for patients with IPF.Gilead Sciences Inc.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGogXyb2IAh397Vg90H21EOLACvtfcHk0lhu-xARDMb0RQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XitVegu7vK&md5=9ba5c10f1fc48f971010f7ed09fd3b62</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1016%2Fs2213-2600%2816%2930421-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fs2213-2600%252816%252930421-0%26sid%3Dliteratum%253Aachs%26aulast%3DRaghu%26aufirst%3DG.%26aulast%3DBrown%26aufirst%3DK.%2BK.%26aulast%3DCollard%26aufirst%3DH.%2BR.%26aulast%3DCottin%26aufirst%3DV.%26aulast%3DGibson%26aufirst%3DK.%2BF.%26aulast%3DKaner%26aufirst%3DR.%2BJ.%26aulast%3DLederer%26aufirst%3DD.%2BJ.%26aulast%3DMartinez%26aufirst%3DF.%2BJ.%26aulast%3DNoble%26aufirst%3DP.%2BW.%26aulast%3DSong%26aufirst%3DJ.%2BW.%26aulast%3DWells%26aufirst%3DA.%2BU.%26aulast%3DWhelan%26aufirst%3DT.%2BP.%2BM.%26aulast%3DWuyts%26aufirst%3DW.%26aulast%3DMoreau%26aufirst%3DE.%26aulast%3DPatterson%26aufirst%3DS.%2BD.%26aulast%3DSmith%26aufirst%3DV.%26aulast%3DBayly%26aufirst%3DS.%26aulast%3DChien%26aufirst%3DJ.%2BW.%26aulast%3DGong%26aufirst%3DQ.%26aulast%3DZhang%26aufirst%3DJ.%2BJ.%26aulast%3DO%25E2%2580%2599Riordan%26aufirst%3DT.%2BG.%26atitle%3DEfficacy%2520of%2520simtuzumab%2520versus%2520placebo%2520in%2520patients%2520with%2520idiopathic%2520pulmonary%2520fibrosis%253A%2520a%2520randomised%252C%2520double-blind%252C%2520controlled%252C%2520phase%25202%2520trial%26jtitle%3DLancet%2520Respir.%2520Med.%26date%3D2017%26volume%3D5%26spage%3D22%26epage%3D32%26doi%3D10.1016%2Fs2213-2600%2816%2930421-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Meissner, E. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McLaughlin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matthews, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gharib, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levy, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sinkus, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Virtaneva, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sturdevant, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martens, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Porcella, S. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goodman, Z. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kanwar, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Myers, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Subramanian, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hadigan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masur, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kleiner, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heller, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kottilil, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kovacs, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morse, C. G.</span></span> <span> </span><span class="NLM_article-title">Simtuzumab treatment of advanced liver fibrosis in HIV and HCV-infected adults: results of a 6-month open-label safety trial</span>. <i>Liver Int.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>36</i></span>,  <span class="NLM_fpage">1783</span>– <span class="NLM_lpage">1792</span>, <span class="refDoi"> DOI: 10.1111/liv.13177</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=10.1111%2Fliv.13177" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=27232579" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvFelsr3O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2016&pages=1783-1792&author=E.+G.+Meissnerauthor=M.+McLaughlinauthor=L.+Matthewsauthor=A.+M.+Gharibauthor=B.+J.+Woodauthor=E.+Levyauthor=R.+Sinkusauthor=K.+Virtanevaauthor=D.+Sturdevantauthor=C.+Martensauthor=S.+F.+Porcellaauthor=Z.+D.+Goodmanauthor=B.+Kanwarauthor=R.+P.+Myersauthor=M.+Subramanianauthor=C.+Hadiganauthor=H.+Masurauthor=D.+E.+Kleinerauthor=T.+Hellerauthor=S.+Kottililauthor=J.+A.+Kovacsauthor=C.+G.+Morse&title=Simtuzumab+treatment+of+advanced+liver+fibrosis+in+HIV+and+HCV-infected+adults%3A+results+of+a+6-month+open-label+safety+trial&doi=10.1111%2Fliv.13177"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Simtuzumab treatment of advanced liver fibrosis in HIV and HCV-infected adults: results of a 6-month open-label safety trial</span></div><div class="casAuthors">Meissner, Eric G.; McLaughlin, Mary; Matthews, Lindsay; Gharib, Ahmed M.; Wood, Bradford J.; Levy, Elliot; Sinkus, Ralph; Virtaneva, Kimmo; Sturdevant, Dan; Martens, Craig; Porcella, Stephen F.; Goodman, Zachary D.; Kanwar, Bittoo; Myers, Robert P.; Subramanian, Mani; Hadigan, Colleen; Masur, Henry; Kleiner, David E.; Heller, Theo; Kottilil, Shyam; Kovacs, Joseph A.; Morse, Caryn G.</div><div class="citationInfo"><span class="NLM_cas:title">Liver International</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1783-1792</span>CODEN:
                <span class="NLM_cas:coden">LIINCM</span>;
        ISSN:<span class="NLM_cas:issn">1478-3223</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Background : Chronic liver injury can result in fibrosis that may progress over years to end-stage liver disease.  The most effective anti-fibrotic therapy is treatment of the underlying disease, however when not possible, interventions to reverse or slow fibrosis progression are needed.  Aim : The aim of this study was to study the safety and tolerability of simtuzumab, a monoclonal antibody directed against lysyl oxidase-like 2 (LOXL2) enzyme, in subjects with hepatitis C virus (HCV), human immunodeficiency virus (HIV), or HCV-HIV co-infection and advanced liver disease.  Methods : Eighteen subjects with advanced liver fibrosis received simtuzumab 700 mg i.v. every 2 wk for 22 wk.  Transjugular liver biopsies were performed during screening and at the end of treatment to measure hepatic venous pressure gradient (HVPG) and to stage fibrosis.  Results : Treatment was well-tolerated with no discontinuations due to adverse events.  No significant changes were seen in HVPG or liver biopsy fibrosis score after treatment.  Exploratory transcriptional and protein profiling using paired pre- and post-treatment liver biopsy and serum samples suggested up-regulation of TGF-β3 and IL-10 pathways with treatment.  Conclusion : In this open-label, pilot clin. trial, simtuzumab treatment was well-tolerated in HCV- and HIV-infected subjects with advanced liver disease.  Putative modulation of TGF-β3 and IL-10 pathways during simtuzumab treatment merits investigation in future trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoh_oC46Qw8xrVg90H21EOLACvtfcHk0lhu-xARDMb0RQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvFelsr3O&md5=3531ad0273e5e77dd501b2db201794a5</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1111%2Fliv.13177&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fliv.13177%26sid%3Dliteratum%253Aachs%26aulast%3DMeissner%26aufirst%3DE.%2BG.%26aulast%3DMcLaughlin%26aufirst%3DM.%26aulast%3DMatthews%26aufirst%3DL.%26aulast%3DGharib%26aufirst%3DA.%2BM.%26aulast%3DWood%26aufirst%3DB.%2BJ.%26aulast%3DLevy%26aufirst%3DE.%26aulast%3DSinkus%26aufirst%3DR.%26aulast%3DVirtaneva%26aufirst%3DK.%26aulast%3DSturdevant%26aufirst%3DD.%26aulast%3DMartens%26aufirst%3DC.%26aulast%3DPorcella%26aufirst%3DS.%2BF.%26aulast%3DGoodman%26aufirst%3DZ.%2BD.%26aulast%3DKanwar%26aufirst%3DB.%26aulast%3DMyers%26aufirst%3DR.%2BP.%26aulast%3DSubramanian%26aufirst%3DM.%26aulast%3DHadigan%26aufirst%3DC.%26aulast%3DMasur%26aufirst%3DH.%26aulast%3DKleiner%26aufirst%3DD.%2BE.%26aulast%3DHeller%26aufirst%3DT.%26aulast%3DKottilil%26aufirst%3DS.%26aulast%3DKovacs%26aufirst%3DJ.%2BA.%26aulast%3DMorse%26aufirst%3DC.%2BG.%26atitle%3DSimtuzumab%2520treatment%2520of%2520advanced%2520liver%2520fibrosis%2520in%2520HIV%2520and%2520HCV-infected%2520adults%253A%2520results%2520of%2520a%25206-month%2520open-label%2520safety%2520trial%26jtitle%3DLiver%2520Int.%26date%3D2016%26volume%3D36%26spage%3D1783%26epage%3D1792%26doi%3D10.1111%2Fliv.13177" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tang, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trackman, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kagan, H. M.</span></span> <span> </span><span class="NLM_article-title">Reaction of aortic lysyl oxidase with β- aminopropionitrile</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1983</span>,  <span class="NLM_volume"><i>258</i></span>,  <span class="NLM_fpage">4331</span>– <span class="NLM_lpage">4338</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=6131892" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=1%3ACAS%3A528%3ADyaL3sXhslGmsr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=258&publication_year=1983&pages=4331-4338&author=S.+S.+Tangauthor=P.+C.+Trackmanauthor=H.+M.+Kagan&title=Reaction+of+aortic+lysyl+oxidase+with+%CE%B2-+aminopropionitrile"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Reaction of aortic lysyl oxidase with β-aminopropionitrile</span></div><div class="casAuthors">Tang, Shiow Shih; Trackman, Philip C.; Kagan, Herbert M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">1983</span>),
    <span class="NLM_cas:volume">258</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">4331-8</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    </div><div class="casAbstract">β-Aminopropionitrile (I) is a potent irreversible inhibitor of lysyl oxidase (II), which initiates crosslinkage formation in elastin and collagen.  The initial interaction of I with aortic II is competitive with elastin or alkyl amine substrates.  Irreversible inhibition develops in a time- and temp.-dependent fashion upon incubation of II with I in the absence of substrate with a limiting inactivation rate const. of 0.16 min-1 and a Ki of 6 μM at 37°.  The labeled C atoms of [1,2-14C]I and [3-14C]I covalently bind to II to equiv. extents and in parallel with the development of inactivation, negating the possibility that the nitrile moiety is eliminated from I by enzymic action.  The Cu content of II is not significantly altered upon interaction with I.  The extent of labeling by [14C]I is reduced by prior treatment of II with carbonyl-modifying reagents, suggesting the possibility of I-II Schiff base formation.  However, I is not processed to a free aldehyde product upon incubation with II.  A mechanism of inhibition is postulated which involves the formation of a covalent bond between an enzyme nucleophile and a ketenimine formed from I by II-assisted β-proton abstraction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr6R41H2SgQY7Vg90H21EOLACvtfcHk0lhu-xARDMb0RQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL3sXhslGmsr4%253D&md5=b64e1c85d58fb8c2c47d8beb939fa59a</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DTang%26aufirst%3DS.%2BS.%26aulast%3DTrackman%26aufirst%3DP.%2BC.%26aulast%3DKagan%26aufirst%3DH.%2BM.%26atitle%3DReaction%2520of%2520aortic%2520lysyl%2520oxidase%2520with%2520%25CE%25B2-%2520aminopropionitrile%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1983%26volume%3D258%26spage%3D4331%26epage%3D4338" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leung, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saturno, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Viros, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Leva, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morrison, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niculescu-Duvaz, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lopes, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dhomen, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Springer, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marais, R.</span></span> <span> </span><span class="NLM_article-title">Lysyl oxidase drives tumour progression by trapping EGF receptors at the cell surface</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">14909</span>, <span class="refDoi"> DOI: 10.1038/ncomms14909</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=10.1038%2Fncomms14909" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=28416796" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=1%3ACAS%3A528%3ADC%252BC2sXmtFKgtbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=14909&author=H.+Tangauthor=L.+Leungauthor=G.+Saturnoauthor=A.+Virosauthor=D.+Smithauthor=G.+Di+Levaauthor=E.+Morrisonauthor=D.+Niculescu-Duvazauthor=F.+Lopesauthor=L.+Johnsonauthor=N.+Dhomenauthor=C.+Springerauthor=R.+Marais&title=Lysyl+oxidase+drives+tumour+progression+by+trapping+EGF+receptors+at+the+cell+surface&doi=10.1038%2Fncomms14909"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33aR"><div class="casContent"><span class="casTitleNuber">33a</span><div class="casTitle"><span class="NLM_cas:atitle">Lysyl oxidase drives tumour progression by trapping EGF receptors at the cell surface</span></div><div class="casAuthors">Tang, Hao Ran; Leung, Leo; Saturno, Grazia; Viros, Amaya; Smith, Duncan; Di Leva, Gianpiero; Morrison, Eamonn; Niculescu-Duvaz, Dan; Lopes, Filipa; Johnson, Louise; Dhomen, Nathalie; Springer, Caroline; Marais, Richard</div><div class="citationInfo"><span class="NLM_cas:title">Nature Communications</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">14909</span>CODEN:
                <span class="NLM_cas:coden">NCAOBW</span>;
        ISSN:<span class="NLM_cas:issn">2041-1723</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Lysyl oxidase (LOX) remodels the tumor microenvironment by crosslinking the extracellular matrix.  LOX overexpression is assocd. with poor cancer outcomes.  Here, we find that LOX regulates the epidermal growth factor receptor (EGFR) to drive tumor progression.  We show that LOX regulates EGFR by suppressing TGFβ1 signalling through the secreted protease HTRA1.  This increases the expression of Matrilin2 (MATN2), an EGF-like domain-contg. protein that traps EGFR at the cell surface to facilitate its activation by EGF.  We describe a pharmacol. inhibitor of LOX, CCT365623, which disrupts EGFR cell surface retention and delays the growth of primary and metastatic tumor cells in vivo.  Thus, we show that LOX regulates EGFR cell surface retention to drive tumor progression, and we validate the therapeutic potential of inhibiting this pathway with the small mol. inhibitor CCT365623.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqjI8odBCa4OLVg90H21EOLACvtfcHk0liGIVeqyaMr8A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXmtFKgtbw%253D&md5=d0db599dc8344c8685196f6d289fd3cf</span></div><a href="/servlet/linkout?suffix=cit33a&amp;dbid=16384&amp;doi=10.1038%2Fncomms14909&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fncomms14909%26sid%3Dliteratum%253Aachs%26aulast%3DTang%26aufirst%3DH.%26aulast%3DLeung%26aufirst%3DL.%26aulast%3DSaturno%26aufirst%3DG.%26aulast%3DViros%26aufirst%3DA.%26aulast%3DSmith%26aufirst%3DD.%26aulast%3DDi%2BLeva%26aufirst%3DG.%26aulast%3DMorrison%26aufirst%3DE.%26aulast%3DNiculescu-Duvaz%26aufirst%3DD.%26aulast%3DLopes%26aufirst%3DF.%26aulast%3DJohnson%26aufirst%3DL.%26aulast%3DDhomen%26aufirst%3DN.%26aulast%3DSpringer%26aufirst%3DC.%26aulast%3DMarais%26aufirst%3DR.%26atitle%3DLysyl%2520oxidase%2520drives%2520tumour%2520progression%2520by%2520trapping%2520EGF%2520receptors%2520at%2520the%2520cell%2520surface%26jtitle%3DNat.%2520Commun.%26date%3D2017%26volume%3D8%26spage%3D14909%26doi%3D10.1038%2Fncomms14909" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit33b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Springer, C.</span>; <span class="NLM_string-name">Marais, R.</span>; <span class="NLM_string-name">Niculescu-Duvaz, D.</span>; <span class="NLM_string-name">Leung, L.</span>; <span class="NLM_string-name">Smithen, D.</span>; <span class="NLM_string-name">Callens, C.</span>; <span class="NLM_string-name">Tang, H.</span></span> <span> </span><span class="NLM_article-title">Methylamine Derivatives as Lysyl Oxidase Inhibitors for the Treatment of Cancer</span>. <span class="NLM_patent">WO2017141049A1</span>, <span class="NLM_year">2017</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&author=C.+Springer&author=R.+Marais&author=D.+Niculescu-Duvaz&author=L.+Leung&author=D.+Smithen&author=C.+Callens&author=H.+Tang&title=Methylamine+Derivatives+as+Lysyl+Oxidase+Inhibitors+for+the+Treatment+of+Cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit33b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DSpringer%26aufirst%3DC.%26atitle%3DMethylamine%2520Derivatives%2520as%2520Lysyl%2520Oxidase%2520Inhibitors%2520for%2520the%2520Treatment%2520of%2520Cancer%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit33c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Leung, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niculescu-Duvaz, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smithen, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lopes, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Callens, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McLeary, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saturno, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aljarah, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zambon, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chambers, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ménard, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bayliss, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knight, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fish, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lawrence, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Challinor, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marais, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Springer, C.</span></span> <span> </span><span class="NLM_article-title">Anti-metastatic inhibitors of lysyl oxidase (LOX): Design and structure-activity relationships</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">5863</span>– <span class="NLM_lpage">5884</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b00335</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b00335" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref33/cit33c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=1%3ACAS%3A528%3ADC%252BC1MXptFymur0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=5863-5884&author=L.+Leungauthor=D.+Niculescu-Duvazauthor=D.+Smithenauthor=F.+Lopesauthor=C.+Callensauthor=R.+McLearyauthor=G.+Saturnoauthor=L.+Daviesauthor=M.+Aljarahauthor=M.+Brownauthor=L.+Johnsonauthor=A.+Zambonauthor=T.+Chambersauthor=D.+M%C3%A9nardauthor=N.+Baylissauthor=R.+Knightauthor=L.+Fishauthor=R.+Lawrenceauthor=M.+Challinorauthor=H.+Tangauthor=R.+Maraisauthor=C.+Springer&title=Anti-metastatic+inhibitors+of+lysyl+oxidase+%28LOX%29%3A+Design+and+structure-activity+relationships&doi=10.1021%2Facs.jmedchem.9b00335"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33cR"><div class="casContent"><span class="casTitleNuber">33c</span><div class="casTitle"><span class="NLM_cas:atitle">Anti-metastatic Inhibitors of Lysyl Oxidase (LOX): Design and Structure-Activity Relationships</span></div><div class="casAuthors">Leung, Leo; Niculescu-Duvaz, Dan; Smithen, Deborah; Lopes, Filipa; Callens, Cedric; McLeary, Robert; Saturno, Grazia; Davies, Lawrence; Aljarah, Mohammed; Brown, Michael; Johnson, Louise; Zambon, Alfonso; Chambers, Tim; Menard, Delphine; Bayliss, Natasha; Knight, Ruth; Fish, Laura; Lawrence, Rae; Challinor, Mairi; Tang, HaoRan; Marais, Richard; Springer, Caroline</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">5863-5884</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Lysyl oxidase (LOX) is a secreted copper-dependent amine oxidase that cross-links collagens and elastin in the extracellular matrix and is a crit. mediator of tumor growth and metastatic spread.  LOX is a target for cancer therapy, and thus the search for therapeutic agents against LOX has been widely sought.  We report herein the medicinal chem. discovery of a series of LOX inhibitors bearing an aminomethylenethiophene (AMT) scaffold.  High-throughput screening provided the initial hits.  Structure-activity relationship (SAR) studies led to the discovery of AMT inhibitors with sub-micromolar half-maximal inhibitory concns. (IC50) in a LOX enzyme activity assay.  Further SAR optimization yielded the orally bioavailable LOX inhibitor CCT365623 (I) with good anti-LOX potency, selectivity, pharmacokinetic properties, as well as anti-metastatic efficacy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrnOAYiFZQNe7Vg90H21EOLACvtfcHk0liGIVeqyaMr8A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXptFymur0%253D&md5=a3318ce21ba6b8fac450b12f4e4e30aa</span></div><a href="/servlet/linkout?suffix=cit33c&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b00335&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b00335%26sid%3Dliteratum%253Aachs%26aulast%3DLeung%26aufirst%3DL.%26aulast%3DNiculescu-Duvaz%26aufirst%3DD.%26aulast%3DSmithen%26aufirst%3DD.%26aulast%3DLopes%26aufirst%3DF.%26aulast%3DCallens%26aufirst%3DC.%26aulast%3DMcLeary%26aufirst%3DR.%26aulast%3DSaturno%26aufirst%3DG.%26aulast%3DDavies%26aufirst%3DL.%26aulast%3DAljarah%26aufirst%3DM.%26aulast%3DBrown%26aufirst%3DM.%26aulast%3DJohnson%26aufirst%3DL.%26aulast%3DZambon%26aufirst%3DA.%26aulast%3DChambers%26aufirst%3DT.%26aulast%3DM%25C3%25A9nard%26aufirst%3DD.%26aulast%3DBayliss%26aufirst%3DN.%26aulast%3DKnight%26aufirst%3DR.%26aulast%3DFish%26aufirst%3DL.%26aulast%3DLawrence%26aufirst%3DR.%26aulast%3DChallinor%26aufirst%3DM.%26aulast%3DTang%26aufirst%3DH.%26aulast%3DMarais%26aufirst%3DR.%26aulast%3DSpringer%26aufirst%3DC.%26atitle%3DAnti-metastatic%2520inhibitors%2520of%2520lysyl%2520oxidase%2520%2528LOX%2529%253A%2520Design%2520and%2520structure-activity%2520relationships%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D5863%26epage%3D5884%26doi%3D10.1021%2Facs.jmedchem.9b00335" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rowbottom, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bain, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calderon, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lasof, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lonergan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Darlington, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prodanovich, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santini, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">King, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goulet, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shannon, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MacKenna, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evans, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hutchinson, J. H.</span></span> <span> </span><span class="NLM_article-title">Identification of 4-(aminomethyl)-6-(trifluoromethyl)-2-(phenoxy)pyridine derivatives as potent, selective, and orally efficacious inhibitors of the copper-dependent amine oxidase, lysyl oxidase-like 2 (LOXL2)</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">4403</span>– <span class="NLM_lpage">4423</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b00345</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00345" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=1%3ACAS%3A528%3ADC%252BC2sXntFSksrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=4403-4423&author=M.+W.+Rowbottomauthor=G.+Bainauthor=I.+Calderonauthor=T.+Lasofauthor=D.+Lonerganauthor=A.+Laiauthor=F.+Huangauthor=J.+Darlingtonauthor=P.+Prodanovichauthor=A.+M.+Santiniauthor=C.+D.+Kingauthor=L.+Gouletauthor=K.+E.+Shannonauthor=G.+L.+Maauthor=K.+Nguyenauthor=D.+A.+MacKennaauthor=J.+F.+Evansauthor=J.+H.+Hutchinson&title=Identification+of+4-%28aminomethyl%29-6-%28trifluoromethyl%29-2-%28phenoxy%29pyridine+derivatives+as+potent%2C+selective%2C+and+orally+efficacious+inhibitors+of+the+copper-dependent+amine+oxidase%2C+lysyl+oxidase-like+2+%28LOXL2%29&doi=10.1021%2Facs.jmedchem.7b00345"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of 4-(Aminomethyl)-6-(trifluoromethyl)-2-(phenoxy)pyridine Derivatives as Potent, Selective, and Orally Efficacious Inhibitors of the Copper-Dependent Amine Oxidase, Lysyl Oxidase-Like 2 (LOXL2)</span></div><div class="casAuthors">Rowbottom, Martin W.; Bain, Gretchen; Calderon, Imelda; Lasof, Taylor; Lonergan, David; Lai, Andiliy; Huang, Fei; Darlington, Janice; Prodanovich, Patricia; Santini, Angelina M.; King, Christopher D.; Goulet, Lance; Shannon, Kristen E.; Ma, Gina L.; Nguyen, Katherine; MacKenna, Deidre A.; Evans, Jilly F.; Hutchinson, John H.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">4403-4423</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">LOXL2 catalyzes the oxidative deamination of ε-amines of lysine and hydroxylysine residues within collagen and elastin, generating reactive aldehydes (allysine).  Condensation with other allysines or lysines drives the formation of inter- and intramol. cross-linkages, a process crit. for the remodeling of the ECM.  Dysregulation of this process can lead to fibrosis, and LOXL2 is known to be upregulated in fibrotic tissue.  Small-mols. that directly inhibit LOXL2 catalytic activity represent a useful option for the treatment of fibrosis.  Herein, the authors describe optimization of an initial hit, resulting in identification of racemic I, a potent irreversible inhibitor of LOXL2 that is highly selective over LOX and other amine oxidases.  Oral administration of I significantly reduced fibrosis in a 14-day mouse lung bleomycin model.  The (R,R)-enantiomer of I (PAT-1251) was selected as the clin. compd. which has progressed into healthy volunteer Phase 1 trials, making it the "first-in-class" small-mol. LOXL2 inhibitor to enter clin. development. KEY LOXL2 inhibitor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrX-yiHL-BRUrVg90H21EOLACvtfcHk0liNPaSuKCvCzg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXntFSksrs%253D&md5=c71db3046b5ed711043b39181fdf87c9</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00345&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00345%26sid%3Dliteratum%253Aachs%26aulast%3DRowbottom%26aufirst%3DM.%2BW.%26aulast%3DBain%26aufirst%3DG.%26aulast%3DCalderon%26aufirst%3DI.%26aulast%3DLasof%26aufirst%3DT.%26aulast%3DLonergan%26aufirst%3DD.%26aulast%3DLai%26aufirst%3DA.%26aulast%3DHuang%26aufirst%3DF.%26aulast%3DDarlington%26aufirst%3DJ.%26aulast%3DProdanovich%26aufirst%3DP.%26aulast%3DSantini%26aufirst%3DA.%2BM.%26aulast%3DKing%26aufirst%3DC.%2BD.%26aulast%3DGoulet%26aufirst%3DL.%26aulast%3DShannon%26aufirst%3DK.%2BE.%26aulast%3DMa%26aufirst%3DG.%2BL.%26aulast%3DNguyen%26aufirst%3DK.%26aulast%3DMacKenna%26aufirst%3DD.%2BA.%26aulast%3DEvans%26aufirst%3DJ.%2BF.%26aulast%3DHutchinson%26aufirst%3DJ.%2BH.%26atitle%3DIdentification%2520of%25204-%2528aminomethyl%2529-6-%2528trifluoromethyl%2529-2-%2528phenoxy%2529pyridine%2520derivatives%2520as%2520potent%252C%2520selective%252C%2520and%2520orally%2520efficacious%2520inhibitors%2520of%2520the%2520copper-dependent%2520amine%2520oxidase%252C%2520lysyl%2520oxidase-like%25202%2520%2528LOXL2%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D4403%26epage%3D4423%26doi%3D10.1021%2Facs.jmedchem.7b00345" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span> <i>Single and Multiple
Dose Safety, Tolerability, PK and Food Effect
Study of PAT-1251 in Healthy Adult Subjects, NCT02852551</i>,
Nov <span class="NLM_year">2016</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+Single+and+Multiple%0ADose+Safety%2C+Tolerability%2C+PK+and+Food+Effect%0AStudy+of+PAT-1251+in+Healthy+Adult+Subjects%2C+NCT02852551%2C%0ANov+2016."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dreport%26sid%3Dliteratum%253Aachs%26jtitle%3DSingle%2520and%2520Multiple%250ADose%2520Safety%252C%2520Tolerability%252C%2520PK%2520and%2520Food%2520Effect%250AStudy%2520of%2520PAT-1251%2520in%2520Healthy%2520Adult%2520Subjects%252C%2520NCT02852551%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rowbottom, M. W.</span>; <span class="NLM_string-name">Hutchinson, J. H.</span>; <span class="NLM_string-name">Evans, J. F.</span>; <span class="NLM_string-name">Bain, G.</span></span> <span> </span><span class="NLM_article-title">Chemical Probes of Lysyl Oxidase-Like 2 and Uses Thereof</span>. <span class="NLM_patent">WO2018048928A1</span>, <span class="NLM_year">2018</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&author=M.+W.+Rowbottom&author=J.+H.+Hutchinson&author=J.+F.+Evans&author=G.+Bain&title=Chemical+Probes+of+Lysyl+Oxidase-Like+2+and+Uses+Thereof"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DRowbottom%26aufirst%3DM.%2BW.%26atitle%3DChemical%2520Probes%2520of%2520Lysyl%2520Oxidase-Like%25202%2520and%2520Uses%2520Thereof%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stangenberg, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saad, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schilter, H. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zaky, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gill, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pollock, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, M. G.</span></span> <span> </span><span class="NLM_article-title">Lysyl oxidase-like 2 inhibition ameliorates glomerulosclerosis and albuminuria in diabetic nephropathy</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">9423</span>, <span class="refDoi"> DOI: 10.1038/s41598-018-27462-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=10.1038%2Fs41598-018-27462-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=29930330" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=1%3ACAS%3A280%3ADC%252BB3c%252FgsF2msw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2018&pages=9423&author=S.+Stangenbergauthor=S.+Saadauthor=H.+C.+Schilterauthor=A.+Zakyauthor=A.+Gillauthor=C.+A.+Pollockauthor=M.+G.+Wong&title=Lysyl+oxidase-like+2+inhibition+ameliorates+glomerulosclerosis+and+albuminuria+in+diabetic+nephropathy&doi=10.1038%2Fs41598-018-27462-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Lysyl oxidase-like 2 inhibition ameliorates glomerulosclerosis and albuminuria in diabetic nephropathy</span></div><div class="casAuthors">Stangenberg Stefanie; Saad Sonia; Zaky Amgad; Pollock Carol A; Wong Muh Geot; Stangenberg Stefanie; Pollock Carol A; Schilter Heidi C; Gill Anthony</div><div class="citationInfo"><span class="NLM_cas:title">Scientific reports</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">9423</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Diabetic nephropathy is characterised by the excessive amount of extracellular matrix in glomeruli and tubulointerstitial space.  Lysyl oxidase-like 2 (LOXL2) is elevated in renal fibrosis and known to play key roles in ECM stabilisation by facilitating collagen cross-links, epithelial to mesenchymal transition and myofibroblast activation.  Thus, targeting LOXL2 may prove to be a useful strategy to prevent diabetic nephropathy.  We explored the renoprotective effect of a selective small molecule LOXL2 inhibitor (PXS-S2B) in a streptozotocin-induced diabetes model.  Diabetic mice were treated with PXS-S2B for 24 weeks and outcomes compared with untreated diabetic mice and with telmisartan treated animals as comparator of current standard of care.  Diabetic mice had albuminuria, higher glomerulosclerosis scores, upregulation of fibrosis markers and increased renal cortical LOXL2 expression.  Treatment with PXS-S2B reduced albuminuria and ameliorated glomerulosclerosis.  This was associated with reduced expression of glomerular fibronectin and tubulointerstitial collagen I.  The renoprotective effects of both PXS-S2B and telmisartan were more marked in the glomerular compartment than in the tubulointerstitial space.  The study reveals that LOXL2 inhibition was beneficial in preserving glomerular structure and function.  Thus, LOXL2 may be a potential therapeutic target in diabetic nephropathy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTqtRzP_i5UFnT4ugvCDgnZfW6udTcc2ebMWaWLpxVlqrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3c%252FgsF2msw%253D%253D&md5=eebbe97c2915983c009e575ec6e76a04</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1038%2Fs41598-018-27462-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41598-018-27462-6%26sid%3Dliteratum%253Aachs%26aulast%3DStangenberg%26aufirst%3DS.%26aulast%3DSaad%26aufirst%3DS.%26aulast%3DSchilter%26aufirst%3DH.%2BC.%26aulast%3DZaky%26aufirst%3DA.%26aulast%3DGill%26aufirst%3DA.%26aulast%3DPollock%26aufirst%3DC.%2BA.%26aulast%3DWong%26aufirst%3DM.%2BG.%26atitle%3DLysyl%2520oxidase-like%25202%2520inhibition%2520ameliorates%2520glomerulosclerosis%2520and%2520albuminuria%2520in%2520diabetic%2520nephropathy%26jtitle%3DSci.%2520Rep.%26date%3D2018%26volume%3D8%26spage%3D9423%26doi%3D10.1038%2Fs41598-018-27462-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yu, P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zuo, D.-M.</span></span> <span> </span><span class="NLM_article-title">Inhibition of a type B monoamine oxidase inhibitor, (E)-2-(4-fluorophenethyl)-3-fluoroallylamine (MDL-72974A), on semicarbazide-sensitive amine oxidases isolated from vascular tissues and sera of different species</span>. <i>Biochem. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1992</span>,  <span class="NLM_volume"><i>43</i></span>,  <span class="NLM_fpage">307</span>– <span class="NLM_lpage">312</span>, <span class="refDoi"> DOI: 10.1016/0006-2952(92)90293-r</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=10.1016%2F0006-2952%2892%2990293-r" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=1739419" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=1%3ACAS%3A528%3ADyaK38XhsVersrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=1992&pages=307-312&author=P.+H.+Yuauthor=D.-M.+Zuo&title=Inhibition+of+a+type+B+monoamine+oxidase+inhibitor%2C+%28E%29-2-%284-fluorophenethyl%29-3-fluoroallylamine+%28MDL-72974A%29%2C+on+semicarbazide-sensitive+amine+oxidases+isolated+from+vascular+tissues+and+sera+of+different+species&doi=10.1016%2F0006-2952%2892%2990293-r"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of a type B monoamine oxidase inhibitor, (E)-2-(4-fluorophenethyl)-3-fluoroallylamine (MDL-72974A), on semicarbazide-sensitive amine oxidases isolated from vascular tissues and sera of different species</span></div><div class="casAuthors">Yu, Peter H.; Zuo, Dong Mei</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Pharmacology</span>
        (<span class="NLM_cas:date">1992</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">307-12</span>CODEN:
                <span class="NLM_cas:coden">BCPCA6</span>;
        ISSN:<span class="NLM_cas:issn">0006-2952</span>.
    </div><div class="casAbstract">(E)-2-(4-Fluorophenethyl)-3-fluoroallylamine hydrochloride (MDL-72974A) has been discovered recently to be a very potent and highly selective type B monoamine oxidase inhibitor.  The authors found that this inhibitor is also capable of inhibiting semicarbazide-sensitive amine oxidases (SSAOs) obtained from vascular tissues and sera of different species.  The inhibition of SSAO by MDL-72974A was irreversible and time-dependent.  It was competitive without preincubation of the enzyme with the inhibitor and demonstrated a mixed-type of inhibition when the enzyme was preincubated with the inhibitor.  The IC50 values were estd. to be 2 × 10-9 M, 5 × 10-9 M, 8 × 10-8 M and 2 × 10-8 M for SSAO for dog aorta, rat aorta, bovine aorta and human umbilical artery, resp.  SSAO obtained from bovine serum was relatively insensitive to MDL-72974A (IC50 = 3 × 10-7 M).  Following i.p. administration of MDL-72974A, rat brain MAO-B was inhibited with the ED50 value being about 0.2 mg/kg.  Rat aorta SSAO was also inhibited and to a similar extent by the same dose.  MDL-72974A is the most potent SSAO inhibitor that has been described thus far.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqd8gbzL_F8zrVg90H21EOLACvtfcHk0liNPaSuKCvCzg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK38XhsVersrg%253D&md5=8f558adce9f09f7218139ce873de4b92</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1016%2F0006-2952%2892%2990293-r&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0006-2952%252892%252990293-r%26sid%3Dliteratum%253Aachs%26aulast%3DYu%26aufirst%3DP.%2BH.%26aulast%3DZuo%26aufirst%3DD.-M.%26atitle%3DInhibition%2520of%2520a%2520type%2520B%2520monoamine%2520oxidase%2520inhibitor%252C%2520%2528E%2529-2-%25284-fluorophenethyl%2529-3-fluoroallylamine%2520%2528MDL-72974A%2529%252C%2520on%2520semicarbazide-sensitive%2520amine%2520oxidases%2520isolated%2520from%2520vascular%2520tissues%2520and%2520sera%2520of%2520different%2520species%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D1992%26volume%3D43%26spage%3D307%26epage%3D312%26doi%3D10.1016%2F0006-2952%2892%2990293-r" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Foot, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deodhar, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turner, C. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yin, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Dam, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silva, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olivieri, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holt, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDonald, I. A.</span></span> <span> </span><span class="NLM_article-title">The discovery and development of selective 3-fluoro-4-aryloxyallylamine inhibitors of the amine oxidase activity of semicarbazide-sensitive amine oxidase/vascular adhesion protein-1 (SSAO/VAP-1)</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">3935</span>– <span class="NLM_lpage">3940</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2012.04.111</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=10.1016%2Fj.bmcl.2012.04.111" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=22595173" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=1%3ACAS%3A528%3ADC%252BC38XntVyrtLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2012&pages=3935-3940&author=J.+S.+Footauthor=M.+Deodharauthor=C.+I.+Turnerauthor=P.+Yinauthor=E.+M.+van+Damauthor=D.+G.+Silvaauthor=A.+Olivieriauthor=A.+Holtauthor=I.+A.+McDonald&title=The+discovery+and+development+of+selective+3-fluoro-4-aryloxyallylamine+inhibitors+of+the+amine+oxidase+activity+of+semicarbazide-sensitive+amine+oxidase%2Fvascular+adhesion+protein-1+%28SSAO%2FVAP-1%29&doi=10.1016%2Fj.bmcl.2012.04.111"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">The discovery and development of selective 3-fluoro-4-aryloxyallylamine inhibitors of the amine oxidase activity of semicarbazide-sensitive amine oxidase/vascular adhesion protein-1 (SSAO/VAP-1)</span></div><div class="casAuthors">Foot, Jonathan S.; Deodhar, Mandar; Turner, Craig I.; Yin, Ping; van Dam, Ellen M.; Silva, Diego G.; Olivieri, Aldo; Holt, Andrew; McDonald, Ian A.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">3935-3940</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A new class of 3-fluoroallyl amine-based SSAO/VAP-1 inhibitors is reported.  These compds. have excellent selectivity over diamine oxidase, MAO-A and MAO-B.  Synthesis and SAR studies leading to compd. 28 (PXS-4159A, I) are reported.  The pharmacokinetic profile of 28 in the rat, together with activity in a murine model of lung inflammation are also disclosed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrFPi3_tFawXLVg90H21EOLACvtfcHk0lg7ux4AsYRVKg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XntVyrtLg%253D&md5=cb02b80379ec2a2a6323b158f2297944</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2012.04.111&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2012.04.111%26sid%3Dliteratum%253Aachs%26aulast%3DFoot%26aufirst%3DJ.%2BS.%26aulast%3DDeodhar%26aufirst%3DM.%26aulast%3DTurner%26aufirst%3DC.%2BI.%26aulast%3DYin%26aufirst%3DP.%26aulast%3Dvan%2BDam%26aufirst%3DE.%2BM.%26aulast%3DSilva%26aufirst%3DD.%2BG.%26aulast%3DOlivieri%26aufirst%3DA.%26aulast%3DHolt%26aufirst%3DA.%26aulast%3DMcDonald%26aufirst%3DI.%2BA.%26atitle%3DThe%2520discovery%2520and%2520development%2520of%2520selective%25203-fluoro-4-aryloxyallylamine%2520inhibitors%2520of%2520the%2520amine%2520oxidase%2520activity%2520of%2520semicarbazide-sensitive%2520amine%2520oxidase%252Fvascular%2520adhesion%2520protein-1%2520%2528SSAO%252FVAP-1%2529%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D22%26spage%3D3935%26epage%3D3940%26doi%3D10.1016%2Fj.bmcl.2012.04.111" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">O’Rourke, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, E. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Podar, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scheyhing, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kessler, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ton-Nu, H. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macdonald, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Linnik, M. D.</span></span> <span> </span><span class="NLM_article-title">Anti-inflammatory effects of LJP 1586 [Z-3-fluoro-2-(4-methoxybenzyl)allylamine hydrochloride], an amine-based inhibitor of semicarbazide-sensitive amine oxidase activity</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>324</i></span>,  <span class="NLM_fpage">867</span>– <span class="NLM_lpage">875</span>, <span class="refDoi"> DOI: 10.1124/jpet.107.131672</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=10.1124%2Fjpet.107.131672" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=17993604" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsFShurY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=324&publication_year=2008&pages=867-875&author=A.+M.+O%E2%80%99Rourkeauthor=E.+Y.+Wangauthor=A.+Millerauthor=E.+M.+Podarauthor=K.+Scheyhingauthor=L.+Huangauthor=C.+Kesslerauthor=H.+Gaoauthor=H.+T.+Ton-Nuauthor=M.+T.+Macdonaldauthor=D.+S.+Jonesauthor=M.+D.+Linnik&title=Anti-inflammatory+effects+of+LJP+1586+%5BZ-3-fluoro-2-%284-methoxybenzyl%29allylamine+hydrochloride%5D%2C+an+amine-based+inhibitor+of+semicarbazide-sensitive+amine+oxidase+activity&doi=10.1124%2Fjpet.107.131672"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Anti-inflammatory effects of LJP 1586 [Z-3-fluoro-2-(4-methoxybenzyl)allylamine hydrochloride], an amine-based inhibitor of semicarbazide-sensitive amine oxidase activity</span></div><div class="casAuthors">O'Rourke, Anne M.; Wang, Eric Y.; Miller, Andrew; Podar, Erika M.; Scheyhing, Kelly; Huang, Li; Kessler, Christina; Gao, Hongfeng; Ton-Nu, Huong-Thu; MacDonald, Mary T.; Jones, David S.; Linnik, Matthew D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">324</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">867-875</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Semicarbazide-sensitive amine oxidase (SSAO, amine oxidase, copper-contg. 3, and vascular adhesion protein-1) is a copper-contg. enzyme that catalyzes the oxidative deamination of primary amines to an aldehyde, ammonia, and hydrogen peroxide.  SSAO is also involved in leukocyte migration to sites of inflammation, and the enzymic activity of SSAO is essential to this role.  Thus, inhibition of SSAO enzyme activity represents a target for the development of small mol. anti-inflammatory compds.  Here, we have characterized the novel SSAO inhibitor, Z-3-fluoro-2-(4-methoxybenzyl)allylamine hydrochloride (LJP 1586), and assessed its anti-inflammatory activity.  LJP 1586 is a potent inhibitor of rodent and human SSAO activity, with IC50 values between 4 and 43 nM.  The selectivity of LJP 1586 was confirmed with a broad panel of receptors and enzymes that included the monoamine oxidases A and B.  Oral administration of LJP 1586 resulted in complete inhibition of rat lung SSAO, with an ED50 between 0.1 and 1 mg/kg, and a pharmacodynamic half-life of greater than 24 h.  In a mouse model of inflammatory leukocyte trafficking oral dosing with LJP 1586 resulted in significant dose-dependent inhibition of neutrophil accumulation, with an effect comparable to that of anti-leukocyte function-assocd. antigen-1 antibody.  In a rat model of LPS-induced lung inflammation, administration of 10 mg/kg LJP 1586 resulted in a 55% significant redn. in transmigrated cells recovered by bronchoalveolar lavage.  The results demonstrate that a selective, orally active small mol. inhibitor of SSAO is an effective anti-inflammatory compd. in vivo and provide further support for SSAO as a therapeutic anti-inflammatory target.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrg6t1pTM6ntbVg90H21EOLACvtfcHk0lg7ux4AsYRVKg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsFShurY%253D&md5=488fa2c75c5488de6cb038c1a253c72e</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1124%2Fjpet.107.131672&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.107.131672%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Rourke%26aufirst%3DA.%2BM.%26aulast%3DWang%26aufirst%3DE.%2BY.%26aulast%3DMiller%26aufirst%3DA.%26aulast%3DPodar%26aufirst%3DE.%2BM.%26aulast%3DScheyhing%26aufirst%3DK.%26aulast%3DHuang%26aufirst%3DL.%26aulast%3DKessler%26aufirst%3DC.%26aulast%3DGao%26aufirst%3DH.%26aulast%3DTon-Nu%26aufirst%3DH.%2BT.%26aulast%3DMacdonald%26aufirst%3DM.%2BT.%26aulast%3DJones%26aufirst%3DD.%2BS.%26aulast%3DLinnik%26aufirst%3DM.%2BD.%26atitle%3DAnti-inflammatory%2520effects%2520of%2520LJP%25201586%2520%255BZ-3-fluoro-2-%25284-methoxybenzyl%2529allylamine%2520hydrochloride%255D%252C%2520an%2520amine-based%2520inhibitor%2520of%2520semicarbazide-sensitive%2520amine%2520oxidase%2520activity%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2008%26volume%3D324%26spage%3D867%26epage%3D875%26doi%3D10.1124%2Fjpet.107.131672" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Foot, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yow, T. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schilter, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deodhar, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Findlay, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDonald, I. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turner, C. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jarolimek, W.</span></span> <span> </span><span class="NLM_article-title">PXS-4681A, a potent and selective mechanism-based inhibitor of SSAO/VAP-1 with anti-inflammatory effects in vivo</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>347</i></span>,  <span class="NLM_fpage">365</span>– <span class="NLM_lpage">374</span>, <span class="refDoi"> DOI: 10.1124/jpet.113.207613</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=10.1124%2Fjpet.113.207613" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=23943052" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhslSqsL3L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=347&publication_year=2013&pages=365-374&author=J.+S.+Footauthor=T.+T.+Yowauthor=H.+Schilterauthor=A.+Busonauthor=M.+Deodharauthor=A.+D.+Findlayauthor=L.+Guoauthor=I.+A.+McDonaldauthor=C.+I.+Turnerauthor=W.+Zhouauthor=W.+Jarolimek&title=PXS-4681A%2C+a+potent+and+selective+mechanism-based+inhibitor+of+SSAO%2FVAP-1+with+anti-inflammatory+effects+in+vivo&doi=10.1124%2Fjpet.113.207613"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">PXS-4681A, a potent and selective mechanism-based inhibitor of SSAO/VAP-1 with anti-inflammatory effects in vivo</span></div><div class="casAuthors">Foot, Jonathan S.; Yow, Tin T.; Schilter, Heidi; Buson, Alberto; Deodhar, Mandar; Findlay, Alison D.; Guo, Lily; McDonald, Ian A.; Turner, Craig I.; Zhou, Wenbin; Jarolimek, Wolfgang</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">347</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">365-374</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Semicarbazide-sensitive amine oxidase (SSAO), also known as vascular adhesion protein-1 (VAP-1), is a member of the copper-dependent amine oxidase family that is assocd. with various forms of inflammation and fibrosis.  To investigate the therapeutic potential of SSAO/VAP-1 inhibition, potent and selective inhibitors with drug-like properties are required.  PXS-4681A [(Z)-4-(2-(aminomethyl)-3-fluoroallyloxy)benzenesulfonamide hydrochloride] is a mechanism-based inhibitor of enzyme function with a pharmacokinetic and pharmacodynamic profile that ensures complete, long-lasting inhibition of the enzyme after a single low dose in vivo.  PXS-4681A irreversibly inhibits the enzyme with an apparent Ki of 37 nM and a kinact of 0.26 min-1 with no obsd. turnover in vitro.  It is highly selective for SSAO/VAP-1 when profiled against related amine oxidases, ion channels, and seven-transmembrane domain receptors, and is superior to previously reported inhibitors.  In mouse models of lung inflammation and localized inflammation, dosing of this mol. at 2 mg/kg attenuates neutrophil migration, tumor necrosis factor-α, and interleukin-6 levels.  These results demonstrate the drug-like properties of PXS-4681A and its potential use in the treatment of inflammation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqhUjl7gonLQrVg90H21EOLACvtfcHk0lg7ux4AsYRVKg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhslSqsL3L&md5=d3c24925c4b717c9405d46be9a82f2d9</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1124%2Fjpet.113.207613&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.113.207613%26sid%3Dliteratum%253Aachs%26aulast%3DFoot%26aufirst%3DJ.%2BS.%26aulast%3DYow%26aufirst%3DT.%2BT.%26aulast%3DSchilter%26aufirst%3DH.%26aulast%3DBuson%26aufirst%3DA.%26aulast%3DDeodhar%26aufirst%3DM.%26aulast%3DFindlay%26aufirst%3DA.%2BD.%26aulast%3DGuo%26aufirst%3DL.%26aulast%3DMcDonald%26aufirst%3DI.%2BA.%26aulast%3DTurner%26aufirst%3DC.%2BI.%26aulast%3DZhou%26aufirst%3DW.%26aulast%3DJarolimek%26aufirst%3DW.%26atitle%3DPXS-4681A%252C%2520a%2520potent%2520and%2520selective%2520mechanism-based%2520inhibitor%2520of%2520SSAO%252FVAP-1%2520with%2520anti-inflammatory%2520effects%2520in%2520vivo%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2013%26volume%3D347%26spage%3D365%26epage%3D374%26doi%3D10.1124%2Fjpet.113.207613" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span> A similar mechanism
has been reported for the related vinyl fluoride, mofegiline;<span class="NLM_contrib-group"><span class="NLM_string-name">Milczek, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonivento, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Binda, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mattevi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDonald, I. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edmondson, D. E.</span></span> <span> </span><span class="NLM_article-title">Structural and Mechanistic Studies of Mofegiline Inhibition of Recombinant Human Monoamine Oxidase B</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">8019</span>– <span class="NLM_lpage">8026</span>, <span class="refDoi"> DOI: 10.1021/jm8011867</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm8011867" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsVKlu73L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=8019-8026&author=E.+M.+Milczekauthor=D.+Boniventoauthor=C.+Bindaauthor=A.+Matteviauthor=I.+A.+McDonaldauthor=D.+E.+Edmondson&title=Structural+and+Mechanistic+Studies+of+Mofegiline+Inhibition+of+Recombinant+Human+Monoamine+Oxidase+B&doi=10.1021%2Fjm8011867"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Structural and Mechanistic Studies of Mofegiline Inhibition of Recombinant Human Monoamine Oxidase B</span></div><div class="casAuthors">Milczek, Erika M.; Bonivento, Daniele; Binda, Claudia; Mattevi, Andrea; McDonald, Ian A.; Edmondson, Dale E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">8019-8026</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Mechanistic and structural studies have been carried out to investigate the mol. basis for the irreversible inhibition of human MAO-B by mofegiline.  Competitive inhibition with substrate shows an apparent Ki of 28 nM.  Irreversible inhibition of MAO-B occurs with a 1:1 M stoichiometry with no observable catalytic turnover.  The absorption spectral properties of mofegiline inhibited MAO-B show features (λmax ≃ 450 nm) unlike those of traditional flavin N(5) or C(4a) adducts.  Visible and near-UV CD spectra of the mofegiline-MAO-B adduct shows a neg. peak at 340 nm with an intensity similar to that of N(5) flavocyanine adducts.  The x-ray crystal structure of the mofegiline-MAO-B adduct shows a covalent bond between the flavin cofactor N(5) with the distal allylamine carbon atom as well as the absence of the fluorine atom.  A mechanism to explain these structural and spectral data is proposed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoyyHGVkF0PcbVg90H21EOLACvtfcHk0ljlJzD6TQjBQw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsVKlu73L&md5=a2155647066b1e971ecc2b7680ee7bee</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1021%2Fjm8011867&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm8011867%26sid%3Dliteratum%253Aachs%26aulast%3DMilczek%26aufirst%3DE.%2BM.%26aulast%3DBonivento%26aufirst%3DD.%26aulast%3DBinda%26aufirst%3DC.%26aulast%3DMattevi%26aufirst%3DA.%26aulast%3DMcDonald%26aufirst%3DI.%2BA.%26aulast%3DEdmondson%26aufirst%3DD.%2BE.%26atitle%3DStructural%2520and%2520Mechanistic%2520Studies%2520of%2520Mofegiline%2520Inhibition%2520of%2520Recombinant%2520Human%2520Monoamine%2520Oxidase%2520B%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D8019%26epage%3D8026%26doi%3D10.1021%2Fjm8011867" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span> A crystal structure
of LOXL2 in a precursor state, with the copper atom missing, was published
recently. Given the conformational changes needed to form the active
LTQ cofactor, this structure is likely unsuitable for future structure
based design efforts;<span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, M.</span></span> <span> </span><span class="NLM_article-title">Crystal structure of human lysyl oxidase-like 2 (hLOXL2) in a precursor state</span>. <i>Proc. Natl. Acad. Sci. U.S.A.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>115</i></span>,  <span class="NLM_fpage">3828</span>– <span class="NLM_lpage">3833</span>, <span class="refDoi"> DOI: 10.1073/pnas.1720859115</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=10.1073%2Fpnas.1720859115" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=29581294" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=1%3ACAS%3A528%3ADC%252BC1cXht1Gqtr%252FM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=115&publication_year=2018&pages=3828-3833&author=X.+Zhangauthor=Q.+Wangauthor=J.+Wuauthor=J.+Wangauthor=Y.+Shiauthor=M.+Liu&title=Crystal+structure+of+human+lysyl+oxidase-like+2+%28hLOXL2%29+in+a+precursor+state&doi=10.1073%2Fpnas.1720859115"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal structure of human lysyl oxidase-like 2 (hLOXL2) in a precursor state</span></div><div class="casAuthors">Zhang, Xi; Wang, Qifan; Wu, Jianping; Wang, Jiawei; Shi, Yigong; Liu, Minhao</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">115</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">3828-3833</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Lysyl oxidases (LOXs), a type of copper- and lysyl tyrosylquinone (LTQ) -dependent amine oxidase, catalyze the oxidative deamination of lysine residues of extracellular matrix (ECM) proteins such as elastins and collagens and generate aldehyde groups.  The oxidative deamination of lysine represents the foundational step for the crosslinking of elastin and collagen and thus is crucial for ECM modeling.  Despite their physiol. significance, the structure of this important family of enzymes remains elusive.  Here we report the crystal structure of human lysyl oxidase-like 2 (hLOXL2) at 2.4-Å resoln.  Unexpectedly, the copper-binding site of hLOXL2 is occupied by zinc, which blocks LTQ generation and the enzymic activity of hLOXL2 in our in vitro assay.  Biochem. anal. confirms that copper loading robustly activates hLOXL2 and supports LTQ formation.  Furthermore, the LTQ precursor residues in the structure are distanced by 16.6 Å, corroborating the notion that the present structure may represent a precursor state and that pronounced conformational rearrangements would be required for protein activation.  The structure presented here establishes an important foundation for understanding the structure-function relationship of LOX proteins and will facilitate LOX-targeting drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrAQtLUIP5TKrVg90H21EOLACvtfcHk0ljlJzD6TQjBQw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXht1Gqtr%252FM&md5=c2b32a9187d289a5b1cc2f7ef485d813</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1720859115&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1720859115%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DQ.%26aulast%3DWu%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DShi%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DM.%26atitle%3DCrystal%2520structure%2520of%2520human%2520lysyl%2520oxidase-like%25202%2520%2528hLOXL2%2529%2520in%2520a%2520precursor%2520state%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2018%26volume%3D115%26spage%3D3828%26epage%3D3833%26doi%3D10.1073%2Fpnas.1720859115" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McDonald, I. A.</span>; <span class="NLM_string-name">Turner, C. I.</span>; <span class="NLM_string-name">Deodhar, M.</span>; <span class="NLM_string-name">Foot, J.
S.</span></span> <span> </span><span class="NLM_article-title">Haloallylamine Inhibitors of SSAO/VAP-1 and Uses Therefor</span>. <span class="NLM_patent">WO2009066152A2</span>, <span class="NLM_year">2009</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2009&author=I.+A.+McDonald&author=C.+I.+Turner&author=M.+Deodhar&author=J.%0AS.+Foot&title=Haloallylamine+Inhibitors+of+SSAO%2FVAP-1+and+Uses+Therefor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DMcDonald%26aufirst%3DI.%2BA.%26atitle%3DHaloallylamine%2520Inhibitors%2520of%2520SSAO%252FVAP-1%2520and%2520Uses%2520Therefor%26date%3D2009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rostovtsev, V. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Green, L. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fokin, V. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharpless, K. B.</span></span> <span> </span><span class="NLM_article-title">A Stepwise Huisgen Cycloaddition Process: Copper(I)-Catalyzed Regioselective “Ligation” of Azides and Terminal Alkynes</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>41</i></span>,  <span class="NLM_fpage">2596</span>– <span class="NLM_lpage">2599</span>, <span class="refDoi"> DOI: 10.1002/1521-3773(20020715)41:14<2596::aid-anie2596>3.0.co;2-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=10.1002%2F1521-3773%2820020715%2941%3A14%3C2596%3A%3AAID-ANIE2596%3E3.0.CO%3B2-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=12203546" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=1%3ACAS%3A528%3ADC%252BD38Xls1Ohsr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2002&pages=2596-2599&author=V.+V.+Rostovtsevauthor=L.+G.+Greenauthor=V.+V.+Fokinauthor=K.+B.+Sharpless&title=A+Stepwise+Huisgen+Cycloaddition+Process%3A+Copper%28I%29-Catalyzed+Regioselective+%E2%80%9CLigation%E2%80%9D+of+Azides+and+Terminal+Alkynes&doi=10.1002%2F1521-3773%2820020715%2941%3A14%3C2596%3A%3Aaid-anie2596%3E3.0.co%3B2-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">A stepwise Huisgen cycloaddition process: copper(I)-catalyzed regioselective "ligation" of azides and terminal alkynes</span></div><div class="casAuthors">Rostovtsev, Vsevolod V.; Green, Luke G.; Fokin, Valery V.; Sharpless, K. Barry</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">2596-2599</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH</span>)
        </div><div class="casAbstract">1,4-Disubstituted 1,2,3-triazoles I (R1 = PhCH2, PhCH2OCH2, 1-adamantyl, etc.; R2 = HO2C, Ph, PhOCH2, Et2NCH2, etc.) were readily and cleanly prepd. via highly efficient and regioselective copper(I)-catalyzed cycloaddn. of azides R1N3 with terminal alkynes R2C≡CH in 82-93% yields.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGptcW2JUNM1r7Vg90H21EOLACvtfcHk0ljlJzD6TQjBQw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xls1Ohsr4%253D&md5=4603664be6639353b5e70f19b9f8d59f</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1002%2F1521-3773%2820020715%2941%3A14%3C2596%3A%3AAID-ANIE2596%3E3.0.CO%3B2-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252F1521-3773%252820020715%252941%253A14%253C2596%253A%253AAID-ANIE2596%253E3.0.CO%253B2-4%26sid%3Dliteratum%253Aachs%26aulast%3DRostovtsev%26aufirst%3DV.%2BV.%26aulast%3DGreen%26aufirst%3DL.%2BG.%26aulast%3DFokin%26aufirst%3DV.%2BV.%26aulast%3DSharpless%26aufirst%3DK.%2BB.%26atitle%3DA%2520Stepwise%2520Huisgen%2520Cycloaddition%2520Process%253A%2520Copper%2528I%2529-Catalyzed%2520Regioselective%2520%25E2%2580%259CLigation%25E2%2580%259D%2520of%2520Azides%2520and%2520Terminal%2520Alkynes%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2002%26volume%3D41%26spage%3D2596%26epage%3D2599%26doi%3D10.1002%2F1521-3773%2820020715%2941%3A14%3C2596%3A%3Aaid-anie2596%3E3.0.co%3B2-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diwu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Panchuk-Voloshina, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haugland, R. P.</span></span> <span> </span><span class="NLM_article-title">A Stable Nonfluorescent Derivative of Resorufin for the Fluorometric Determination of Trace Hydrogen Peroxide: Applications in Detecting the Activity of Phagocyte NADPH Oxidase and Other Oxidases</span>. <i>Anal. Biochem.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>253</i></span>,  <span class="NLM_fpage">162</span>– <span class="NLM_lpage">168</span>, <span class="refDoi"> DOI: 10.1006/abio.1997.2391</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=10.1006%2Fabio.1997.2391" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=9367498" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=1%3ACAS%3A528%3ADyaK2sXnsFahsr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=253&publication_year=1997&pages=162-168&author=M.+Zhouauthor=Z.+Diwuauthor=N.+Panchuk-Voloshinaauthor=R.+P.+Haugland&title=A+Stable+Nonfluorescent+Derivative+of+Resorufin+for+the+Fluorometric+Determination+of+Trace+Hydrogen+Peroxide%3A+Applications+in+Detecting+the+Activity+of+Phagocyte+NADPH+Oxidase+and+Other+Oxidases&doi=10.1006%2Fabio.1997.2391"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">A stable nonfluorescent derivative of resorufin for the fluorometric determination of trace hydrogen peroxide: applications in detecting the activity of phagocyte NADPH oxidase and other oxidase spectrochemical analysis fluorometrics</span></div><div class="casAuthors">Zhou, Mingjie; Diwu, Zhenjun; Panchuk-Voloshina, Nataliya; Haugland, Richard P.</div><div class="citationInfo"><span class="NLM_cas:title">Analytical Biochemistry</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">253</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">162-168</span>CODEN:
                <span class="NLM_cas:coden">ANBCA2</span>;
        ISSN:<span class="NLM_cas:issn">0003-2697</span>.
    
            (<span class="NLM_cas:orgname">Academic Press</span>)
        </div><div class="casAbstract">The enzymic detn. of hydrogen peroxide can be accomplished with high sensitivity and specificity using N-acetyl-3,7-dihydroxyphenoxazine (Amplex Red), a highly sensitive and chem. stable fluorogenic probe for the enzymic detn. of H2O2.  Enzyme-catalyzed oxidn. of Amplex Red, which is a colorless and nonfluorescent deriv. of dihydroresorufin, produces highly fluorescent resorufin, which has an excitation max. at 563 nm and emission max. at 587 nm.  The reaction stoichiometry of Amplex Red and H2O2 was detd. to be 1:1.  This probe allows detection of 5 pmol H2O2 in a 96-well fluorescence microplate assay.  When applied to the measurement of NADPH oxidase activation, the Amplex Red assay can detect H2O2 release from as few as 2000 phorbol myristate acetate-stimulated neutrophils with a sensitivity 5- to 20-fold greater than that attained in the scopoletin assay under the same exptl. conditions.  Furthermore, the oxidase-catalyzed assay using Amplex Red results in an increase in fluorescence on oxidn. rather than a decrease in fluorescence as in the scopoletin assay.  In comparison with other fluorometric and spectrophotometric assays for the detection of monoamine oxidase and glucose oxidase, this probe is also found to be more sensitive.  Given its high sensitivity and specificity, Amplex Red should have a broad application for the measurement of H2O2 in a variety of oxidase-mediated reactions and very low levels of H2O2 in food, environmental waters, and consumer products.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo-7MWSaM2nZLVg90H21EOLACvtfcHk0libjUAnOuZ3mA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXnsFahsr4%253D&md5=56ad0d7f78ede7a6fc0c6a9208dec947</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1006%2Fabio.1997.2391&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1006%252Fabio.1997.2391%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DM.%26aulast%3DDiwu%26aufirst%3DZ.%26aulast%3DPanchuk-Voloshina%26aufirst%3DN.%26aulast%3DHaugland%26aufirst%3DR.%2BP.%26atitle%3DA%2520Stable%2520Nonfluorescent%2520Derivative%2520of%2520Resorufin%2520for%2520the%2520Fluorometric%2520Determination%2520of%2520Trace%2520Hydrogen%2520Peroxide%253A%2520Applications%2520in%2520Detecting%2520the%2520Activity%2520of%2520Phagocyte%2520NADPH%2520Oxidase%2520and%2520Other%2520Oxidases%26jtitle%3DAnal.%2520Biochem.%26date%3D1997%26volume%3D253%26spage%3D162%26epage%3D168%26doi%3D10.1006%2Fabio.1997.2391" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kuo, W.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, M.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsai, C.-N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, T.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, M.-F.</span></span> <span> </span><span class="NLM_article-title">Imatinib Mesylate Improves Liver Regeneration and Attenuates Liver Fibrogenesis in CCL4-Treated Mice</span>. <i>J. Gastrointest. Surg.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">361</span>– <span class="NLM_lpage">369</span>, <span class="refDoi"> DOI: 10.1007/s11605-011-1764-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=10.1007%2Fs11605-011-1764-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=22068968" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=1%3ACAS%3A280%3ADC%252BC387mvFajtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2012&pages=361-369&author=W.-L.+Kuoauthor=M.-C.+Yuauthor=J.-F.+Leeauthor=C.-N.+Tsaiauthor=T.-C.+Chenauthor=M.-F.+Chen&title=Imatinib+Mesylate+Improves+Liver+Regeneration+and+Attenuates+Liver+Fibrogenesis+in+CCL4-Treated+Mice&doi=10.1007%2Fs11605-011-1764-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Imatinib mesylate improves liver regeneration and attenuates liver fibrogenesis in CCL4-treated mice</span></div><div class="casAuthors">Kuo Wen-Ling; Yu Ming-Chin; Lee Ju-Fang; Tsai Chi-Neu; Chen Tse-Ching; Chen Miin-Fu</div><div class="citationInfo"><span class="NLM_cas:title">Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">361-9</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUNDS:  Imatinib mesylate (STI-571), a tyrosine kinase inhibitor, has previously been demonstrated to attenuate liver fibrogenesis through inhibition of the activation of hepatic stellate cells (HSCs) in CCL(4)-treated rat models.  AIMS:  This study aimed to further evaluate the role of STI-571 in liver regeneration.  MATERIALS AND METHODS:  All animals were divided into four groups, and mice were treated with or without CCL(4) and STI-571 (n = 6 for each group).  RESULTS:  Activated cultured HSCs in vitro with STI-571 administration showed increased apoptosis and reduced proliferation, as determined by flow cytometric analysis, 3-(4, 5-cimethylthiazol-2-yl)-2, 5-diphenyl tetrazolium bromide assay, and confocal microscopy.  STI-571 treatment attenuated liver fibrosis in vivo, as was evident in the results of histology, mRNA level, and expression analysis of smooth muscle actin and type I collagen.  Mice treated with STI-571 had increased liver weight ratio and the improvement in liver regeneration was compatible with the change of serum interleukin 6 levels (p < 0.05).  Further, increased apoptosis and a reduced proliferation were observed in the CCL(4)-treated mice after STI-571 treatment based on the immunohistochemical staining of Annexin V, phosphorylated STAT3, and PCNA.  CONCLUSION:  STI-571 treatment effectively attenuated liver fibrogenesis and improved in liver regeneration in vivo and induced apoptosis in HSCs both in vitro and in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRQPWxRp6ppkxe4jJGKT5N0fW6udTcc2eYkKo8vpKHY7bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC387mvFajtQ%253D%253D&md5=53541b37647f583777a5b725240d649e</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1007%2Fs11605-011-1764-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11605-011-1764-7%26sid%3Dliteratum%253Aachs%26aulast%3DKuo%26aufirst%3DW.-L.%26aulast%3DYu%26aufirst%3DM.-C.%26aulast%3DLee%26aufirst%3DJ.-F.%26aulast%3DTsai%26aufirst%3DC.-N.%26aulast%3DChen%26aufirst%3DT.-C.%26aulast%3DChen%26aufirst%3DM.-F.%26atitle%3DImatinib%2520Mesylate%2520Improves%2520Liver%2520Regeneration%2520and%2520Attenuates%2520Liver%2520Fibrogenesis%2520in%2520CCL4-Treated%2520Mice%26jtitle%3DJ.%2520Gastrointest.%2520Surg.%26date%3D2012%26volume%3D16%26spage%3D361%26epage%3D369%26doi%3D10.1007%2Fs11605-011-1764-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Aono, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nishioka, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inayama, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ugai, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kishi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uehara, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Izumi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sone, S.</span></span> <span> </span><span class="NLM_article-title">Imatinib as a novel antifibrotic agent in bleomycin-induced pulmonary fibrosis in mice</span>. <i>Am. J. Respir. Crit. Care Med.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>171</i></span>,  <span class="NLM_fpage">1279</span>– <span class="NLM_lpage">1285</span>, <span class="refDoi"> DOI: 10.1164/rccm.200404-531oc</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=10.1164%2Frccm.200404-531oc" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=15735062" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=1%3ACAS%3A280%3ADC%252BD2M3ntFWmtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=171&publication_year=2005&pages=1279-1285&author=Y.+Aonoauthor=Y.+Nishiokaauthor=M.+Inayamaauthor=M.+Ugaiauthor=J.+Kishiauthor=H.+Ueharaauthor=K.+Izumiauthor=S.+Sone&title=Imatinib+as+a+novel+antifibrotic+agent+in+bleomycin-induced+pulmonary+fibrosis+in+mice&doi=10.1164%2Frccm.200404-531oc"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Imatinib as a novel antifibrotic agent in bleomycin-induced pulmonary fibrosis in mice</span></div><div class="casAuthors">Aono Yoshinori; Nishioka Yasuhiko; Inayama Mami; Ugai Momoyo; Kishi Jun; Uehara Hisanori; Izumi Keisuke; Sone Saburo</div><div class="citationInfo"><span class="NLM_cas:title">American journal of respiratory and critical care medicine</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">171</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1279-85</span>
        ISSN:<span class="NLM_cas:issn">1073-449X</span>.
    </div><div class="casAbstract">Imatinib mesylate is a potent and specific tyrosine kinase inhibitor against c-ABL, BCR-ABL, and c-KIT, and has been demonstrated to be highly active in chronic myeloid leukemia and gastrointestinal stromal tumors.  We examined the antifibrotic effects of imatinib using a bleomycin-induced lung fibrosis model in mice because imatinib also inhibits tyrosine kinase of platelet-derived growth factor receptors (PDGFRs).  Imatinib inhibited the growth of primary murine lung fibroblasts and the autophosphorylation of PDGFR-beta induced by PDGF.  Administration of imatinib significantly prevented bleomycin-induced pulmonary fibrosis in mice, partly by reducing the number of mesenchymal cells incorporating bromodeoxyuridine.  Analysis of bronchoalveolar lavage cells demonstrated that imatinib did not suppress early inflammation on Days 7 and 14 caused by bleomycin.  These results suggest that imatinib has the potential to prevent pulmonary fibrosis by inhibiting the proliferation of mesenchymal cells, and that imatinib might be useful for the treatment of pulmonary fibrosis in humans.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT6Hl7Y7MSGmVZoq0fPSOTvfW6udTcc2eYkKo8vpKHY7bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2M3ntFWmtw%253D%253D&md5=998232993f5ca1d46769358d0ac73cb1</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1164%2Frccm.200404-531oc&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1164%252Frccm.200404-531oc%26sid%3Dliteratum%253Aachs%26aulast%3DAono%26aufirst%3DY.%26aulast%3DNishioka%26aufirst%3DY.%26aulast%3DInayama%26aufirst%3DM.%26aulast%3DUgai%26aufirst%3DM.%26aulast%3DKishi%26aufirst%3DJ.%26aulast%3DUehara%26aufirst%3DH.%26aulast%3DIzumi%26aufirst%3DK.%26aulast%3DSone%26aufirst%3DS.%26atitle%3DImatinib%2520as%2520a%2520novel%2520antifibrotic%2520agent%2520in%2520bleomycin-induced%2520pulmonary%2520fibrosis%2520in%2520mice%26jtitle%3DAm.%2520J.%2520Respir.%2520Crit.%2520Care%2520Med.%26date%3D2005%26volume%3D171%26spage%3D1279%26epage%3D1285%26doi%3D10.1164%2Frccm.200404-531oc" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ashcroft, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simpson, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Timbrell, V.</span></span> <span> </span><span class="NLM_article-title">Simple method of estimating severity of pulmonary fibrosis on a numerical scale</span>. <i>J. Clin. Pathol.</i> <span class="NLM_year" style="font-weight: bold;">1988</span>,  <span class="NLM_volume"><i>41</i></span>,  <span class="NLM_fpage">467</span>– <span class="NLM_lpage">470</span>, <span class="refDoi"> DOI: 10.1136/jcp.41.4.467</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=10.1136%2Fjcp.41.4.467" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=3366935" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=1%3ACAS%3A280%3ADyaL1c3htlOltg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=1988&pages=467-470&author=T.+Ashcroftauthor=J.+M.+Simpsonauthor=V.+Timbrell&title=Simple+method+of+estimating+severity+of+pulmonary+fibrosis+on+a+numerical+scale&doi=10.1136%2Fjcp.41.4.467"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Simple method of estimating severity of pulmonary fibrosis on a numerical scale</span></div><div class="casAuthors">Ashcroft T; Simpson J M; Timbrell V</div><div class="citationInfo"><span class="NLM_cas:title">Journal of clinical pathology</span>
        (<span class="NLM_cas:date">1988</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">467-70</span>
        ISSN:<span class="NLM_cas:issn">0021-9746</span>.
    </div><div class="casAbstract">A continuous numerical scale for determining the degree of fibrosis in lung specimens was devised for correlation with other pulmonary variables such as lung function tests or mineral burden.  Grading was scored on a scale from 0 to 8, using the average of microscope field scores.  The system allows fibrosis to be measured in small samples of tissue (1 cm) which can provide a detailed description of the changes in a lung, currently not possible with most existing methods.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT5mGFCkDKSIzUE-swuRqsHfW6udTcc2eb9DiK_N_GrEbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaL1c3htlOltg%253D%253D&md5=d1da07e3ba735d309aa78d3955474bfd</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1136%2Fjcp.41.4.467&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1136%252Fjcp.41.4.467%26sid%3Dliteratum%253Aachs%26aulast%3DAshcroft%26aufirst%3DT.%26aulast%3DSimpson%26aufirst%3DJ.%2BM.%26aulast%3DTimbrell%26aufirst%3DV.%26atitle%3DSimple%2520method%2520of%2520estimating%2520severity%2520of%2520pulmonary%2520fibrosis%2520on%2520a%2520numerical%2520scale%26jtitle%3DJ.%2520Clin.%2520Pathol.%26date%3D1988%26volume%3D41%26spage%3D467%26epage%3D470%26doi%3D10.1136%2Fjcp.41.4.467" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Balle, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perregaard, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramirez, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larsen, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Søby, K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liljefors, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andersen, K.</span></span> <span> </span><span class="NLM_article-title">Synthesis and Structure–Affinity Relationship Investigations of 5-Heteroaryl-Substituted Analogues of the Antipsychotic Sertindole. A New Class of Highly Selective α1Adrenoceptor Antagonists</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>46</i></span>,  <span class="NLM_fpage">265</span>– <span class="NLM_lpage">283</span>, <span class="refDoi"> DOI: 10.1021/jm020938y</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm020938y" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=1%3ACAS%3A528%3ADC%252BD38XpsVegtLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2003&pages=265-283&author=T.+Balleauthor=J.+Perregaardauthor=M.+T.+Ramirezauthor=A.+K.+Larsenauthor=K.+K.+S%C3%B8byauthor=T.+Liljeforsauthor=K.+Andersen&title=Synthesis+and+Structure%E2%80%93Affinity+Relationship+Investigations+of+5-Heteroaryl-Substituted+Analogues+of+the+Antipsychotic+Sertindole.+A+New+Class+of+Highly+Selective+%CE%B11Adrenoceptor+Antagonists&doi=10.1021%2Fjm020938y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and Structure-Affinity Relationship Investigations of 5-Heteroaryl-Substituted Analogues of the Antipsychotic Sertindole. A New Class of Highly Selective α1 Adrenoceptor Antagonists</span></div><div class="casAuthors">Balle, Thomas; Perregaard, Jens; Ramirez, Martha Teresa; Larsen, Anna Kirstine; Soby, Karina Krojer; Liljefors, Tommy; Andersen, Kim</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">265-283</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A new class of 5-heteroaryl-substituted 1-(4-fluorophenyl)-3-(4-piperidinyl)-1H-indoles, e.g., I (X = NH, O), as highly selective and potentially CNS-active α1-adrenoceptor antagonists is described.  The compds. are derived from the antipsychotic sertindole.  The structure-affinity relationships of the 5-heteroaryl substituents, and the substituents on the piperidine nitrogen atom were optimized with respect to affinity for α1 adrenoceptors and selectivity in respect to dopamine (D1-4) and serotonin (5-HT1A-1B and 5-HT2A,2C) receptors.  The most selective compd. obtained, 3-{4-[1-(4-fluorophenyl)-5-(1-methyl-1,2,4-triazol-3-yl)-1H-indol-3-yl]-1-piperidinyl}propionitrile (II), has affinities of 0.99, 3.2, and 9.0 nM for the α1a, α1b, and α1d adrenoceptor subtypes, resp., and a selectivity for adrenergic α1a receptors in respect to dopamine D2, D3, and D4 and serotonin 5-HT2A and 5-HT2C higher than 900, comparable to the selectivity of prazosin.  Compd. II is more than 150-fold selective in respect to serotonin 5-HT1A and 5-HT1B receptors.  A new basic pharmacophore for α1-adrenoceptor antagonists based on a previously reported pharmacophore model for dopamine D2 antagonist is suggested.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp7ipwqVAJLKrVg90H21EOLACvtfcHk0ljUsZ76BIRkTA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XpsVegtLY%253D&md5=518924c375dc409bb74dd1d3f682681f</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1021%2Fjm020938y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm020938y%26sid%3Dliteratum%253Aachs%26aulast%3DBalle%26aufirst%3DT.%26aulast%3DPerregaard%26aufirst%3DJ.%26aulast%3DRamirez%26aufirst%3DM.%2BT.%26aulast%3DLarsen%26aufirst%3DA.%2BK.%26aulast%3DS%25C3%25B8by%26aufirst%3DK.%2BK.%26aulast%3DLiljefors%26aufirst%3DT.%26aulast%3DAndersen%26aufirst%3DK.%26atitle%3DSynthesis%2520and%2520Structure%25E2%2580%2593Affinity%2520Relationship%2520Investigations%2520of%25205-Heteroaryl-Substituted%2520Analogues%2520of%2520the%2520Antipsychotic%2520Sertindole.%2520A%2520New%2520Class%2520of%2520Highly%2520Selective%2520%25CE%25B11Adrenoceptor%2520Antagonists%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2003%26volume%3D46%26spage%3D265%26epage%3D283%26doi%3D10.1021%2Fjm020938y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">de
Bruin, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Rooden, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ward, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wesseling, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van den Nieuwendijk, A. M. C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Boeckel, C. A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Driessen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kisselev, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Florea, B. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van der
Stelt, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Overkleeft, H. S.</span></span> <span> </span><span class="NLM_article-title">Asymmetric synthesis of lysine analogues with reduced basicity, and their incorporation into proteasome inhibitors</span>. <i>Eur. J. Org. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_fpage">5921</span>– <span class="NLM_lpage">5934</span>, <span class="refDoi"> DOI: 10.1002/ejoc.201701174</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=10.1002%2Fejoc.201701174" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhslagsbvL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&pages=5921-5934&author=G.+de%0ABruinauthor=E.+J.+van+Roodenauthor=D.+Wardauthor=C.+Wesselingauthor=A.+M.+C.+H.+van+den+Nieuwendijkauthor=C.+A.+A.+van+Boeckelauthor=C.+Driessenauthor=A.+F.+Kisselevauthor=B.+I.+Floreaauthor=M.+van+der%0ASteltauthor=H.+S.+Overkleeft&title=Asymmetric+synthesis+of+lysine+analogues+with+reduced+basicity%2C+and+their+incorporation+into+proteasome+inhibitors&doi=10.1002%2Fejoc.201701174"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Asymmetric synthesis of lysine analogues with reduced basicity, and their incorporation into proteasome inhibitors</span></div><div class="casAuthors">de Bruin, Gerjan; van Rooden, Eva J.; Ward, David; Wesseling, Charlotte; van den Nieuwendijk, Adrianus M. C. H.; van Boeckel, Constant A. A.; Driessen, Christoph; Kisselev, Alexei F.; Florea, Bogdan I.; van der Stelt, Mario; Overkleeft, Herman S.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Organic Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">2017</span>
        (<span class="NLM_cas:issue">39</span>),
    <span class="NLM_cas:pages">5921-5934</span>CODEN:
                <span class="NLM_cas:coden">EJOCFK</span>;
        ISSN:<span class="NLM_cas:issn">1099-0690</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Most known β2-selective proteasome inhibitors suffer from relatively poor cell permeability as the result of a net pos. charge caused by the basic moiety at P1.  In this paper, we describe the synthesis of oligopeptide vinyl sulfones that contain different amino acids bearing amino groups with reduced basicity at P1 and/or P3.  For this, we developed the first enantioselective synthesis of lysine(4-ene) and lysine(4-yne).  These amino acids, as well as histidine and diaminopropionic-acid-glycine, were incorporated at the P1 and/or P3 positions of oligopeptide vinyl sulfones.  All inhibitors were found to inhibit β2, but with a loss of potency compared to our most potent and selective β2 inhibitor, LU-102.  These results notwithstanding, our results provide important insights for the future design of β2-selective proteasome inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqxdaoHyPyG27Vg90H21EOLACvtfcHk0ljUsZ76BIRkTA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhslagsbvL&md5=cc4321236acb824cca3af6708d16736f</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1002%2Fejoc.201701174&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fejoc.201701174%26sid%3Dliteratum%253Aachs%26aulast%3Dde%2BBruin%26aufirst%3DG.%26aulast%3Dvan%2BRooden%26aufirst%3DE.%2BJ.%26aulast%3DWard%26aufirst%3DD.%26aulast%3DWesseling%26aufirst%3DC.%26aulast%3Dvan%2Bden%2BNieuwendijk%26aufirst%3DA.%2BM.%2BC.%2BH.%26aulast%3Dvan%2BBoeckel%26aufirst%3DC.%2BA.%2BA.%26aulast%3DDriessen%26aufirst%3DC.%26aulast%3DKisselev%26aufirst%3DA.%2BF.%26aulast%3DFlorea%26aufirst%3DB.%2BI.%26aulast%3Dvan%2Bder%2BStelt%26aufirst%3DM.%26aulast%3DOverkleeft%26aufirst%3DH.%2BS.%26atitle%3DAsymmetric%2520synthesis%2520of%2520lysine%2520analogues%2520with%2520reduced%2520basicity%252C%2520and%2520their%2520incorporation%2520into%2520proteasome%2520inhibitors%26jtitle%3DEur.%2520J.%2520Org.%2520Chem.%26date%3D2017%26spage%3D5921%26epage%3D5934%26doi%3D10.1002%2Fejoc.201701174" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref52"><div class="reference"><strong class="refLabel"><a href="#ref52" class="rightTabRefNumLink">52</a></strong><div class="NLM_citation" id="rightTab-cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shieh, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tamaye, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yasunobu, K. T.</span></span> <span> </span><span class="NLM_article-title">A purification procedure for the isolation of homogeneous preparations of bovine aorta amine oxidase and a study of its lysyl oxidase activity</span>. <i>Biochim. Biophys. Acta</i> <span class="NLM_year" style="font-weight: bold;">1975</span>,  <span class="NLM_volume"><i>377</i></span>,  <span class="NLM_fpage">229</span>– <span class="NLM_lpage">238</span>, <span class="refDoi"> DOI: 10.1016/0005-2744(75)90305-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=10.1016%2F0005-2744%2875%2990305-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=235299" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=1%3ACAS%3A528%3ADyaE2MXht1Slt7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=377&publication_year=1975&pages=229-238&author=J.+J.+Shiehauthor=R.+Tamayeauthor=K.+T.+Yasunobu&title=A+purification+procedure+for+the+isolation+of+homogeneous+preparations+of+bovine+aorta+amine+oxidase+and+a+study+of+its+lysyl+oxidase+activity&doi=10.1016%2F0005-2744%2875%2990305-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Purification procedure for the isolation of homogeneous preparations of bovine aorta amine oxidase and a study of its lysyl oxidase activity</span></div><div class="casAuthors">Shieh, James J.; Tamaye, Randolph; Yasunobu, Kerry T.</div><div class="citationInfo"><span class="NLM_cas:title">Biochimica et Biophysica Acta, Enzymology</span>
        (<span class="NLM_cas:date">1975</span>),
    <span class="NLM_cas:volume">377</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">229-38</span>CODEN:
                <span class="NLM_cas:coden">BBEZAD</span>;
        ISSN:<span class="NLM_cas:issn">0924-1086</span>.
    </div><div class="casAbstract">It was reported that bovine aorta amine oxidase oxidizes lysine residues in tropoelastin to allylsine (R. B. Rucker and B. L. O'Dell (1971)).  Pure bovine aorta amine oxidase was isolated by DEAE-cellulose, hydroxylapatite, Bio-Gel A-1.5 m and concanavalin A-Sepharose 4B chromatog.  Enzymic, chromatog., and immunochem. tests disclosed that pure bovine aorta amine oxidase was not a lysyl oxidase capable of oxidizing the lysine residues of tropoelastin to allylsine.  The bovine aorta amine oxidase prepn. used by Rucker and O'Dell was apparently contaminated with lysyl oxidase.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrZAUhL5XTEPbVg90H21EOLACvtfcHk0lgJ2ohoPUToaQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaE2MXht1Slt7g%253D&md5=d5fc9ef0d26f35af273bb349a1cd8aaa</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1016%2F0005-2744%2875%2990305-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0005-2744%252875%252990305-8%26sid%3Dliteratum%253Aachs%26aulast%3DShieh%26aufirst%3DJ.%2BJ.%26aulast%3DTamaye%26aufirst%3DR.%26aulast%3DYasunobu%26aufirst%3DK.%2BT.%26atitle%3DA%2520purification%2520procedure%2520for%2520the%2520isolation%2520of%2520homogeneous%2520preparations%2520of%2520bovine%2520aorta%2520amine%2520oxidase%2520and%2520a%2520study%2520of%2520its%2520lysyl%2520oxidase%2520activity%26jtitle%3DBiochim.%2520Biophys.%2520Acta%26date%3D1975%26volume%3D377%26spage%3D229%26epage%3D238%26doi%3D10.1016%2F0005-2744%2875%2990305-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref53"><div class="reference"><strong class="refLabel"><a href="#ref53" class="rightTabRefNumLink">53</a></strong><div class="NLM_citation" id="rightTab-cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schilter, H. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collison, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Russo, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foot, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yow, T. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vieira, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tavares, L. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mattes, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teixeira, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jarolimek, W.</span></span> <span> </span><span class="NLM_article-title">Effects of an anti-inflammatory VAP-1/SSAO inhibitor, PXS-4728A, on pulmonary neutrophil migration</span>. <i>Respir. Res.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">42</span>– <span class="NLM_lpage">49</span>, <span class="refDoi"> DOI: 10.1186/s12931-015-0200-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=10.1186%2Fs12931-015-0200-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=25889951" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=1%3ACAS%3A280%3ADC%252BC2MjlvVehug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2015&pages=42-49&author=H.+C.+Schilterauthor=A.+Collisonauthor=R.+C.+Russoauthor=J.+S.+Footauthor=T.+T.+Yowauthor=A.+T.+Vieiraauthor=L.+D.+Tavaresauthor=J.+Mattesauthor=M.+M.+Teixeiraauthor=W.+Jarolimek&title=Effects+of+an+anti-inflammatory+VAP-1%2FSSAO+inhibitor%2C+PXS-4728A%2C+on+pulmonary+neutrophil+migration&doi=10.1186%2Fs12931-015-0200-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Effects of an anti-inflammatory VAP-1/SSAO inhibitor, PXS-4728A, on pulmonary neutrophil migration</span></div><div class="casAuthors">Schilter Heidi C; Foot Jonathan S; Yow Tin T; Jarolimek Wolfgang; Collison Adam; Mattes Joerg; Russo Remo C; Russo Remo C; Vieira Angelica T; Tavares Livia D; Teixeira Mauro M; Jarolimek Wolfgang</div><div class="citationInfo"><span class="NLM_cas:title">Respiratory research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">42</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND AND PURPOSE:  The persistent influx of neutrophils into the lung and subsequent tissue damage are characteristics of COPD, cystic fibrosis and acute lung inflammation.  VAP-1/SSAO is an endothelial bound adhesion molecule with amine oxidase activity that is reported to be involved in neutrophil egress from the microvasculature during inflammation.  This study explored the role of VAP-1/SSAO in neutrophilic lung mediated diseases and examined the therapeutic potential of the selective inhibitor PXS-4728A.  METHODS:  Mice treated with PXS-4728A underwent intra-vital microscopy visualization of the cremaster muscle upon CXCL1/KC stimulation.  LPS inflammation, Klebsiella pneumoniae infection, cecal ligation and puncture as well as rhinovirus exacerbated asthma models were also assessed using PXS-4728A.  RESULTS:  Selective VAP-1/SSAO inhibition by PXS-4728A diminished leukocyte rolling and adherence induced by CXCL1/KC.  Inhibition of VAP-1/SSAO also dampened the migration of neutrophils to the lungs in response to LPS, Klebsiella pneumoniae lung infection and CLP induced sepsis; whilst still allowing for normal neutrophil defense function, resulting in increased survival.  The functional effects of this inhibition were demonstrated in the RV exacerbated asthma model, with a reduction in cellular infiltrate correlating with a reduction in airways hyperractivity.  CONCLUSIONS AND IMPLICATIONS:  This study demonstrates that the endothelial cell ligand VAP-1/SSAO contributes to the migration of neutrophils during acute lung inflammation, pulmonary infection and airway hyperractivity.  These results highlight the potential of inhibiting of VAP-1/SSAO enzymatic function, by PXS-4728A, as a novel therapeutic approach in lung diseases that are characterized by neutrophilic pattern of inflammation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ0DDPb95t7V9K0qsdY6Nc1fW6udTcc2eZGWXHAWyt1YLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2MjlvVehug%253D%253D&md5=8a1e21dcc37596356424720fd11bcc1d</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1186%2Fs12931-015-0200-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs12931-015-0200-z%26sid%3Dliteratum%253Aachs%26aulast%3DSchilter%26aufirst%3DH.%2BC.%26aulast%3DCollison%26aufirst%3DA.%26aulast%3DRusso%26aufirst%3DR.%2BC.%26aulast%3DFoot%26aufirst%3DJ.%2BS.%26aulast%3DYow%26aufirst%3DT.%2BT.%26aulast%3DVieira%26aufirst%3DA.%2BT.%26aulast%3DTavares%26aufirst%3DL.%2BD.%26aulast%3DMattes%26aufirst%3DJ.%26aulast%3DTeixeira%26aufirst%3DM.%2BM.%26aulast%3DJarolimek%26aufirst%3DW.%26atitle%3DEffects%2520of%2520an%2520anti-inflammatory%2520VAP-1%252FSSAO%2520inhibitor%252C%2520PXS-4728A%252C%2520on%2520pulmonary%2520neutrophil%2520migration%26jtitle%3DRespir.%2520Res.%26date%3D2015%26volume%3D16%26spage%3D42%26epage%3D49%26doi%3D10.1186%2Fs12931-015-0200-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref54"><div class="reference"><strong class="refLabel"><a href="#ref54" class="rightTabRefNumLink">54</a></strong><div class="NLM_citation" id="rightTab-cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kitz, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, I. B.</span></span> <span> </span><span class="NLM_article-title">Esters of methanesulfonic acid as irreversible inhibitors of acetylcholinesterase</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1962</span>,  <span class="NLM_volume"><i>237</i></span>,  <span class="NLM_fpage">3245</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=14033211" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=1%3ACAS%3A528%3ADyaF38Xks1Cmsrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=237&publication_year=1962&pages=3245&author=R.+Kitzauthor=I.+B.+Wilson&title=Esters+of+methanesulfonic+acid+as+irreversible+inhibitors+of+acetylcholinesterase"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Esters of methanesulfonic acid as irreversible inhibitors of acetylcholinesterase</span></div><div class="casAuthors">Kitz, R.; Wilson, Irwin B.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">1962</span>),
    <span class="NLM_cas:volume">237</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">3245-49</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    </div><div class="casAbstract">Nine esters (anhydrides) of methanesulfonic acid, analogs to well known carbamate (e.g. neostigmine) and phosphate (e.g. paraoxon) inhibitors, were examd. as possible irreversible inhibitors of acetylcholinesterase.  Five were active.  Of these, 4 formed initial reversible complexes.  The progressive development of irreversible inhibition was slowed by reversible inhibitors, indicating that the active site is involved.  The inhibited enzyme is not reactivated by water or by hydroxylamine, hydrazine, acetate, or pyridine-2-aldoxime methiodide.  It is reactivated by pyridine-3-aldoxime methiodide.  On the basis of the evidence presented, it may be concluded safely that the active methanesulfonates form methanesulfonyl enzyme derivs. and, therefore, belong to the class of acid-transferring or oxydiaphoric inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoXvcQevCYwCbVg90H21EOLACvtfcHk0lgJ2ohoPUToaQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaF38Xks1Cmsrg%253D&md5=f3993cf79ebb66299fada0ad04b15860</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKitz%26aufirst%3DR.%26aulast%3DWilson%26aufirst%3DI.%2BB.%26atitle%3DEsters%2520of%2520methanesulfonic%2520acid%2520as%2520irreversible%2520inhibitors%2520of%2520acetylcholinesterase%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1962%26volume%3D237%26spage%3D3245" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref55"><div class="reference"><strong class="refLabel"><a href="#ref55" class="rightTabRefNumLink">55</a></strong><div class="NLM_citation" id="rightTab-cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Holt, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cendron, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zanotti, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rigo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Paolo, M. L.</span></span> <span> </span><span class="NLM_article-title">Multiple binding sites for substrates and modulators of semicarbazide-sensitive amine oxidases: kinetic consequences</span>. <i>Mol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>73</i></span>,  <span class="NLM_fpage">525</span>– <span class="NLM_lpage">538</span>, <span class="refDoi"> DOI: 10.1124/mol.107.040964</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=10.1124%2Fmol.107.040964" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=17989349" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=1%3ACAS%3A528%3ADC%252BD1cXht1ymtrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=2008&pages=525-538&author=A.+Holtauthor=D.+J.+Smithauthor=L.+Cendronauthor=G.+Zanottiauthor=A.+Rigoauthor=M.+L.+Di+Paolo&title=Multiple+binding+sites+for+substrates+and+modulators+of+semicarbazide-sensitive+amine+oxidases%3A+kinetic+consequences&doi=10.1124%2Fmol.107.040964"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Multiple binding sites for substrates and modulators of semicarbazide-sensitive amine oxidases: kinetic consequences</span></div><div class="casAuthors">Holt, Andrew; Smith, David J.; Cendron, Laura; Zanotti, Giuseppe; Rigo, Adelio; Di Paolo, Maria Luisa</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmacology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">73</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">525-538</span>CODEN:
                <span class="NLM_cas:coden">MOPMA3</span>;
        ISSN:<span class="NLM_cas:issn">0026-895X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Human semicarbazide-sensitive amine oxidase (SSAO) is a target for novel anti-inflammatory drugs that inhibit enzymic activity.  However, progress in developing such drugs has been hampered by an incomplete understanding of mechanisms involved in substrate turnover.  We report here results of a comparative study of human and bovine SSAO enzymes that reveal binding of substrates and other ligands to at least two (human) and up to four (bovine) distinct sites on enzyme monomers.  Anaerobic spectroscopy reveals binding of substrates (spermidine and benzylamine) and of an imidazoline site ligand (clonidine) to the reduced active site of bovine SSAO, whereas interactions with oxidized enzyme are evident in kinetic assays and crystn. studies.  Radioligand binding expts. with [3H]tetraphenylphosphonium, an inhibitor of bovine SSAO that binds to an anionic cavity outside the active site, reveal competition with spermidine, benzylamine, and clonidine, indicating that these ligands also bind to this second anionic region.  Kinetic models of bovine SSAO are consistent with one spermidine mol. straddling the active and secondary sites on both oxidized and reduced enzyme, whereas these sites are occupied by two individual mols. of smaller substrates such as benzylamine.  Clonidine and other imidazoline site ligands enhance or inhibit activity as a result of differing affinities for both sites on oxidized and reduced enzyme.  In contrast, although analyses of kinetic data obtained with human SSAO are also consistent with ligands binding to oxidized and reduced enzyme, we obsd. no apparent requirement for substrate or modulator binding to any secondary site to model enzyme behavior.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp9kU0mAyme37Vg90H21EOLACvtfcHk0liF55cqkjsLCQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXht1ymtrY%253D&md5=2cc605a9cb13c427a8654fd2f14851d0</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1124%2Fmol.107.040964&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fmol.107.040964%26sid%3Dliteratum%253Aachs%26aulast%3DHolt%26aufirst%3DA.%26aulast%3DSmith%26aufirst%3DD.%2BJ.%26aulast%3DCendron%26aufirst%3DL.%26aulast%3DZanotti%26aufirst%3DG.%26aulast%3DRigo%26aufirst%3DA.%26aulast%3DDi%2BPaolo%26aufirst%3DM.%2BL.%26atitle%3DMultiple%2520binding%2520sites%2520for%2520substrates%2520and%2520modulators%2520of%2520semicarbazide-sensitive%2520amine%2520oxidases%253A%2520kinetic%2520consequences%26jtitle%3DMol.%2520Pharmacol.%26date%3D2008%26volume%3D73%26spage%3D525%26epage%3D538%26doi%3D10.1124%2Fmol.107.040964" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref56"><div class="reference"><strong class="refLabel"><a href="#ref56" class="rightTabRefNumLink">56</a></strong><div class="NLM_citation" id="rightTab-cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Holt, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palcic, M. M.</span></span> <span> </span><span class="NLM_article-title">A peroxidase-coupled continuous absorbance plate-reader assay for flavin monoamine oxidases, copper-containing amine oxidases and related enzymes</span>. <i>Nat. Protoc.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">2498</span>– <span class="NLM_lpage">2505</span>, <span class="refDoi"> DOI: 10.1038/nprot.2006.402</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=10.1038%2Fnprot.2006.402" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=17406497" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtFGjtLrJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2006&pages=2498-2505&author=A.+Holtauthor=M.+M.+Palcic&title=A+peroxidase-coupled+continuous+absorbance+plate-reader+assay+for+flavin+monoamine+oxidases%2C+copper-containing+amine+oxidases+and+related+enzymes&doi=10.1038%2Fnprot.2006.402"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">A peroxidase-coupled continuous absorbance plate-reader assay for flavin monoamine oxidases, copper-containing amine oxidases and related enzymes</span></div><div class="casAuthors">Holt, Andrew; Palcic, Monica M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Protocols</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2498-2505</span>CODEN:
                <span class="NLM_cas:coden">NPARDW</span>;
        ISSN:<span class="NLM_cas:issn">1750-2799</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">This absorbance plate-reader-based assay is suitable for the examn. of monoamine oxidase and copper amine oxidase activities vs. numerous substrates.  The assay is robust, continuous, rapid, highly quant., reasonably sensitive, inexpensive and suitable for automation.  In the presence of a suitable amine substrate, amine oxidase enzymes generate hydrogen peroxide, which then drives the peroxidase-dependent oxidn. of 4-aminoantipyrine.  A subsequent interaction with vanillic acid generates stoichiometric amts. of a red quinoneimine dye, the appearance of which is monitored at 498 nm.  An alternative procedure in which vanillic acid is replaced by 2,4-dichlorophenol enhances sensitivity but precludes the measurement of monoamine oxidases due to inhibition of these enzymes by dichlorophenol.  Some substrates with low redox potentials, such as catecholamines, are not suitable for inclusion in this assay.  A researcher familiar with the procedure can manually generate data for 30 full kinetic curves, composed of ten triplicate points, in 8 h.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrM4Zljfb0I57Vg90H21EOLACvtfcHk0liF55cqkjsLCQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtFGjtLrJ&md5=e226ec15739a0cadb733639303e35609</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1038%2Fnprot.2006.402&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnprot.2006.402%26sid%3Dliteratum%253Aachs%26aulast%3DHolt%26aufirst%3DA.%26aulast%3DPalcic%26aufirst%3DM.%2BM.%26atitle%3DA%2520peroxidase-coupled%2520continuous%2520absorbance%2520plate-reader%2520assay%2520for%2520flavin%2520monoamine%2520oxidases%252C%2520copper-containing%2520amine%2520oxidases%2520and%2520related%2520enzymes%26jtitle%3DNat.%2520Protoc.%26date%3D2006%26volume%3D1%26spage%3D2498%26epage%3D2505%26doi%3D10.1038%2Fnprot.2006.402" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref57"><div class="reference"><strong class="refLabel"><a href="#ref57" class="rightTabRefNumLink">57</a></strong><div class="NLM_citation" id="rightTab-cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Copeland, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Basavapathruni, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moyer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scott, M. P.</span></span> <span> </span><span class="NLM_article-title">Impact of enzyme concentration and residence time on apparent activity recovery in jump dilution analysis</span>. <i>Anal. Biochem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>416</i></span>,  <span class="NLM_fpage">206</span>– <span class="NLM_lpage">210</span>, <span class="refDoi"> DOI: 10.1016/j.ab.2011.05.029</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=10.1016%2Fj.ab.2011.05.029" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=21669181" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=1%3ACAS%3A528%3ADC%252BC3MXptVakurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=416&publication_year=2011&pages=206-210&author=R.+A.+Copelandauthor=A.+Basavapathruniauthor=M.+Moyerauthor=M.+P.+Scott&title=Impact+of+enzyme+concentration+and+residence+time+on+apparent+activity+recovery+in+jump+dilution+analysis&doi=10.1016%2Fj.ab.2011.05.029"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">Impact of enzyme concentration and residence time on apparent activity recovery in jump dilution analysis</span></div><div class="casAuthors">Copeland, Robert A.; Basavapathruni, Aravind; Moyer, Mikel; Scott, Margaret Porter</div><div class="citationInfo"><span class="NLM_cas:title">Analytical Biochemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">416</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">206-210</span>CODEN:
                <span class="NLM_cas:coden">ANBCA2</span>;
        ISSN:<span class="NLM_cas:issn">0003-2697</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Jump diln. anal. is commonly used to evaluate the reversibility of inhibition and to quantify the residence time of the inhibitor-enzyme complex.  During hit and lead characterization, one sometimes observes apparently linear progress curves after jump diln. that display activity recoveries that are intermediate between those expected for fully reversible and irreversible inhibition.  Computer simulations of progress curves after jump diln. indicate that seemingly linear progress curves can result when dealing with tight-binding inhibitors if substoichiometric concns. of inhibitor are preincubated with enzyme.  In this situation, the activity recovered is comparable to that expected for instantaneously reversible inhibitors.  In addn., simulations demonstrate that intermediate values of activity recovery may be obsd. for compds. with modestly slow dissocn. rates (i.e., residence times >0 min but ≤20 min) when the attending curvature of the data is not accounted for.  The observation of intermediate values of recovery can, thus, serve as an indication of either modest residence time or a contaminating inactivator within an inhibitor sample, in either case prompting greater scrutiny of the test compd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpMe9Zt5K_fKrVg90H21EOLACvtfcHk0liF55cqkjsLCQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXptVakurk%253D&md5=4bb34803356e35d7a2de0de4d50bd90a</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1016%2Fj.ab.2011.05.029&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ab.2011.05.029%26sid%3Dliteratum%253Aachs%26aulast%3DCopeland%26aufirst%3DR.%2BA.%26aulast%3DBasavapathruni%26aufirst%3DA.%26aulast%3DMoyer%26aufirst%3DM.%26aulast%3DScott%26aufirst%3DM.%2BP.%26atitle%3DImpact%2520of%2520enzyme%2520concentration%2520and%2520residence%2520time%2520on%2520apparent%2520activity%2520recovery%2520in%2520jump%2520dilution%2520analysis%26jtitle%3DAnal.%2520Biochem.%26date%3D2011%26volume%3D416%26spage%3D206%26epage%3D210%26doi%3D10.1016%2Fj.ab.2011.05.029" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref58"><div class="reference"><strong class="refLabel"><a href="#ref58" class="rightTabRefNumLink">58</a></strong><div class="NLM_citation" id="rightTab-cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">O’Donoghue, R. J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knight, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richards, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prêle, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lau, H. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jarnicki, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bozinovski, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vlahos, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thiem, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKenzie, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stumbles, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laurent, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McAnulty, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rose-John, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, G. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ernst, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mutsaers, S. E.</span></span> <span> </span><span class="NLM_article-title">Genetic partitioning of interleukin-6 signalling in mice dissociates Stat3 from Smad3-mediated lung fibrosis</span>. <i>EMBO Mol. Med.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">939</span>– <span class="NLM_lpage">951</span>, <span class="refDoi"> DOI: 10.1002/emmm.201100604</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=10.1002%2Femmm.201100604" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=22684844" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht1ylurzF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2012&pages=939-951&author=R.+J.+J.+O%E2%80%99Donoghueauthor=D.+A.+Knightauthor=C.+D.+Richardsauthor=C.+M.+Pr%C3%AAleauthor=H.+L.+Lauauthor=A.+G.+Jarnickiauthor=J.+Jonesauthor=S.+Bozinovskiauthor=R.+Vlahosauthor=S.+Thiemauthor=B.+S.+McKenzieauthor=B.+Wangauthor=P.+Stumblesauthor=G.+J.+Laurentauthor=R.+J.+McAnultyauthor=S.+Rose-Johnauthor=H.+J.+Zhuauthor=G.+P.+Andersonauthor=M.+R.+Ernstauthor=S.+E.+Mutsaers&title=Genetic+partitioning+of+interleukin-6+signalling+in+mice+dissociates+Stat3+from+Smad3-mediated+lung+fibrosis&doi=10.1002%2Femmm.201100604"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">Genetic partitioning of interleukin-6 signalling in mice dissociates Stat3 from Smad3-mediated lung fibrosis</span></div><div class="casAuthors">O'Donoghue, Robert J. J.; Knight, Darryl A.; Richards, Carl D.; Prele, Cecilia M.; Lau, Hui Ling; Jarnicki, Andrew G.; Jones, Jessica; Bozinovski, Steven; Vlahos, Ross; Thiem, Stefan; McKenzie, Brent S.; Wang, Bo; Stumbles, Philip; Laurent, Geoffrey J.; McAnulty, Robin J.; Rose-John, Stefan; Zhu, Hong Jian; Anderson, Gary P.; Ernst, Matthias R.; Mutsaers, Steven E.</div><div class="citationInfo"><span class="NLM_cas:title">EMBO Molecular Medicine</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">939-951</span>CODEN:
                <span class="NLM_cas:coden">EMMMAM</span>;
        ISSN:<span class="NLM_cas:issn">1757-4684</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Idiopathic pulmonary fibrosis (IPF) is a fatal disease that is unresponsive to current therapies and characterized by excessive collagen deposition and subsequent fibrosis.  While inflammatory cytokines, including interleukin (IL)-6, are elevated in IPF, the mol. mechanisms that underlie this disease are incompletely understood, although the development of fibrosis is believed to depend on canonical transforming growth factor (TGF)-β signalling.  We examd. bleomycin-induced inflammation and fibrosis in mice carrying a mutation in the shared IL-6 family receptor gp130.  Using genetic complementation, we directly correlate the extent of IL-6-mediated, excessive Stat3 activity with inflammatory infiltrates in the lung and the severity of fibrosis in corresponding gp130757F mice.  The extent of fibrosis was attenuated in B lymphocyte-deficient gp130757F;μMT-/- compd. mutant mice, but fibrosis still occurred in their Smad3-/- counterparts consistent with the capacity of excessive Stat3 activity to induce collagen 1α1 gene transcription independently of canonical TGF-β/Smad3 signalling.  These findings are of therapeutic relevance, since we confirmed abundant STAT3 activation in fibrotic lungs from IPF patients and showed that genetic redn. of Stat3 protected mice from bleomycin-induced lung fibrosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoXc6SZBKl3w7Vg90H21EOLACvtfcHk0liF55cqkjsLCQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht1ylurzF&md5=2906a89576dfc4a7caccb1df7bd5cd66</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1002%2Femmm.201100604&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Femmm.201100604%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Donoghue%26aufirst%3DR.%2BJ.%2BJ.%26aulast%3DKnight%26aufirst%3DD.%2BA.%26aulast%3DRichards%26aufirst%3DC.%2BD.%26aulast%3DPr%25C3%25AAle%26aufirst%3DC.%2BM.%26aulast%3DLau%26aufirst%3DH.%2BL.%26aulast%3DJarnicki%26aufirst%3DA.%2BG.%26aulast%3DJones%26aufirst%3DJ.%26aulast%3DBozinovski%26aufirst%3DS.%26aulast%3DVlahos%26aufirst%3DR.%26aulast%3DThiem%26aufirst%3DS.%26aulast%3DMcKenzie%26aufirst%3DB.%2BS.%26aulast%3DWang%26aufirst%3DB.%26aulast%3DStumbles%26aufirst%3DP.%26aulast%3DLaurent%26aufirst%3DG.%2BJ.%26aulast%3DMcAnulty%26aufirst%3DR.%2BJ.%26aulast%3DRose-John%26aufirst%3DS.%26aulast%3DZhu%26aufirst%3DH.%2BJ.%26aulast%3DAnderson%26aufirst%3DG.%2BP.%26aulast%3DErnst%26aufirst%3DM.%2BR.%26aulast%3DMutsaers%26aufirst%3DS.%2BE.%26atitle%3DGenetic%2520partitioning%2520of%2520interleukin-6%2520signalling%2520in%2520mice%2520dissociates%2520Stat3%2520from%2520Smad3-mediated%2520lung%2520fibrosis%26jtitle%3DEMBO%2520Mol.%2520Med.%26date%3D2012%26volume%3D4%26spage%3D939%26epage%3D951%26doi%3D10.1002%2Femmm.201100604" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i66"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.9b01283">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_30232"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a class="ext-link" href="/">ACS Publications website</a> at DOI: <a class="ext-link" href="/doi/abs/10.1021/acs.jmedchem.9b01283">10.1021/acs.jmedchem.9b01283</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Collagen oxidation assay; Kitz–Wilson plot for <b>PXS-5120A</b>; Picro Sirius Red and ALT/AST readouts from the CCl<sub>4</sub> liver fibrosis model; IHC staining for both models; analytical data for key compounds; and CEREP off-target screening results for <b>PXS-5120A</b> (<b>12k</b>) (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.9b01283/suppl_file/jm9b01283_si_001.pdf">PDF</a>)</p></li><li><p class="inline">Molecular formula (SMILES string) of each compound along with relevant in vitro data (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.9b01283/suppl_file/jm9b01283_si_002.csv">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b01283/suppl_file/jm9b01283_si_001.pdf">jm9b01283_si_001.pdf (1.65 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b01283/suppl_file/jm9b01283_si_002.csv">jm9b01283_si_002.csv (3.15 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.9b01283&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.9b01283%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2019.62.issue-21%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.9b01283" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                1MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"67994fe5cf793d36","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
